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Fungal infections affect a broad spectrum of the population, including premature 
babies, the elderly and individuals with a range of disease- or medically-induced co-
morbidities. Fungal pathogens such as Candida albicans and Aspergillus fumigatus 
cause a variety of conditions, from minor infections to life threatening disease. Some 
fungi, including C. albicans and Candida glabrata can be commensal living in 
harmony with the superficial microflora, but these organisms can behave as 
opportunistic pathogens when individuals become immunodeficient due to co-
morbidities or become immunocompromised due to AIDS or through medical 
intervention. Fungal infections have become recognised in recent years as a growing 
health burden that currently causes around 1.5 million deaths per year worldwide.  
The azole antifungal drugs (imidazoles and triazoles) are used widely to treat fungal 
infections and as antifungal prophylaxis. The azole drugs target the fungal enzyme 
lanosterol 14α-demethylase (Erg11p, CYP51). This monospanning bitopic membrane 
protein belongs to the CYP51 class in the cytochrome P450 superfamily of enzymes 
and is involved in the rate-limiting step of ergosterol biosynthesis. Ergosterol is the 
fungal equivalent of cholesterol and is required for fungal cell growth. Fungal 
pathogens have evolved several mechanisms of resistance that diminish the action of 
the azole drugs. The emergence of resistant fungal strains due to mutations in CYP51 
can limit therapeutic options and make treatment of fungal infections increasingly 
problematic. The need for better drugs that overcome resistance is becoming 
increasingly urgent. The present project builds on the research of Monk et al. who 
successfully crystallised and obtained the first high-resolution X-ray structures of a 
fungal CYP51. The aim of this project is to investigate the effect of CYP51 mutations 
on enzyme structure and function, including different types of triazole drug, by using 
Saccharomyces cerevisiae Erg11p as a model for the homologous enzymes in 
pathogenic fungi.  
A S. cerevisiae overexpression system was used to hyper-express the wild type and 
the mutant ScErg11p enzymes in order to obtain sufficient quantities of protein for 
structure-function studies. The C. albicans CYP51 mutations Y132F/H, K143R, 
G464S and the double mutation Y132F G464S (Y140F/H, K151R, G464S and Y140F 
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G464S S. cerevisiae numbering), as well as the CYP51A G54E/R/W mutations of A. 
fumigatus (G73E/R/W S. cerevisiae numbering) have been reproduced in a C-terminal 
hexahistidine-tagged version of S. cerevisiae Erg11p (ScErg11p6×His). In addition, 
the innate resistance of A. fumigatus CYP51A to fluconazole (FLC) was investigated 
using the S. cerevisiae Erg11p T322I mutant. Microdilution assays were used to 
determine triazole susceptibilities of these strains. ScErg11p6×His mutant and wild 
type enzymes were purified from crude membranes by solubilisation with the 
detergent n-decyl-β-D-maltoside followed by affinity and size exclusion 
chromatography. Spectral analysis of the purified protein was used to determine 
dissociation constants for triazole drugs. Purified preparations of the enzyme were 
also used to obtain crystals for X-ray crystallographic analysis. High-resolution (1.98 
– 2.35 Å) X-ray crystal structures were obtained for mutant enzymes in complex with 
triazole drugs and without added ligand, as well as for the wild type enzyme in 
complex with FLC.  
Microdilution assays revealed that strains overexpressing ScErg11p6×His Y140F/H 
or Y140F G464S had reduced susceptibility to the short-tailed triazoles FLC and 
voriconazole but not the long-tailed triazole itraconazole. Strains overexpressing 
ScErg11p6×His G464S, T322I and K151R mutants had triazole susceptibility patterns 
similar to the wild type enzyme overexpressing strain but the G73E/R/W mutants 
showed increased susceptibility to all triazoles tested. Binding studies revealed that 
the triazole binding was tight for all the mutant enzymes.  
The high-resolution (2.05 Å) structure of wild type ScErg11p6×His in complex with 
FLC revealed a water-mediated hydrogen bonding network between residue Y140 and 
the hydroxyl group of the drug. The crystal structures of the ScErg11p6×His 
Y140F/H mutants showed that these mutations disrupted the key water-mediated 
hydrogen-bonding network seen in the wild type enzyme complex. The disruption of 
these interactions is proposed to weaken the interactions between the drug and the 
mutant enzyme leading to resistance. These observations explain reduced 
susceptibility to FLC and voriconazole and the retention of susceptibility to 
itraconazole of these mutants.  
The X-ray crystal structures of the ScErg11p6×His G73E/W mutants in complex with 
itraconazole showed that the drug bound in different conformations compared to the 
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wild type enzyme structure. The piperazine ring of the itraconazole molecule acts as a 
hinge, which can adopt different conformations. The crystal structures indicated 
potential π-anion interactions between the tail of the itraconazole and the E73 residue 
and π stacking interactions between W73 and the tail of itraconazole. The bending of 
the drug molecule was found to accommodate each mutation. The conformation of 
itraconazole bound to the G73W mutant had not been seen previously. These extra 
interactions between the drug and the site of the mutation in part explain the increased 
susceptibility of G73E/W mutant strains to itraconazole. 
The structure of ScErg11p6×His G464S revealed that the mutated residue had 
replaced polar interactions between a water molecule and the propionate group of the 
heme. No obvious tilting of the heme was observed in this mutant. The 
ScErg11p6×His T322I and G73W mutant structures without added ligand revealed 
some density in the active site and some movement of the carbonyl group of helix I 
residue G314, previously seen in the wild type ScErg11p6×His structure in complex 
with lanosterol. Residue G314 may be involved in catalysis by potentially stabilising 
oxygen bound heme iron intermediates.   
In summary, this work provides insight into the molecular interactions between the 
triazole drugs and the CYP51 enzyme. The high-resolution structure of the wild type 
enzyme in complex with FLC has allowed us to identify the potential basis for 
resistance of the Y140F/H mutants, which we confirmed by recreating those 
mutations in our S. cerevisiae system. In addition, other mutations reproduced in our 
system reveal that despite a relatively high sequence similarity amongst fungal 
CYP51s, our model does not adequately reflect the effect of the same mutations in 
pathogenic fungi. This knowledge will aid in the structure-directed design of next-
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5-FC   Flucytosine 
A. fumigatus  Aspergillus fumigatus 
ABC   ATP-binding cassette 
AIDS   Acquired immune deficiency syndrome  
AMB   Amphoterecin B 
bp   Base pairs 
C-terminal  Carboxy terminal 
C. albicans  Candida albicans 
C. glabrata  Candida glabrata 
C. neoformans  Cryptococcus neoformans 
cmc   Critical micelle concentration 
CYP450/CYP  Cytochrome P450 
CYP51  Sterol 14α-demethylase 
DM   Decyl-β-D-maltoside 
DMSO   Dimethyl sulfoxide 
EB   Elution buffer 
Erg11p  Lanosterol 14α-demethylase 
FLC   Fluconazole  
FPLC   Fast Protein Liquid Chromatography 
FSL   Fungus-specific loop 
Fur1p   Uracil phosphoribosyl transferase 
GTED   Glycerol tris EDTA 
H. capsulatum  Histoplasma capsulatum 
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HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIS1   ATP phosphoribosyltransferase gene 
HIV   Human Immunodeficiency Virus  
ISA   Isavuconazole 
ITC   Itraconazole  
KTC   Ketoconazole 
M. tuberculosis Mycobacterium tuberculosis 
m/z   Mass to charge ratio 
MCZ   Miconazole  
MDR   Multidrug resistance 
MES   2-(N-morpholino)ethansulfonic acid 
MFS   Major Facilitator Superfamily 
MH1   Amphipathic helix 1 
MIC80 Minimum inhibitory concentrations at 80% growth inhibition 
N-terminal  Amino terminal 
Ni-NTA  Nickel-nitrilotriacetic acid 
OD600nm  Optical density at a wavelength of 600 nm  
ORF   Open reading frame 
PAGE   Poly-acrylamide gel electrophoresis 
PCR   Polymerase chain reaction 
PCZ   Posaconazole  
PDB ID  Protein Data Bank Identity Code 
PDR   Pleiotropic drug resistance 
PDR5   Pleiotropic drug resistance 5 
PEG   Polyethylene glycol 
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PGK   3-phosphoglycerate kinase 
PMSF   Phenylmethylsulfonyl fluoride 
rpm   Revolutions per minute 
S. cerevisiae  Saccharomyces cerevisiae 
SD   Synthetic defined  
SDS   Sodium dodecyl sulphate 
SEC   Size exclusion chromatography 
SEM   Standard error of the mean 
T. brucei  Trypanosoma brucei 
T. cruzi  Trypanosoma cruzi 
TE buffer  Tris-HCl EDTA contained buffer  
TEMED  Tetramethylethylenediamine 
TMH1   Transmembrane helix 1  
TR   Tandem repeat 
URA3   Orotidine-5'-phosphate (OMP) decarboxylase gene 
VCZ   Voriconazole  
YPAD   Yeast extract-peptone-dextrose with adenine sulfate 
YPD   Yeast extract-peptone-dextrose 
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1.1 The role of fungi in the biosphere 
The fungal kingdom is thought to consist of at least 1.5 million species 
(Hawksworth, 1991, Hawksworth, 2001) that diverged from a common ancestor 
about 1.5 billion years ago (Hedges et al., 2004). More recent estimates, based on 
molecular tools and the ratios of fungi to plant species suggest there are as many as 
5.1 million fungal species in 10 phyla (Blackwell, 2011). Fungi are eukaryotic 
organisms that contribute to the biosphere in ways that are essential to many forms 
of life on Earth. For example, saprophytic fungi recycle organic material, mainly 
plant detritus, and many fungi have developed symbiotic relationships with the 
roots of plants. Without decomposition of plant material, the accumulation of plant 
debris would prevent the growth of new plants and important nutrients would not be 
recycled. Given the longevity of the fungal kingdom, the presence of fungi in a 
wide range of ecosystems and their ability to adapt using a variety of interactions 
and reproductive strategies, it is hardly surprising that the members of this kingdom 
show extensive genetic, phenotypic and morphological diversity. 
Fungi also make major contributions to human activities including industry, 
medicine and biological research. The food industry benefits from the fermentation 
processes carried out by yeast to make bread, alcoholic beverages such as beer and 
wine and products such as soy sauce. Mushrooms are fungal fruiting bodies that 
have been used as sources of foods, poisons and hallucinogens for millennia. The 
introduction of antibiotics is regarded as a major turning point in medicine. 
Penicillin, the first of the modern antibiotics used in the clinic, was prepared on an 
industrial scale from the fungus Penicillium notatum (Elander, 2003). Since then 
yeast and filamentous fungi have been used by the pharmaceutical industry to 
produce a variety of antibiotics. Saccharomyces cerevisiae or Baker’s yeast is a 
well-established eukaryotic model organism. S. cerevisiae provides a powerful 
research tool due to its relatively well understood biochemistry, physiology and 
genetics, as well as several other traits discussed in Section 1.13.  
Unfortunately, not all fungi are good for humankind. Around 300 fungal species are 
known to infect humans (Taylor et al., 2001) while many more species affect the 
plants and animals that we husband. Among the pathogens of humans, a small 
group can be regarded as pathogens that cause common diseases while the rest 
Chapter 1: General Introduction 
 3 
cause rare mycoses. Members of the fungal genera Candida, Cryptococcus, 
Pneumocystis and Aspergillus cause invasive fungal infections responsible for 
about 90% of all reported fungal-related deaths (Denning and Hope, 2010). Fungal 
pathogens also affect major crops and can significantly affect crop production 
(Oerke, 2006). For example rice blast disease is caused by Magnaporthe oryzae and 
wheat rusts are caused by Puccinia spp. Other crop fungal diseases include grey 
mould which can cause spoilage of ~200 plant species. Prominent examples include 
powdery mildew of grasses such as barley, leaf scald in cereals and wheat 
headblight (Dean et al., 2012). Some fungi produce toxic secondary metabolites 
called mycotoxins (Logrieco and Visconti, 2013). Highly carcinogenic aflatoxins 
are produced by the phytopathogens Aspergillus flavus and Aspergillus parasiticus. 
These fungal species usually reside in soil and decompose plant matter but during 
favourable conditions they can contaminate crops.  
1.2 Individuals at risk of fungal infections 
Healthy individuals commonly carry fungi as commensals that are kept in check by 
physical barriers such as the skin and by the innate immune system operating at 
mucus membranes (Underhill and Iliev, 2014). For example ~40% of healthy 
individuals carry Candida albicans in their oral cavities. Overgrowth of fungi can 
cause superficial fungal infections of the skin and mucous membranes even in 
healthy individuals. Fungal infections of the skin, eyes, nails and hair occur in about 
25% of the world’s population (Havlickova et al., 2008). Infections caused by 
dermatophytes include athlete’s foot (Tinea pedis), ringworm of the groin (Tinea 
cruris) and nail infections (Tinea unguium). These infections can be transmitted 
through physical contact with contaminated material. Superficial yeast infections 
are also common. For example, when the normal microbial flora is disrupted due to 
antibiotic use, C. albicans can overgrow causing oral and vaginal thrush (Underhill 
and Iliev, 2014). It is estimated that 3 out of 4 women will experience vaginal 
thrush in their reproductive years. If physical barriers are breached, for example due 
to large area skin scrapes or burns, opportunistic fungal pathogens can enter the 
body more easily, thus putting the affected individual at a greater risk of invasive 
fungal infection.  
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Many individuals in modern populations are immune deficient due to 
underdeveloped, failing or redirected immune systems (Reust, 2013). This situation 
is exacerbated when medicine applies therapies that compromise patients’ immune 
systems (Richardson, 2005). Deficient or compromised immune systems render 
individuals susceptible to various microbial infections, including fungal infections. 
Immunodeficient groups include HIV patients, premature babies, females of 
reproductive age, the elderly and the infirm. Immunocompromised patients include 
cancer patients undergoing chemotherapy or radiotherapy, transplant patients 
undergoing immune suppressive therapies and AIDS patients (Segal et al., 2006).  
The fungal infections of immunodeficient individuals are usually superficial 
(Havlickova et al., 2008). While such infections are likely to be more extensive than 
in healthy individuals, and although quality of life can be significantly affected, 
these infections are usually readily treated. Oral and vaginal thrush can be 
effectively treated with Canesten®, which contains clotrimazole as the active 
ingredient. There are a number of different topical agents to treat athlete’s foot such 
as terbinafine (Lamisil® cream), nystatin (Nilstat® cream) or miconazole 
(Daktarin® cream). Immunocompromised individuals are not only more susceptible 
to superficial infections but also to invasive infections that can be fatal because they 
damage key organs such as the kidney and brain (Richardson, 2005).  
1.3 The threat of fungal infections 
Among microbial infections, the infections caused by fungi are readily overlooked. 
This situation is changing due to several factors that have increased the apparent 
prevalence of fungal infections. These include improved diagnostic techniques, 
greater numbers of premature babies, co-morbidity especially in an aging 
population and the use of immunosuppressive agents (Brown et al., 2012). Another 
factor has been the application of antifungal prophylaxis in susceptible patients, 
which has led to the emergence of clinical isolates that are resistant to the current 
treatments. Fungal infections have been estimated to cause about 1.5 million deaths 
per year worldwide (Global Action Fund for Antifungal Infections, 2015). An even 
greater segment of the human population is probably adversely affected by the 
impact of fungal infections on food supplies (Fisher et al., 2012). The Irish potato 
famine is just one historic example of this problem. Key crops such as wheat, 
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soybean, apples, bananas and some grasses would not be sustainable without 
antifungal intervention.  
1.3.1 Candida species  
C. albicans, Candida glabrata, Candida tropicalis, Candida parapsilosis and 
Candida kruzei are reported to cause 95% of all candidiasis cases (Pfaller et al., 
2012a). In the United States Candida species are the fourth most common cause of 
hospital-acquired bloodstream infections. They account for ~10% of all nosocomial 
infections and have an attributed mortality rate of about 40% (Pfaller and Diekema, 
2007).  
Infection by C. albicans is more common in Asia-Pacific, European, African and 
Middle Eastern regions, accounting for ~66% of all Candida infections, than in 
North and South Americas where it accounts for about 50% of reported infections 
(Pfaller et al., 2010). In recent years C. glabrata has become much more common 
in North America (21%) than in South America (7.4%; Pfaller et al., 2010). 
Treatment of C. glabrata is becoming increasingly problematic due to the 
emergence of clinical isolates that are innately resistant to echinocandins and 
fluconazole (FLC), drugs commonly used to treat mycoses caused by Candida 
species (Pfaller et al., 2012b, Chapeland-Leclerc et al., 2010). Findings from the 
global antifungal surveillance program ARTEMIS on 256,882 Candida isolates 
from 41 countries revealed that 15.7% of C. glabrata isolates were FLC resistant 
compared with only 1.4% of C. albicans isolates (Pfaller et al., 2010). 
C. parapsilosis is another emerging fungal pathogen of considerable regional 
significance. C. parapsilosis is more prevalent in North America (13.6%) and South 
America (10.3%) than in Europe (4.2%; Pfaller et al., 2010). This pathogen has a 
tendency to persist in hospitals and rest homes. It is known to cause biofilms in 
catheters and other prosthetic devices (Trofa et al., 2008). Unlike other fungal 
pathogens, it is frequently found on the hands of healthcare workers and is thus 
readily transmitted to patients and from device to device.  
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1.3.2 Aspergillus species 
Aspergillus species are ubiquitous in the biosphere with their conidia found in the 
air and soil (Kwon-Chung and Sugui, 2013). Infections related to Aspergillus 
include allergic bronchopulmonary aspergillosis, severe asthma with fungal 
sensitisation, chronic pulmonary aspergillosis and invasive aspergillosis (Global 
Action Fund for Antifungal Infections, 2015). Aspergillus conidia enter the body 
through the lungs. If they are not cleared by the immune system the patient may be 
at risk of invasive aspergillosis. Aspergillus fumigatus is the most frequent cause of 
invasive aspergillosis, and although less common infections by Aspergillus flavus, 
Aspergillus terreus and Aspergillus niger remain important (Perfect et al., 2001). 
The individuals most likely to acquire invasive aspergillosis include cancer patients, 
especially those suffering leukaemia, as well as transplant and lung disease patients. 
Invasive aspergillosis is less common than candidiasis but is fatal in at least 50% of 
cases (Lin et al., 2001).  
1.3.3 Cryptococcus species 
The majority of cryptococcal infections are caused by Cryptococcus neoformans 
and Cryptococcus gattii, with meningitis likely to result from invasive infections 
(Lin and Heitman, 2006). C. gattii causes infections in immunocompetent 
individuals, especially in tropical and subtropical regions, while C. neoformans is 
an opportunistic pathogen of immunocompromised patients. C. neoformans has 
been found on eucalyptus trees common in California (Pfeiffer and Ellis, 1991). 
Prior to the introduction of high activity antiretroviral therapy (HAART) 
cryptococcal meningitis was responsible for the deaths of many AIDS patients in 
that region. In Sub-Saharan Africa, where AIDS, tuberculosis and malaria are 
endemic, cryptococcal infections kill over 400,000 people per year (Park et al., 
2009). Solid organ transplant patients have a 0.26 - 5% chance of cryptococcal 
infection and this has a 50% mortality rate (Wu et al., 2002). 
1.3.4 Pneumocystis species 
Pneumocystis jirovecii, previously known as Pneumocystis carinii, is a fungal 
pathogen that causes pneumocystis pneumonia. This disease was predominantly 
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associated with HIV and AIDS patients, but is now recognised more frequently in 
other immunosuppressed patients (Calderon et al., 2010). In England, from 2000-
2010 there was an average increase of 7% per year in pneumonia cases caused by P. 
jirovecii (Maini et al., 2013). The mortality rates in hospitals range from 7-11% 
and, among the critically ill, from 26-62% (Morris and Norris, 2012).  
1.4 Diagnosing fungal infections 
The progression of fungal disease can be rapid. Patients can die within 3-4 days of 
displaying symptoms of infection such as mild fever. Given the variability of 
responses of and within the fungal species to antifungals in current use, it is now 
regarded as critical to rapidly identify infective fungi at the phenotypic and 
genotypic levels to ensure effective treatment can be implemented (Richardson and 
Warnock, 2012). For example A. fumigatus is intrinsically resistant to the azole 
drugs FLC and ketoconazole (KTC), with voriconazole (VCZ), itraconazole (ITC) 
and posaconazole (PCZ) being significantly more effective against the pathogen. 
This is discussed in more detail in Section 5.1.2. The resistance of A. terreus to 
amphotericin B (AmB) but not the triazole drugs (Walsh et al., 2003) is discussed in 
Section 1.7.2.  
Current methods for the identification of infective fungi include culture-based 
approaches, direct microscopy and molecular-based approaches (Richardson and 
Warnock, 2012). Direct microscopy of a fungal specimen relies heavily on the 
quality of the tissue sample and requires a skilled mycologist to correctly identify 
the infective species. For example, P. jirovecii has very poor growth in vitro but 
methods for culturing this pathogen are being developed with promising results 
(Schildgen et al., 2014). Currently, direct microscopic analysis of respiratory 
samples is the main diagnostic tool for its identification. Polymerase chain reaction 
(PCR)-based techniques have been shown to be sensitive enough for P. jirovecii 
identification from brochoalveolar lavage fluid but they still strongly depend on 
clinical validation for diagnosis (Fan et al., 2013).  
Aspergillus species are difficult to culture from the blood of infected patients so 
non-culture methods have been applied. One of the techniques used is detection of 
galactomannan, a component of the cell wall of the Aspergillus species, using an 
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enzyme-linked immunosorbent assay (ELISA) or a more sensitive double-sandwich 
ELISA (Singh and Paterson, 2005). PCR-based methods have high accuracy in the 
identification of the Aspergillus species but false positives can arise as Aspergillus 
DNA can be found in the lungs of healthy individuals. The PCR-based methods are 
being explored but have yet to be implemented in diagnostic laboratories (Alanio 
and Bretagne, 2014).  
The identification of Candida species can be carried out using culture and non-
culture based methods. Chromogenic media-based systems such as CHROMagar 
Candida differentiate amongst C. albicans, C. tropicalis and C. kruzei exploit the 
cleavage of chromogenic substrates by species-specific enzymes to yield coloured 
colonies (Horvath et al., 2003). This method requires a 24 - 48 hour culture step and 
is unable to distinguish closely related species such as C. dubliniensis that is 
frequently co-isolated with C. albicans (Campanha et al., 2005). Commercially 
available biochemical kits vary in price, accuracy and require culture times ranging 
from 4 – 72 hours. Molecular techniques such as PCR-based methods and mass 
spectrometry have been shown to effectively identify Candida species (Spanu et al., 
2012, Kanbe et al., 2002, Lau et al., 2008). They are fast and reliable but most 
diagnostic laboratories are not equipped to carry out such tests.  
1.5 Antimicrobial resistance 
The discovery of antibiotics has been a major step in the history of science and 
medicine. The first widely used antimicrobials, the sulphonamides, were introduced 
in 1937. Resistant microorganisms were detected not long after. Alexander Fleming 
discovered penicillin in 1928 and resistance caused by the enzyme penicillinase was 
identified in bacteria before the drug was introduced to the clinic (Abraham and 
Chain, 1940). Antibiotics are now so widely available that their use is often 
misdirected. This is a major problem as the incidence of antibiotic resistant 
bacterial infections is growing and there is a threat of returning to the pre-antibiotic 
era. 
Fungal pathogens also develop resistance and the repertoire of drugs available for 
treatment of fungal infections is more limited than the range of antibiotics available 
to treat bacterial infections. The development of broad-spectrum antifungals has 
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proven difficult. Fungi are eukaryotes, which significantly limits the features that 
can be used to distinguish between the pathogen and the host. A study by Liu et al. 
identified 240 essential genes conserved in 10 fungal genomes including S. 
cerevisiae, C. albicans, C. glabrata, C. neoformans and A. fumigatus, and only 20% 
of those genes have structurally dissimilar homologues (less than 40% identity) in 
the human genome (Liu et al., 2006). The same study showed that 85-93% of 
essential genes in individual fungal genomes had homologues with >40% similarity 
in the human genome i.e. the bulk of genes with highly conserved homologues 
among fungal species have similar homologues in humans. This limits the number 
of essential enzymes as potential targets for broad-spectrum antifungals to less than 
50. 
1.6 Multidrug resistance in fungi 
The resistance of an organism to a broad spectrum of structurally and functionally 
unrelated compounds is termed multidrug resistance (MDR), reviewed by Gulshan 
and Moye-Rowley (Gulshan and Moye-Rowley, 2007). One of the principal 
mechanisms by which MDR is achieved in fungi is through the overexpression of 
efflux pumps. In yeast two major classes of efflux pumps are involved in xenobiotic 
transport: the ATP-binding cassette (ABC) transporters and the major facilitator 
superfamily (MFS) transporters. In C. albicans Cdr1p and Cdr2p are examples of 
ABC transporters (Prasad et al., 1995, Sanglard et al., 1997) and Mdr1p is an MFS 
transporter (Goldway et al., 1995). ABC efflux pumps are primary transporters that 
couple drug efflux to ATP hydrolysis while MFS transporters are secondary 
transporters that couple efflux to electrochemical gradients. Drug tolerance is a 
process that allows for the development of MDR. It is a rapid, xenobiotic-induced 
response which, when followed by genetic modification, can allow the protective 
response of MDR to be maintained (Cannon et al., 2007). The tolerance phenotype 
can be due to the induction of drug efflux pumps with broad-range specificity for 
xenobiotics, including the imidazole and triazole antifungals. The efflux activity 
reduces the intracellular concentration of the drugs to levels at which they are no 
longer effective. The tolerance and subsequent MDR can be life threatening 
because many of the available antifungal drugs are rendered ineffective. The 
increased frequency of MDR strains detected in the clinic, and the increased 
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difficulty associated with treating such strains, including their ability to limit 
therapeutic options, leads to a need for novel therapies.  
1.7 Current antifungal treatments and associated resistance 
mechanisms 
There are five main classes of antifungals currently used in the clinic or as over-the-
counter medications. All apart from flucytosine ultimately target the fungal cell 
wall and membrane structures. Ergosterol and its biosynthesis provides important 
primary targets because this sterol is required for growth of most fungi and is found 
in the cell membranes of fungi but not mammals. The ergosterol biosynthesis 
pathway is described in detail in Section 1.8. The five major classes of antifungal 
drugs used to treat fungal infections are summarised in the following sections. 
1.7.1 Flucytosine 
Flucytosine (5-FC) is a base analogue that acts by inhibiting DNA synthesis and 
aborting RNA translation (Figure 1.1). 5-FC is internalised by cytosine permease 
and converted to 5-fluorouridine monophosphate by the action of enzymes cytosine 
deaminase and uracil phosphoribosyl transferase. The 5-fluorouridine blocks fungal 
DNA synthesis by inhibiting thymidylate synthase and affects fungal RNA 
biosynthesis by causing premature chain termination (Polak and Scholer, 1975). 
Resistance to 5-FC occurs mainly by mutations in enzymes associated with its 
metabolism, in particular cytosine deaminase and uracil phosphoribosyl transferase 
(Hope et al., 2004). Lowered activity of those enzymes prevents the conversion of 
5-FC to 5-fluorouridine. In C. albicans, a single nucleotide change that results in an 
R101C mutation in uracil phosphoribosyl transferase confers resistance to 5-FC 
(Dodgson et al., 2004). 
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Figure 1.1 Antifungals: flucytocine, amphotericin B (polyene), terbinafine 
(allylamine) and micofungin (echinocandin). 
1.7.2 Polyenes 
AmB and nystatin are amphipathic molecules that belong to a class called polyene 
antibiotics (Figure 1.1). The polyenes are thought to self-assemble into ionic 
transmembrane pores in eukaryotic lipid bilayers that cause the lethal leakage from 
the cytosol of cations, including mainly K+ (Ermishkin et al., 1976). A recent study 
suggests that the binding to ergosterol alone is sufficient for their antifungal activity 
while pore formation may be a secondary mechanism of action (Gray et al., 2012). 
The limited selectivity of polyenes for ergosterol over cholesterol leads to toxicity 
in mammals (Medoff et al., 1983). As a result AmB has multiple side effects 
including nephrotoxicity, anemia, fever and nausea and infusion-related problems, 
causing the drug to acquire the nickname “Amphoterrible”. AmB is usually 
delivered intravenously, solubilized in sodium deoxycholate (Laniado-Laborin and 
Cabrales-Vargas, 2009). Incorporating the drug into more expensive liposomal and 
other lipid formulations has enabled less toxic delivery systems (Walsh et al., 
1998). A recent study has found some AmB derivatives to be less toxic than AmB 
in a mouse model of systemic candidiasis (Davis et al., 2015). These derivatives are 
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promising as they show greater selectivity for ergosterol than cholesterol compared 
to AmB. 
Resistance to polyenes can occur if the ergosterol content in the fungal plasma 
membrane is lowered (Young et al., 2003). Loss-of-function mutations in C. 
albicans C-5 sterol desaturase (Erg3p) lower ergosterol levels in the plasma 
membrane. These mutations also confer cross-resistance to azoles. A. terreus is 
intrinsically resistant to AmB, however the molecular mechanism responsible for 
this resistance is poorly understood. It was found that the ergosterol content in A. 
terreus was more variable than A. fumigatus and that A. terreus isolates with the 
lowest ergosterol content are least susceptible to AmB (Walsh et al., 2003). In 
addition, a recent study suggested that A. terreus is more resilient to oxidative 
damage as it has a higher catalase activity than susceptible strains (Blum et al., 
2013), indicating that several factors may contribute to the resistance. 
1.7.3 Allylamines 
The allylamines, which include terbinafine and naftifine, are antimycotic drugs that 
inhibit squaline epoxidase (Erg1p; Figure 1.1). Squaline epoxidase catalyses the 
first step of ergosterol biosynthesis (Section 1.8). Allylamines are fungicidal against 
filamentous fungi but are fungistatic for most pathogenic yeast, including most 
Candida species (Kontoyiannis and Lewis, 2002). Mutations in ERG1 and efflux by 
ABC transporters give rise to allylamine resistance (Leber et al., 2003). 
1.7.4 Echinocandins 
Despite the discovery of echinocandins in the 1970s, these semisynthetic macrolide 
derivatives (Figure 1.1) were introduced into the clinic after 2000 and are the 
newest class of antifungals in clinical use (Richardson and Warnock, 2012). They 
inhibit the plasma membrane enzyme β-1,3-glucan synthase and thereby interfere 
with the biosynthesis of the essential cell wall component β-1,3-glucan. 
Echinocandins are fungicidal against most Candida species, fungistatic against A. 
fumigatus, but are not effective against C. neoformans (Richardson and Warnock, 
2012). Current formulations are expensive and their limited oral bioavailablility 
requires them to be injected. Resistance to echinocandins primarily arises from 
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mutations in the Fks1p subunit of β-1,3-glucan synthase complex (Park et al., 
2005). For the moment there appears to be limited resistance to echinocandins, 
which may be due to the limited use of these more costly antifungals. More 
frequent use in the clinic as a prophylactic measure is expected to lead to a greater 
frequency of mutations that cause echinocandin resistance. Recent reports indicate 
frequencies of up to 13% echinocandin resistance among clinical isolates of C. 
glabrata (Alexander et al., 2013). Resistance can arise due to reversible 
physiological alterations that produce tolerance or via mutations (Walker et al., 
2010). MDR does not confer resistance to echinocandins, as caspofungin and 
micofungin are not substrates of the drug efflux pumps that confer resistance to 
many azoles i.e. C. albicans Cdr1p, Cdr2p and Mdr1p (Niimi et al., 2006). 
1.7.5 Azoles 
The azoles are the largest class of antifungals used in the clinic as well as over-the-
counter medications. They can be divided into two sub-classes: imidazoles and 
triazoles, based on the heterocycle that coordinates to the heme iron of their target – 
the cytochrome P450 lanosterol 14α-demethylase. The imidazoles, which contain 
an imidazole ring as the coordinating moiety, include KTC, miconazole and 
clotrimazole. The triazoles have a 1,2,4-triazole ring instead. They include FLC and 
VCZ, which have short tails, as well as PCZ and ITC, which have the long tails 
(Figure 1.2).  
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Figure 1.2 Triazole drugs fluconazole, voriconazole, itraconazole and 
posaconazole.  
The azole drugs bind to and inhibit the function of the enzyme lanosterol 14α-
demethylase (Erg11p) (Yoshida and Aoyama, 1987, Podust et al., 2001), a member 
of CYP51 family in the cytochrome P450 superfamily. This enzyme is the focus of 
this dissertation. It is denoted as CYP51 or Erg11p in fungal systems and is 
involved in the ergosterol biosynthesis pathway (Section 1.8). In mammals, the 
homologous enzyme is involved in the biosynthesis of cholesterol (Risley, 2002). In 
many fungal systems, inhibition of the 14α-demethylation of lanosterol by Erg11p 
depletes cell membranes of ergosterol, thus affecting the fluidity of the lipid bilayer 
and therefore fungal growth. Inhibition of Erg11p also leads to the accumulation of 
toxic metabolites of lanosterol e.g. fecosterol (Sanglard and Bille, 2002).  
The active site of Erg11p contains an iron protoporphyrin moiety, to which a 
nitrogen atom in the imidazole or triazole ring can coordinate (Kontoyiannis and 
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Lewis, 2002). The imidazoles are usually applied as topical agents for mucosal or 
skin infections while the triazoles are used systemically. Triazoles have better 
pharmacokinetic properties than imidazoles and interact less with mammalian 
P450s.  
The imidazole and triazole drugs are usually fungistatic rather than fungicidal for 
pathogenic fungi, including C. albicans. This occurs because the drug depletes 
ergosterol to a level that prevents fungal division and the cells enter a quiescent 
state (Dahl et al., 1987), with growth resuming once a “sparking” level of ergosterol 
is synthesised (Pinto and Nes, 1983). The fungistatic effect may also be due to drug 
tolerance (Sanglard et al., 2003) that results from the azole-induced expression of 
drug efflux pumps (Monk and Goffeau, 2008). A practical result of such effects is 
the “trailing growth” found in experiments that measure the minimum inhibitory 
concentration (MIC) of azole drugs in enriched synthetic medium such as YPD 
(Manavathu et al., 1998). As a consequence, the impact of azole drugs is normally 
measured as an MIC80 i.e. the concentration of the drug that gives 80% inhibition of 
cell growth yield compared with the no drug control. 
The first generation triazoles FLC and ITC were introduced in the clinic in the 
1980s and subsequent generations of triazole drugs including VCZ and PCZ were 
introduced in the 1990s. Although FLC is not as potent as other azoles it has 
superior pharmacokinetic properties including a longer half-life and better 
bioavailability (Table 1.1). While ITC and VCZ are fungicidal against A. fumigatus, 
FLC is ineffective against this important fungal pathogen (Manavathu et al., 1998). 
The azole drugs were believed to enter fungal cells by passive diffusion but it was 
recently shown that they are taken up by facilitated diffusion into all four fungal 
species tested i.e. S. cerevisiae, C. albicans, C. neoformans and C. kruzei 
(Mansfield et al., 2010).  
Resistance to azoles can arise in several ways and these mechanisms can occur in 
different combinations in different fungi. These mechanisms include mutations in 
Erg11p that reduce the affinity of azole binding, overexpression of Erg11p due to 
altered regulation or aneuploidy in ERG11, efflux via ABC and MFS transporters 
and tolerance to methylated sterols via mutations in sterol Δ5,6-desaturase (Erg3p; 
Parker et al., 2014). The loss-of-function mutations in ERG3 allow for the 
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conversion of harmful fecosterols to better-tolerated products, as discussed in the 
next Section 1.8. 
Table 1.1 Pharmacokinetic and pharmacodynamic properties of triazole drugs  
Parameter Triazole drug 
ISA FLC VCZ ITC PCZ 
Formulations Oral and 
IV 
Oral and IV Oral and 
IV 
Oral* Oral 





Half-life 56 – 104 
hours 
24 – 30 
hours 
6 – 12 
hours 
24 – 30 
hours 













Low (1.2) High (8.4) Very high 
(15.9) 
Very high (21.7) 
This table is modified from Falci and Pasqualotto (Falci and Pasqualotto, 2013). 
CNS is central nervous system, CSF is cerebrospinal fluid, IV is intravenous. *IV 
formulations of ITC are no longer widely available. 
1.7.5.1 New triazoles in clinical trials 
There are several triazole drugs that are currently in various stages of clinical 
evaluation. The ones of special note include VT-1161, isavuconazole (ISA), 
ravuconazole and albaconazole, all having tails of medium length (Figure 1.3) 
(Pasqualotto et al., 2010). VT-1161 has a tetrazole ring as a coordinating moiety 
and it was shown to have superior selectivity for the fungal CYP51 enzyme 
compared to the human CYP51 (Warrilow et al., 2014). VT-1161 is currently in 
stage II clinical trials (Hoekstra et al., 2014, Warrilow et al., 2014).  
Ravuconazole is very similar to ISA and has the usual 2,4-difluoro phenyl 
substituent whereas ISA has a 2,5-difluoro phenyl moiety. ISA was approved in the 
US in March 2015 for the treatment of invasive aspergillosis (McCormack, 2015). 
This drug is currently in Phase III clinical trials for treatment of candidiasis and 
invasive fungal infections caused by rare moulds. Isavuconazonium is a water-
soluble prodrug of ISA that is administered orally and as an intravenous 
formulation. Isavuconazonium is rapidly cleaved by plasma esterases yeilding its 
active moiety ISA and an inactive product. ISA has favourable pharmacokinetic 
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properties compared to triazoles in current use (Table 1.1, Falci and Pasqualotto, 
2013, Pettit and Carver, 2015). Given its pharmacokinetic properties and 
effectiveness against Aspergillus spp. ISA may become the drug of choice for 
treating invasive aspergillosis.  
 
Figure 1.3 Novel triazole drugs ravuconazole, albaconazole, isavuconazole and 
VT-1161. 
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1.8 Ergosterol biosynthesis pathway 
Ergosterol, like its mammalian equivalent cholesterol, maintains the rigidity and 
permeability of the lipid bilayer. The ergosterol biosynthesis pathway (Figure 1.4) 
is targeted by azole and allylamine antifungals. The presence of ergosterol in yeast 
membranes instead of cholesterol provides the basis for the differential mechanism 
of action of the polyene antimycotic drugs.  
Lanosterol is synthesised from farnesyl pyrophosphate by enzymes squalene 
synthase (Erg9p), squalene epoxidase (Erg1p) and lanosterol synthase (Erg7p). The 
allylamines such as naftifine and terbinafine target squalene epoxidase. Lanosterol 
14α-demethylase (Erg11p) is thought to carry out the rate-limiting step in ergosterol 
biosynthesis and is targeted by the azole drugs. The enzymes sterol C-14 reductase 
(Erg24p), sterol C-4 methyloxidase (Erg25p), sterol C-3 dehydrogenase (Erg26p) 
and sterol C-3 keto reductase (Erg27p) then convert demethylated lanosterol into 
zymosterol. The recent finding that zymosterol is the main sterol found in purified 
enzyme preparations of Erg11p (Monk et al., 2014b) may indicate that Erg11p has a 
central role in a multi-enzyme complex. Erg11p may present its product 4-
demethylcholesta-8,14,12-trienol so that subsequent enzymes in the ergosterol 
biosynthesis pathway can modify it to zymosterol. Erg24p is a membrane–
associated protein that reduces the double bond in 4-demethylcholesta-8,14,12-
trienol to give 14-dimethyl zymosterol. The occurrence of physical interactions 
between Erg11p with Erg25p and Erg27p have been demonstrated (Mo and Bard, 
2005). Erg25p and Erg26p are known to form a complex that uses Erg27p as a 
scaffold. The zymosterol is then esterified with unsaturated fatty acid for storage in 
lipid droplets and transits to the plasma membrane as required (Parks and Casey, 
1995).  
Sterol C-8 isomerase (Erg2p) converts fecosterol to episterol. C-5 desaturase 
(Erg3p) then converts episterol to ergostatrienol by means of introducing a C-5-6 
double bond. Erg3p normally acts downstream of lanosterol 14α-demethylase 
(Erg11p) but can also desaturate lanosterol directly in a pathway that leads to toxic 
fecosterols. The mutations which inactivate Erg3p reduce the buildup of these toxic 
sterols, with ergosta-7,22-dienol-3β-ol being a main sterol found in resistant strains 
(Nolte et al., 1997). 
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Figure 1.4 Ergosterol biosynthesis pathway. The principal sites of inhibition of 
this pathway by the allylamine and azole drugs are shown. 
 
 
Chapter 1: General Introduction 
 20 
1.9 Cytochrome P450 enzymes 
The cytochrome P450 (CYP, P450) enzymes catalyse the oxidation of exogenous 
and endogenous substrates. This heme-thiolate-containing superfamily has diverse 
roles including drug metabolism and bioactivation, biosynthesis of antibiotics, 
human steroid metabolism and xenobiotic detoxification. They are found in almost 
all organisms with some important exceptions, for example, the Archaea kingdom 
of unicellular organisms and many bacteria including Escherichia coli, 
Rhodopseudomonas spp. and Chromatium spp. (Volkman, 2003). In humans the 
P450s are responsible for metabolising about 75% of all marketed drugs with 
CYP3A4 alone modifying around half of those drugs (Guengerich, 2008). 
Prokaryotic P450s are soluble cytoplasmic proteins, whereas the eukaryotic 
enzymes, apart from mitochondrial P450s, have a single transmembrane helix, 
which tethers it to the lipid bilayer (Johnson and Stout, 2013).  
Based on function, the P450s can be broadly divided into two groups. One group is 
involved in the xenobiotic metabolism and the other takes part in biosynthetic 
pathways. The first group of P450 families are flexible enzymes, which allow for 
the binding of various structurally dissimilar substrates. Six substrate recognition 
sites (SRS) have been identified as parts of the enzyme thought to be involved in 
binding and recognition of substrates (Gotoh, 1992). The SRSs have considerable 
sequence variability, which posed difficulties in their original identification. 
Mutating important residues within the SRS was found to change the substrate 
specificity of the enzyme (Matsunaga et al., 1990, Lindberg and Negishi, 1989).  
The second group of P450s have a much smaller range of substrates and are less 
able to tolerate mutations. While still maintaining the P450 fold, their substrate 
channels are able to accommodate particular substrates. Sterol 14α-demethylase 
(CYP51) is regarded as the most ancient family among the P450s (Aoyama et al., 
1996). CYP51s carry out essentially the same role across the kingdoms and have an 
amino acid sequence identity of at least 28% between the mammalian and fungal 
enzymes (Lepesheva and Waterman, 2007).  
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1.9.1 Catalytic cycle of P450s 
The cytochrome P450 enzymes contain a protoporphyrin IX ring with iron (III) 
coordinating to the sulfur atom of a cysteine residue at the active site.  The P450s 
are monooxygenases that use activated molecular oxygen to add one oxygen atom 
to the substrate and reduce the other to water. This reaction requires two electrons 
which come from NAD(P)H via its cognate reductase enzyme. Initially this 
superfamily of enzymes was identified in rat liver microsomes (Klingenberg, 1958) 
by their unique absorption at 450 nm in a reduced state when CO is bound to the 
heme iron. However, under the same conditions, an absorbance maximum at 420 
nm indicates that the P450 enzyme is no longer active (Omura and Sato, 1967). The 
CO assay is a useful tool for measuring the quantity of functional enzyme in a 
preparation (Omura and Sato, 1964b).  
In its resting state the heme iron is usually in an oxidised ferric form Fe3+ with a 
water molecule bound as its sixth axial ligand (Figure 1.5, step 1). This results in a 
low spin state for the iron and gives the heme an absorption peak of around 420 nm. 
When the catalytic cycle begins the axial water is displaced by a substrate (type I 
ligand), the heme iron goes into a high spin state but it remains in its ferric 
oxidation state (Figure 1.5, step 2). It is noteworthy that nitrogen heterocycles such 
as azoles (type II ligands) replace the water in the active site further stabilising the 
low spin form of the iron.   
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Figure 1.5 The catalytic cycle of cytochrome P450. Figure modified from Ener et 
al. (Ener et al., 2010). Copyright 2015, Proceedings of the National Academy of 
Sciences of the United States of America. 
Delivery of the first electron from the cognate reductase changes the heme iron 
from the ferric (Fe3+) to the ferrous (Fe2+) state (Figure 1.5, step 3). This results in 
the binding of the molecular oxygen via a coordinate bond to form a ferric 
superoxide complex (Figure 1.5, step 4). Following the second electron transfer, the 
distal oxygen is protonated and forms a ferric hydroperoxo complex (Figure 1.5, 
step 5). A second protonation results in the formation of a water molecule and a 
very reactive iron (IV)-oxo radical complex. This complex has recently been 
captured using a CYP119 from Sulfolobus acidocaldarius and characterised 
spectroscopically and kinetically (Rittle and Green, 2010). This highly reactive 
species extracts the hydrogen from the substrate (Figure 1.5, step 7) forming a 
substrate radical, which quickly reacts with the protonated iron (IV) species to 
generate the ferric enzyme and the hydroxylated product. The findings of Rittle et 
al. (2010) support this mechanism of action as the kinetic analysis shows that the 
rate at which the iron (IV) complex oxidizes unactivated hydrocarbons has an 
incredibly fast second-order rate constant of kapp = 1.1 × 107 M−1s−1 (Rittle and 
Green, 2010).  
CYP51s convert lanosterol to 4,4-dimethyl-5a-cholesta-8,24-dien-3-β-ol via three 
consecutive mono-oxygenase reaction cycles as described above. The first step 
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converts the 14α-methyl group to an alcohol, the second step converts it to an 
aldehyde and in the final step formic acid is removed (Fischer et al., 1991). 
1.9.2 P450 structural fold 
The first X-ray structure for a P450 was obtained for camphor hydroxylase, a 
cytochrome P450cam of the CYP101 family that was isolated from the soil 
bacterium Pseudomonas putida (Poulos et al., 1986). Structural fold terminology 
for P450s originated from the structure of this enzyme (Figure 1.6) (Poulos et al., 
1987). Even though the overall structural fold of the P450 catalytic domain is 
conserved between species, the membrane association of eukaryotic non-
mitochondrial P450 proteins has presented a challenge in their purification and 
structural resolution.  
In the P450cam structure, the sulfur atom of cysteine 357 is bound to the heme iron. 
The active site is located on the opposite side of the heme. One edge of the heme is 
wedged in between helix I and helix L. Residues from helices I, B’, the B’-C loop, 
β3 sheet and β5 sheet contribute to the substrate channel. Helices F and G together 
with the F-G loop form a lid that closes off the active site (Figure 1.6).  
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Figure 1.6 Structure of cytochrome P450cam (PDB entry: 2CPP). The overall 
structural fold of cytochrome P450 catalytic domain contains α-helices labelled A-L 
(for clarity helix J is not labelled - it is located between helix I and helix K) and β-
sheets labelled 1-5 according to Poulos (Poulos et al., 1987). The heme moiety 
borders the active site. The camphor molecule is at the active site in the substrate 
channel (magenta).  
Helix I has a characteristic “kink” in most P450 enzymes. In cytochrome P450cam of 
P. putida this “kink” is thought to be due to the disruption of normal α-helix 
hydrogen bonding pattern in helix I and establishment of a hydrogen bond between 
the side chain of the highly conserved T252 and the carbonyl group of G248. This 
arrangement has also been proposed to accommodate the bound dioxygen (Poulos, 
2007).   
1.9.3 P450s in Saccharomyces cerevisiae 
There are three cytochrome P450 enzymes in S. cerevisiae. Two are involved in 
ergosterol biosynthesis and the third is cytochrome P450 DIT2, an enzyme that is 
involved in spore wall development (Briza et al., 1994). Erg11p or CYP51 belongs 
to a family of CYP51 lanosterol 14α-demethylases and is the main target of the 
azole drugs. CYP51 knock out strains of the yeast S. cerevisiae are lethal. Erg11p 
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converts lanosterol to its demethylated product as described in Section 1.9.1. C22-
desaturase (Erg5p) belongs to a family of CYP61 enzymes and was discovered 
during the yeast genome project. The ERG5 gene was found to be non-essential in 
yeast (Skaggs et al., 1996). The azole drugs inhibit Erg5p as well as Erg11p but this 
C22-desaturase occurs much later in the ergosterol biosynthetic pathway (Figure 
1.4; Kelly et al., 1997). With inhibition of Erg11p the subsequent reactions in the 
pathway are blocked, implying that the effect of azoles on Erg5p is unlikely to be of 
importance. 
1.10 Structural information on fungal CYP51s 
In general, the eukaryotic non-mitochondrial CYP51s are thought to have an 
amphipathic helix (MH1) of variable length followed by a transmembrane helix 
(TMH1). A series of α-helices (A-L), β-sheets (1-4) and the heme in the active site 
contribute to the catalytic domain with a common P450 fold. No crystal structures 
of fungal CYP51s were reported before 2014. Furthermore, the structures of other 
eukaryotic CYP51s were incomplete because the constructs used were modified, 
with the transmembrane helix deleted, to assist purification and crystallisation 
(Chen et al., 2010, Strushkevich et al., 2010). It is of considerable interest to 
determine whether the truncated enzyme behaves in the same manner as the full-
length protein. 
1.10.1 In silico models of fungal CYP51s 
Some fungal CYP51 structures obtained by homology modelling used published 
cytochrome P450 X-ray structures as templates. Earlier models are based on P450 
structures such as P450cam from Pseudomonas putida (Boscott and Grant, 1994, 
Morris and Richards, 1991) and P450BM3 from Bacillus megaterium (Ji et al., 
2000, Holtje and Fattorusso, 1998). The release of M. tuberculosis CYP51 structure 
allowed for the use of this better suited structure for homology modelling as M. 
tuberculosis CYP51 has a sequence identity of 26-28% with fungal CYP51s 
(Podust et al., 2001; Figure 1.7). This led to several models of C. albicans CYP51 
(Xiao et al., 2004, Sheng et al., 2004). In silico models for A. fumigatus CYP51A 
(Xiao et al., 2004, Sheng et al., 2004) and C. neoformans CYP51 (Sheng et al., 
2009) were also constructed based on the CYP51 structure of M. tuberculosis. The 
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structural modelling and docking approaches have been used to investigate the 
interactions between the enzyme and the azole drugs, with a further aim of 










Figure 1.7 ClustalW (1.2.1) multiple sequence alignment of the primary 
sequences of fungal, mycobacterial and human lanosterol 14α-demethylases. 
Saccharomyces cerevisiae CYP51 (ScErg11), Candida albicans CYP51 (CaErg11), 
Candida glabrata CYP51 (CgErg11p), Aspergillus fumigatus CYP51A 
(AfErg11A), Homo sapiens CYP51 (HsCYP51) and Mycobacterium tuberculosis 
CYP51 (MtErg11). An asterisk signifies conserved residues, a colon indicates 
conservation of residues with similar properties and a period indicates conservation 
of residues with less similar properties. Highlighted residues are frequently found 
mutated to reduce drug binding in pathogenic fungi. The cysteine residue that 
coordinates to the heme iron is marked with a triangle. Secondary structure 
amphipathic helix (MH1), transmembrane helix (TMH1), α-helices (A-L), most β
-sheets and the fungus-specific loop (FSL) are marked. Note: Helix C is shorter in 
M. tuberculosis CYP51. For clarity some β-sheets are not indicated. The figure is 
on the next page. 
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Figure legend is on the previous page 
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1.10.2 X-ray crystal structures of fungal CYP51s 
In 2014 a series of X-ray structures of a full-length S. cerevisiae CYP51 were 
published (Monk et al., 2014b). These structures allowed the identification of the 
orientation of the enzyme in relation to the lipid bilayer. These structures and 
companion biochemical studies provided evidence that the transmembrane helix 
helps position the catalytic domain partly in the lipid bilayer (Figure 1.8). The 
dataset refinement statistics from this study are listed in Appendix G, Table G-2. 
Two of those structures were released to the Protein Data Bank (PDB) - ScErg11p 
with ITC in the active site (PDB ID: 4K0F/5EQB) and with lanosterol in the active 
site (PDB ID 4LXJ). In 2015, an A. fumigatus CYP51B structure was published in 
complex with VCZ (PDB ID: 4UYM) and VNI (PDB ID: 4UYL, VNI has an 
imidazole group as a coordinating moiety) (Hargrove et al., 2015). The A. fumigatus 
CYP51B structure has the highly conserved CYP450 fold. However, the structure 
was truncated, with TMH1 and MH1 removed, in order to facilitate purification and 
crystallisation. 
 
Figure 1.8 The overall fold of S. cerevisiae Erg11p with its proposed 
orientation in the lipid bilayer (PDB ID: 4ZDY). 
To date (September 2015) there are 49 published structures of CYP51s complexed 
with various ligands lodged to the PDB ranging in resolution from 1.5 Å to 3.12 Å. 
Of these structures, 19 are of Trypanosoma cruzi CYP51, 9 of Trypanosoma brucei 
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CYP51, 3 of Homo sapiens CYP51, 1 of Leishmania infantum CYP51, 12 of M. 
tuberculosis CYP51, 2 of A. fumigatus CYP51 and 3 of S. cerevisiae CYP51 
(including 1 from this thesis). 
1.11 CYP51s as drug targets 
Organisms that rely on sterol production and cannot obtain compatible sterols from 
the host organism are good candidates for targeting CYP51. The CYP51 family of 
enzymes are a major drug target in fungi and are also under extensive development 
as drug targets for tropical diseases. The CYP51 of T. cruzi has been shown to be a 
valid target for treatment of Chagas disease (Lepesheva et al., 2008). Clinical trials 
revealed that PCZ has antitrypanosomal activity in the treatment of chronic Chagas 
disease (Molina et al., 2014). Targeting CYP51 is also effective in some protozoan 
Leishmania species (de Macedo-Silva et al., 2013, Shakya et al., 2011). CYP51 is 
also a potential target in the disease-causing, free-living amoebae Acanthamoeba 
and Naegleria that are also dependent on sterol biosynthesis (Choi et al., 2014). In 
contrast in T. brucei, the cause of African sleeping sickness, CYP51 is a poor target 
because the pathogen obtains cholesterol from the host by receptor mediated 
endocytosis. 
Sterol 14α-demethylases have five known substrates: lanosterol, 24,25-
dihydrolanosterol, 29-norlanosterol, 24-methylenedihydrolanosterol (eburicol), and 
24-methylenedihydro-29-norlanosterol (obtusifoliol; Figure 1.9). Sterol 
biosynthesis in fungi and protozoa are strain and species specific, for example 
fungal CYP51s use lanosterol but A. fumigatus and some filamentous 
phytopathogens catalyse the conversion of eburicol to its demethylated product (van 
Nistelrooy et al., 1996, Price et al., 2015b). Vertebrates produce cholesterol in a 
pathway similar to fungi in which CYP51 14-demethylates lanosterol, as discussed 
in detail by Risley (Risley, 2002). Mammalian and yeast CYP51s demethylate both 
lanosterol and 24,25-dihydrolanosterol (Lepesheva and Waterman, 2007). Plants 
produce phytosterols via the isoprenoid pathway. This results in obtusifoliol that is 
demethylated by the CYP51 enzyme obtusifoliol 14α-demethylase (Piironen et al., 
2000).  
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Figure 1.9 CYP51 substrates. Lanosterol, 24-methylenedihydrolanosterol 
(eburicol), 24,25-dihydrolanosterol, 24-methylenedihydro-29-norlanosterol 
(obtusifoliol) and 29-norlanosterol. * denotes carbon 14 in lanosterol. 
1.12 Resistant Erg11p mutants  
Fungal infections are becoming a significant burden on healthcare systems 
worldwide (Diekema et al., 2012, Pfaller and Diekema, 2010, Pfaller et al., 2010). 
Challenges in the treatment of fungal infections currently lie with the limited 
classes and numbers of effective drugs and the increasing incidence of resistant 
isolates. The limited number of effective drugs results from high diversity of fungal 
organisms that limit the options for broad-spectrum antimycotic drugs as discussed 
in Section 1.5. Prophylactic use of fungistatic azoles in susceptible patients and 
prolonged administration of those treatments has contributed to the emergence of 
resistant fungal pathogens (Perlin, 2009). The use of azole fungicides in agriculture 
can also lead to development of cross-resistance to medical triazoles e.g. in A. 
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fumigatus and C. glabrata (Snelders et al., 2012, Faria-Ramos et al., 2014). Both 
studies were able to induce resistance in susceptible strains using azole-based 
fungicides in laboratory conditions and confirmed that those strains have cross-
resistance to medical triazoles. Moreover, the resistant laboratory strains evolved 
similar mechanisms of resistance to those commonly found in the environmental 
and clinical isolates. 
Fungal CYP51 is a target for the azole drugs and one of the ways resistance to 
azoles arises is due to the mutations in CYP51. Many of these mutations reduce the 
affinity of the drug for its target, rendering the drug less effective. There is a need to 
design better drugs to combat fungal infections. In order to overcome antifungal 
resistance, an in depth understanding of how the mutations affect the interactions 
between CYP51 and the azole drugs is needed. The list of mutations discussed in 
this thesis are summarised in Table 1.2. A more detailed description of these 
mutations is covered in the introduction to Chapters 4 and 5.  
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Table 1.2 S. cerevisiae Erg11p amino acid substitutions equivalent to mutations 
in clinical isolates of the pathogenic fungi Candida albicans, Cryptococcus 




Mutations in CYP51 from clinical 
























Intrinsic resistance to 
fluconazole 
AfCYP51A 




















G448S   
ScErg11p 
G464S 
CaCYP51 = Candida albicans CYP51; CnCYP51 = Cryptococcus neoformans 
CYP51; HcCYP51 = Histoplasma capsulatum CYP51; ScErg11p = Saccharomyces 
cerevisiae CYP51; AfCYP51 = Aspergillus fumigatus CYP51 
1.13 S. cerevisiae as a model organism  
S. cerevisiae or Baker’s yeast provides a robust eukaryotic model that has been 
widely used in many scientific fields, including metabolic analysis, drug discovery 
and biotechnology. The genome sequence of this organism was released in 1996 
(Goffeau et al., 1996). The many molecular biology-based applications of S. 
cerevisiae include gene-cloning, genetic engineering, heterologous protein 
expression for laboratory and commercial purposes as well as in screens that detect 
protein-protein interactions. Several factors have encouraged the use of this simple 
unicellular eukaryote. For example, it is readily grown on a defined media, it has a 
well-understood life cycle, its genome sequence is known and many of its post-
translational modifications are characteristic of eukaryotes.  
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1.13.1 Homologous recombination 
Homologous recombination is an invaluable attribute of S. cerevisiae. This trait 
allows for targeted gene replacement, where a DNA construct contains a gene of 
interest, a selectable marker and matching sequences to the upstream and 
downstream of the target sequence in the genome. The ends of the designed DNA 
fragment interact with the homologous regions in the genome, replacing the 
intervening chromosomal sequence (Figure 1.10; Langston and Symington, 2005). 
S. cerevisiae can be transformed with foreign DNA in the form of a plasmid or with 
linearised DNA to disrupt or replace defined genomic sequences. 
Figure 1.10 Schematic representation of homologous recombination. Upstream 
region is denoted as US, downstream as DS and gene of interest as GOI. 
1.13.2 The Pleiotropic Drug Resistance Network  
In yeast, MDR is referred to as pleiotropic drug resistance (PDR). Aspects of PDR 
in the model yeast S. cerevisiae were described at the molecular level more than 
three decades ago. The phenomenon of PDR is thought to be ancient in origin and 
to have evolved long before the modern antifungal drugs were applied in the clinic 
(Gbelska et al., 2006). In PDR, transcriptional regulators play a crucial role by 
acting as sensors of chemically unrelated foreign toxins - xenobiotics 
(Kolaczkowska and Goffeau, 1999). Currently, about 10 transcriptional regulators 
are thought to be associated with the PDR network and these target about 70 
different genes (Kolaczkowska and Goffeau, 1999). Pdr1p is a key transcriptional 
regulator involved in PDR and appears to have the most target genes (Balzi and 
Goffeau, 1995). Pdr1p is a promoter resident regulator, which means it is 
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constitutively bound to its promoters. This allows for the basal transcription of the 
PDR genes as well as the induction of early drug-dependent responses (Fardeau et 
al., 2007).  
The early drug-dependent responses are key for the development of genetic 
modifications, which lead to PDR. The main mechanisms by which the PDR 
network confers drug resistance involve the overexpression of ABC and MFS 
transporters. The ABC transporters in the S. cerevisiae PDR network include Pdr5p, 
Snq2p, Pdr10p, Pdr15p and Ycf1p reviewed by Prasad and Goffeau (Prasad and 
Goffeau, 2012) and the MFS transporters include Tpo1p and Flr1p reviewed by Dos 
Santos et al. (Dos Santos et al., 2014).  
1.13.3 Pdr1-3 mutation 
Certain mutations in PDR1 confer high levels of resistance by causing constitutive 
overexpression of target genes. The pdr1-3 mutation in PDR1 is the F815S gain-of-
function mutation in Pdr1p (Carvajal et al., 1997). This mutation occurs in a 
negative regulatory domain of the protein and enables functional hyper-expression 
of efflux pumps Pdr5p, Snq2p, Yor1p, Pdr10p and Pdr15p (Carvajal et al., 1997, 
Decottignies et al., 1998). Pdr5p is the most prominent and extensively studied 
ABC transporter in S. cerevisiae that is regulated by Pdr1p (Balzi et al., 1994). 
1.13.4 A membrane protein overexpression system 
S. cerevisiae was used to develop a system for heterologous expression of 
membrane and soluble proteins. This system was initially established by 
Decottignies et al. (Decottignies et al., 1998) to study the yeast ABC transporters 
Pdr5p and Yor1p and has been further developed and utilised for characterisation of 
the membrane proteins involved in drug resistance (Nakamura et al., 2001, 
Lamping et al., 2007, Monk et al., 2014a). The S. cerevisiae host strain ADΔ has 
seven ABC transporter genes, chromosomal uracil selection marker (URA3) and the 
PDR3 transcriptional regulator genes deleted. The pdr1-3 gain-of-function mutation 
is used to give constitutive overexpression from the PDR5 locus. The ADΔ host 
strain is essentially identical to the AD1-8u- strain but the URA3 open reading frame 
has been completely deleted rather than containing an inactivating single nucleotide 
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mutation. The AD2Δ was developed later and is identical to ADΔ, but with the 
histidine marker (HIS1) deleted. The AD1-8u-, ADΔ and AD2Δ host strains have 
been used to overexpress proteins of interest from the PDR5 locus. The 
transformation cassette contains the PDR5 promoter, the gene of interest with 
affinity tag such as a hexaHistidine(His)-tag, a 3-phosphoglycerate kinase (PGK) 
terminator and the URA3 selection marker plus PDR5 downstream sequence 
(Figure 1.11; Lamping et al., 2007). 
Figure 1.11 Membrane protein hyper-expression system. A S. cerevisiae strain 
deficient in 7 ABC transporters and the PDR3 transcriptional regulator is used to 
overexpress ScErg11p from the PDR5 locus. The transformation cassette contains 
the PDR5 promoter, ScERG11 with a C-terminal His-tag, a 3-phosphoglycerate 
kinase (PGK) terminator, the URA3 selection marker and a PDR5 downstream 
sequence. Modified from (Lamping et al., 2007).  
1.14 Aims of this project 
The emergence of resistant fungal pathogens is a threat that calls for the 
identification of more effective drugs that can overcome resistance. Mutations in 
fungal Erg11p/CYP51s play an important role in the development of resistance to 
the triazole drugs. Understanding how these mutations affect the drug binding at the 
structural level is expected to give insight that will aid the design of more effective 
drugs.  
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At the commencement of this project (June 2012), the ability to overexpress, purify, 
crystallise and resolve the structure of S. cerevisiae Erg11p, as subsequently 
published in Monk et al., 2014 (Monk et al., 2014b), had been achieved. Important 
limitations of this work were that while structures with the substrate lanosterol and 
the long-tailed triazole inhibitor had been obtained at high resolutions (1.95-2.1 Å), 
the co-crystal structures obtained in complex with FLC and VCZ were at much 
lower resolutions (>2.6 Å). The low-resolution structures were of insufficient 
resolution and quality to detect important features in the active site that might 
influence the affinity of drug binding.  
The first aim of this project was to obtain a high-resolution structure of ScErg11p in 
complex with FLC that would reveal features such as the presence of water-
mediated hydrogen bond networks.  
The first part of the research predicted how some mutations might impact antifungal 
resistance to short- and long-tailed triazoles.  
The second aim of the project was to investigate the effect of CYP51 mutations on 
enzyme structure and function by using S. cerevisiae Erg11p as a model for 
pathogenic yeast. The Erg11p Y132F/H, K143R and G464S mutations of C. 
albicans and the CYP51A G54E/R/W mutations of A. fumigatus are the focus of 
this thesis (Table 1.2). In addition, the innate resistance of A. fumigatus CYP51A to 
FLC was investigated using the S. cerevisiae Erg11p T322I mutant. 
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2.1 Yeast strains  
The S. cerevisiae strain AD2Δ was used as the host to engineer strains hyper-
expressing wild type and mutant ScErg11p. The strains generated and/or used in 
this study are listed in Appendix A.1 (Table A-1). 
2.2 Chemicals 
The triazole drugs FLC, ITC, VCZ, PCZ along with polyethylene glycol-400 
(PEG-400), imidazole, L-histidine, luminol, p-coumaric acid and sodium 
dithionite were purchased from Sigma-Aldrich Ltd (St. Louis, MO, USA). 
Glycerol was purchased from Merck (Summit, NJ, USA). Acrylamide/bis-
acrylamide (40%; 19:1) solution, ammonium persulfate (APS) and N,N,N’,N’-
tetramethylethylenediamine (TEMED) were purchased from Bio-Rad (Hercules, 
CA, USA). Phenylmethanesulfonyl fluoride (PMSF) and Roche EDTA-free 
protease inhibitor pills were obtained from Roche Diagnostics (Basel, 
Switzerland). The detergent n-decyl-β-D-maltoside (DM) was purchased from 
Affymetrix Inc. (Santa Clara, CA, USA). 
2.3 Culture media and growth conditions 
The culture media used in the present study are shown in Table 2.1. Yeast 
strains were maintained on yeast peptone dextrose (YPD) medium solidified 
with 2% agar and cultured in liquid YPD medium (Table 2.1). Synthetic defined 
(SD) dropout medium was used for selection of transformants. SD media with 
complete supplement mixture was used for minimum inhibitory concentration 
(MIC) assays of drug efficacy with yeast strains (see below). Culture media 
were prepared using deionised distilled water (ddH2O). YPD medium was 
autoclaved at 121 °C for 15 min and SD medium was autoclaved at 117 °C for 
15 min.   
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Table 2.1 Culture medium composition 
Culture media Component (wt/vol) Supplier* 
YPD medium 1% bacto-yeast extract BD Difco™  
2% bacto-peptone BD Difco™  
2% glucose Merck 
2% agar (with or without) Oxoid Ltd 
SD uracil dropout 
medium 
0.67% yeast nitrogen base 
(without amino acids) 





2% agar Oxoid Ltd  
2% glucose Merck 
SD histidine 
dropout medium 
0.67% yeast nitrogen base 
(without amino acids) 





2% agar Oxoid Ltd  
2% glucose Merck 
Buffered SD 
medium (pH 6.8) 
0.67% yeast nitrogen base 
(without amino acids) 




2% glucose Merck 
10 mM MES and 20 mM 
HEPES buffered with Tris 
Sigma-Aldrich Ltd  
*The addresses of suppliers are as follows: BD Difco™ Laboratories Inc 
(Franklin Lakes, NJ, USA), Formedium™ (Norfolk, UK), Oxoid Ltd 
(Hampshire, UK).  
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2.4 Cloning of ScErg11p6×His 
2.4.1 Oligonucleotides  
Desalted oligonucleotides purchased from Sigma-Aldrich Ltd were prepared as 
100 µM stocks in elution buffer (EB, 10 mM Tris-HCl pH 8.5) from the 
QIAquick PCR purification kit (Qiagen Ltd, Limburg, Netherlands). Stock 
solutions were diluted in molecular biology grade RNase and DNase free H2O 
(5 PRIME Inc., Gaithersburg, MD, USA) to make 3.2 µM working solutions. 
Stock and working solutions were stored at -20 °C.  
2.4.2 Agarose gel electrophoresis  
DNA fragments were separated according to size, using agarose gel 
electrophoresis. DNA (10×) gel loading dye (Appendix A.2.2) was mixed with 
samples prior to loading onto the agarose gel (Appendix A.2.5). A 1 kb Plus 
DNA molecular ladder (Invitrogen, Carlsbad, CA, USA; Appendix A.2.4) was 
used to estimate the sizes of DNA fragments. The gel consisted of solidified 
0.8% (wt/v) agarose (Invitrogen) containing Tris-acetate EDTA (TAE) running 
buffer (Appendix A.2.3). The gel was subject to electrophoresis at 100 V for 60 
min. Ethidium bromide (3-5 µL of 2 mg/mL) was added to the gel and to the 
TAE running buffer in the tank to enable visualisation of DNA bands under UV 
illumination after electrophoresis.  
2.4.3 Polymerase Chain Reaction 
All polymerase chain reactions (PCRs), except colony PCR, were carried out 
using KOD Hot Start DNA polymerase (Novagen, Madison, WI, USA). 
Molecular biology grade RNase and DNase free H2O (5 PRIME Inc.) was used 
in all molecular biology manipulations and PCR reactions. Each PCR reaction 
contained 5 µL of 10× reaction buffer, 5 µL of 2 mM dNTPs, 2.4 µL of 25 mM 
MgSO4, 5 µL of each oligonucleotide primer (3.2 µM), 1 µL of KOD DNA 
polymerase (1 U/µL) and 10 – 60 ng of template DNA in a total volume of 
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50 µL. The thermocycling conditions are described in Table 2.2. All PCR 
reactions were carried out using the DNA Engine® Thermal Cycler (Bio-Rad). 
2.4.4 Recombinant PCR 
Recombinant PCR was used to fuse together 2 or 3 fragments of DNA in order 
to prepare transformation cassettes. The reaction conditions are as described in 
Section 2.4.3 and the thermal cycling conditions are as indicated in Table 2.2, 
but with the number of cycles reduced to 20. Two-fragment recombinant PCR 
used equimolar amounts of template. Three-fragment recombinant PCR used 
equimolar amounts of the bordering fragments and a 4-fold greater amount of 
the central fragment. 
Table 2.2 PCR Thermocycling conditions 
Polymerase KOD ExTaq 
Step Temperature Duration Temperature Duration 
1 95 °C 2 min 94 °C 15 sec 
2 95 °C 20 sec 94 °C 20 sec 
3 55 °C 10 sec 55 °C 10 sec 
4 68 °C 1 min / 1 kb 72 °C 1 min / 1 kb 
Steps 2 – 4 repeated for a total of 20* or 35 
cycles 
Steps 2 – 4 repeated for a 
total of 25 cycles 
5 68 °C 10 min 68 °C 10 min 
6 4 °C Hold 4 °C Hold 
*20 cycles was used for recombinant PCR reactions.  
2.4.5 Colony PCR 
Colony PCR was carried out using TaKaRa ExTaq DNA polymerase (Takara 
Bio Inc., Shiga, Japan). Each PCR reaction contained 2 µL of 10× buffer, 1.8 µL 
of 2.5 mM dNTPs, 2 µL of each oligonucleotide primer (3.2 µM), 0.15 µL of 
DNA polymerase (5 U/µL) and 1 – 2 µL of yeast suspension as DNA template 
in a total volume of 20 µL. Template DNA was obtained directly from yeast 
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colonies. A yeast suspension was prepared as follows: sufficient cells to fit on 
the tip of a toothpick were obtained from a yeast colony, resuspended in 10 µL 
of Milli-Q H2O (Appendix A.2.1) and heat treated at 95 °C for 5 min to release 
the DNA. The thermocycling conditions used for colony PCR are described in 
Table 2.2. 
2.4.6 PCR purification and DNA gel extraction 
QAIquick® PCR clean up and DNA gel extraction kits (Qiagen Ltd) or the 
NucleoSpin® PCR and Gel clean up kit (Macherey-Nagel, Düren, Germany) 
were used to purify PCR products and DNA fragments. The DNA purifications 
were carried out according to each manufacturer’s protocol.  
2.4.7 Preparation of competent yeast cells 
Competent S. cerevisiae cells were prepared fresh for each transformation. 
Preparation of competent yeast cells and their transformation was carried out 
using an Alkali-Cation™ Yeast Transformation kit from Qbiogene (Irvine, CA, 
USA). A 10 mL overnight (o/n) culture was grown in YPD from a single yeast 
colony. A flask containing 250 mL of YPAD medium (YPD with 30 mg/L of 
adenine sulphate added prior to autoclaving) was inoculated with an aliquot of 
the overnight culture to OD600nm = 0.1. The cells were cultured for 5 – 6 hours to 
OD600nm = 0.4 – 0.6 and harvested by centrifugation at 3820 g (5000 rpm) for 5 
min in a Sorvall® RC6 centrifuge using a FiberLite™ F14-6 rotor. The cell 
pellet was washed in 10 mL of TE buffer and pelleted again at 3820 g for 5 min. 
The pellet was resuspended in 5 mL of lithium/cesium acetate solution, 
incubated for 30 min at 30 °C with shaking at 100 rpm, centrifuged at 3820 g 
for 5 min and resuspended in 1 mL of TE buffer. The resultant competent cells 
were used the same day for transformation. 
2.4.8 Yeast transformation 
Competent S. cerevisiae cells (100 µL) were mixed with 5 µL of carrier DNA, 5 
µL of histamine solution and 800 – 1000 ng of DNA transformation cassette in 
a total volume of 10 µL. Salmon sperm carrier DNA (10 mg/mL) was heat 
Chapter 2: Materials and Methods 
 43 
denatured for 3 min at 94 °C and immediately placed on ice. The mixture was 
incubated at room temperature for 15 min with gentle mixing. PEG (0.8 mL) 
was added to 0.2 mL of TE/Cation MIXX and mixed with the cell suspension. 
The solution was incubated at 30 °C for 10 min, subject to heat shock at 42 °C 
for 10 min in a water bath and the cells pelleted at 11,000 g for 10 sec in a 
microcetrifuge. The supernatant was discarded, the pellet of cells resuspended 
in 200 µL of SOS media (sterile 1 M Sorbitol, 0.3× YPD and 10 mM CaCl2) 
and spread on agar plates containing SD dropout medium (Table 2.1). The 
plates were incubated for 2 – 3 days at 30 °C. Colony PCR was used to identify 
transformants containing DNA inserts of desired size and at the correct 
chromosomal location. Yeast genomic DNA was isolated using Y-DER kit 
(Thermo Fisher, Waltham, MA, USA) according to the manufacturer’s 
instructions. Cassette sequencing of genomic DNA (see below) was used to 
confirm insertion of the open reading frame at the expected location and in the 
correct orientation. 
2.4.9 DNA sequence analysis 
The ScERG11 DNA cassettes were amplified using primers PDR5_US and 
PDR5_288_DS_Rev (Appendix B.1, Table B-1). The His1 disruption cassette 
was amplified using primers ScErg11_US_801 and ScEr11_ter_rev (Appendix 
B.1, Table B-2). Genetic manipulations are described in more detail in Sections 
5.3.1 and 5.3.2. All DNA cassettes were verified by DNA sequence analysis 
carried out at the Genetic Analysis Services facility in the Department of 
Anatomy, University of Otago, Dunedin, New Zealand. At the facility, Sanger 
sequencing is carried out using BigDye® Terminator Version 3.1 Ready 
Reaction Cycle Sequencing Kit. DNA sequences were analysed using FinchTV 
software (Geospiza) and BLAST algorithms for comparison with the expected 
sequence etc.  
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2.5 Determination of azole susceptibility 
2.5.1 MIC80 assay 
Minimum inhibitory concentrations at 80% growth inhibition (MIC80) were 
measured using liquid microdilution assays in order to determine the 
susceptibility patterns of mutant and wild type ScErg11p overexpressing strains 
to triazole drugs. Triazole drugs are fungistatic rather than fungicidal and can 
show trailing growth at drug concentrations several-fold in excess of the MIC80. 
Therefore MICs were measured at 80% growth inhibition (MIC80) compared to 
no drug controls, even though trailing growth is not generally observed for the 
S. cerevisiae strains used in the present study when they are cultured in SD 
medium. 
Two-fold serial dilutions of FLC, ITC and VCZ were prepared in 96-well 
microtiter plates using SD medium (Table 2.1; Niimi et al., 2004). Roswell Park 
Memorial Institute medium (RPMI) is routinely used for standardised 
microdilution assays with C. albicans (Clinical and Laboratory Standards 
Institute M27-A3 method for azole drugs). However S. cerevisiae grows poorly 
in this medium and SD media is used instead (Niimi et al., 2004). Each well was 
inoculated at a cell density of OD600nm = 0.005 in a total volume 200 µL. The 
microtiter plates were incubated in 30 °C for 48 hours with shaking at 200 rpm. 
A BioTek Synergy™ 2 multi-mode plate reader (BioTek Instruments, 
Winooski, VT, USA) was used to determine OD600nm as a measure of cell 
growth. Each MIC80 was determined in triplicate for three clones of each strain 
in three separate experiments (27 separate measurements). 
2.6 ScErg11p6×His purification 
2.6.1 Cell culture and harvesting 
ScErg11p6×His was prepared according to the method described by Monk et al. 
(Monk et al., 2014b). Yeast cells were grown in 1.5 L YPD liquid cultures in 5 
L flasks to OD600nm ~10 at 30 °C with shaking at 200 rpm. The cells were 
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harvested by centrifugation with a Sorvall® RC6 centrifuge using a FiberLite™ 
F14-6 rotor at 3820 g for 5 min at 4 °C. The cells were washed by 
centrifugation in ice-cold ddH2O and resuspended in cold cell breakage buffer 
(Appendix A.3.1). Cell pellets were stored at -80 °C. 
2.6.2 Preparation of a crude membrane fraction from yeast 
Cell pellets were thawed on ice. The pH of the ice-cold cell suspension was 
adjusted to 7.5 on with 1 M Tris. The 350 mL chamber of a Beadbeater 
(BioSpec Products Inc.) was half-filled with cold glass beads and then filled 
completely with the cell suspension and additional buffer. The Beadbeater, with 
its chamber surrounded by ice, was run for five 1 min bursts, with the cells 
cooled for 3 – 4 min intervals in between. Cell disruption was evaluated by light 
microscopy with 70 – 80% breakage usually achieved. The pH of the 
homogenate was readjusted on ice to 7.2 with 1 M Tris after the breakage. 
Nuclei and cell debris were removed by twice pelleting the suspension at 3820 g 
for 10 min at 4 °C. The supernatant was recovered and crude membranes were 
pelleted by centrifugation at 205,000 g (42,000 rpm) for 70 min at 4 °C using a 
Ti45 rotor in Beckman Coulter Optima™ L-100K Ultracentrifuge. The 
supernatant was removed by aspiration and the membrane pellets washed by 
centrifugation in GTED-20 buffer (Appendix A.3.2) at 205,000 g for 45 min at 
4 °C. The washed pellets were resuspended in a minimal volume of GTED-20 
and stored at -80 °C. The amount of protein in the membrane preparation was 
estimated using the Lowry method (Bio-Rad) (Lowry et al., 1951) with bovine 
serum albumin (Thermo Fisher) as a standard. 
2.6.2.1 Miniaturised method for crude membrane preparations 
A 5 mL overnight culture was pelleted at 3000 g for 5 min at 4 °C. Cell pellet 
was resuspended in 1 mL of cold ddH2O and transferred to a 1.5 mL Eppendorf 
tube. The cells were pelleted by centrifugation at 3000 g for 5 min in a benchtop 
refrigerated centrifuge (Sigma 1-15pk) and resuspended in 250 µL of cold cell 
breakage buffer (Appendix A.3.1). 400 µL of glass beads were added to the cell 
suspension. The cells were homogenised using a shaker-vortex for 10 min at a 
speed of ~1000 rpm. The cell homogenate was centrifuged at 2000 g for 10 min 
Chapter 2: Materials and Methods 
 46 
to remove cell debris and the remainder of glass beads. The supernatant was 
centrifuged at 15,000 g for 1 hour. The membrane pellet was washed with 1 mL 
GTED-20 buffer (Appendix A.3.2) and precipitated at 15,000 g for 1 hour. The 
washed pellets were resuspended in 100 µL of GTED-20 and stored at -80 °C. 
2.6.3 Crude membrane solubilisation  
Crude membranes were washed with protein solubilisation buffer (Appendix 
A.3.3) and pelleted by centrifugation at 105,000 g (30,000 rpm) for 70 min at 4 
°C. This step removes the bulk of the EDTA that can interfere with the Ni-
NTA-agarose column chromatography. The supernatant was removed by 
aspiration and the membrane pellets were resuspended in solubilising buffer 
containing 10× critical micelle concentration (CMC) of the detergent n-decyl-β-
D-maltoside (DM, Appendix A.3.4). The membranes were solubilised for 
1 hour on a rotating mixer in the detergent-containing solubilisation buffer 
(1 mL per 5 mg protein). The detergent-insoluble fraction was removed by 
centrifugation at 105,000 g for 70 min at 4 °C in a Ti45 rotor. The supernatant 
was used for Ni-NTA affinity purification. 
2.6.4 Affinity chromatography 
2.6.4.1 Imidazole elution 
Ni-NTA affinity chromatography was used to purify ScErg11p6×His from DM-
solubilised membranes. The Ni-NTA-agarose beads (Qiagen) were washed 
twice with 5 mL of binding buffer (Appendix A.3.5) per 0.5 mL of packed 
beads to replace the bead storage solution. The solubilised membrane fraction 
was added to the washed Ni-NTA-agarose affinity matrix (2 mL of packed 
matrix per 1 g of crude membrane protein) in 50 mL falcon tubes and rotated 
end over end overnight at 4 °C.	  The resultant mixture was added to a Bio-Rad 
Econocolumn and the matrix allowed to settle. The column was washed with 10 
mL of binding buffer per 0.5 mL of matrix to remove non-specifically bound 
protein. The ScErg11p6×His was eluted with affinity column elution buffer 
(Appendix A.3.6). If the protein was to be co-purified with a drug, it was added 
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to the protein preparation at this point. The triazole drugs FLC, VCZ, ITC or 
PCZ were added to the pooled fractions at final concentrations of 40 µM for 
FLC and VCZ and 20 µM for PCZ and ITC. The untreated or drug-treated 
samples were kept at 4 °C until further purification by size exclusion 
chromatography (SEC). 
2.6.4.2 Histidine elution 
For characterisation by spectrophotometric analysis (cytochrome P450 type II 
difference spectra), ScErg11p6×His was eluted with L-histidine instead of 
imidazole during affinity purification. The Ni-NTA-agarose beads were pre-
washed and the packed column with ScErg11p6×His bound to the beads were 
washed with solubilisation buffer containing 16 mM DM detergent (Appendix 
A.3.4) and 2 mM L-histidine. The protein was eluted with solubilisation buffer 
containing 16 mM DM and 50 mM L-histidine. The L-histidine was removed 
from the sample by washing the enzyme with solubilisation buffer containing 16 
mM DM by using 50 kDa molecular-weight cut-off Amicon Ultra-4 centrifugal 
filters (Merck Millipore Ltd, Cork, Ireland). The removal of L-histidine was 
checked by taking the absolute spectra of the sample using the Ultrospec™ 
6300 pro UV/Visible spectrophotometer as described in Section 2.7.2. The 
heme peak for wild type protein with no ligand was at ~417 nm. With L-
histidine bound the peak was detected at ~420 nm.  The samples recovered were 
refrigerated at 6 °C. 
2.6.5 Size exclusion chromatography 
Affinity purified fractions were further purified by size exclusion 
chromatography (SEC) on a Superdex 200 10/300 GL column (GE Healthcare, 
Buckinghamshire, UK) using the Äkta fast protein liquid chromatography 
(FPLC) purifier 10 (GE Healthcare). The column, which was stored in 20% 
ethanol, was prewashed with ddH2O and then equilibrated with 2 column 
volumes (~60 mL) of SEC buffer (Appendix A.3.7) at a flow rate of 0.4 mL per 
min. If the enzyme was to be co-purified with a drug, the appropriate drug (10 
µM for FLC, VCZ and 2 µM for PCZ and ITC) was added to the SEC buffer. 
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The column was eluted at a flow rate of 0.4 mL per min and 0.5 mL fractions 
were collected. The red-coloured fractions containing the 62 kDa 
ScErg11p6×His were pooled and concentrated using 50 kDa molecular-weight 
cut-off Amicon Ultra-4 centrifugal filters.   
2.7 Biochemical characterisation of ScErg11p6×His  
2.7.1 Protein concentration estimation 
For crystallisation, the concentration of the purified protein was estimated using 
the 280 nm protein peak in an absorbance spectrum obtained with an 
Ultrospec™ 6300 pro UV/Visible spectrophotometer. The absolute absorbance 
spectrum of the purified protein was measured between 250 nm and 500 nm. 
The protein concentration was calculated using the Beer-Lambert Law 
(Equation 2.1) where A280 is the absorbance at 280 nm, c is the protein 
concentration, 𝑙 is the cuvette path length and ε is the extinction coefficient.  
Equation 2.1 Beer-Lambert Law 
𝑐   =
𝐴!"#
𝜀  ×  𝑙 
The extinction coefficient (ε)  of  a  protein is calculated based on the number of 
tryptophans, tyrosines and cysteines present in the protein (Equation 2.2) (Pace 
et al., 1995). The extinction coffecicient of ScErg11p6×His was calculated to be 
81960 M-1 cm-1. 
Equation 2.2 Extinction coefficient calculation  
𝜀 = 5500  ×   #Trp +   1490  ×   #Tyr +   125  ×  (#Cys) 
2.7.2 Absolute absorbance spectra of ScErg11p6×His 
The absolute spectrum of the purified protein was determined using Ultrospec™ 
6300 pro UV/Visible spectrophotometer using the buffer that the protein is 
suspended in as a blank e.g. SEC buffer. The absolute absorbance spectra for 
SEC and affinity purified protein preparations were routinely obtained to 
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determine the heme to protein peak (A280nm) ratio as well as whether the protein 
has bound the appropriate ligand. The heme of the ScErg11p6×His produces 
peaks at ~424 nm with imidazole bound, 421 nm with ITC and 417-418 nm 
when its ligand free. 
2.7.3 SDS-polyacrylamide gel electrophoresis 
ScErg11p6×His protein preparations were analysed by SDS-PAGE in the 
Protean mini gel system (Bio-Rad) using the method described by Laemmli 
(Laemmli, 1970). The components of the stacking and separating gels (8% 
acrylamide) are listed in Appendix A.4, Table A-2. The gel tank was filled with 
running buffer (Appendix A.4.1) and the PageRuler™ Plus prestained protein 
standards (5 µL, Fermentas Life Sciences, Waltham, MA, USA) were added to 
bordering sample wells to estimate the sizes of the proteins in samples. Prior to 
loading, protein samples were treated with 6× protein loading buffer (Appendix 
A.4.2). The samples were subject to electrophoresis for 90 min at 100 V. The 
gels were stained with Coomassie blue R250 (Appendix A.4.3) for at least 1 
hour and destained for at least 2 hours in destaining solution (Appendix A.4.4). 
The destained gels were stored in 10% acetic acid. Gels were photographed 
using the Gel Doc imaging system (Bio-Rad). 
2.7.4 Western blot analysis  
2.7.4.1 Preparation of protein samples for quantitation of expression 
Cells were harvested from strains in the logarithmic growth phase (OD600nm = 6-
7). Crude membrane samples were obtained using a miniaturised method 
described in Section 2.6.2.1. In brief, cell cultures (5 mL) were harvested by 
centrifugation, broken using glass beads and a crude membrane fraction 
obtained by differential centrifugation. Crude membrane samples (10 µg of 
protein) and coloured protein markers were separated by SDS-PAGE in pairs, 
on 8% acrylamide gels (Section 2.7.3). One gel was immediately stained with 
Coomassie R250 and the other was electrotransferred to nitrocellulose. 
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2.7.4.2 Electrotransfer and Immunostaining 
Proteins separated by SDS-PAGE were transferred onto a nitrocellulose 
membrane (Amersham Hybond ECL, GE Healthcare) using 20 mM Tris-HCl 
pH 8.5, 192 mM glycine and 20% methanol electrotransfer buffer.  The 
acrylamide gel, nitrocellulose membrane, blotting paper and scrubber pads were 
briefly soaked in the electrotransfer medium and a sandwich comprising a 
scrubber pad, 3 layers of blotting paper, the gel, the nitrocellulose membrane 
and a further 3 layers of blotting paper and another scrubber pad was placed into 
a blotting cassette that was inserted into a protein transfer apparatus (Mini Trans 
- Blot®, Bio-Rad). The tank was filled with cold electrotransfer buffer and the 
proteins transferred at 100V for 1.5 hours at 4 °C. 
The nitrocellulose membrane was incubated for 1 hour at room temperature in 
blocking solution (2.5 mg/mL skim milk, 0.02% Tween-20 in phosphate 
buffered saline [PBS]). The blot was then immunodecorated by incubation in 
blocking solution containing a 1:3000 dilution (16 mU/mL) of anti-6×His-
peroxidase antibody (mouse monoclonal antibody, Roche) for 1 hour at room 
temperature. The membrane was then washed 3 times for 5 min in washing 
solution (0.1 % Tween-20 in PBS).  
2.7.4.3 Detection of immunocomplexes by chemiluminescence 
The nitrocellulose membrane was incubated for 2 min in freshly prepared 
detection solution which contained 5.5 mg of Luminol dissolved in 60 µL of 
DMSO, 0.28 mg of p-coumaric acid dissolved in 10 µL of DMSO and 7.7 µL of 
30% hydrogen peroxide added to 25 mL of 0.1 M Tris-HCl pH 8.6 buffer. The 
nitrocellulose membrane covered in transparent plastic wrap was exposed in the 
dark to X-ray film (Amersham Hyperfilm ECL, GE Healthcare) for 30 sec or 60 
sec. The X-ray film was developed, briefly washed with water and fixed 
according to manufacturers specification (Kodak, Rochester, NY). The amount 
of ScErg11p6×His protein in each lane was analysed using Image Lab 3.0 
software (Bio-Rad). The amount of protein in the wild type strain (MMLY 941 
or AD3Δ_ScErg11) was normalised to 1 and compared to mutant enzyme 
overexpressing strains. 
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2.7.5 Mass spectrometry 
The presence of wild type or mutant ScErg11p6×His was verified by mass 
spectrometry of tryptic fragments at the Centre for Protein Research (University 
of Otago, New Zealand). Purified protein preparations were separated by SDS-
PAGE and the Coomassie stained protein bands of interest were excised from 
the gel. The protein band was digested with trypsin, which cleaves at an 
arginine or a lysine, unless followed by a proline. Protein digestion using a 
robotic workstation DigestPro MSi (Intavis AG, Cologne, Germany) was 
carried out according to the protocol by Shevchenko et al. (Shevchenko et al., 
1996). A full mass spectrum was acquired in the mass range of 300-2000 mass 
to charge ratio (m/z) on an Orbitrap mass analyser with a resolution of 60,000 at 
m/z 400 and an automatic gain control target of 5e5. The data obtained was 
searched against the SWISS-PROT amino acid sequence database using the 
Mascot search engine. The search was set up for tryptic peptides with a 
maximum of 3 missed cleavage sites. Protein sequence coverage of at least 75% 
was obtained in all cases. 
2.7.6 Determination of CYP450 concentration  
Carbon monoxide (CO) binding spectra was used to calculate the concentration 
of functional cytochrome P450 enzyme in affinity purified protein preparations. 
The measurements were carried out according to the protocol described by 
Guengerich et al. (Guengerich et al., 2009). A 2 mL solution of enzyme diluted 
in solubilisation buffer with detergent DM (~1 µM; Appendix A.3.4) was split 
between 2 cuvettes. CO gas (BOC Gases Ltd, Dunedin, NZ) was bubbled 
through the enzyme solution in the sample cuvette. Sodium dithionite (~1 mg) 
was added to the sample cuvette after CO bubbling and to the reference cuvette. 
The CYP450 concentration was calculated using the resulting difference 
spectrum, which gave a peak at 445 nm (Equation 2.3). The extinction 
coefficient of 91 mM-1 cm-1 was used for the difference in absorbance between 
450 and 490 nm (Omura and Sato, 1964a).    
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Equation 2.3 CYP450 concentration calculation 
(ΔA450  –   ΔA490)/0.091   =   nmol  of  CYP450  per  mL i.e µM 
The difference spectra were recorded with a Cary 1 Bio UV-visible 
spectrophotometer using 10 mm light path UV transparent plastic cuvettes (GE 
Healthcare Life Sciences).  
2.7.7 CYP450 type II difference spectra 
L-histidine-affinity purified ScErg11p6×His enzyme was used to measure the 
binding of triazole drugs. Titrations with drugs were carried out using 1 µM of 
ScErg11p6×His enzyme with the concentration of CYP450 determined using 
CO binding spectra. The triazole drugs ITC, PCZ, VCZ and FLC were dissolved 
in DMSO (200 mM) and added to the sample cuvette and a corresponding 
amount of DMSO was added to the reference cuvette. The concentration range 
of the triazole drugs was 0.1 – 3 µM. The total amount of DMSO added was 
<2% of the total volume in the cuvette. Type II difference spectra (Warrilow et 
al., 2010b) were recorded between 350 – 500 nm using a Cary 1 Bio UV-visible 
spectrophotometer. The difference in absorbance between the trough at ~410 
nm and the peak at ~428 nm was plotted against drug concentration. The 
dissociation constants (Kds) were calculated by fitting obtained data to either the 
Hill equation (Equation 2.4) or the rearrangement of the Morrison equation 
(Equation 2.5). In these calculations Δ𝐴!"#    is the maximum change in 
absorbance, [Azole] is the azole concentration, Et is the total amount of enzyme 
present and n is the Hill coefficient. The best fitting equation was chosen by 
using the Akaike information criterion (Akaike, 1974).  
Equation 2.4 The Hill equation 
∆𝐀   =   𝚫𝑨𝒎𝒂𝒙   𝐀𝐳𝐨𝐥𝐞 𝒏/  ( 𝐀𝐳𝐨𝐥𝐞 𝒏 +   𝑲𝒅𝒏)   
Equation 2.5 The rearrangement of the Morrison equation 
∆𝑨 = ∆𝑨𝒎𝒂𝒙  ×   𝑬𝒕 + 𝑨𝒛𝒐𝒍𝒆 +𝑲𝒅 − [ 𝑬𝒕 + 𝑨𝒛𝒐𝒍𝒆 +𝑲𝒅 𝟐
− 𝟒  ×  𝑬𝒕  ×   𝑨𝒛𝒐𝒍𝒆 𝟎.𝟓}/𝟐  ×  𝑬𝒕 
All calculations for the dissociation constant (Kd) were carried out using 
GraphPad Prism 6 Software. 
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2.8 Crystallisation of ScErg11p6×His  
2.8.1 Crystallisation conditions  
A hanging-drop vapour-diffusion method was used to crystallise 
ScErg11p6×His (Monk et al., 2014b). The reservoir solution contained 45% 
PEG-400 in 100 mM glycine-NaOH buffer in the pH range of 9.30 - 9.55. The 
drop volume was 4 µL in a 1:1 ratio of reservoir solution and ~20 mg/mL of 
protein in SEC buffer. The drops were thoroughly mixed on a round cover slide 
(Hampton Research, Aliso Viejo, CA, USA) prior to sealing the slide over the 
appropriate well of a 24 well plate (Hampton Research). Crystals started to form 
after approximately one week of incubation at 18 °C. Crystals were picked 
using an appropriate size nylon loop (MiTeGen, Ithaca, NY, USA) and flash-
cooled in liquid nitrogen. 
2.8.2 Data collection 
Crystals were pre-screened at the Macromolecular X-ray Crystallography Suite 
in the Department of Biochemistry (University of Otago, New Zealand). The 
copper X-ray radiation anode tube and the Rigaku R-AXIS IV++ area detector 
were used to screen the crystals. Crystals diffracting to a resolution of 3 Å or 
higher were subsequently sent to the Australian Synchrotron. Full datasets were 
collected at the Australian Synchrotron (Clayton, Vic, Australia). The 
macromolecular crystallography beamlines used for data collection were the 
MX1 beamline (ADSC Quantum 210r detector) and the MX2 microbeam 
(ADSC Quantum 315r detector). The crystals were kept frozen under an N2 
cryostream at -180 °C during data collection. The complete datasets were 
collected at a wavelength of 0.954 Å.  
2.8.3 Data processing 
Diffraction data processing was carried out using iMosflm (Battye et al., 2011) 
and SCALA (Evans, 2006) from the CCP4 suite (Winn et al., 2011). Phaser-MR 
(McCoy et al., 2007) from Phenix software suite (Adams et al., 2010) was used 
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for molecular replacement using ScErg11p6×His complexed with lanosterol 
(PDB ID: 4LXJ) as a template (Monk et al., 2014b). Phenix.refine (Afonine et 
al., 2012) was used for the refinement. COOT (Emsley et al., 2010) was used to 
visualise the structure after each round of refinement. The triazole inhibitors 
were modelled into the appropriate density near the heme in the active site. 
Water molecules were modelled if at least one hydrogen bond was detected (2.5 
– 3.3 Å). Bond length restraints were applied for Fe – nitrogen (2.15 Å) and Fe 
– sulfur (2.33 Å) distances during refinement (phenix.refine). The constraints 
were based on the average coordinate bond distance of more than 80 known Fe 
– N (triazole) complexes and 4 heme Fe – S complexes in the Cambridge 
Structural Database. The crystallographic information files (.cif) for triazole 
inhibitors were obtained from running the Grade Global Phasing online tool 
(Global Phasing Ltd, Cambridge, UK). The crystallographic information files 
for ITC and PCZ were altered. To obtain the correct conformation of the 
piperazine ring in either the chair or the twisted boat shapes the crystallographic 
information file had extra chiral restraints for nitrogen atoms of the ring added 
to it, otherwise the puckering of the ring did not assume either of those shapes 
(Appendix F).   
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Chapter 3                                      
Structural insights into binding of the 
antifungal drug fluconazole to      
Saccharomyces cerevisiae                       
lanosterol 14α-demethylase  
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3.1 Introduction  
Until 2014, X-ray structures of eukaryotic CYP51s were obtained by deletion of 
the transmembrane helix to improve expression and crystallization 
(Strushkevich et al., 2010). These include the human CYP51 enzyme (PDB IDs: 
3LD6, 3JUV, 3JUS) (Strushkevich et al., 2010) and CYP51 enzymes from the 
protozoa T. cruzi and T. brucei (PDB IDs: 2WX2, 2WV2, 2X2N; Chen et al., 
2010). Other CYP51 structures available include M. tuberculosis CYP51 (e.g. 
PDB ID: 1EA1; Podust et al., 2001) and L. infantum CYP51 (PDB ID: 3L4D; 
Hargrove et al., 2011). The only structural information available on fungal 
CYP51s was from homology models based on the truncated structures of other 
P450s and more recently human CYP51 and M. tuberculosis CYP51 (Boscott 
and Grant, 1994, Fraczek et al., 2011, Xiao et al., 2004).  
The first full-length structure of a fungal CYP51 was determined by X-ray 
crystallography of Erg11p from the yeast S. cerevisiae (Monk et al., 2014b). 
Two structures were deposited in the PDB; one with the native substrate 
lanosterol (PDB ID: 4LXJ) bound in the active site in a pre-catalytic state and 
the other with the long-tailed triazole drug ITC (PDB ID: 4K0F) at resolutions 
of 2.19 Å and 1.90 Å, respectively. Structures of Erg11p complexed with FLC 
or VCZ could only be refined at significantly lower resolution (≥2.5 Å) and 
were not deposited in the PDB (Appendix G, Table G-2; Monk et al., 2014b).  
Elucidation of the structure of the complete enzyme identified the likely 
orientation of the enzyme in relation to the lipid bilayer. The amphipathic N-
terminal membrane helix 1 (MH1) and adjacent transmembrane helix (TMH1) 
are oriented at about 60º to each other, and contacts between TMH1 and the 
catalytic domain help position the catalytic domain partly in the lipid bilayer. 
The enzyme has a common P450 fold with α-helices (A-L) and β-sheets (1-4) 
constituting the catalytic domain with the heme cofactor forming the active site. 
The entrance to the substrate channel is in direct contact with the surface of the 
lipid bilayer. This ensures that the entry of the lipidic substrate is directly from 
the surface of the membrane. In this report, we present the high-resolution 
crystal structure of full-length S. cerevisiae Erg11p in complex with the short-
tailed triazole FLC that reveals key hydrogen bond networks in the active site. 
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3.2 Materials and methods 
The materials and methods used in this chapter are described in Chapter 2. The 
strains used in this chapter are listed in Appendix A.1 (Table A-1).  
3.3 Results and Discussion 
3.3.1 Drug susceptibility of S. cerevisiae strains expressing Erg11p 
As expected, deletion of the HIS1 ORF in the ADΔ strain did not alter the azole 
susceptibility pattern in the derivative strain AD2Δ. Both the parent and 
derivative strain were equally highly sensitive to the triazoles tested (Table 3.1). 
Constitutive hyper-expression of ScErg11p6×His from the PDR5 locus under 
control of the gain-of-function pdr1-3 mutation increased resistance for the 
AD2Δ to FLC 6-fold, ITC 3.5-fold and VCZ 5-fold. Removal of the 
endogenous ScERG11 in the AD3ΔScErg11p strain did not significantly 
increase susceptibility to these triazoles. This showed that the azole resistance 
was dependent on the recombinant ScErg11p6×His and not the native 
ScErg11p. 
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Table 3.1 MIC80 values for S. cerevisiae strains to FLC, ITC and VCZ 
Strain MIC80 µg/ml 
FLC  ITC VCZ 
ADΔ 0.4 (± 0.04) 0.03 (± 0.000)  0.05 (± 0.001) 
AD2Δ 0.4 (± 0.04) 0.03 (± 0.000)  0.05 (± 0.001) 
AD2Δ ScErg11p 2.4 (± 0.13) 0.106 (± 0.001) 0.24 (± 0.02) 
AD3Δ ScErg11p 2.1 (± 0.02) 0.105 (± 0.004) 0.25 (± 0.05) 
MIC80 values were determined as described in Chapter 2. The table shows the 
mean for 3 separate clones of each strain using data obtained in triplicate 
measurements from at least 3 different experiments (a total of 9 determinations 
per strain). SEM indicated in brackets.  
3.3.2 Spectral characteristics of purified ScErg11p 
The absorbance spectrum for ScErg11p6×His in its low spin ferric state showed 
a heme Soret (γ) band at 417 nm and δ, β and α peaks at 350, 535 and 571 nm, 
respectively (Figure 3.1). One electron reduced spectra obtained using sodium 
dithionite gave a blue shift of the Soret peak from 417 nm to 414 nm. CO 
binding to the ferrous ScErg11p6×His produced a characteristic red shift to 445 
nm. The minor shoulder at the 420 nm indicated the presence of a small amount 
of inactive P420 complex in the purified enzyme preparation. The absolute, 
reduced and CO spectra for purified ScErg11p6×His were comparable to those 
obtained previously for S. cerevisiae microsomal preparations by Yoshida and 
Aoyama (Yoshida and Aoyama, 1987) and indicated that the ScErg11p6×His 
preparation was active.   
Chapter 3: CYP51 structure complexed with Fluconazole 
 59 
 
Figure 3.1 Spectral characterization of ScErg11p6×His. The absolute spectra 
of the ferric protein (solid trace), the ferrous protein reduced with sodium 
dithionite (dashed trace) and the reduced protein with bound carbon monoxide 
(dotted trace). Spectra were recorded using 1.5 µM of ScErg11p6×His. 
3.3.3 Binding of triazole drugs to ScErg11p6×His  
The binding of the FLC (Figure 3.2a) and VCZ (data not shown) to 
ScErg11p6×His gave type II difference spectra caused by the coordination of 
the nitrogen atom in the triazole ring to the heme iron, replacing the water 
ligand and stabilising the low-spin form (Locuson et al., 2007). The absorbance 
spectra of ScErg11p6×His in the presence of the triazoles caused a red shift of 
the heme Soret peak from 417 nm to 421 nm for both VCZ and FLC. The 
difference spectra obtained with 1 µM ScErg11p6×His enzyme in the presence 
of excess FLC and VCZ were very similar, with a peak at 428 nm and a trough 
at 410 nm (Table 3.2). The binding is normally characterized as tight if the Kd 
values are lower or equal to the enzyme concentration and the Morrison 
equation is generally used to fit the data (Morrison, 1969). However, analysis of 
the change in absorbance caused by drug binding versus the concentration of 
triazole drug added, gave the best fit using the Hill equation and not the 
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rearrangement of the Morrison equation (Figure 3.2b and Table 3.2). The 
[Azole]0.5 values were similar for the two drugs as were the Kd values (Table 
3.2).  
 
Figure 3.2 Binding of FLC and VCZ to ScErg11p6×His. (a) Difference 
spectra demonstrating type II binding of FLC obtained by incremental additions 
of the drug to 1 µM of ScErg11p×His. (b) Saturation curves for FLC (filled 
circles) and VCZ (hollow circles) fitted to the Hill equation with ΔA plotted 
against azole concentration. 
Similar to previous studies with C. albicans CYP51, the [Azole]0.5 values were 
found to be about half the P450 concentration, indicating tight binding for VCZ 
and FLC (Warrilow et al., 2010a, Lamb et al., 1997). The Kd value for FLC of 
74 (±15) nM is comparable to those previously obtained using the Morrison 
equation for CaCYP51 in two different studies i.e. 46.6 (±10.6) nM (Warrilow 
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et al., 2010a) and 60 (±10) nM (Park et al., 2011). The apparent Hill numbers of 
3 for FLC and and 2.7 for VCZ, are unlikely to be due to positive cooperativity 
between ScErg11p monomers. They are more likely to result from multiple 
interactions between the ligand and the internal active site of an enzyme (Prinz 
and Schonichen, 2008) that behaves as monomer within its own detergent 
vesicle. Consistent with this hypothesis, size exclusion chromatography of the 
affinity purified enzyme gives enzyme-containing detergent vesicles that 
migrate with an apparent molecular size of  <100 kDa, (Monk et al., 2014b). 
Table 3.2 Binding of triazole drugs to affinity purified ScErg11p6×His 




FLC 0.048 410 428 0.074 (± 0.015) 3.0 0.43 
VCZ 0.051 410 428 0.082 (± 0.018) 2.7 0.4 
The binding of azole drugs to 1 µM Ni-NTA affinity purified ScErg11p6×His 
was determined as described in Materials and methods. IC50 value is denoted as 
[Azole]0.5. 
3.3.4 X-ray crystal structure of S. cerevisiae Erg11p in complex with 
FLC  
Full-length S. cerevisiae lanosterol 14α-demethylase (ScErg11p6×His) co-
purified with FLC during SEC was used for crystallization. Data collection 
parameters and refinement statistics are presented in Appendix G, Table G-1. 
Molecular replacement was carried out using the full length ScErg11p6×His 
(PDB ID: 4LXJ) and revealed a single monomer in the asymmetric unit (PDB 
ID: 4WMZ) comprising MH1, TM1 and the catalytic domain as seen previously 
(Monk et al., 2014b). The enzyme appears to be a rigid molecule, as the tertiary 
structure and the shape of the substrate channel is unchanged, regardless of the 
size of the ligand (lanosterol, ITC or FLC) bound in the active site (Monk et al., 
2014b). Some differences in the ScErg11p6×His in complex with FLC, 
compared with the two previously deposited structures, were detected in side 
chains of residues of the transmembrane helix, in side chains of residues of 
helix-F’, helix-G and the F’/G loop that connects them, and in some parts of the 
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enzyme exposed to the solvent. The F/G loop is buried in the membrane and this 
region has the highest β-factors together with the transmembrane helix and three 
residues Y439, S440 and V441 in all three structures, as previously discussed 
(Monk et al., 2014b). The residues Y439-V441 are within the N-terminal 
portion of a fungus-specific loop and are located at the surface of the protein.  
The proposed egress channel that bifurcates from the substrate channel shows 
some density in the present structure like the two previously published 
structures (Monk et al., 2014b). The density has been proposed to be the 
zymosterol rather than the immediate product 4,4-dimethylcholesta-8,14,24-
trienol, based on mass spectrometry of the purified enzyme (Monk et al., 
2014b). The side chains of residues around this secondary vestibule are 
positioned similarly amongst all three structures except H128, which has been 
modelled into different positions due to the limited density. This flexibility may 
be required to accommodate the exit of the product or interaction with 
subsequent enzymes in the ergosterol biosynthesis pathway e.g. Erg24 and the 
Erg25-Erg28 complex (Mo and Bard, 2005). The aromatic ring of the F241 is in 
an unfavourable position in the ScErg11p FLC structure like the lanosterol and 
ITC structures (PDB IDs: 4LXJ and 4K0F), possibly to accommodate the 
product molecule in the egress channel.  
3.3.5 FLC binding 
FLC binds within the active site of the enzyme, with clear evidence of the 
ligand apparent immediately following the solution from molecular replacement 
(Figure 3.3a). The triazole ring of FLC is coordinated to the iron within the 
heme cofactor (Fe---N distance 2.13 Å) corroborating the spectrophotometric 
data showing type II binding. The immediate environment surrounding FLC is 
hydrophobic as would be expected from the nature of the substrate lanosterol. 
Residues within 4 Å of FLC are illustrated in Figure 3.3b and include Y126, 
F134, I139, Y140, F236, G310, V311, G314, G315, T318, L380 and M509. The 
2,4-difluorophenyl ring of FLC lies adjacent to G310 and the coordinated 
triazole ring abuts G314 on the consensus motif GXXXG for sterol binding on 
helix-I. Consistent with other eukaryotic CYP51 structures, such as the 
Trypanosoma CYP51s, the bend in helix-I of ScErg11p at this motif is less 
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acute than in the M. tuberculosis CYP51 structure (Podust et al., 2001). Two 
water molecules form hydrogen bond networks with FLC (Figure 3.3c). The 
first water (743) mediates hydrogen bonds between the hydroxyl groups of FLC 
and Y140 as well as a propionate of the heme cofactor. The second water (790) 
forms hydrogen bonds with the carbonyl oxygen of S382, the hydroxyl of Y126 
and N4 of the second triazole ring which points away from the heme (Figure 
3.3c). In the previously published structures of ScErg11p6×His complexed with 
lanosterol and ITC neither water 743 nor 790 was observed. Previously reported 
structures of other CYP51s complexed with FLC have the inhibitor bound in a 
similar manner. The orientation of the 2,4-difluorophenyl ring matches that seen 
in the M. tuberculosis (PDB ID: 1EA1) and T. cruzi (PDB ID: 2WX2) CYP51 
structures (Chen et al., 2010). The 2,4-difluorophenyl ring is rotated 180º in 
several other structures but this would appear to be potentially unfavourable as 
the 2-fluoro substituent and the hydroxyl group of FLC are in close proximity 
(PDB ID: 2WV2, 2WUZ; Chen et al., 2010). This alternate orientation (2WUZ) 
is stabilized by a hydrogen bond between the fluorine substituent and the 
hydroxyl of Y103 (corresponding to Y126 in ScErg11p6×His; Chen et al., 
2010). This residue (Y103) shows a great deal of flexibility amongst the 
trypanosomal structures including occupying the site for the key water 743.  
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Figure 3.3 FLC binding in the active site of ScErg11p. (a) OMIT map for 
FLC [Fo - Fc map (green mesh) contoured at 3σ, 2Fo - Fc map (blue mesh) 
contoured at 1σ]. The Fo - Fc map was calculated using Fcalc refined from 
coordinates with no ligand at the active site. The 2Fo - Fc map is that following 
final refinement. The main chain is indicated in grey and the fluconazole is 
indicated as sticks, with C atoms cyan, N atoms blue, O atoms red and F atoms 
pale blue. The heme is shown as sticks with C atoms coloured magenta.  (b) 
Side chains of amino acid residues within 4 Å of FLC are indicated in grey. 
Main chain atoms are shown for G310, G314 and G315. (c) Water mediated 
hydrogen bonding (yellow dashed lines) between HOH743, FLC, heme and 
Y140, as well as between HOH790, FLC, and S382.  
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VCZ, another short-tailed antifungal agent, is similar to FLC and only differs in 
that the second non-coordinating triazole is replaced with a fluoropyrimidine 
group along with the addition of a methyl group. In the previous modelled 
structure obtained with a lower resolution data set (2.8 Å), the fluoropyrimidine 
ring is positioned in the same plane as the triazole with the fluoro substituent 
positioned in the opposite direction to the hydroxyl of the inhibitor and the 
methyl group (Monk et al., 2014b). The presence of the key water (743) would 
also provide the potential for a hydrogen bond with N3 of the fluoropyrimidine 
in this orientation over the flipped conformation. 
3.3.6 Antifungal resistance 
Mutations, which reduce the effectiveness of azole drugs, are frequently found 
in resistant pathogenic fungi. Of the residues within 4 Å of FLC in 
ScErg11p6×His that have residues equivalent to those found to be mutated in C. 
albicans Erg11p, only Y132F/H (Y140F/H in ScErg11p) is known to confer 
resistance to FLC as a single mutation (Sanglard et al., 1998, Flowers et al., 
2015). The others confer resistance in combination with additional mutations or 
confer susceptible phenotypes alone (Morio et al., 2010). The single amino-acid 
substitutions Y132F, K143R, F145L, S405F, D446E, G448E, F449V, G450E, 
and G464S in C. albicans Erg11p have been found to confer resistance to FLC 
(Flowers et al., 2015). The FLC MICs for those mutants were increased ~4-fold 
compared to those for the susceptible strain. Our structure shows that only 
Y132F, K143R and G464S are located close enough to the active site and the 
heme cofactor to directly affect the binding of FLC. Residues D446, G448, 
F449, and G450 (fungus-specific loop) as well as F145 and S405 are too far 
away to directly affect the heme or interfere with FLC binding.  
The Y132F/H mutation in C. albicans is commonly found in clinical isolates of 
other fungal pathogens of humans and plants that have reduced susceptibility to 
FLC and other azoles (Becher and Wirsel, 2012, Wheat et al., 2006a). As 
described above, a key water molecule (743) mediates hydrogen bonds between 
the hydroxyl group of the inhibitor, the hydroxyl group of Y140, and the 
propionate group of the heme (Figure 3.3c). Homologous mutations at Y140 to 
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either phenylalanine or histidine could disrupt this hydrogen-bonding network 
and therefore reduce susceptibility to FLC.  
Mutations equivalent to G464S (S. cerevisiae and C. albicans numbering) have 
been found in both C. albicans and A. fumigatus (Figure 3.4). The C. albicans 
G464S mutation has been found in clinical isolates and gives rise to FLC 
resistance (Sanglard et al., 1998, Flowers et al., 2015, Chau et al., 2004), while 
the equivalent G448S mutation in A. fumigatus CYP51B is thought to confer 
resistance to the long-tailed drugs ITC and PCZ but not resistance to the short-
tailed VCZ drug (Bueid et al., 2010). It has been suggested that this substitution 
would disrupt the positioning of the heme, reduce the binding of the azole, and 
increase resistance (Fraczek et al., 2011). However, its differential effect on 
short-tailed azoles compared to long-tailed azoles is not understood. G464 is 
located on the same face of the heme as the coordinating cysteine residue and is 
close to a propionate group of the cofactor that makes a hydrogen bond to a 
water molecule (Figure 3.4). The G464S mutation may replace this water and 
alter the interaction with the heme carboxylate, thus potentially tilting the heme.  
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Figure 3.4 Sites of mutation in C. albicans and A. fumigatus CYP51 (residues 
G464 and K151 in ScErg11p). The main chain is indicated as a grey ribbon 
and fluconazole is indicated as sticks (C atoms cyan, N atoms blue, O atoms red 
and F atoms pale blue). The heme cofactor is also shown as sticks (magenta C 
atoms). Hydrogen bonds between the water molecule at G464 and the heme 
propionate as well as K151 and the second heme propionate are shown (yellow 
dashed lines). Hydrogen bonding is also shown between HOH743, FLC, heme 
and Y140, as well as between HOH790, FLC, and S382. 
The K143R mutation in C. albicans CYP51 (K151 S. cerevisiae numbering) 
confers resistance to FLC (Manavathu et al., 1999). This residue is also located 
on the same side of the heme cofactor as the coordinating cysteine (Figure 3.4). 
In the current crystal structure, the side chain of K151 forms an ionic interaction 
with the carboxylate group of the heme. The change from lysine to arginine, 
while being functionally conservative, results in the addition of a large 
guanidinium group in an environment optimized for lysine. The change causes 
local disruption, but its extent is unknown.  
A. fumigatus has innate resistance to FLC, which may be a result of sequence 
differences between the two homologues of CYP51 present in this species. Most 
fungal species have a threonine at the position corresponding to T322 on helix I 
(S. cerevisiae numbering). A. fumigatus CYP51A has an isoleucine at this 
position (A. fumigatus CYP51A numbering, I301) whereas A. fumigatus 
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CYP51B maintains the threonine (A. fumigatus CYP51B numbering, T315). It 
has been hypothesized that this difference confers resistance to FLC (Edlind et 
al., 2001). Alanine mutagenesis at the homologous T315 position in C. albicans 
has been shown to result in increased resistance to FLC CYP51 (Lamb et al., 
1997). The current structure of ScErg11p shows that T322 is located adjacent to 
the active site on helix-I and close to an ethylene group of the heme but about 
10 Å from the iron coordinated triazole group. G310 (S. cerevisiae numbering) 
is within a distance of 4 Å of the drug. Glycine or alanine is accommodated in 
this position in fungal CYP51s, apart from A. fumigatus CYP51A, which has 
threonine (T289), and in one of two sequences available for Coccidioides 
immitis RS CYP51 (T303). This residue appears to be in better position than 
T322 to alter the binding of FLC (Figure 3.3b). 
3.3.7 Future prospects 
The high resolution X-ray crystal structure of full-length recombinant S. 
cerevisiae CYP51 (ScErg11p6×His) complexed with FLC and the resultant 
discovery of hydrogen bonding networks involving key waters within the active 
site provides the basis for detailed exploration of both the binding and resistance 
mechanisms of azole antifungal drugs, in particular FLC and VCZ, in fungal 
pathogens. Due to the strong homology of fungal CYP51s, ScErg11p can be 
used as a model, both structurally and experimentally, to study mutations that 
have been observed in resistant clinical isolates of fungal pathogens. The 
presence of a water-mediated hydrogen bond network between inhibitor and 
Y140 in the active site of lanosterol 14α-demethylase when complexed with the 
short chain FLC but not with the long chain ITC, as well as the interactions of 
the long tail of ITC in the enzyme entrance channel (Monk et al., 2014b), may 
explain the differential susceptibility to FLC and ITC conferred by mutations 
equivalent to Y140F/H. Structural and functional analysis will enable rigorous 
determination of the effects of these mutations on the protein and its affinity for 
these drugs. 
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4.1 Introduction 
Fungal infections of plants, crops, fruit and stored produce are a major problem, 
especially in temperate and tropical climates. This problem is likely to be 
compounded by extensive monoculture, where natural barriers to fungal 
infection are insufficient and the widespread application of fungicides is 
required e.g. for control of the soybean phytopathogen Phakopsora pakyrhizi or 
the wheat pathogen Zymoseptoria tritici (also known as Mycosphaerella 
graminicola) (Gianessi and Reigner, 2006, Fry, 2012). Several generations of 
triazole agrochemicals have been used since the 1970s to target phytopathogens 
and to counter shifts in susceptibility that often follow the introduction of new 
fungicides (Klittich, 2008). Similarly, multiple generations of azole drugs have 
been developed to circumvent non-specific interactions with liver drug 
metabolising enzymes and the emergence of drug resistance by fungal 
pathogens of humans. 
Triazole drugs are becoming less effective in treating mycoses of humans and 
animals and in preventing the devastating effects of phytopathogens on crop 
production (Pfaller and Diekema, 2007, Pfaller et al., 2010, Price et al., 2015a). 
This has occurred because of the emergence of less susceptible fungal strains 
(Parker et al., 2014). Resistance to azoles used in medicine has arisen, in part, 
because of the use of prophylaxis with susceptible patients and prolonged 
treatment courses (Tashiro et al., 2012, Howard et al., 2009). A contribution to 
this problem by azole-based agrochemicals has been recognised recently, with 
these fungicides shown to induce cross-resistance to medical triazoles in A. 
fumigatus and C. glabrata strains (Snelders et al., 2012, Faria-Ramos et al., 
2014). There is an increasingly urgent need to design antifungals and 
agrochemicals capable of overcoming triazole resistance. This can be best 
achieved by understanding the molecular basis of susceptibility and resistance 
to existing antifungal agents. 
A common mechanism of resistance occurs due to mutations in the enzymatic 
target of the azole drugs, lanosterol 14α-demethylase. The C. albicans CYP51 
(CaCYP51) Y132F/H mutations have been detected frequently in clinical 
isolates and lead to a 4-fold increase in resistance to FLC (determined by MIC 
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assays) (Sanglard et al., 1998, Flowers et al., 2015). Homologous mutations 
occur in the CYP51 genes of other fungal pathogens of man and plants (Figure 
4.1). For example, the Y145F mutation in C. neoformans CYP51 (Sionov et al., 
2012) and Y136F mutation in H. capsulatum CYP51 (Wheat et al., 2006b) both 
confer resistance to the short-tailed triazoles FLC and VCZ but not to the long-
tailed triazoles PCZ or ITC. Similarly, the mutations Y137F in Z. tritici CYP51 
(Leroux and Walker, 2011) and Y136F in Uncinula necator CYP51 (Delye et 
al., 1997) confer reduced susceptibility to the short-tailed azole fungicide 
triadimenol. The structurally homologous amino acid residue in S. cerevisiae is 
Y140. This tyrosine residue appears to be conserved among the CYP51 genes of 
humans and most fungal pathogens but in plants it is a conserved phenylalanine 
(Lepesheva and Waterman, 2011). 
 
Figure 4.1 Primary sequence alignment of fungal, human and plant 
CYP51s in the region of ScErg11p Y140. Alignment of fungal enzymes H. 
capsulatum CYP51 (HcCYP51), Z. tritici CYP51 (ZtCYP51), U. necator 
CYP51 (UnCYP51), A. fumigatus CYP51A (AfCYP51A), C. neoformans 
CYP51 (CnCYP51), C. albicans CYP51 (CaCYP51), and S. cerevisiae CYP51 
(ScErg11p). The human (HsCYP51) and a plant sequences Arabidopsis thaliana 
(AtCYP51) were compared to the fungal enzyme sequence. The frequently 
mutated tyrosine residue, equivalent to Y132 in CaCYP51 and Y140 in 
ScErg11p is highlighted in grey. The asterisk indicates conserved residues, the 
colon represents conservative mutations and the full stop indicates semi-
conservative mutations. Alignment was carried out using ClustalW sequence 
alignment program.  
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The selection pressure exerted by individual triazole drugs can differ. For 
example, the Z. tritici CYP51 Y137F mutation arose after the introduction of 
triadimenol but essentially disappeared in the field following the introduction of 
prothioconazole (Cools and Fraaije, 2013), a pro-drug that is metabolised to the 
active short-tailed triazole agrochemical prothioconazole-desthio (Figure 4.2; 
Parker et al., 2013).  
 
Figure 4.2 Triazole fungicides prothioconazole-desthio, prothioconazole 
and triadimenol. 
The accumulation of multiple mutations in CYP51 can lead to significant 
reductions in triazole susceptibility. For example the Y131F I475T combination 
of mutations has been detected in CYP51 in strains of the phytopathogen P. 
pachyrhizi (Schmitz et al., 2014). The comparable double mutation Y132H 
I471T is found in CYP51 of the triazole resistant Darlington strain of C. 
albicans (Kakeya et al., 2000). The mutations of the Darlington strain have a 
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synergistic effect. The Y132H CaCYP51 expressed in a Pdr5p deficient S. 
cerevisiae strain had an MIC of 16 µg/mL to FLC, the I471T mutant had an 
MIC of 6 µg/mL and the Y132H I471T double mutant has an MIC of >256 
µg/mL compared to an MIC of 1.5 µg/mL in a control strain (Kakeya et al., 
2000).  
In A. fumigatus the corresponding mutation in CYP51A is Y121F. This 
mutation can occur alone (Lescar et al., 2014) or together with the T289A 
mutation and tandem repeat 46 (TR46) in the promoter region (van der Linden et 
al., 2013). The Y121F mutation confers increased resistance to VCZ but not 
ITC or PCZ (Lescar et al., 2014) while the TR46 Y121F T289A mutation is 
associated with failure of VCZ therapy plus a slightly reduced susceptibility to 
ITC and PCZ (van der Linden et al., 2013).  
At the commencement of this project in 2012, a paucity of structural 
information on fungal lanosterol 14α-demethylase had meant that the molecular 
mechanisms that determine the reduced susceptibility/resistance conferred by 
mutations in this protein were not well understood. In 2014, Monk et al. 
reported high-resolution structures of full-length S. cerevisiae hexahistidine-
tagged Erg11p (ScErg11p6×His) in complex with its substrate lanosterol (1.9 Å, 
PDB ID: 4LXJ) and the long chain azole itraconazole (ITC, 2.1Å, PDB ID: 
4K0F) as well as structures with the substrate analogue estriol (2.1 Å) and the 
short chain triazole drugs VCZ (2.8 Å) and FLC (2.4 Å) (Appendix G, Table G-
2; Monk et al., 2014b). More recently, and in Chapter 3, we published a higher-
resolution (2.05 Å) structure of ScErg11p6×His in complex with FLC (PDB ID: 
4WMZ; Sagatova et al., 2015). Based on this structure, the ScErg11p Y140F/H 
mutations were proposed to modify a water-mediated hydrogen bond network 
involving the hydroxyl group of FLC, thus weakening the binding of the drug. 
The aim of the present chapter was to test this hypothesis. 
In the present study, high-resolution X-ray crystal structures of the 
ScErg11p6×His Y140F mutant in complex with ITC, FLC, VCZ and PCZ and 
the Y140H mutant in complex with FLC and ITC provide evidence that 
disruption of this hydrogen bond network leads to weaker drug binding for the 
short-tailed triazoles but not the long-tailed triazoles studied in this chapter.  
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4.2 Materials and Methods 
The materials and methods used in this chapter are described in detail in 
Chapter 2. Materials and methods specific to this chapter are described in the 
following sections. 
4.2.1 Construction of yeast strains overexpressing ScErg11p6×His 
Y140F/H  
ScErg11p Y140F/H constructs were made by recombinant PCR using genomic 
DNA from the ADΔ ScErg11p6×His overexpressing strain (MMLY 941; 
Appendix A.1, Table A-1) as template. Together with standard outside primers 
(PDR5F and PDR5DS; Appendix B.1, Table B-1) the forward primer 
ScErg11_Y140F_f (AAGGTGTTATTTTCGATTGTCCAAATTC) and the reverse 
primer ScErg11_Y140F_r (TTGGACAATCGAAAATAACACCTTTACC) were 
used to create fragments for recombinant PCR to introduce the Y140F mutation. 
Similarly, the forward primer ScErg11_Y140H_f 
(AAGGTGTTATTCATGATTGTCCAAATTC) with reverse primer 
ScErg11_Y140H_r (TTGGACAATCATGAATAACACCTTTACC) were used to 
introduce the Y140H mutation. The AD2Δ strain was transformed with linear 
ScERG11 DNA transformation cassettes that included a C-terminal 
hexahistidine tag, together with a transcriptional terminator and a URA3 
selection marker, bordered by sequences from the PDR5 locus for integration 
via heterologous recombination as described by Lamping et al. (Lamping et al., 
2007). Transformants expressing the URA3 marker were selected using SD-ura 
agar plates incubated for 48-72 hours at 30°C. Colony PCR performed on the 
resultant transformants was used to identify clones with the transformation 
cassette inserted at the correct position and in the correct orientation. The 
ScERG11 open reading frame and the presence of the expected mutation were 
confirmed by DNA sequence analysis. The resulting strains used for subsequent 
analysis were denoted AD2ΔScErg11_Y140F and AD2ΔScErg11_Y140H 
(Appendix A.1, Table A-1). The native ERG11 was deleted from mutant strains 
by replacement with a disruption cassette containing the His1 marker. 
Transformants were selected on SD-his agar plates. Colony PCR and DNA 
Chapter 4: Y140F/H mutations in ScErg11p 
 75 
sequence analysis were used to confirm the correct inserts. The resulting strains 
were designated AD3ΔScErg11_Y140F and AD3ΔScErg11_Y140H (Appendix 
A.1, Table A-1).  
4.3 Results 
4.3.1 Quantitation of ScErg11p6×His expression in crude membrane 
fractions 
Coomassie blue R250 stained SDS-polyacrylamide gel profiles (Figure 4.3a) 
and western blot analysis (Figure 4.3b) of crude membrane fractions obtained 
from cells overexpressing ScErg11p6×His, ScErg11p6×His Y140F or 
ScErg11p6×His Y140H from the PDR5 locus show that the mutant enzymes 
were expressed in this fraction at levels near to but slightly lower than the wild 
type enzyme. The Coomassie blue stained gels show, as expected, that the 62 
kDa native enzyme was expressed at several-fold lower levels than the 
recombinant hexahistine-tagged enzyme expressed from the PDR5 locus. The 
Coomassie stained gels indicated the lanes containing mutant Erg11p contained 
a slightly reduced 62 kDa band than the control MMLY941 strain 
overexpressing wild type ScErg11p6×His from the PDR5 locus and native 
enzyme from ERG11 locus. While the comparison must be indirect, as other 
proteins may contribute to this band, reduction of the 62 kDa band compared to 
AD2Δ crude membrane preparation suggests that the mutant Y140F/H mutant 
enzymes were expressed at comparable levels to the wild type ScErg11p6×His 
expressed from the PDR5 locus. The western blots showed that the mouse anti-
6×His-peroxidase antibody was specific for the hexahistidine tag found on the 
constructs expressed from the PDR5 locus and did not recognise the 
endogenous non-tagged native enzyme expressed from the ERG11 locus (Figure 
4.3b). Quantitation of the digitally captured western blot by Image Lab 3.0 (Bio-
Rad) software showed that ScErg11p6×His Y140F and ScErg11p6×His Y140H 
were expressed at 96% and 83%, respectively, of the level of the wild type 
ScErg11p6×His enzyme.  
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Figure 4.3 SDS-PAGE and western blot analysis of ScErg11p6×His wild 
type (WT) and Y140F/H mutant proteins. A Coomassie stained 8% 
acrylamide SDS-PAGE gel of samples of crude membranes (10 g) from strains 
overexpressing wild type and mutant ScErg11p6×His, with the AD2Δ strain 
used as a negative control. Ten µL of each sample at 1 µg/µL mixed with 2 µL 
of 6× SDS loading dye was separated on each lane. (b) Proteins 
electrotransferred to nitrocellulose membranes were decorated with a mouse 
anti-6×His-peroxidase monoclonal antibody and visualised using 
chemiluminescence as described in Section 2.7.4. 
Analysis of the Ni-NTA and SEC purified 62 kDa band by tryptic digestion and 
mass spectrometry showed at least 78% coverage of the primary sequence of 
ScErg11p6×His and confirmed the presence of the expected mutations at Y140 
(Appendix D.8, D.9).  
Carbon monoxide spectra obtained with dithionite-reduced wild type and 
mutant enzymes gave a peak at 445 nm, which showed that the bulk of each 
enzyme was functional. The presence of a slightly larger shoulder at 420 nm for 
the mutant enzymes indicated that each mutant enzyme had more non-
functional enzyme compared to the wild type (Figure 3.1). The spectral profiles 
for both mutant enzymes were the same and hence only a representative profile 
is shown in Figure 4.4. 
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Figure 4.4 The absolute and CO bound spectral profile of ScErg11p6×His 
Y140F mutant. The absolute spectrum profile is shown as a continuous line. 
The spectrum obtained with a dithionite-reduced and CO bound sample is 
presented as a dotted line. 
4.3.2 Azole susceptibilities of strains overexpressing ScErg11p6×His 
Y140F/H  
The susceptibilities of S. cerevisiae AD3Δ strains (native ERG11 deleted) 
overexpressing Erg11p6×His Y140F/H mutants to triazole drugs were measured 
as MIC80 values (Table 4.1). Overexpression of ScErg11p6×His Y140F in the 
AD3ΔScErg11p_Y140F strain conferred two-fold lower susceptibility to FLC 
than strain AD3ΔScErg11p that overexpressed wild type ScErg11p6×His i.e. 
MIC80 = 4.0 µg/mL and 2.1 µg/mL, respectively. The same mutant conferred a 
less than 2-fold reduction in susceptibility to VCZ. The MIC80 values were 0.42 
µg/mL for the strain overexpressing ScErg11p6×His Y140F and 0.25 µg/mL for 
the strain overexpressing wild type ScErg11p6×His. Strain 
AD3ΔScErg11p_Y140H showed slightly greater susceptibilities to FLC (3.4 
µg/ml) and VCZ (0.29 µg/mL) than the Y140F mutant. Although strain 
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AD3ΔScErg11p_Y140H showed a reduction in susceptibility to FLC (3.4 
µg/mL) compared to the control strain (2.1 µg/mL) overexpressing the wild 
type enzyme, it gave a susceptibility to VCZ (0.29 µg/mL) that was comparable 
to the wild type enzyme (0.25 µg/mL). 
Susceptibilities to ITC were comparable for the strains overexpressing the 
ScErg11p6×His Y140F, ScErg11p6×His Y140H and the wild type enzyme i.e. 
0.090 µg/mL, 0.077 µg/mL and 0.105 µg/mL, respectively.  
Table 4.1 MIC80 values for wild type and mutant strains overexpressing 
ScErg11p6×His 
MIC80s are shown as the mean value for 3 separate clones of each strain using 
data obtained in triplicate measurements from at least 3 different experiments (a 
total of 9 determinations per strain). SEM values are indicated in brackets. 
4.3.3 Spectral characterisation of triazole binding to wild type and 
mutant ScErg11p6×His 
Ni-NTA affinity-purified mutant and wild type preparations of ScErg11p6×His 
(1 µM) were used to detect and quantitate type II azole binding (Warrilow et al., 
2010a). The preparations used for this analysis were eluted from the affinity 
column using histidine and washed by centrifugal filtration to remove bound 
histidine. The absolute spectra showed an oxidised Soret peak at ~417 nm for 
wild type ScErg11p6×His and at 420 nm for the Y140F/H enzymes. Type II 
difference spectra were obtained for all triazoles tested. The titrations of each 
mutant with FLC, VCZ, ITC and PCZ are shown in Figure 4.5 and titration 
characteristics are listed in Table 4.2.  
Strain 
MIC80 µg/mL 
FLC VCZ ITC 
AD3ΔScErg11p 2.1 (±0.02) 0.25 (±0.050) 0.105 (±0.004) 
AD3ΔScErg11p_Y140F 4.0 (±0.20) 0.42 (±0.016) 0.090 (±0.006) 
AD3ΔScErg11p_Y140H 3.4 (±0.02) 0.29 (±0.002) 0.077 (±0.006) 
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Table 4.2 Type II difference spectra characteristics of ScErg11p6×His wild 
type and Y140F/H mutants 
 
For each mutant enzyme-drug complex, the difference in absorbance between 
the λpeak at 424 – 428 nm and the λtrough at 406 – 410 nm was 2-3-fold less than 
that obtained for the wild type enzyme which showed a λpeak at 428 nm and 
λtrough at 410 nm. It is of note that although difference spectra obtained for the 
mutant enzymes were pronounced and well-defined peaks, the Y140F enzyme 
showed troughs that were shallower and broader (Figure 4.5). The Y140H 
enzyme gave a narrower trough than the Y140F preparation for the binding of 
FLC, PCZ and VCZ. In contrast, this mutant enzyme gave a broader trough, 
similar to that of the Y140F mutant, for the binding of ITC.  
ScErg11p  Wild-type Y140F Y140H 
Triazole ΔAmax λtrough  λpeak ΔAmax λtrough  λpeak ΔAmax λtrough  λpeak 
FLC 0.048 410 428 0.023 406 425 0.016 410 428 
VCZ 0.051 410 428 0.019 408 424 0.018 410 424 
ITC 0.037 410 428 0.014 406 425 0.016 406 424 
PCZ 0.031 410 428 0.016 410 424 0.016 409 424 
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Figure 4.5 Type II difference spectra for FLC binding to ScErg11p6×His 
wild type and Y140F/H mutant enzymes. (a) Wild type ScErg11p6×His, (b) 
ScErg11p6×His Y140F and (c) ScErg11p6×His Y140H mutant enzyme type II 
difference spectra. The range of FLC concentrations used was 0.2 – 3.0 µM. 
The type II binding obtained with 1 µM wild type ScErg11p6×His or Y140F/H 
enzymes showed sigmoidal dose-response curves (Figure 4.6). The binding 
curves were analysed using the Hill equation and the resultant Kd values 
presented in  Table 4.3. These values indicate tight binding of each drug i.e. the 
Kd for each ligand was lower than the concentration of the enzyme present in 
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the assay. The Kd values for the mutant enzymes were similar to ones obtained 
for the wild type enzyme i.e. within the margin of the standard error.  
 
 
Figure 4.6 Triazole binding to ScErg11p6×His and Y140F/H mutant 
enzymes. Triazole binding for (a) fluconazole, (b) voriconazole, (c) 
posaconazole and (d) itraconazole to affinity purified wild type ScErg11p6×His 
(), the ScErg11p6×His Y140F (¡) and ScErg11p6×His Y140H (). All the 
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 Table 4.3 Triazole binding to affinity purified wild type and 
ScErg11p6×His Y140F/H 
ScErg11p Triazole Kd (µM) Hill 
number 
[Azole]0.5 
Wild-type FLC 0.074 (±0.015) 3.0 0.43 
VCZ 0.082 (±0.018) 2.7 0.40 
ITC 0.123 (±0.027) 1.6 0.28 
PCZ 0.078 (±0.023) 2.2 0.32 
Y140F FLC 0.13 (± 0.05) 1.86 0.33 
VCZ 0.03 (± 0.02) 2.60 0.27 
ITC 0.13 (± 0.07) 1.83 0.33 
PCZ 0.15 (± 0.07) 1.57 0.29 
Y140H FLC 0.11 (± 0.06) 1.68 0.27 
VCZ 0.22 (± 0.07) 1.23 0.29 
ITC 0.13 (± 0.06) 1.48 0.25 
PCZ 0.10 (± 0.04) 1.57 0.23 
Values in brackets indicate standard errors. IC50 value is denoted as [Azole]0.5.  
4.3.4 X-ray crystal structures of mutant ScErg11p6×His in complex 
with triazole drugs 
The data collection and refinement parameters obtained for X-ray crystal 
structures described in this report are presented in Appendix G, Tables G-3 and 
G-4. The presence of the ligands in the active site is shown by the OMIT maps 
in Figure 4.7.  
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Figure 4.7 OMIT maps for triazole binding to ScErg11p6×His Y140F/H 
mutants. Triazole drugs are shown as sticks, C atoms yellow, N atoms blue, O 
atoms red, Cl atoms green and F atoms pale blue. The heme is shown with C 
atoms in magenta. The OMIT maps 2Fo - Fc map (blue) are contoured at 1σ 
and the Fo - Fc map (green) are contoured at 3σ. Both maps were calculated 
using Fcalc refined from coordinates with no ligand at the active site. The 
electron density is shown for (a) FLC, (b) VCZ, (c) ITC and (d) PCZ binding in 
the active site of ScErg11p6×His Y140F mutant. The electron density is shown 
for (e) FLC and (f) ITC in the active site of ScErg116×His Y140H mutant. 
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4.3.4.1 Binding of the long-tailed drugs ITC and PCZ to ScErg11p6×His 
Y140F/H mutants 
X-ray crystal structures were obtained for ScErg11p6×His Y140F in complex 
with ITC and PCZ (PBD IDs: 4ZDY and 4ZE1, respectively) in the active site 
at resolutions of 2.02 Å and 2.05 Å (Appendix G, Table G-3), respectively, and 
for ScErg11p6×His Y140H in complex with ITC at a resolution of 2.30 Å 
(Appendix G, Table G-4). Both the ScErg11p6×His Y140F and Y140H 
structures showed binding of the long-tailed triazole ITC essentially identical to 
that seen previously with wild type ScErg11p×His (PDB ID: 4K0F) (Figure 
4.8). The most significant feature detected in the active site, apart from the 
mutated residues, was the presence of a water molecule (843) between a heme 
propionate and the aromatic side chain of the F140 (Figure 4.8a; arrow) that was 
not seen in the wild type structure (PDB ID: 4K0F; Monk et al., 2014b). Water 
843 replaced the hydrogen bond between the hydroxyl group of Y140 and the 
propionate group of the heme (water 743 is in a nearby position in wild type 
ScErg11p6×His FLC structure PDB ID: 4WMZ) but it makes no polar contacts 
with the inhibitor and it is unlikely to substantially affect ITC binding. The 
equivalent water molecule was not detected in the structure of ScErg11p6×His 
Y140H in complex with ITC or in the crystal structure of ScErg11p Y140F in 
complex with PCZ. The absence of this water is unlikely to be due to limited 
resolution as the mutant ScErg11p6×His Y140F complexes with ITC and PCZ 
and ScErg11p6×His Y140H complex with ITC were of comparable resolution, 
i.e. 2.02 Å, 2.05 Å and 2.30 Å, respectively. Each crystal structure of the mutant 
enzyme showed the long tail of each triazole inhibitor bound within the 
substrate channel in an extended conformation, with the piperazine ring in the 
chair conformation. This conformation was stabilised via a water-mediated 
hydrogen bond network between the nitrogen atom of the piperazine ring (N20 
in ITC and NBT in PCZ), the main chain amide of H381 and the main chain 
amide of S382.  
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Figure 4.8 Binding of ITC and PCZ to ScErg11p6×His Y140F/H. 
ScErg11p6×His Y140F in complex with (a) ITC and (b) PCZ; and (c) 
ScErg11p6×His Y140H in complex with ITC. ScErg11p6×His Y140F is shown 
in lilac cartoon (PDB ID: 4ZDY, 4ZE1) and ScErg11p6×His Y140H is depicted 
in yellow cartoon (PDB ID: 4ZE2). Hydrogen bonds are shown as yellow 
dashed lines and water molecules as red spheres. ITC (green), PCZ (grey), the 
side chains of residues 140 and 126, the backbone of F384 and the heme 
(magenta) are shown as sticks. Water 843 is indicated with an arrow. 
4.3.4.2 Binding of the short-tailed triazoles FLC and VCZ to 
ScErg11p6×His Y140F/H  
The structure of ScErg11p6×His Y140F in complex with FLC (PDB ID: 4ZDZ) 
showed the drug bound to the wild type ScErg11p6×His structure in a similar 
conformation (PDB ID: 4WMZ), with any differences in the interactions 
between the drug and the enzyme ascribed to the mutation. As described in our 
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previous report (Sagatova et al., 2015; Chapter 3), the structure of 
ScErg11p6×His in complex with FLC included a water molecule (743) that 
hydrogen bonds with the hydroxyl group of FLC, the hydroxyl of Y140 and one 
of the propionates of the heme (Figure 4.9a). In addition, the non-coordinated 
triazole of FLC and the main chain carbonyl of S382 formed a hydrogen bond 
network mediated by water 790. This water was not detected in mutant 
ScErg11p6×His in complex with ITC or PCZ because the tails of these ligands 
occupy that space. A water molecule equivalent to water 743 (numbered 843 in 
the mutant structures) was found in ScErg11p6×His Y140F in complex with 
FLC but the hydrogen bond with Y140 was abolished as a result of the Y140F 
mutation (Figure 4.9b). In addition, the Y140F mutation prevented formation of 
a hydrogen bond between the propionate group of the heme and the tyrosine 
hydroxyl. A new hydrogen bond between the propionate and water 843 now 
exists. The hydrogen bond network disrupted by the Y140F mutation results in 
the presence of an additional water molecule (numbered 844), which is 
hydrogen bonded to water 843 and the second propionate group of the heme 
(Figure 4.9b).  
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Figure 4.9 Binding of short chain azoles to ScErg11p6×His wildtype and 
Y140F/H mutant enzymes. Water-mediated interactions are shown for (a) 
wildtype ScErg11p6×His in complex with FLC, (b) ScErg11p6×His Y140F in 
complex with FLC, (c) ScErg11p6×His Y140F in complex with VCZ, and (d) 
ScErg11p6×His Y140H in complex with FLC. The wild type protein is depicted 
in grey cartoon (PDB ID: 4WMZ), the Y140F mutant in lilac (PDB ID: 4ZDZ, 
4ZE0) and the Y140H mutant in yellow (PDB ID: 4ZE3). Hydrogen bonds are 
shown with dashed lines and water molecules as red spheres. FLC (cyan), VCZ 
(green), the side chains of residue Y/F/H140, Y126, the backbone of S382 and 
F384 and the heme (magenta) are shown as sticks. Water 844 is indicated with 
an arrow. Note: the hydrogen bonds between Y126 and F384 are not shown in 
panels (a), (b) and (d). 
The crystal structure of the Y140F mutant in complex with VCZ showed that 
water 843 was the only water hydrogen bonded to the ligand (Figure 4.9c). The 
position of the fluorine atom on the pyrimidine ring prevents the presence of the 
additional water (844) seen with FLC. 
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FLC showed similar binding to the wild type ScErg11p6×His and 
ScErg11p6×His Y140H structures (Figure 4.9d). Water molecule 843 is present 
in the mutant structure and forms a single short hydrogen bond with the 
hydroxyl group of FLC. This water displays a higher B-factor of 49 compared 
to 30 for water 743 in the wild type structure and 37 for water 843 in the Y140F 
mutant structure. However, it is unlikely to form a hydrogen bond with the 
imidazole of H140, as the orientation of the nitrogen atom lone pair of electrons 
is not appropriate for this to occur. A new polar contact (bond distance 2.7 Å) 
observed between N2 of the imidazole of H140 and the side chain hydroxyl of 
T130 orients the H140 side chain closer to T130 than is seen with Y140 or F140 
side chains (Figure 4.9d). For ScErg11p6×His Y140H in complex with ITC, the 
orientation of the imidazole ring was similar but the N2 of the H140 imidazole 
and the hydroxyl of T130 are separated by 3.4 Å (Figure 4.8c).  
4.4 Discussion  
Triazole resistant phenotypes in the yeast S. cerevisiae have been obtained by 
creating the single site Y140F/H mutations in lanosterol 14α-demethylase that 
have homologues in numerous species of pathogenic fungi (Becher and Wirsel, 
2012). Whole cell assays (MIC80 measurements) were used to confirm the 
reduced susceptibility of ScErg11p6×His Y140F/H mutants to FLC and VCZ. 
The <2-fold differences in MIC80 values detected using overexpression of wild 
type and mutant ScErg11p6×His in the yeast system were not as dramatic as 
previously reported for the C. albicans CYP51 Y132H mutation but show a 
similar trend (Sanglard et al., 1998). In addition potential structural differences 
between CaCYP51 and ScErg11p, which have a sequence similarity of 65%, 
and a reduction in the amount of overexpressed ScErg11p6×His Y140H mutant 
by up to 17% compared with the overexpressed wild type enzyme may explain 
this observation for this mutant. Structural and functional analysis of these 
mutants demonstrated how water-mediated hydrogen bonds between a drug and 
the target protein within the active site, can affect the binding of the short-tailed 
triazole drugs FLC and VCZ but not the long long-tailed triazoles ITC and PCZ. 
The affinity purified ScErg11p6×His Y140F/H enzymes differed from the wild 
type enzyme in both their absolute spectra and the type II difference spectra that 
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resulted from azole binding. The difference in the wavelength for maximum 
absorbance for the oxidised heme Soret peak between the Y140F/H mutant 
enzymes (420 nm) and the wild type enzyme (417 nm) is consistent with these 
mutations altering the electronic environment of the heme. Disruption of the 
short hydrogen bond between Y140 and the heme propionate is the common 
feature that may explain this effect in both the Y140F and Y140H mutants. The 
detection of wider troughs in the type II absorbance spectra, with the minima 
around 410 nm indicated that most of the iron in the Y140F/H mutant enzymes 
is in a low spin state prior to drug addition (Locuson et al., 2007). The different 
environments in the active site that result from the more polar side chain of the 
Y140H mutant and the aromatic group of the Y140F mutant may explain the 
subtle differences in triazole susceptibility and type II difference spectra of the 
two mutant enzymes.  
Binding of the triazole drugs shifted the Soret peak of the wild type enzyme 
from 417 nm to 421 – 422 nm due to their replacement of heme iron bound 
water molecule that is thought to stabilise the low spin state (described in 
Section 1.9.1). The binding of the triazole drugs to ScErg11p6×His Y140F/H 
shifted the Soret peak from 420 to 421 nm and therefore produced a 
significantly smaller shift in the wavelength of the Soret peak. This mutant 
phenotype also gave a lower ΔAmax in the type II difference spectra than the 
wild type enzyme (Table 4.2). However, the Kd values obtained in the presence 
of 1 µM wild type or mutant enzyme for each triazole drug indicated “tight” 
binding with affinities in the nanomolar range ( Table 4.3). In addition, the 
crystal structures obtained with the mutant enzymes in complex with all four 
triazole drugs did not indicate limited occupancy (Figure 4.7).  
A correlation between resistant phenotype and azole affinity for CYP51 enzyme 
was previously reported for the C. albicans CYP51 G464S (Kelly et al., 1999b), 
T315A (Lamb et al., 1997) and S279F (Warrilow et al., 2012) mutants but not 
for the I471T mutant (Warrilow et al., 2010a). Previous reports of the C. 
albicans CYP51 Y132H mutant have provided conflicting results. One study 
reported that FLC binding to Y132H CaCYP51 elicited a type I response 
instead of the usual type II response (Kelly et al., 1999a). Another study 
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reported a type II response and a Kd value similar to the wild type enzyme (Park 
et al., 2011). Our studies show that affinities between the wild type enzyme and 
the Y140F/H mutants are within the error margins of the determined values for 
all triazoles tested. This observation may reflect the intrinsic difficulties in 
extracting high precision binding information needed to calculate inhibitor 
affinities when tight enzyme-inhibitor complexes are formed in a near 
stoichiometric manner. Alternatively the similarity in Kds might be a 
coincidental outcome of compensatory changes in inhibitor on and off rates 
caused by the mutations. Such effects may not be observed in equilibrium 
binding studies or in the crystal structures prepared in the presence of excess 
inhibitor. Further discussion on this is covered in Chapter 6.  
The crystal structures previously obtained for wild type ScErg11p6×His in 
complex with the substrate lanosterol (PDB ID: 4XLJ) or the long-tailed 
inhibitor ITC (PDB ID: 4K0F, Monk et al., 2014b) showed a hydrogen bond 
between one of the heme propionates and the hydroxyl group of Y140 and no 
water molecules in proximity (5 Å) of this substrate or inhibitor within the 
active site. The previously reported structure of ScErg11p6×His in complex 
with the short-tailed FLC (PDB ID: 4WMZ) showed that Y140, located on the 
B’C loop, forms a hydrogen bond network with the heme propionate group and 
the hydroxyl group of FLC via a water molecule 743 (Figure 4.9a). A limitation 
of the present study is the lack of high-resolution structures of ScErg11p6×His 
and the Y140H mutant in complex with VCZ. A structure of ScErg11p6×His in 
complex with VCZ was previously noted by Monk et al. (Monk et al., 2014b) 
but the resolution of this structure (2.8 Å) was insufficient to visualise any water 
network. VCZ is structurally similar to FLC and contains a hydroxyl group that 
should interact with the Y140 residue via a comparably located water molecule. 
We have shown that the ScErg11p6×His Y140F mutation disrupts this hydrogen 
bond network between enzyme and both FLC and VCZ. These results appear, at 
least in part, to explain the FLC and VCZ resistance of this mutant and the 
retention of susceptibility to ITC and PCZ, because the key hydroxyl is replaced 
by a 1,3-dioxolane moiety in both long-tailed triazoles. 
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Calorimetric studies have shown that it is energetically favourable to include a 
water molecule at the protein-ligand interface, providing evidence that water-
mediated interactions can stabilise protein-ligand complexes (Ladbury, 1996). 
Sharrow et al. demonstrated that the loss of water-mediated hydrogen bonding 
due to a tyrosine to phenylalanine mutation reduced favourable enthalpy and the 
binding affinity of a ligand to its target protein (Sharrow et al., 2005). The 
water-mediated polar interactions between Y140 and the hydroxyl of FLC and 
VCZ optimally stabilise the binding of those drugs. Fungi have evolved a 
mechanism of resistance, shared with plants, that disrupts this stabilising 
interaction. 
The binding of the long-tailed triazoles ITC and PCZ to wild type 
ScErg11p6×His and the Y140F/H mutants pushes Y126 to a position so it 
interacts with the second propionate group of the heme and the main chain 
amide of F384 (Figure 4.8). This overall configuration is less constrained when 
the short-tailed triazole FLC occupied the active site providing more space 
(Figure 4.9). Y126 maintains its hydrogen bond with the main chain amide of 
F384 but is positioned further from the heme propionate. Water 7901 forms 
hydrogen bonds with the main chain carboxyl of S382, the hydroxyl of Y126 
and N3 of the non-coordinating triazole ring of FLC. How this conformation, 
together with the loss of the hydrogen bond between Y126 and the heme 
propionate, might affect the electronic configuration of the heme is not 
understood.  
In the ScErg11p6×His Y140F structure complexed with VCZ there was only 
one water molecule found at the mutation site and the orientation of 
fluoropyrimidine ring of VCZ excluded water 790 (Figure 4.9). A hydrogen 
bond was maintained between Y126 and the main chain amide of F384 but a 
water-mediated polar interaction between the fluoropyrimidine ring and the 
carbonyl of S382 was not detected.  
As seen in the X-ray crystal structures of ScErg11p6×His, the enzyme forms 1-
1 complexes with the long-tailed triazoles PCZ and ITC in essentially identical 
                                                
1 Water 790 in PDB ID: 4WMZ, 811 in PDB ID: 4ZE3 and 839 in PDB ID: 
4ZDZ 
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conformations that extend from the active site through the channel to the 
membrane-associated entry site. In the three structures of ScErg11p6×His in 
complex with ITC or PCZ presented here the piperazine ring is in a chair 
conformation. This accommodates a water molecule that forms a hydrogen bond 
network with the piperazine N1, the main chain amide of H381 and the main 
chain amide and carbonyl of S382. Structures of T. brucei CYP51 in complex 
with PCZ show the ligand in two different conformations (Chen et al., 2010). 
An extended conformation of the triazole tail resulted when the PCZ piperazine 
ring was in a chair conformation while a twisted boat shape accommodated a 
bent conformation. The two different conformations of PCZ may potentially be 
accommodated by a difference in the conformation at the opening to the channel 
of the N-terminal truncated T. brucei CYP51 (PDB ID: 2X2N; Chen et al., 
2010) compared with full-length ScErg11p6×His (PDB: 4K0F). Helix F’ and 
the F’G loop allow for a slightly bigger opening to the substrate channel in the 
T. brucei CYP51 structure than in ScErg11p. Whether the larger opening is 
independent of the N-terminus truncation has yet to be determined. 
Triazole drugs currently in either clinical trials or clinical use include VT-1161, 
ravuconazole, albaconazole and isavuconazole (ISA; Figure 1.3; Pasqualotto et 
al., 2010, Hoekstra et al., 2014, Warrilow et al., 2014). All four of these 
compounds have the hydroxyl group that could interact with Y140 (S. 
cerevisiae numbering) via a water mediated hydrogen bond network. Therefore, 
we postulate that these drugs may prove less effective against CYP51 mutations 
equivalent to Y140F/H. ISA has been approved for treatment of invasive 
aspergillosis in the US (McCormack, 2015). However clinical isolates of A. 
fumigatus with the TR46/Y121F/T289A CYP51 mutations are found in many 
parts of the world (Chowdhary et al., 2014b, Chowdhary et al., 2014a, Lavergne 
et al., 2015). Such mutants have the potential to be resistant to ISA due to the 
Y121F mutation, which confers resistance to VCZ (Lescar et al., 2014, van der 
Linden et al., 2013). The novel tetrazole compound VT-1161 is currently in 
phase II clinical trials. It was shown to be a potent inhibitor of C. albicans 
CYP51 (Warrilow et al., 2014). Thus mutations equivalent to ScErg11p 
Y140F/H have the potential to confer resistance to this drug. However, it is 
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worth noting that the longer tails of those azoles (VT-1161 and ISA) may 
provide extra interactions not present in FLC and VCZ binding.  
The agrochemicals tebuconazole and prothioconazole-desthio both have a 
similarly located hydroxyl group that may be expected to generate resistance via 
the equivalent mutations in fungal phytopathogens e.g. Z. tritici CYP51 Y137F 
and P. pachyrhizi CYP51 Y131F I475T (Leroux and Walker, 2011, Schmitz et 
al., 2014). This characteristic is likely to be shared by the C. albicans 
Darlington strain, which expresses the Y132H I471T mutations in lanosterol 
14α-demethylase (Kakeya et al., 2000). Finally, plant CYP51s normally have a 
conserved phenylalanine residue at the position equivalent to Y140 (e.g. F124 in 
A. thaliana; (Lepesheva and Waterman, 2011), which may contribute to their 
intrinsic resistance to these agrochemical fungicides. 
In conclusion, ScErg11p6×His crystal structures have revealed that the 
resistance conferred by the Y140F/H mutations is due to disruption of a water-
mediated hydrogen-bond network between the hydroxyl groups of FLC and 
VCZ and the enzyme plus a modification in the electronic environment of the 
heme. We predict that this type of resistance could be avoided by substituting 
the hydroxyl of group of FLC and VCZ with the 1,3-dioxolanyl group of ITC or 
PCZ in order to minimise those water-mediated interactions. It may also be 
possible to replace the hydroxyl group in antifungals like FLC, VCZ, VT-1161, 
prothioconazole and tebuconazole with alternative substituents that will give 
more favourable binding to fungal CYP51s and circumvent the impact of 
mutations equivalent to Y140F/H. 
 
Note: Based on the work described in this chapter an article entitled “Triazole 
resistance mediated by mutations of a conserved active site tyrosine in fungal 
lanosterol 14alpha-demethylase” was published in Scientific Reports. This 
article is included in the final Appendix of this thesis under section Attached 
Articles. 
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Chapter 5                         
Investigation of triazole susceptibilities 
conferred on Saccharomyces cerevisiae                      
lanosterol 14α-demethylase by homologous 
mutations found in fungal pathogens  
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5.1 Introduction  
Mutations in CYP51(s) found in fungal pathogens can confer resistance to 
azole-based antimycotics. CYP51 mutations of the prominent fungal pathogen 
C. albicans reported in the literature have been summarised in reviews by Morio 
et al. and Ying et al. (Morio et al., 2010, Ying et al., 2013). These mutations are 
dispersed throughout the primary sequence but Marichal et al. were able to 
identify three hotspots; amino acids 105-165, 266-287 and 405-488 (Marichal et 
al., 1999). Flowers et al. have identified several single site mutations in 
CaCYP51 that give at least 4-fold resistance to FLC (Flowers et al., 2015). They 
used the full-length crystal structure of ScErg11p6×His in complex with 
lanosterol (PDB ID: 4LXJ; Monk et al., 2014b) to show that those resistance-
conferring mutations are located in proximity to the heme, the substrate channel 
or in the fungus-specific external loop. Mutations close to the heme are thought 
to alter its tilt, hydrophobic or electronic environment and thus potentially affect 
the binding of the azoles in the active site. Mutations in the substrate channel 
may directly interfere with access to the active site or the binding of long-tailed 
triazoles such as ITC and PCZ e.g. the G54 mutations in A. fumigatus CYP51A 
discussed below (Section 5.1.2). How the fungus-specific loop (residues 428 – 
459 in CaCYP51, 432 – 457 in ScErg11p) affects azole binding has yet to be 
established, despite this region bearing several single site mutations that confer 
resistance to FLC e.g. D446E, Y447H, G448E, F449V, G450E and V456I (C. 
albicans numbering; Flowers et al., 2015, Alvarez-Rueda et al., 2011). The 
CaCYP51 mutations Y447H and V456I allow the fungal strain to retain its 
catalytic activity in the presence of FLC (Alvarez-Rueda et al., 2011). This 
suggests that the mutants could have preferential binding for lanosterol over 
FLC or more efficient catalysis. However, since the amino acid residues of the 
fungus-specific loop are too far away from the active site cavity to directly 
affect the binding of azoles, resistance caused by mutations in this region may 
be due to improved catalytic efficiency resulting from enhanced interactions 
with other enzymes, for example NADPH-cytochrome P450 reductase. In 
mammalian CYP450s the reductase is known to interact with the neighbouring 
helix C (Bridges et al., 1998).   
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The focus of this chapter is on mutations in fungal CYP51s which, based on our 
previous crystal structures, appear to be close enough to the heme, the active 
site or the substrate entry channel to either alter the environment of the heme or 
directly disrupt the binding of triazole drugs. Structural and functional analysis 
of these mutations recreated in S. cerevisiae Erg11p was expected to provide 
insight into their effect on enzyme conformation and its affinity for the triazole 
antifungals. 
5.1.1 Triazole resistance in Candida albicans  
The CaCYP51 Y132F/H, K143R and G464S mutations have been discussed in 
Section 3.3.6. The in-depth structural and functional analysis of the Y132F/H 
CaCYP51 mutation recreated as ScErg11p6×His Y140F/H has been described 
in Chapter 4. The CaCYP51 G464S mutation has been found to confer 
resistance to FLC either alone or in combination with other mutations (Sanglard 
et al., 1998, Chau et al., 2004, Flowers et al., 2015). Spectrophotometric 
analysis using microsomal preparations from S. cerevisiae cells expressing the 
CaCYP51 G464S mutant found that the mutant enzyme had reduced affinity for 
FLC and lower catalytic activity than the wild type enzyme (Kelly et al., 
1999b). It was suggested that the positioning of the heme within the enzyme 
could be altered due to the mutation. The CaCYP51 G464S mutation 
corresponds to G448S in A. fumigatus CYP51A. In A. fumigatus this single site 
mutation has been shown to confer resistance to the short-tailed triazole VCZ 
but not the long-tailed triazoles ITC or PCZ (Howard et al., 2009, Pelaez et al., 
2012). Pelaez et al. (Pelaez et al., 2012) analysed the resistance of the clinical A. 
fumigatus mutant strain with microdilution assays. To my knowledge the 
AfCYP51 G448S mutant was not expressed and tested in S. cerevisiae.  
The G464S mutation has been found in combination with Y132H and R467K, 
as well as with Y132H and H283R (Sanglard et al., 1998, Chau et al., 2004). 
These combinations of mutations can have synergistic effects. For example, the 
Y132H and G464S mutations each conferred a 4-fold increase in resistance to 
FLC compared to the wild type enzyme. However, when both mutations were 
present in CaCYP51 the resistance of the strain to FLC was increased to 32-fold 
(Sanglard et al., 1998). It is interesting to note that G464S and Y132H are 
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located on the opposite sides of the heme (Figure 5.1). As described in Chapter 
3, the Y140F/H mutations of ScErg11p abolish the hydrogen bond between the 
heme propionate group and the hydroxyl group of the Y140. Based on the 
structure of ScErg11p6×His in complex with FLC (PDB ID: 4WMZ; Sagatova 
et al., 2015), the mutant G464S hydroxyl group was proposed to replace a water 
molecule that makes a hydrogen bond to the second propionate group (Figure 
3.4). As well as testing this hypothesis by recreating the G464S CaCYP51 
mutation in ScErg11p6×His, it was of interest to investigate whether the Y140F 
and G464S mutations cumulatively or synergistically affect FLC resistance and 
how the binding of this drug is affected on the structural level. 
 
 
Figure 5.1 S. cerevisiae Erg11p with ITC bound in the active site. Residues 
with carbons coloured green are structurally homologous to those thought to 
confer reduced drug susceptibility in pathogenic fungi. 
Two other mutations, which can be found in association with Y132H and 
G464S in CaCYP51, are R467K and H283R. CaCYP51 R467 is homologous to 
the ScErg11p R467 residue that is located close to G464 but does not interact 
with the heme. H283 in CaCYP51 is homologous to N290 in ScErg11p. It is 
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located in the C-terminal end of helix H in a position too distant from the heme 
to directly interact with it. Therefore the effect of those mutations was not 
pursued in this study. 
5.1.2 Triazole resistance in Aspergillus fumigatus  
A. fumigatus is intrinsically resistant to FLC and KTC but the molecular basis 
for the resistance has yet to be determined. This pathogen has two isoforms of 
the CYP51 enzyme, CYP51A and CYP51B (Mellado et al., 2001). Both 
isozymes catalyse sterol demethylation and neither is essential for cell growth. 
However, deletion of both CYP51 genes is lethal (Hu et al., 2007). Disruption 
of cyp51A but not cyp51B significantly reduced the minimal inhibitory 
concentration (MIC) for both KTC and FLC (Mellado et al., 2005). Therefore, it 
is thought that CYP51A is responsible for the intrinsic resistance to these 
azoles. VCZ is not susceptible to this intrinsic resistance mechanism and has 
been a drug of choice in the treatment of invasive aspergillosis since its 
introduction to the clinic in 2002 (Denning and Bromley, 2015). VCZ also 
crosses the blood brain barrier and can be used for treatment of cerebral 
aspergillosis, a previously incurable disease. Despite being more effective than 
AMB at treating invasive aspergillosis, the use of VCZ has significant toxicity 
and pharmacokinetic issues (Table 1.1).  
ITC and PCZ are used as prophylactic treatments of aspergillosis. PCZ is only 
available in oral formulations and has limited absorption. The more recently 
released triazole drug ISA has better properties such as increased water 
solubility and a longer half life (Table 1.1) than VCZ and has been approved for 
the treatment of invasive aspergillosis in the USA (Section 1.7.5.1; 
McCormack, 2015).  
One of many primary sequence differences between the CYP51A and CYP51B 
isoforms is I301 in CYP51A, which corresponds to T315 in CYP51B. It was 
proposed that I301 of CYP51A could be responsible for the reduced 
susceptibility of A. fumigatus to FLC because this residue was thought to be 
located in the active site near the heme (Edlind et al., 2001). This idea was 
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discussed in Section 3.3.6. The residue homologous with I301 in ScErg11p is 
T322I (Figure 5.1).  
One mechanism that confers azole resistance in A. fumigatus with a high 
prevalence among clinical isolates involves point mutations in the cyp51A gene. 
Three amino residues in CYP51A frequently associated with mutations 
conferring azole resistance are G54, M220 and L98 (Rodriguez-Tudela et al., 
2008). The L98H mutation is always accompanied by a 34 bp tandem repeat 
(TR34) in the promoter region of the cyp51A. TR34 increases the levels of 
cyp51A mRNA transcripts (Snelders et al., 2010). Several different amino acid 
substitutions occur at the G54 (E/K/V/R/W) and M220 (K/I/T/V) positions. The 
full-length structure of ScErg11p6×His enzyme (Monk et al., 2014b) shows that 
both sets of mutations are located near the mouth of the substrate channel.  
Mutations in CYP51A at position G54 are thought to confer resistance to ITC 
and PCZ by disrupting the interaction of long-tailed azoles with the mouth of 
the substrate channel. A recent study found that long-term prophylactic 
treatment with ITC induces mutations at G54 in A. fumigatus CYP51A (Tashiro 
et al., 2012). The G54R/W/E mutants appear to be susceptible to the short-tailed 
triazole VCZ (Mann et al., 2003). In addition, the latest generation triazole, ISA, 
has been found to be effective against those mutants (Howard et al., 2013). This 
implies that these mutations do not interfere with the binding of this triazole, 
which has a medium length tail. 
The resistance of CYP51A G54 mutants has been investigated by expressing the 
A. fumigatus CYP51A in S. cerevisiae (Alcazar-Fuoli et al., 2011). The S. 
cerevisiae strain used was deficient in the dominant multidrug efflux pump 
Pdr5p while expression of the endogenous ScERG11 was repressed by using a 
tetracycline-regulated promoter. This study confirmed the reduced susceptibility 
of these strains to ITC and PCZ and their retention of susceptibility to VCZ. Of 
all the mutations at this position it was reported that the G54W mutant was least 
susceptible to both ITC and PCZ (Alcazar-Fuoli et al., 2011). The paper of 
Alcazar-Fuoli et al. concluded that characteristics of specific A. fumigatus 
CYP51A alleles could be investigated in the heterologous host S. cerevisiae. As 
this laboratory has not been able to express the A. fumigatus CYP51A enzyme 
Chapter 5: Biochemical and structural characterisation of ScErg11p mutants 
 101 
in yeast, it was decided to use overexpressed ScErg11p as a surrogate. The 
structural homolog of G54 in A. fumigatus CYP51A is G73 in S. cerevisiae.  
5.1.3 Aims of this chapter 
Understanding of the mechanistic basis of resistance mutations in the CYP51s 
of fungal pathogens has been limited due to a paucity of structural information 
for this enzyme. This study investigated the molecular mechanisms of resistance 
at the structural and biochemical level by using S. cerevisiae Erg11p as a model 
for fungal CYP51s. The aims of this study were:  
1. To introduce the mutations G73E/R/W, K151R, T322I, G464S and the 
double mutation Y140F G464S into S. cerevisiae Erg11p.  
2. To determine the triazole susceptibilities of the S. cerevisiae strains 
harbouring mutations in ScErg11p.  
3. To purify and biochemically characterise the mutant ScErg11p enzymes, 
including their stability and drug binding affinities.  
4. To crystallise the mutant ScErg11ps in complex with triazole drugs. 
5. To visualise how the mutations in the structure of ScErg11p affect drug 
binding. 
5.2 Materials and methods 
5.2.1 General 
The general materials and methods used in this chapter are described in Chapter 
2. The strains used in this chapter are listed in Appendix A.1 (Table A-1). 
Materials and methods specific to this chapter are described in the following 
sections. 
5.2.2 Oligonucleotide primers 
The primers used in recombinant PCR to introduce ScErg11p mutations are 
listed in Table 5.1. The general primers used for making the ScERG11 mutant 
transformation cassettes are listed in Appendix B.1. 
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Table 5.1 Oligonucleotide primers used to make mutations in ScERG11 



















*f denotes a forward primer and r denotes a reverse primer. Mutated codons are 
highlighted in bold.  
5.2.3 Streak microseeding  
The ScErg11p6×His K151R enzyme did not form crystals under the conditions 
used for the wild type enzyme or the other mutants studied. The streak seeding 
method was used in an attempt to introduce nucleation sites in drops of the 
mutant protein and encourage crystallisation (Bergfors, 2003). Several crystals 
of wild type ScErg11p6×His were washed in reservoir solution to remove 
precipitate.  Microcrystals obtained by smashing the washed crystals into small 
fragments with a pipette tip were briefly centrifuged in a microcentrifuge to 
settle any large fragments. The hanging drop vapour diffusion method was used 
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for crystallisation with microseeding. The reservoir solution contained 40 or 
50% PEG-400 in 100 mM glycine in the pH range 9.3 - 9.5. The drop volume 
was 2 µL with a 1:1 ratio of reservoir solution and purified mutant protein at 20 
mg/mL. After overnight pre-equilibration at 4 °C, cover slips were opened and 
drops were seeded with wild type ScErg11p6×His microcrystals. A cat whisker 
was dipped into a seeding solution and dragged through the pre-equilibrated 
drop. The coverslip containing the drop was sealed onto the reservoir plate and 
incubated at 18 °C.  
5.3 Results 
5.3.1 Cloning of ScErg11p6×His mutants 
Mutant ScERG11 transformation cassettes were prepared by amplifying three 
DNA fragments from the PDR5 locus of the genomic DNA of the ADΔ 
ScErg11p6×His overexpressing strain (MMLY 941). The fragments were fused 
together and amplified by using recombinant PCR with the outside primers 1 
and 6 as illustrated in Figure 5.2. The G73E mutant is used as an example in this 
figure. The transformation cassettes for the other mutants described were made 
in the same way using mutation specific primers (Table 5.1). The remaining 
oligonucleotide primer sequences are listed in Appendix B.1, Table B-1. The 
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Figure 5.2 Construction of ScERG11 G73E mutant transformation cassette. 
Genomic DNA of strain MMLY 941 was used as a template for the introduction 
of a DNA change into a transformation cassette. The transformation cassette 
contains the PDR5 upstream region, ScERG11 with a C-terminal His-tag, the 3-
phosphoglycerate kinase (PGK) terminator, the URA3 selection marker and a 
PDR5 downstream sequence. The upstream region of the ScERG11 G73E 
transformation cassette was amplified using primers PDR5F (1) and 
ScErg11_G73E_r (2), the middle region using primers ScErg11_G73E_f (3) 
and ScUra3-rev (4) and the downstream region using primers Ura3-PDR5DS 
(5) and PDR5DS (6). Recombinant PCR using the outside primers 1 and 6 were 
used to fuse the fragments and generate the full-length cassette.  
An example of the preparation of a transformation cassette containing single 
mutations in ScERG11 as described in Figure 5.2 and the agarose gel 
electrophoresis profiles obtained for two mutations (G73E and T322I) are 
shown in Figure 5.3. The amplified cassettes were separated by agarose gel 
electrophoresis and purified using a gel extraction kit. The purified 
transformation cassette for each mutant, which also contained the URA3 
selection marker was used to transform the AD2Δ host strain. Solidified SD 
uracil dropout medium was used to select ura+ transformants. 
Chapter 5: Biochemical and structural characterisation of ScErg11p mutants 
 105 
 
Figure 5.3 Construction of ScERG11 G73E and T322I transformation 
cassettes by recombinant PCR. Individual DNA fragments, amplified from 
genomic DNA of strain MMLY 941 to introduce mutations, together with a 407 
bp downstream region, were fused by recombinant PCR. The DNA fragments 
were separated by electrophoresis on a 0.8 % agarose gel. Lane M: Molecular 
markers (1 kb Plus DNA molecular ladder, Invitrogen). Lane 1: the upstream 
region of the ScERG11 G73E transformation cassette obtained with primers 
PDR5F and ScErg11_G73E_r (917 bp). Lane 2: the middle region of the 
ScERG11 G73E transformation cassette obtained with primers 
ScErg11_G73E_f and ScUra3-rev (2797 bp). Lane 3: the upstream region of 
ScERG11 T322I transformation cassette (1660 bp) obtained with primers 
PDR5F and ScErg11_T322I_r. Lane 4: the middle region of ScERG11 T322I 
transformation cassette (2049 bp) obtained with primers ScErg11_T322I_f and 
ScUra3-rev. Lane 5: the ScERG11 G73E transformation cassette obtained by 
recombinant PCR using primers PDR5F and PDR5DS. Lane 6: the ScERG11 
T322I transformation cassette obtained by recombinant PCR using primers 
PDR5F and PDR5DS. The size of the ScERG11 G73E and T322I 
transformation cassettes was expected to be 4117 bp. 
The ScErg11p6×His Y140F G464S mutant was created using template genomic 
DNA obtained from the strain overexpressing ScErg11p6×His Y140F 
(AD3ΔScErg11p_Y140F; described in Chapter 4), with the G464S mutation 
introduced using primers specific for this mutation (Table 5.1). 
Correct integration of the transformation cassettes was confirmed by colony 
PCR using primers PDR5_US and ScErg11_ORF_183R (Appendix B.1, Table 
B-1). Fragments of the expected size (1417 bp) were detected on 0.8 % agarose 
gels in clones that were positive for the insert (Appendix B.1, Figure B-1). 
Genomic DNA was extracted from colonies positive for the insert and the 
ScERG11 cassette was amplified using primers PDR5_US and 
PDR5_288_DS_Rev. The complete open reading frame of 6×His tagged 
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ScERG11 was sequenced and the expected mutations confirmed for each 
mutant. The strains prepared in this study are listed in Appendix A.1, Table A-1. 
The strains were named according to the mutation in ScERG11 gene and 
whether or not the native ERG11 was intact or removed by insertion of the 
ScHis1 gene disruption cassette. For example, the G73E mutant strain with 
native ERG11 intact was named AD2ΔScErg11p_G73E and with native ERG11 
removed AD3ΔScErg11p_G73E. 
5.3.2 Deletion of ERG11 native to the S. cerevisiae host  
The ScHis1 disruption cassette specific for the native ERG11 open reading 
frame was constructed from 3 DNA fragments (Figure 5.4) obtained by PCR 
using the oligonucleotide primer sequences listed in Appendix B.2, Table B-2. 
Sequences immediately upstream and downstream of the ERG11 open reading 
frame and the ScHIS1 gene together with its endogenous promoter were 
amplified. The three DNA fragments were amplified from the genomic DNA of 
S. cerevisiae strain ADΔ-pABC5’ (MMLY 1760; Lamping et al., 2007).  
 
Figure 5.4 Construction of the ScHis1 disruption cassette. Genomic DNA of 
strain MMLY 1760 was used to amplify 3 separate fragments using primers 1 – 
6. The ScHis1 disruption cassette contains the ScERG11 upstream region 
(ERG11 US), ScHIS1 open reading frame (ScHIS1 ORF) and ScERG11 
downstream sequence (ERG11 DS). The ERG11 US was amplified using 
primers ScErg11_US-773 (1) and ScErg11US-387R (2), the middle region 
comprising the ScHIS1 promoter and ORF using primers ScErg11xHisF (5) and 
ScErg11xHisR (6) and the ERG11 DS region using primers ScErg11DS60 (3) 
and ScErg11DS346R_Δ (4). Recombinant PCR outside primers 1 and 4 were 
used to fuse and amplify the full-length gene disruption cassette. 
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The ScHis1 gene disruption cassette, designed to delete native ERG11 in strains 
created using AD2Δ as host, was prepared by recombinant PCR using the 
external primers ScErg11_US-773 and ScErg11DS346R_Δ to fuse the 
fragments generated as described in Figure 5.5. Amplimers of the cassette were 
separated by agarose gel electrophoresis (Figure 5.5) and purified using a gel 
extraction kit. Strain AD2ΔScErg11p6×His was transformed with the gel 
purified transformation cassette and his+ transformants selected using solidified 
SD histidine dropout media. 
 
 
Figure 5.5 Construction of the ScHis1 disruption cassette for native ERG11. 
The DNA fragments shown in lanes 1-3 were amplified by PCR from the 
genomic DNA of strain MMLY 1760. PCR fragments were separated by 
electrophoresis on a 0.8 % agarose gel. Lane M: molecular markers (1 kb Plus 
DNA molecular ladder, Invitrogen). Lane 1: the upstream region of the ScHis1 
transformation cassette (387 bp). Lane 2: the middle region of the ScHis1 
transformation cassette (1753 bp). Lane 3: the downstream region of the ScHis1 
transformation cassette (287 bp). Lane 4: the ScHis1 transformation cassette 
created by recombinant PCR (2379 bp).  
Colony PCR using primers ScErg11_US_801 and ScHis1_ORF_493R followed 
by electrophoresis on 0.8% agarose gels (Appendix B.2, Figure B-2) detected 
the presence of a DNA fragment of the size (1604 bp) expected for insertion of 
the disruption cassette into the genome at the ERG11 locus. Genomic DNA of 
his+ colonies indicating the presence of the cassette was extracted, the ScHIS1 
disruption cassette amplified using primers ScErg11_US_801 and 
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ScErg11_ter_rev and sequenced. The oligonucleotide primer and ScHIS1 
cassette sequences are listed in Appendix B.2. The ScERG11 mutant cassette at 
the PDR5 locus was also amplified from genomic DNA and sequenced to 
ensure that it had not been further modified due to deletion of the native ERG11. 
Deletion of native ERG11 gave viable transformants for all strains apart from 
the ScErg11p6×His G73W mutant. Multiple attempts to delete native ERG11 
gene from this strain were unsuccessful. The strains created in this study are 
listed in Appendix A.1, Table A-1. 
5.3.3 Azole susceptibility assays  
Microdilution drug susceptibility assays (MIC80 determinations) were performed 
on wild type and mutant S. cerevisiae strains that expressed mutant ScERG11 
from the PDR5 locus, without (AD2Δ background) and with (AD3Δ 
background) the native ERG11 deleted. A comparison of the susceptibilities of 
these strains to selected triazole drugs were used to evaluate the contribution of 
the native enzyme to the wild type and mutant phenotypes. 
5.3.3.1 Single mutations in ScErg11p expressed from the PDR5 locus 
The MIC80 values for the strains carrying a single mutation in ScErg11p 
expressed from the PDR5 locus are presented as a histogram in Figure 5.6 and 
tabulated in Table 5.2. It was expected that each mutant strain would show 
comparable or reduced susceptibility relative to the wild type ScErg11p6×His 
overexpressing strain, to some or all the triazoles tested, regardless of whether 
the native enzyme was expressed. In Chapter 3, we reported that removal of the 
endogenous ScErg11p from the wild type overexpressing strain did not 
significantly alter susceptibilities to the tested triazole drugs. This finding was 
interpreted as showing that the reduced triazole susceptibility of the strain was 
due to the constitutive overexpression of hexahistidine-tagged ERG11 from the 
pdr1-3 regulated PDR5 locus and was essentially unaffected by the expression 
of the native ERG11.  
Strains overexpressing ScErg11p6×His containing the T322I and G464S 
mutations gave susceptibilities comparable to the wild type strain for each of the 
triazole drugs tested (FLC, VCZ and ITC). Deletion of the endogenous 
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ScERG11 from the AD2ΔScErg11p_T322I and AD2ΔScErg11p_G464S strains 
did not significantly alter susceptibility to any of these triazoles. This indicates 
that these mutant enzymes are fully functional and do not confer significant 
resistance when overexpressed. 
In several instances, co-expression of the wild type and mutant enzymes led to 
increased susceptibility to all the triazole drugs compared to co-expression of 
the wild type enzyme from both the native and PDR5 loci. This was observed 
with the G73 series of mutants and the K151R mutant in the AD2Δ background. 
For the co-expressed K151R mutant the MIC80 was reduced by about 0.2-0.5-
fold for all three triazoles tested. For the G73 mutants the MIC80 was reduced 
approximately 2.5-fold for FLC and VCZ but not ITC. These results suggested 
reduced functional expression of the co-expressed mutant enzymes relative to 
the wild type enzyme. Alternatively, the mutant enzymes could be 
hypersensitive to the triazoles. For the G73 mutants, there appeared to be a 
significant contribution to susceptibility patterns from the native enzyme, 
because its deletion to give the AD3Δ background reduced the azole MIC80 at 
least 2-fold. The MIC80s of the AD3ΔScErg11p strain for FLC, VCZ and ITC 
were 1.9 µg/mL, 0.248 µg/mL, and 0.105 µg/mL, respectively (Table 5.2). The 
AD3ΔScErg11p_G73E and AD3ΔScErg11p_G73R strains were 4 times more 
susceptible to FLC with an MIC80 value of 0.5 µg/mL. The MIC80s of the 
AD3ΔScErg11p_G73E/R strains were ~2-fold lower for ITC (0.05 and 0.06 
µg/mL) and ~5-fold lower for VCZ (0.038 and 0.047 µg/mL) than for the 
control AD3ΔScErg11p strain (Table 5.2). These results are consistent with the 
expression of less functional mutant Erg11p or the mutant enzyme could be 
hypersensitive to the triazole drugs. Furthermore, we were unable to obtain a 
viable phenotype by deletion of native ScERG11 from AD2ΔScErg11p_G73W. 
This result showed that the native enzyme contributed to the active enzyme 
detected in the AD2ΔScErg11p_G73W strain and that the G73W mutation 
produces an inactive enzyme.  
Strains AD2ΔScErg11p_K151R and AD3ΔScErg11p_K151R, with the native 
ERG11 deleted, were more susceptible to FLC, VCZ and ITC than 
AD2ΔScErg11p or AD3ΔScErg11p. The AD2ΔScErg11p_K151R strain had 
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higher MIC80 values for FLC and VCZ than AD3ΔScErg11p_K151R, while the 
MIC80 for ITC was 0.064 µg/mL for both strains. The AD3ΔScErg11p_K151R 
strain was twice as susceptible to FLC, VCZ and ITC (MIC80 = 1.2 µg/mL, 
0.117 µg/mL, and 0.064 µg/mL, respectively) than AD3ΔScErg11p (MIC80 = 
1.9 µg/mL, 0.248 µg/mL, and 0.105 µg/mL, respectively; Table 5.2). These data 
indicate that the native Erg11p contributes significantly to triazole sensitivity in 
the AD2ΔScErg11p_K151R strain and that the mutant enzyme in the 
AD3ΔScErg11p_K151R is either less well functionally expressed or 
hypersensitive relative to the control overexpressed wild type enzyme.  
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Figure 5.6 Triazole susceptibilities conferred by expression of wild type and 
mutant ScErg11p6×His. MIC80s for (a) FLC, (b) ITC and (c) VCZ. Strains 
retaining native wild type ERG11 (2Δ) or with the native ERG11 deleted (3Δ) 
overexpress either wild type or mutant hexaHis-tagged ScERG11 from the 
PDR5 locus. The following mutations were introduced into ScErg11p6×His: 
G73E, G73R, G73W, T322I, K151R and G464S. The MIC80s were determined 
as described in Section 2.5.1 after 48 hours at 30 °C. The histogram gives the 
mean MIC80 for each clone using data obtained in triplicate measurements from 
at least 3 separate experiments. Error bars represent SEM. * A strain expressing 
ScErg11p6×His G73W with the native ERG11 deleted could not be obtained. 
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Table 5.2 Liquid MIC80 values for strains overexpressing wild type 
ScErg11p6×His or ScErg11p6×His with single mutations 
Strain MIC80s µg/mL 
FLC  ITC VCZ 
AD2ΔScErg11p 1.90 (±0.10)* 0.106 (±0.006) 0.239 (±0.017) 
AD3ΔScErg11p 1.90 (±0.02) 0.105 (±0.004) 0.248 (±0.010) 
AD2ΔScErg11p_G73E 0.83 (±0.02) 0.09 (±0.007) 0.136 (±0.039) 
AD3ΔScErg11p_G73E 0.50 (±0.06) 0.05 (±0.001) 0.038(±0.006) 
AD2ΔScErg11p_G73R 0.91 (±0.03) 0.097 (±0.007) 0.082 (±0.010) 
AD3ΔScErg11p_G73R 0.50 (±0.01) 0.062 (±0.006) 0.047(±0.004) 
AD2ΔScErg11p_G73W 0.95 (±0.05) 0.103 (±0.006) 0.089 (±0.010) 
AD2ΔScErg11p_T322I 2.10 (±0.17) 0.09 (±0.007) 0.253 (±0.023) 
AD3ΔScErg11p_T322I 2.02 (±0.06) 0.095 (±0.007) 0.282(±0.011) 
AD2ΔScErg11p_K151R 1.67 (±0.06) 0.064 (±0.002) 0.183 (±0.023) 
AD3ΔScErg11p_K151R 1.20 (±0.07) 0.064 (±0.008) 0.117 (±0.008) 
AD2ΔScErg11p_G464S 1.82 (±0.10) 0.076 (±0.009) 0.247 (±0.014) 
AD3ΔScErg11p_G464S 1.80 (±0.10) 0.112 (±0.008) 0.241 (±0.025) 
*Standard error of the mean is shown in parentheses. Cells were grown in SD 
media. MIC80 values were determined as after 48 hours at 30°C. 
5.3.3.2 The ScErg11p6×His Y140F G464S double mutant 
The strains AD2ΔScErg11p_D/M and AD3ΔScErg11p_D/M, which 
overexpress ScErg11p6×His Y140F G464S, were prepared and analysed 
separate from the rest of the mutants described in this chapter. Therefore their 
drug susceptibilities are presented separately. The AD2Δ and AD3Δ strains 
expressing the ScErg11p6×His Y140F mutant from the PDR5 locus have been 
described in Chapter 4. They showed significantly greater resistance to FLC and 
VCZ but not ITC than control strains overexpressing wild type ScErg11p×His. 
For the experiment shown in Figure 5.7 and tabulated in Table 5.3, strains 
AD3ΔScErg11p_Y140F and AD3ΔScErg11p were used as controls. Deletion of 
native ERG11 from AD2ΔScErg11p_D/M gave strain AD3ΔScErg11p_D/M 
with similar or slightly increased susceptibility to all three triazoles (Figure 5.7). 
This indicates that the native Erg11p makes a minimal contribution to azole 
sensitivity in these strains. The MIC80 of the Y140F G464S strain 
AD3ΔScErg11p_D/M to FLC (5.5 µg/mL) was ~4-fold higher than for the 
AD3ΔScErg11p6×His (1.4 µg/mL) control strain and only slightly higher than 
for the ScErg11p6×His Y140F (4.3 µg/mL) strain (Figure 5.7; Table 5.3), 
despite the G464S mutation alone having no effect on FLC resistance (Figure 
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5.6). Similarly the MIC80 of AD3ΔScErg11p_D/M for VCZ was 0.185 µg/mL 
compared to the wild type and Y140F values of 0.08 µg/mL and 0.131 µg/mL, 
respectively (Table 5.3). Thus, the ScErg11p6×His Y140F G464S enzyme is 
functional and confers enhanced resistance to the short-tailed triazoles FLC and 
VCZ but does not confer resistance to the long-tailed triazole ITC. 
Table 5.3 Liquid MIC80 values for strains overexpressing ScErg11p6×His 
Y140F with single and double mutations (D/M, Y140F G464S) 
Strain MIC80s µg/mL 
FLC  ITC VCZ 
AD3ΔScErg11p 1.4 (±0.2)* 0.105 (±0.002) 0.08 (±0.007) 
AD3ΔScErg11p_Y140F 4.3 0.095 (±0.06) 0.131 (±0.025) 
AD2ΔScErg11p_D/M 6.1 (±0.4) 0.089 0.195 (±0.020) 
AD3ΔScErg11p_D/M 5.5 (±0.08) 0.063 (±0.007) 0.185(±0.019) 
*Standard error of the mean is shown in parentheses. Cells were grown in SD 
media. MIC80s were determined as after 48 hours at 30°C.  
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Figure 5.7 Triazole susceptibility of Y140F G464S ScErg11p6×His 
overexpressing strains to triazole drugs. (a) FLC, (b) ITC and (c) VCZ. 
Strains retaining wild type ERG11 (2Δ) and with the wild type ERG11 deleted 
(3Δ) overexpress either wild type or mutant hexaHis-tagged ERG11 from the 
PDR5 locus. The ScERG11 G464S Y140F double mutation was introduced as 
described in Section 5.3.1. Cells were seeded at OD600nm = 0.005. The MIC80 
values were determined as described in Section 2.5.1 after 48 hours at 30 °C. 
The histogram gives the mean MIC80 for each clone using data obtained in 
triplicate measurements from at least 3 separate experiments. Error bars 
represent SEM. 
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5.3.4 Purification of ScErg11p6×His from mutant strains 
The strains overexpressing wild type and mutant ScErg11p6×His used for 
protein purification had the endogenous ScERG11 removed (AD3Δ) in all cases 
except the G73W mutant. The AD2ΔScErg11p_G73W mutant strain was used 
for protein purification as deletion of native ERG11 gave a non-viable 
phenotype. This approach did not affect the quality of the protein preparation as 
the Ni-NTA affinity purification step binds His-tagged protein only. Crude 
membranes were routinely prepared from 6 L cultures grown on YPD to 
OD600nm = 9 – 12 in baffled flasks as described in Section 2.6.2. The Ni-NTA 
affinity chromatography and SEC purification was carried out as described in 
Sections 2.6.4 and 2.6.5, respectively. SDS-PAGE was used to determine the 
relative amount of protein recovered and the quality of the preparation at each 
stage of purification.  
All mutant enzymes were purified either without added ligand (apo-enzyme) or 
co-purified with a triazole drug during the SEC step. Samples obtained during 
affinity chromatography and SEC purification gave Coomassie stained SDS-
PAGE profiles that were similar for the wild type enzyme and the G73E/R/W, 
K151R and T322I mutant enzymes. In contrast, both the ScErg11p6×His G464S 
and the Y140F G464S double mutant preparations showed signs of 
denaturation/degradation. In the interest of brevity, the following sections show 
results for the G73R mutant, representing mutants with normal purification 
profiles, and for the G464S mutant and the Y140F G464S double mutant. 
Samples obtained during purifications from ~1 g of crude membrane protein, 
were retained for analysis by SDS-PAGE on 8% acrylamide gels (Figure 5.8). 
The molecular mass of ScErg11p6×His is ~62 kDa (arrow). The Coomassie 
stained gel shows clear overexpression of ScErg11p6×His in the lane with the 
crude membranes. The solubilisation of ScErg11p6×His from crude membranes 
with DM was efficient as most of the enzyme represented by the ~62 kDa band 
was found in the supernatant and not the insoluble fraction pelleted by 
centrifugation. There was some loss of co-migrating protein species during 
affinity purification. The red coloured fraction L, eluted from the Ni-NTA 
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matrix with 200 mM imidazole, was pooled, concentrated to 1 mL by 
centrifugal filtration and further purified by SEC. 
 
Figure 5.8 Purification of the ScErg11p6×His G73R (a) and G464S (b) 
mutant proteins. A Coomassie stained 8% acrylamide SDS-PAGE gel of 
samples of crude membranes (CM; 40 µg), supernatant (S) and pellet (P) 
obtained after solubilising crude membranes and precipitating the insoluble 
fraction by centrifugation, flow through (FT) after the supernatant (S) was 
incubated with Ni-NTA agarose beads, washes of ScErg11p6×His bound to the 
Ni-NTA column (W1 and W2), eluted fractions that were clear (E1 and E3) and 
the red coloured fractions pooled for further purification by SEC (L). The 
ScErg11p6×His band migrating just above the 55 kDa molecular weight (MW) 
marker is indicated by an arrow. 10 µL of sample mixed with 2 µL of 6× SDS 
loading dye was loaded on each lane. 
The volume of samples applied to both gels in Figure 5.8 was identical but the 
62 kDa protein band in the L fraction obtained with the G464S mutant stained 
less intensely than that of G73R mutant. SEC of ScErg11p6×His G73R purified 
without added ligand gave a different elution profile at A280nm compared to 
enzyme purified with ITC (Figure 5.9 a,c). Despite the protein elution profiles 
being otherwise essentially identical, the addition of ITC to Ni-NTA purified 
protein before SEC purification gave a third A280nm peak on the SEC 
chromatogram. The additional peak is probably due to DMSO used to dissolve 
ITC, as related ligands such as FLC that are dissolved in water do not give this 
peak.  
SDS-PAGE of peak 1 (up to 13 mL) of the SEC elution profiles (Figure 5.9a, c), 
included ScErg11p6×His plus bands migrating faster and slower (Figure 5.9b, 
d), indicating the presence of contaminants or aggregated and/or degraded 
material. The fractions eluted after the peak 2 (15 mL) contained bands of 
smaller size than ScErg11p6×His, indicating impurities or degraded protein. 
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Fractions eluting between 13.5 mL and 15 mL in the SEC chromatogram were 
dominated by the 62 kDa band and were combined and used for crystallisation. 




Figure 5.9 SEC purification of ScErg11p6×His G73R. (a) SEC elution profile 
of ScErg11p6×His G73R apo-enzyme and (b) the corresponding SDS-PAGE 
gel showing selected fractions from the SEC elution profile. (c) SEC 
chromatogram of ScErg11p6×His G73R co-purified with ITC (2 µM) and (d) 
the corresponding SDS-PAGE gel showing selected fractions from the SEC 
elution profile. In both (a) and (c), the majority of the G73R mutant enzyme 
eluted in peak 2 (13.5 – 15 mL fraction). Peak 3 is in the 15 – 17 mL fraction 
(c). MW, protein molecular weight markers. L, sample of the Ni-NTA affinity 
purified preparation loaded onto the SEC column. 10 µL of sample mixed with 
2 µL of 6× SDS loading dye was loaded in each lane. Fractions eluted in peak 2 
were diluted 2-4-fold while the rest were loaded without dilution. 
The SEC chromatogram for ScErg11p6×His G464S showed a lower protein 
yield than the G73R mutant (compare Figure 5.9 and Figure 5.10). The lower 
absorbance (A280nm) profile of the red, heme-containing peak 2 for 
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ScErg11p6×His G464S indicated a lower concentration of intact protein in this 
fraction. Peak 1 indicated protein aggregation and denaturation occurred to 
comparable extents for both mutants. SDS-PAGE did not reveal significant 
degradation products throughout the entire elution profile (Figure 5.10). 
Collectively, these results indicate that the G464S mutation in ScErg11p6×His 
leads to a smaller amount of enzyme in the membrane.  
 
Figure 5.10 SEC purification of ScErg11p6×His G464S. (a) SEC 
chromatogram of ScErg11p6×His G464S apo-enzyme and (b) the 
corresponding SDS-PAGE gel with samples of selected SEC fractions. (c) SEC 
chromatogram of ScErg11p6×His G464S co-purified with ITC (2 µM) and (d) 
the corresponding SDS-PAGE gel. In both (a) and (c), the majority of the 
protein was recovered in peak 2 (the 13.5 – 15 mL fraction). Peak 3 is the 15 – 
17.5 mL fraction. MW, protein molecular weight markers. L, sample of the Ni-
NTA affinity purified preparation loaded onto the SEC column. 
The ScErg11p6×His Y140F G464S band appeared to be present in crude 
membranes in amounts consistent with ScErg11p6×His G464S but the double 
mutation gave an enzyme that appeared to be significantly degraded/denatured 
during preparation (Figure 5.11). On detergent extraction and elution from the 
Ni-NTA matrix, an additional band was detected at ~55 kDa (Figure 5.11). 
Finally, the affinity purified ScErg11p6×His Y140F G464S protein preparation 
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appeared yellow rather than the usual red colour. These results indicated that 
ScErg11p6×His Y140F G464S may be unstable and degrades during 
purification. However, the enzyme is functional within the cell since deletion of 
the native ERG11 gives viable mutant strains in the AD3Δ background.  
 
Figure 5.11 Purification of ScErg11p6×His Y140F G464S. (a) Detergent 
solubilisation and Ni-NTA affinity purification, (b) SEC purified protein. 
Analysis on 8% acrylamide SDS-PAGE gels of samples of crude membranes 
(CM; 40 µg), supernatant (S) and pellet (P) obtained after solubilising crude 
membranes and precipitating the insoluble fraction by centrifugation, flow 
through (FT) after the supernatant (S) was incubated with Ni-NTA agarose 
beads, washes of ScErg11p6×His bound to Ni-NTA column (W1, W2 and W3), 
eluted fractions (E1 and E3) that were clear. The yellow fraction pooled for 
further purification by SEC (L). Twice affinity purified protein (SEC). The 
ScErg11p6×His band indicated by an arrow migrates just above the 55 kDa 
molecular weight marker (MW). 10 µL of sample mixed with 2 µL of 6× SDS 
loading dye was loaded in each lane. 
The ScErg11p6×His Y140F G464S double mutant was co-purified by SEC with 
ITC. The SEC purification confirmed that much of the affinity-purified protein 
was aggregated or degraded as evidenced by the presence of more intense peaks 
1 and 3 in the elution profile (Figure 5.12a). Absorption spectra of the SEC 
purified fractions revealed that the majority of ScErg11p6×His Y140F G464S, 
which retained the heme (judged by the intensity of the heme peak, data not 
shown) was eluted in peak 2 (Figure 5.12a, fractions 13 – 15 mL). The ratio of 
the heme Soret peak at ~420 nm to the protein peak at 280 nm was much lower 
for the purified ScErg11p6×His Y140F G464S than the wild type enzyme 
(Figure 5.13) or any of the other mutants studied (Appendix C, Figure C-2).  
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Figure 5.12 SEC of ScErg11p6×His Y140F G464S co-purified with ITC. (a) 
SEC elution profile of ScErg11p6×His Y140F G464S. The protein in fraction 2 
(13.5 – 15 mL) was pooled and concentrated to 1 mL and separated by SEC. (b) 
SEC chromatogram of the second SEC purification of peak 2 fraction of (a). 
A highly purified sample of ScErg11p6×His Y140F G464S was obtained by 
using two rounds of SEC purification in the presence of ITC (Figure 5.12b). 
There was significant loss of protein using this approach and the preparation 
had a low heme content judging by its absolute absorption spectra Figure 5.13b. 
Control wild type protein co-purified with ITC shows a strong type II binding 
heme Soret peak with maximum absorbance at ~421 nm (Figure 5.13a). The 
absorbance spectrum of the ScErg11p6×His Y140F G464S preparation showed 
a weak heme Soret peak with maximum absorbance at ~417 nm (Figure 5.13b), 
indicating less heme is present and that ITC is not bound. CO binding studies 
confirmed that most of the affinity purified ScErg11p6×His Y140F G464S was 
denatured (Figure 5.14b).  
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Figure 5.13 Absolute absorbance spectra of SEC purified (a) 
ScErg11p6×His and (b) ScErg11p6×His Y140F G464S double mutant. The 
wild type and the double mutant protein were co-purified with ITC. The heme 
Soret peak maxima were at ~421 nm and ~417 nm respectively.  
5.3.5 Mass spectrometry 
All mutations in ScErg11p6×His were confirmed by mass spectrometry of the 
SDS-PAGE purified 62 kDa band which was subjected to tryptic digestion. The 
peptide coverage for each mutant is described in Appendix D.  
5.3.6 Spectral characteristics of mutant ScErg11p6×His 
The absorption maximum of the heme peak (Soret band) in wild type 
ScErg11p6×His without added ligand is usually seen at ~417 nm (Figure 3.1). 
As discussed in Chapter 4 the Y140F/H mutation changed the electronic 
environment of the heme such that the absorption maximum of apo-enzyme is 
~420 nm. The heme Soret peak maxima obtained for apo-protein samples are 
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Table 5.4 Soret peak maximum of wild type and mutant ScErg11p6×His 
without added ligand 
ScErg11p6×His Soret peak maximum 
WT 417.3 (± 0.18)* 
G73E 418.0 (± 0.14) 
G73R 418.8 (± 0.24) 
G73W 418.0 (± 0.28) 
T322I 418.5 (± 0.42) 
K151R 419.2 (± 0.24) 
G464S 416.5 (± 0.18) 
Y140F G464S 414 
* Numbers in brackets indicate standard deviation after 6 measurements for all 
enzymes apart from the double mutant, which was measured once. 
5.3.6.1 Determination of cytochrome P450 concentration  
The concentration of functional enzyme in ScErg11p6×His preparations was 
determined by carbon monoxide binding studies as described in Section 2.7.6. 
The ScErg11p6×His G73E/R/W, K151R and T322I mutants gave carbon 
monoxide difference spectra profiles similar to the wild type enzyme. Figure 
5.14a, c shows the difference spectra obtained for the wild type enzyme and the 
G73R mutant, as a representative of the aforementioned mutants. The 
absorbance peak for the functional CYP450 enzyme should be at about 450 nm. 
In the case of ScErg11p6×His the reduced carbon monoxide bound protein gave 
a peak at 445 nm. The wild type and the G73R mutant enzymes with carbon 
monoxide bound, had a small peak at 417 nm, indicating the presence of some 
denatured CYP450 enzyme in the protein preparation. The majority of purified 
Y140F G464S double mutant enzyme was non-functional as indicated by the 
large peak at 417 nm Figure 5.14b and the slight shoulder at 445 nm. The 
G464S single mutant has a slightly bigger shoulder at 445 nm than the double 
mutant, but most of the protein was non-functional (Figure 5.14d). This result is 
consistent with weak absolute spectra Soret peaks obtained for the G464S single 
mutant and the Y140F G464S double mutant (Table 5.4). Consequently, the 
preparations provided insufficient functional enzyme to obtain type II difference 
spectra. 
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Figure 5.14 Carbon monoxide difference spectra for ScErg11p6×His wild 
type and mutant protein. The difference spectra are shown for 
ScErg11p6×His (a) wild type protein and the mutants (b) Y140F G464S, (c) 
G73R and (d) G464S.  The difference spectra were obtained using equal 
amounts of ScErg11p6×His protein in a control sample, which was reduced by 
sodium dithionite, and a test sample, which was reduced by sodium dithionite 
after the solution was saturated with carbon monoxide. The peak at 445 nm 
represents functional CYP450 and a peak at 417 nm is non-functional CYP450. 
5.3.6.2 Type II binding characteristics of ScErg11p6×His 
Characteristic type II difference spectra were obtained as a result of triazole 
binding to ScErg11p6×His. The type II difference spectra had well defined 
peaks at 428 nm and well defined troughs at 410 nm (Figure 3.2). The Kd values 
for wild type enzyme were calculated using the Hill equation (Table 5.5). The 
type II binding experiments were repeated and showed consistent Kd values for 
ITC, VCZ and PCZ binding, but FLC binding showed slightly greater variation 
due to differences in the Hill number generated from the binding curves (Table 
5.5). The maximum difference between the peak and the trough (ΔAmax) showed 
some variation, which did not affect the Kd values (Table 5.5). The Kd values 
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indicate that the binding is tight for all triazoles tested but VCZ and PCZ bind 
tighter to ScErg11p6×His than FLC and ITC.  
Table 5.5 Type II binding characteristics of triazoles to ScErg11p6×His 
Triazole 
ScErg11p6×His  
ΔAmax Kd (µM) Hill no.a [Azole]0.5 
FLC 1* 0.048 0.074 (± 0.015) 3 0.43 
FLC 2 0.044 0.141 (± 0.028) 1.5 0.27 
FLC 3 0.049 0.211 (± 0.031) 2 0.46 
VCZ 1* 0.051 0.082 (± 0.018) 2.7 0.40 
VCZ 2 0.036 0.051 (± 0.019) 2 0.23 
VCZ 3 0.037 0.069 (± 0.018) 2.1 0.28 
ITC 1* 0.037 0.123 (± 0.027) 1.6 0.28 
ITC 2 0.047 0.177 (± 0.062) 1.7 0.36 
PCZ 1* 0.034 0.078 (± 0.023) 2.2 0.32 
PCZ 2 0.031 0.057 (± 0.013) 2.3 0.29 
* FLC 1 and VCZ 1 values are from Chapter 3, PCZ 1 and ITC 1 values are 
from Chapter 4. The rest are repeats carried out for this Chapter. Values in 
brackets indicate standard errors.  a Hill coefficient. IC50 value is denoted as 
[Azole]0.5. 
5.3.6.3 Type II binding characteristics of ScErg11p6×His mutants 
The binding of the triazole drugs FLC, VCZ, ITC and PCZ to ScErg11p6×His 
G73E/R/W, K151R, T322I mutant enzymes produced type II difference spectra. 
The type II binding spectra were obtained as described in Section 2.7.7. 
Representative difference spectra for FLC binding are presented in Figure 5.15.  
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Figure 5.15 Type II difference spectra of FLC binding to ScErg11p6×His 
(a) G73E, (b) K151R, (c) G73W and (d) T322I mutants. The difference 
spectra was obtained by incremental additions of FLC dissolved in DMSO to 
1 µM ScErg11p6×His mutant enzyme in the sample cuvette and a 
corresponding amount of DMSO added to 1 µM enzyme in the reference 
cuvette.  
The G73E/W ScErg11p6×His mutants gave ΔAmax values (Table 5.6) and the 
peak (428 nm) and the trough (410 nm) wavelengths that were comparable to 
the wild type ScErg11p6×His (Table 5.5). The G73R ScErg11p6×His mutant 
had a slightly smaller overall ΔAmax, with the peak and the trough shifted 
slightly to 413 nm and 430 nm, respectively, for FLC binding and the trough 
only shifted to 415 nm for VCZ binding. The K151R and T322I 
ScErg11p6×His mutants showed smaller ΔAmax values compared to the wild 
type enzyme (Table 5.6). In addition, the peak and the trough values were 
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slightly shifted for the K151R mutant to 424 nm and to 408 nm for ITC and 
PCZ binding and the peak only to 426 nm with VCZ binding. 
The triazole drugs were titrated against 1 µM ScErg11p6×His mutant enzyme. 
The absorbance difference between the peak and the trough of the type II 
spectra was plotted against the triazole concentration to generate binding curves 
(Figure 5.16). The resultant Kd values are presented in Table 5.6. The obtained 
Kd values are in the nanomolar range indicating that the binding is tight.  
Table 5.6 Type II binding of triazole drugs to ScErg11p6×His wild type and 
mutants enzymes 
ScErg11p  Triazole ΔAmax Equation* Kd (µM) Hill no.a [Azole]0.5 
WT FLC 0.044 Hill 0.141 (± 0.028) 1.5 0.27 
VCZ 0.036 Hill 0.051 (± 0.019) 2 0.23 
ITC 0.033 Hill 0.123 (± 0.027) 1.6 0.28 
PCZ 0.034 Hill 0.078 (± 0.023) 2.2 0.32 
G73E FLC 0.043 Morrison 0.008 (± 0.007) n/a 0.45 
VCZ 0.043 Hill 0.08 (± 0.025) 2.5 0.36 
ITC 0.034 Hill 0.07  (± 0.04) 1.9 0.25 
PCZ 0.042 Hill 0.10 (± 0.04) 2.1 0.36 
G73R FLC 0.030 Hill 0.08 (± 0.02) 2.6 0.37 
VCZ 0.028 Hill 0.12 (± 0.10) 1.7 0.29 
ITC 0.030 Hill 0.08 (± 0.04) 2.2 0.31 
PCZ 0.031 Hill 0.04 (± 0.02) 2.3 0.25 
G73W FLC 0.051 Hill 0.47 (± 0.097) 2.3 0.71 
VCZ 0.053 Morrison 0.014 (± 0.007) n/a 0.51 
ITC 0.047 Morrison 0.023 (± 0.009) n/a 0.52 
PCZ 0.047 Morrison 0.005 (± 0.006) n/a 0.44 
K151R FLC 0.032 Morrison 0.038 (± 0.018) n/a 0.56 
VCZ 0.034 Morrison 0.007 (± 0.008) n/a 0.54 
ITC 0.025 Morrison 0.008 (± 0.007) n/a 0.45 
PCZ 0.039 Morrison 0.323 (± 0.168) n/a 0.79 
T322I FLC 0.028 Hill 0.12 (± 0.03) 2.0 0.34 
VCZ 0.028 Hill 0.10 (± 0.04) 2.2 0.36 
ITC 0.024 Hill 0.12 (± 0.03) 1.9 0.32 
PCZ 0.027 Hill 0.09 (± 0.04) 2.1 0.32 
* The preferred equation to fit the data was chosen using the Akaike 
information criterion. Values in brackets indicate standard errors. a Hill 
coefficient. IC50 value is denoted as [Azole]0.5. 
The majority of the data fitted the Hill equation best. The Hill coefficients were 
in the range between 1.5 and 2.6. The use of the Morrison equation resulted in 
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Kd values that were lower than when the data was fitted to the Hill equation. 
The Kd values were mostly in the range of 40 – 120 nM for the G73E/R and 
T322I mutants, which is comparable to the wild type enzyme. A Kd of 8 nM was 
calculated for FLC binding by the G73E mutant. All triazoles tested showed 
high binding affinity with the G73W mutant (5 – 23 nM) apart from FLC, 
which had a Kd value of 470 nM. The Kd values estimated for the K151R mutant 
ranged from 7 – 38 nM for the binding of FLC, VCZ and ITC with 323 nM for 
PCZ. However the high standard error values indicate that the curve was poorly 
fitted by the equation (Figure 5.16d). 
 
Figure 5.16 Triazole binding curves to ScErg11p6×His wild type and 
mutants based on type II difference spectra. The triazole drugs (a) FLC, (b) 
VCZ, (c) ITC and (d) PCZ were titrated against 1 µM ScErg11p6×His enzyme. 
The absorbance difference between the trough and the peak was plotted against 
the triazole concentration to generate binding curves. The wild type enzyme is 
represented in solid circles (), the G73E mutant solid squares (¡), G73R 
mutant solid triangles (), G73W mutant solid diamonds (®), K151R mutant 
hollow squares (£) and T322I mutant hollow triangles (r). 
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5.3.7 X-ray crystallographic analysis of ScErg11p6×His mutants 
The X-ray crystal structures obtained for the ScErg11p6×His mutants described 
in this chapter are listed in Table 5.7. The data collection and refinement 
statistics are listed in Appendix G, Tables G-5 and G-6. Structure coordinate 
files (.pdb and .mtz) are available in Appendix G on a CD attached to the thesis. 
Protein purified without ligand (apo) did not form crystals as readily as protein 
with ligands (FLC or ITC), presumably due to ligand stabilisation of the protein.   
Crystals picked less than a month after forming gave better diffraction patterns 
than the crystals that were left in the drops for over a month. In addition, freshly 
purified protein was usually more successful in producing well diffracting 
crystals than protein preparations that were left refrigerated for a period of time 
(over one week) prior to setting up crystallisation plates. The mutant structures 
are isomorphous to the previously obtained ScErg11p6×His structures PDB 
IDs: 4LXJ and 4K0F (Monk et al., 2014b) and 4WMZ (Chapter 3; Sagatova et 
al., 2015). 
Table 5.7 ScErg11p6×His mutant crystal structures. 
ScErg11p6×His 
mutant 
Apo* FLC ITC 
G73E  ü ü 
G73R  ü  
G73W ü  ü 
G464S  ü ü 
T322I ü ü ü 
*No ligand was added during purification/crystallisation. 
The crystal structures of mutants that had no ligand added are referred to as apo 
in this study, however there was density in the active sites of the apo 
ScErg11p6×His G73W and T322I structures. Monk et al., (Monk et al., 2014b) 
previously detected some density in the active site of the wild type 
ScErg11p6×His ‘empty pocket’ structure. The ScErg11p6×His K151R enzyme 
did not produce any crystals after several attempts using the vapour diffusion 
method with regular (45%) and increased (up to 50%) concentration of the 
precipitant PEG-400, as well as use of the microseeding technique described in 
Section 5.2.3.  
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5.3.7.1 ScErg11p6×His G73E and G73W in complex with ITC 
The structures of ScErg11p6×His G73E and G73W in complex with ITC were 
obtained to the resolution of 1.98 Å and 2.15 Å, respectively (Appendix G, 
Table G-5). Molecular replacement showed that the complexes were essentially 
identical to the wild type structure but with evidence for the presence of the 
mutant residues, the ligand and changes in the conformation of some residues, 
as discussed in the following sections.  
Both mutant structures showed a conformation of ITC different to that reported 
for the wild type (PDB ID: 4K0F; Monk et al., 2014b) and ScErg11p6×His 
Y140F/H in complex with ITC (PDB ID: 4ZDY and 4ZE3) structures (Chapter 
4). The piperazine ring of ITC, which has been modelled as either a chair or 
twisted boat conformation, accommodates this difference as a type of hinge 
(Figure 5.17). The chair conformation of the six membered piperazine ring 
allows for the extended conformation of the drug. 
 
Figure 5.17 Three conformations of ITC molecule detected in ScErg11p. 
The three conformations of ITC detected in three different structures are 
overlaid. The extended ITC conformation (C atoms green) with the piperazine 
ring in a chair conformation found in the wild type ScErg11p6×His (Monk et 
al., 2014b). The bent ITC conformation (C atoms yellow) with the piperazine 
ring modelled in a twisted boat shape found in the ScErg11p6×His G73E 
structure. The twisted ITC conformation (C atoms cyan) with the piperazine 
ring in a chair shape but with the tail of the molecule twisted found in the 
ScErg11p6×His G73W structure. 
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In the structure of ScErg11p6×His G73E in complex with ITC the piperazine 
ring adopts the twisted boat shape, which facilitates the bent shape of ITC. The 
tail of the ITC molecule was bent away from the E73 residue. There are possible 
π-anion interactions between the carboxylate group of the E73 residue and the 
triazole-5-one group of the ITC molecule (Mascal et al., 2002, Schwans et al., 
2013). Chen et al. observed the same conformation for PCZ in complex with T. 
brucei CYP51 (resolution 2.6 Å and 2.7 Å; Chen et al., 2010). Due to the 
scattered Fo-Fc electron density maps obtained with two of their structures, 
they suggested that PCZ has two conformers in a dynamic equilibrium.  
In the ScErg11p6×His G73E structure in complex with ITC no density was 
detected initially following phase solution for the β or γ carbons for the E73 but 
there was some density for the carboxyl group (Figure 5.18). After refinement, 
the 2Fo-Fc density at the mutation site showed all the atoms of the glutamic 
acid residue. 
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Figure 5.18 OMIT maps for ITC in complex with ScErg11p6×His (a) G73E 
and (b) G73W mutants. Electron density is shown for ITC and the site of the 
mutations G73E and G73W immediately following phasing and prior to 
modelling of the inhibitor. The final modelled ITC and the mutated residues are 
shown as sticks with C atoms represented in yellow. For all structures 
represented as sticks the N atoms are in blue, O atoms in red, Cl atoms in green 
and F atoms are in light blue. The heme is shown with C atoms in magenta in all 
subsequent figures. Unless otherwise stated the electron density map 2Fo - Fc 
(blue) is contoured at 1σ and the Fo - Fc map is contoured at 3σ (green) or -3
σ (red). Maps are ccp4 maps generated by Phenix for visualisation in PyMOL. 
Both maps were calculated using Fcalc refined from coordinates with no ligand 
or mutant residue present at the active site. All OMIT maps show the overlay of 
the final structure with the maps after molecular replacement (phaser). Arrows 
indicate the piperazine ring.  
ITC in complex with ScErg11p6×His G73W adopted a different conformation 
to that seen with ScErg11p6×His G73E (Figure 5.17). The piperazine ring was 
modelled as the chair conformation but the tail of the ligand was slightly twisted 
in order to accommodate the W73 residue. There are π-stacking interactions 
between the W73 and the triazol-5-one group of ITC. 
Structures of ScErg11p6×His G73W and G73E in complex with ITC showed no 
electron density in the egress channel, but some residues around the egress 
channel had different conformations compared to the wild type structure 
complexed with ITC (PDB ID: 4K0F). These residues had different rotamers 
and positions (Figure 5.19), particularly the side chains of the residues F241, 
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L129, F384, H128 and R98. In the G73E/W ITC structures those residues point 
into the egress channel and the F241 side chain occupies space within the 
“egress channel”. The same residues in the structure of the wild type enzyme in 
complex with ITC point away from the channel to accommodate the ligand in it. 
 
 
Figure 5.19 Conformation of amino acid residues surrounding the egress 
channel. The structure of ScErg11p6×His G73E in complex with ITC was 
aligned with wild type ScErg11p6×His in complex with ITC (PDB ID: 4K0F). 
ITC and the residues around the egress channel are shown as sticks. C atoms are 
represented in yellow for the G73E structure with C atoms in grey for ITC 
molecule. C atoms are cyan for the wild type egress channel residues and the 
ITC molecule. ITC is in the bent conformation (piperazine ring as a twisted 
boat) in the G73E structure and in an extended conformation (piperazine ring as 
a chair) in the wild type structure. 
The bend in the ITC molecule is more acute in the G73E structure than the 
G73W structure. The bend in ITC in the mutant structures shifts the tail of the 
ITC molecule closer to the egress channel, pushing out any potential product 
and allowing the side chain of F241 to occupy that region. 
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There are three water molecules in the substrate channel close to the piperazine 
ring of ITC in the structure of ScErg11p6×His Y140F in complex with ITC 
(PDB ID: 4ZDY). Those waters form a hydrogen-bonding network with each 
other and the surrounding amino acid residues, which form a hydrophilic 
pocket. Residues S382, H381, S508 and F506 all interact with those water 
molecules via hydrogen bonds. One of the water molecules is hydrogen bonded 
to the piperazine ring of ITC. The piperazine ring acts as a hinge in order for the 
two more rigid components to fit into the substrate channel. In the presence of 
mutation at G73, this hinge adopts more unusual conformations in order to fit 
the channel when a larger residue compared to the wild type glycine occupies it. 
This prevents the piperazine from forming a hydrogen bond to the water 
molecule in both mutant structures.  
5.3.7.2 ScErg11p6×His G73E and G73R mutant structures in complex 
with FLC  
Structures of ScErg11p6×His G73E and G73R in complex with FLC were 
obtained at resolutions of 2.25 Å and 2.20 Å, respectively (Appendix G, Table 
G-5). The OMIT maps show good density for the ligand after molecular 
replacement in both structures (Figure 5.20). The side chains E73 and R73 in 
both FLC structures showed limited density after refinement. The E73 had no 
density immediately after molecular replacement and the 2Fo-Fc density only 
covered the β-carbon of the residue after refinement. The R73 residue lacks 
density for the β and γ carbons (Figure 5.20c). As described in Section 3.3.5 the 
binding of the short-tailed ligand FLC to wild type ScErg11p6×His (PDB ID: 
4WMZ; Sagatova et al., 2015) involves a network of water-mediated hydrogen 
bonds. Both waters found in the wild type structure are present in these mutant 
structures in the same positions i.e. water molecules 743 and 790 are hydrogen 
bonded to FLC in both mutant structures.  
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Figure 5.20 OMIT maps for FLC binding to ScErg11p6×His G73E and 
G73R. Electron density for (a) FLC in the ScErg11p6×His G73E structure, (b) 
FLC in the ScErg11p6×His G73R structure and (c) R73 in the G73R structure. 
The density E73 was not detected after molecular replacement. FLC and the 
R73 are shown as sticks with C atoms depicted in yellow.  
There is density present in the egress channel in both the ScErg11p6×His G73E 
and G73R mutant-FLC structures but it is smaller than that previously reported 
in the wild type lanosterol structure (PDB ID: 4LXJ). The residues around the 
egress channel are in similar conformations to those in the wild type protein in 
complex with FLC. There are unmodelled densities in the substrate channels of 
both mutants, which are also present in the wild type ScErg11p6×His FLC 
structure (Figure 5.21). In the wild type structure the density is modelled as a 
water molecule, however it could possibly be a bigger molecule with a polar 
group (Figure 5.21a) as it is close enough to the peptide chain to make hydrogen 
bonds with the carbonyl group of residue P379 and amide group of H381. The 
structure of ScErg11p6×His G73R in complex with FLC has several smaller 
unmodelled blobs in the same region (Figure 5.21b) that are similar to those 
detected in the structure of G73E ScErg11p6×His in complex with FLC.  
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Figure 5.21 Unmodelled blobs of electron density in the substrate channels 
of (a) ScErg11p6×His and (b) ScErg11p6×His G73R in complex with FLC. 
C atoms of FLC (sticks) and amino acid side chains (lines) are presented in 
yellow and the secondary structure is presented as grey cartoon. The electron 
density maps after final refinement are shown in this figure. 
Several amino acid residues in the fungus-specific loop (amino acids 432 - 457) 
have limited density (438 – 441) in all of the structures along with high B-
factors. The structure of ScErg11p6×His G73E in complex with FLC had no 
density for those residues (Figure 5.22a) so they were not included in the model. 
In contrast, the ScErg11p6×His G73R structure in complex with FLC had 
reasonable density in that region (Figure 5.22b). In the rest of the mutant 
structure this region has been modelled in similar to that presented in Figure 
5.22b.  
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Figure 5.22 Electron density maps for residues of the fungus-specific loop 
in ScErg11p6×His G73E (a) and G73R (b) mutants. Electron density is 
shown for residues S437, S438, Y439, S440, V441 and G442. Residues are 
depicted as sticks with C atoms in yellow. The density maps after final 
refinement are shown in this figure. 
5.3.7.3 ScErg11p6×His T322I and G73W mutant apo structures 
The ScErg11p6×His G73W and T322I apo structures have been determined to 
the resolutions of 2.10 Å and 2.35 Å, respectively (Appendix G, Tables G-5 and 
G-6). There was clear crystallographic evidence for the presence of the 
mutations (Figure 5.23), which was confirmed by the data obtained using mass 
spectrometry (Section 5.3.5).  
 
Figure 5.23 OMIT maps of mutation sites in ScErg11p6×His (a) T322I and 
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Both apo structures showed some density in the active site (Figure 5.24). There 
is difficulty in determining what this density represents. However, the density at 
the heme iron could represent molecular oxygen (Figure 5.24), which was 
modelled into the ScErg11p6×His structure in complex with lanosterol (PDB 
ID: 4LXJ; Monk et al., 2014b). 
 
Figure 5.24 Substrate channel density of (a) G73W and (b) T322I 
ScErg11p6×His apo structures. The density maps after final refinement are 
shown in this figure. Arrows point to the density beside the heme iron. 
The density in the substrate channel of both apo structures did not accommodate 
water molecules. Following refinement of the structures with waters modelled 
into the substrate channel, there was considerable Fo-Fc density around the 
waters (Figure 5.25). 
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Figure 5.25 The (a) T322I and (b) G73W ScErg11p6×His apo structures 
with water molecules modelled into the substrate channel density. Density 
maps obtained after refinement with water molecules in the substrate channel 
are shown.  
The carbonyl group of residue G314 in the ScErg11p6×His T322I and G73W 
apo structures occupies a similar position in the ScErg11p6×His lanosterol 
structure (PDB ID: 4LXJ). An overlay of the mutant apo structures with 
ScErg11p6×His in complex with FLC (PDB ID: 4WMZ) showed that the G314 
carbonyl group is closer (2.8 Å) to the hydroxyl group of T318 and the occupant 
of the density at the heme iron in the apo structures compared its position in the 
triazole bound structure (Figure 5.26). The coordination of the triazole ring to 
the heme iron pushes G314 away from the heme and the T318 hydroxyl group 
(3.1 Å). The G314 carbonyl in the apo structure is shifted by 1.7 Å upon 
binding of the triazole drug. The same overlay also reveals that the distance 
between the carbonyl of G314 in the apo structure and the closest carbon atom 
of FLC in the ScErg11p6×His FLC structure is 1.9 Å. In the ScErg11p6×His 
FLC structure this distance is 3.4 Å. 
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Figure 5.26 Positions of residues G314 and T318 in ScErg11p6×His in 
complex with FLC and the ScErg11p6×His G73W apo structure. (a) Front 
view, (b) side view (rotated approximately 90°). Helix I residues are presented 
in cyan for the ScErg11p6×His in complex with FLC (PDB ID: 4WMZ) and the 
hydrogen bond distance between the carbonyl of G314 and the hydroxyl of 
T318 is 3.1 Å. Helix I residues are presented in yellow for the ScErg11p6×His 
G73W apo structure, and the hydrogen bond distance between the carbonyl of 
G314 and the hydroxyl of T318 is 2.8 Å. Hydrogen bonds are represented by 
yellow dashed lines.  
The residue M509 located in the substrate channel is in a different conformation 
in the ScErg11p6×His G73W apo structure compared to the wild type structure 
(Figure 5.27) and the rest of the mutants, including the ScErg11p6×His T322I 
apo structure. This indicates that there is flexibility of this and surrounding 
residues in the substrate channel. In the ScErg11p6×His G73W structure M509 
occupies space in the substrate channel, pointing towards the egress channel 
(Figure 5.27, M509 in cyan), whereas in the structure of wild type 
ScErg11p6×His in complex with FLC this residue is tucked away from 
occupying space in the channel (Figure 5.27, M509 in yellow). There is also a 
small overlap between the blobs of density in the substrate channel of wild type 
ScErg11p6×His in complex with FLC (Figure 5.21) and the positioning of the 
M509 residue in the G73W apo structure. However, that density is much larger 
than the side chain of M509. This may either indicate this residue exists in 
multiple conformations or that there is an additional ligand present at this 
residue. 
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Figure 5.27 Conformation of the M509 residue in the ScErg11p6×His 
G73W apo structure compared to the ScErg11p6×His apo structure. The 
ScErg11p6×His G73W apo structure was aligned to the structure of wild type 
ScErg11p6×His in complex with FLC structure. The M509 and S508 residues 
are shown as sticks with C atoms coloured cyan in the G73W apo substrate 
channel and in yellow in the wild type FLC structure.  
The amino acid residues around the egress channel in both apo structures were 
found to be in similar conformations to those found with wild type 
ScErg11p6×His in complex with FLC.  
5.3.7.4 ScErg11p6×His T322I mutant structures  
The structures of ScErg11p6×His T322I mutant enzyme in complex with ITC 
and FLC were determined at resolutions of 2.35 Å and 2.00 Å, respectively 
(Appendix G, Table G-6). There is clear evidence for the presence of the 
mutation and the ligand in both structures (Figure 5.28). The binding of the 
ligands ITC and FLC was found to be similar to that seen in the wild type 
ScErg11p6×His structures (PDB ID: 4WMZ and 4K0F).  
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Figure 5.28 OMIT maps for the mutation site T322I and the ligands (a) 
FLC and (b) ITC in structures of ScErg11p6×His T322I. C atoms are shown 
in yellow for I322, ITC and FLC. Helix I is presented as yellow cartoon.  
The I322 residue is located on helix I. In both structures the distance between 
the closest atoms of I322 (Cγ1) and heme (CBB carbon) was found to be ~4 Å 
and the δ carbon of I322 is pointing away from the heme (Figure 5.28). In the 
wild type ScErg11p6×His FLC structure (PDB ID: 4WMZ) the side chain 
hydroxyl of T322 makes a hydrogen bond to the carbonyl group of T318 and a 
water molecule (Figure 5.29b). These interactions were disrupted due to the 
mutation to a non-polar residue (Figure 5.29a). The hydrogen bond between the 
amide of residue 322 and carbonyl of T318 was the same in both structures, 
maintaining the integrity of the helix. 
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Figure 5.29 Residue 322 interactions in the (a) T322I and (b) wild type 
ScErg11p6×His structures in complex with FLC. C atoms are shown in 
yellow for I322, T322 and T318 and in cyan for FLC. Helix I is presented as 
yellow cartoon. Hydrogen bonds are presented as yellow dashed lines. 
5.3.7.5 ScErg11p6×His G464S mutant structures 
The ScErg11p6×His G464S mutant structures in complex with ITC and FLC 
have been obtained at the resolution of 2.24 Å and 2.15 Å, respectively 
(Appendix G, Table G-6). There was clear evidence for the presence of the 
mutation and the ligand in both structures (Figure 5.30). The binding of ITC and 
FLC was found to be similar to the binding of these ligands in the structures of 
wild type ScErg11p6×His (PDB ID: 4WMZ and 4K0F). 
Residue S464 is located on the K’L loop several residues away from the 
conserved cysteine 470. The S464 is hydrogen bonded to the propionate group 
of the heme, replacing the water molecule, which is present in the structure of 
wild type ScErg11p6×His (PDB ID: 4WMZ; Figure 3.4). The hydrogen bond of 
S464 to the heme propionate did not noticeably alter the tilt of the heme. A 
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Ramachandran plot indicates that the conformation of this residue is an outlier 
in both structures. The G464 residue in the wild type structures is in the allowed 
region of the Ramachanran plot. 
 
Figure 5.30 OMIT maps for mutation site G464S and ligands (a) FLC and 
(b) ITC in ScErg11p6×His G464S structures. C atoms are shown in yellow 
for S464, ITC and FLC. Helix L and the K’L loop are presented in yellow 
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5.4 Discussion 
The aim of this study was to reproduce and characterise resistance-conferring 
CYP51 mutations from clinical isolates of fungal pathogens using S. cerevisiae 
Erg11p as a surrogate. All chosen mutations were successfully introduced into 
the S. cerevisiae overexpression system. All strains with mutant enzymes, apart 
from the ScErg11p6×His G73W, were viable when the native ERG11 was 
deleted. Contrary to expectation, the introduction of single mutations into 
ScErg11p6×His did not produce strains with triazole resistant phenotypes. 
However, biochemical and crystallographic investigation of the mutant enzymes 
showed that each mutation modified the enzyme when compared to wild type 
ScErg11p6×His.  
As noted in the Section 5.3.7.2, residues 438 – 441 in the fungus-specific loop 
(amino acids 432 - 457) have limited density and have high B-factors in all of 
the mutant structures. This indicates that the fungus-specific loop is a flexible 
entity. The flexibility of the loop may be involved with interactions with its 
cognate CYP450 reductase. In the ScErg11p6×His structures there are two 
charged residues R469 (K’L loop) and E473 (helix L), which interact directly 
and indirectly, respectively with the conserved cysteine (470), as well as two 
residues, S437 and S438, from the fungus-specific loop (Figure 5.31). The two 
serine residues of the fungus-specific loop may interact with the charged 
residues and move away upon the binding of the reductase. Hargrove et al. also 
see a flexible fungus-specific loop in the structures of the A. fumigatus CYP51B 
(PDB IDs: 4UYM, 4UYL; Hargrove et al., 2015). They propose that the fungus-
specific loop is involved in the regulation of the electron transfer from the 
CYP450 cognate reductase. Their findings are consistent with what is seen in 
our structures. 
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Figure 5.31 Conformation of amino acid residues potentially involved in 
electron transfer. The ScErg11p6×His in complex with FLC structure (PDB 
ID: 4WMZ) is shown as a representative in this image. Fungus-specific loop 
residues (FSL) S437 and S437, helix L residue E473, loop K’L residues R469 
and C470 and the heme are shown in sticks. C atoms of the main chain are grey. 
Electrostatic interaction and hydrogen bonds are shown as yellow dashed lines. 
5.4.1 Technical considerations 
We initially used Soret peak shift experiments to estimate the dissociation 
constants (Kd) for triazole drug binding to ScErg11p6×His wild type and mutant 
enzymes (Appendix E). The enzyme concentration for those experiments was 
determined using the A280 peak of an SEC purified preparation. This approach 
provided an estimate of the total amount of protein rather than the amount of 
functional CYP450 protein in the preparation, unlike the carbon monoxide 
binding spectral assay (Section 5.3.6.1). The Hill equation (Equation 2.4), 
which does not take into account the enzyme concentration along with the 
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rearrangement of the Morrison equation (Equation 2.5), which does, were both 
used to estimate the Kd values. Since the enzyme concentration was inaccurate 
this may have resulted in an inappropriate equation being used to fit the data. 
Hence, the results for the Soret peak shift experiments are presented in the 
Appendix E.  
Given these problems, it was decided to use the carbon monoxide spectral 
assays to more accurately estimate the concentration of functional CYP450 
enzyme present in protein preparations (Omura and Sato, 1964a). Still, Soret 
peak shift experiments can give reliable Kd values if the protein concentration of 
functional CYP51 is estimated using the carbon monoxide method. Locuson et 
al. (Locuson et al., 2007) compared the accuracy of the type II difference 
spectra to the Soret peak shift. They have concluded that although both methods 
can give similar Kd values, the type II difference spectra are more informative 
than the heme Soret peak shift, especially in the case of human drug 
metabolising CYP450s. The type II difference spectra can reveal if there is more 
high spin or low spin CYP450 present prior to addition of the drug based on the 
trough. A trough at 410 nm indicates that the CYP450 iron is mostly in low spin 
form while a trough at 390 nm represents high spin. All of the type II binding 
studies in this thesis revealed a trough around 410 nm, consistent with a low 
spin state. 
The majority of studies on CYP51 enzymes use type II binding studies to 
characterise azole binding (Park et al., 2010, Warrilow et al., 2010a, Warrilow 
et al., 2010b, Zelenko et al., 2014, Podust et al., 2007). In the present study type 
II difference spectra were used to estimate the Kds for triazoles. A recent study 
by Warrilow et al. shows that there are significant problems associated with 
estimation of Kd values using purified enzyme (Warrilow et al., 2015). This is 
further discussed in Chapter 6. 
5.4.2 Apo enzyme mutant structures 
Structures were obtained for the ScErg11p6×His G73W and the T322I without 
added ligands. They reveal that there is some movement of helix I residue G314 
(Figure 5.26). The position of the carbonyl group of residue G314 found in 
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those structures is similar to the wild type lanosterol structure (PDB ID: 4LXJ) 
(Monk et al., 2014b). Residue G314 is part of the sequence G310VLMG314, 
which is a consensus motif (GXXXG) involved in binding lanosterol (Monk et 
al., 2014b). G314, together with T318, is involved in creating the characteristic 
kink of helix I. The hydrogen bond between the side chain of T318 and carbonyl 
of G314 disrupts the regular hydrogen-bonding pattern of an α-helix (i, i + 4 NH 
--- O=C). In cytochrome P450cam of P. putida helix I residue T252, which 
corresponds to T318 of ScErg11p, has been implicated in protonation of 
molecular oxygen. T252 is not the direct proton donor, but it is postulated to 
stabilise the Fe-OOH complex by acting as a H-bond acceptor (Poulos, 2007). 
The apo structures discussed here reveal that the movement of the carbonyl 
group of G314 places it closer to the heme iron than the side chain of residue 
T318. In addition, a rotation of approximately 180° of the side chain T318 
would be required in order to interact with any oxygen species. This indicates 
that G314 in ScErg11p could be involved in catalysis by stabilising the Fe-OOH 
complex. 
Both apo structures are not completely without ligand. Weak electron density in 
the active site indicates presence of a ligand (Figure 5.24). The ligand seems to 
have low occupancy, presenting a challenge in its identification. The ligand 
could be imidazole as it is used in affinity purification. However, prior to setting 
crystals the protein preparation is checked spectrophotometrically. The presence 
of significant iron coordinated imidazole would be obvious as this should move 
the heme Soret peak from ~417 nm to ~425 nm. Also, as indicated by Figure 
5.25, water molecules do not occupy the density. Other possibilities include 
spectrophotometrically undetectable levels of triazole contamination from the 
SEC column or the presence of traces of lanosterol, the natural ligand of 
ScErg11p that might have remained in the active site of a portion of the enzyme 
during purification.  
5.4.3 G73E/R/W ScErg11p6×His mutants  
Collectively the G73E/R/W ScErg11p6×His mutant-overexpressing strains 
conferred increased susceptibility to FLC, VCZ and ITC. These susceptibility 
patterns do not appear consistent with previous literature for strains of A. 
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fumigatus CYP51A G54 mutants (Escribano et al., 2012, Tashiro et al., 2012, 
Warrilow et al., 2015, Mann et al., 2003). The G54 mutants of A. fumigatus 
have also been reported to confer resistance to ITC and PCZ when expressed in 
S. cerevisiae from a plasmid, with levels of the native enzyme regulated by a 
TET-promoter system (Alcazar-Fuoli et al., 2011). It would be interesting to 
partially replicate this approach by overexpressing AfCYP51A in our yeast 
expression system and abolishing expression of the native enzyme by deleting 
ScERG11. Unfortunately, AfCYP51A has yet to be successfully expressed in 
our expression system. 
Deletion of the native ERG11 ORF from AD2ΔScErg11p_G73W resulted in a 
non-viable strain. This suggests that the presence of the bulky tryptophan 
residue at this position in ScErg11p6×His disrupts the catalytic activity of the 
enzyme. The possibility of G73W mutant enzyme being misfolded or not 
expressed in sufficient amounts is excluded as the enzyme was purified from 
crude membranes of AD2ΔScErg11p_G73W strain and characterised by X-ray 
crystallography and with the carbon monoxide and type II spectral studies. 
Reduction in the catalytic activity of ScErg11p6×His by the mutations at G73 
may explain the susceptible phenotypes of those mutants. It may also explain 
why the native ERG11 contributes more significantly to resistance levels in the 
G73E/R mutant strains than in other mutants (Figure 5.6).  
The MIC80 values obtained for the G73E/R/W mutant strains show they are 
more susceptible to FLC and VCZ than to ITC compared to the wild type 
enzyme overexpressing strain. However, Soret heme peak shift and type II 
binding studies did not reveal significant differences between the binding 
affinities of short-tailed and long-tailed triazoles to the G73E/R/W mutant 
enzymes. Our crystallographic data indicates that there are extra interactions 
between the site of the G73E/W mutations and the triazole-5-one ring in the tail 
of the long-tailed triazole ITC (Figure 5.18). The extra interactions of the 
G73E/W enzymes with long-tailed triazoles may enable the drug to dissociate 
less quickly after it binds. However, as previously stated, there are no obvious 
differences in the Kds between short and long triazole drug binding for these 
mutants. Compared to the wild type enzyme the G73E/R/W mutants bind 
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triazoles with similar affinity or tighter, apart from G73W mutant FLC affinity 
(470 nM). It is noted that all enzyme preparations showed tight binding. This 
may have masked mutation-specific differences in affinities in assays that 
required 1 µM enzyme. The development of an assay of fungal CYP51 activity 
that used concentrations of enzyme well below Kd values would be of 
considerable value in resolving this problem. It is therefore of considerable 
interest that Riley et al. (Riley et al., 2015) have recently developed a 
fluorescence-based assay for T. cruzi CYP51 that uses 
benzyloxymethyloxycyanocoumarin (Vivid® BOMCC) as a substrate that 
yields the fluorescent product 3-cyano-7-hydroxycoumarin.  
Egress channel residues have been found to be in a different conformation in 
two mutant structures (ScErg11p6×His G73E/W) in complex with ITC 
compared to the wild type structure. The flexibility of these residues around the 
egress channel suggests that they have to move in order to accommodate the 
demethylated product. 
A. fumigatus has two CYP51 homologues and, as far as we are aware, the G54 
mutation has been found only in CYP51A (Mann et al., 2003). One homology 
modelling study of AfCYP51A, based on the human CYP51 structure (PDB ID: 
3JUS; Strushkevich et al., 2010), was used to suggest that G54 mutations have 
the potential to block the channel entry or directly interact with the long-tailed 
triazoles (Fraczek et al., 2011). 
Our findings indicate that the mutation in the mouth of the substrate channel of 
ScErg11p×His may reduce the catalytic activity of the enzyme and provide 
extra interactions for the binding of the long-tailed triazoles. As the writing of 
this thesis was in the final stages Warrilow et al. (Warrilow et al., 2015) 
published a study on the AfCYP51A G54W mutant. The assay of AfCYP51A 
G54W mutant reconstuituted with the cognate reductase has demonstrated that 
the mutation reduces the catalytic activity of AfCYP51A 3-fold compared to the 
wild type enzyme. In addition this mutation was shown to confer 11- and 34-
fold higher IC50 values to ITC and PCZ, respectively, compared to a moderate 
2-fold increase to VCZ.  
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One way the differential effect of mutations in the mouth of the substrate 
channel on ScErg11p and AfCYP51 could be explained is if the AfCYP51A 
substrate channel opening is narrower than it is in ScErg11p. The presence of a 
bulky residue at the G54 mutation site of AfCYP51A could provide insufficient 
space to accommodate the tail of a long-tailed triazole. The result would be 
reduced binding of long-tailed triazoles and without affecting the binding of 
short-tailed triazoles. However, homology models of AfCYP51A based on the 
ScErg11p provide no convincing evidence for this hypothesis. 
5.4.4 T322I and K151R ScErg11p6×His mutants  
The triazole susceptibilities of the mutant strains overexpressing 
ScErg11p6×His T322I was comparable to the strains overexpressing wild type 
ScErg11p6×His. The type II binding studies also revealed that the affinity of the 
triazole drugs to the T322I mutant enzyme are comparable to those of the wild 
type enzyme. The Kd values obtained for this mutant from the heme Soret peak 
shift experiments show too much variation to be reliable, for reasons discussed 
above. However, the heme Soret peak shift was smaller at the binding of FLC, 
ITC and PCZ compared to the wild type enzyme. In addition the ΔAmax from the 
type II binding spectra was smaller for all triazoles tested with this mutant 
enzyme. This may indicate that the heme environment is somehow altered, even 
though the T322 residue does not interact directly with the heme. The change 
from a hydrophilic to a hydrophobic residue may have had an influence on the 
heme as it is a conjugated molecule. Crystallographic data also shows that the 
mutation alters some interactions of the helix I. The abolition of polar 
interactions between T322 and T318 seen in the wild type structure (PDB ID: 
4WMZ; Figure 5.29) may have also had an effect on the heme. 
Perhaps I301 of AfCYP51A (T322I in ScErg11p6×His) is involved in the 
intrinsic FLC resistance, but in combination with other factors not present in the 
ScErg11p6×His. This may explain why the ScErg11p6×His T322I mutant 
showed an unchanged pattern of triazole susceptibility. 
The K151R mutant strain had slightly increased susceptibility to all triazoles 
tested, specifically after removal of the native ERG11. This mutant failed to 
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produce crystals even though the K151R mutation is adjacent to the active site 
(K151 forms a salt bridge with a heme propionate), which should have allowed 
for all the contacts involved in the formation of the crystal lattice to remain as 
they are in the wild type enzyme. The mutation may have had an effect on the 
overall fold of the protein despite the purification profile and the carbon 
monoxide binding studies showing that the mutant protein retained functional 
heme after purification. In the wild type ScErg11p6×His enzyme K151 is 
adjacent to the propionate group of the heme and forms hydrogen bonds with 
the carbonyl groups of R469 and R467, residues that are located on the same 
loop as the conserved C470 (Figure 5.32). Replacement of K151 with a bulkier 
residue might result in the complete loss of these interactions if the arginine 
adopts a different conformation to the lysine. Alternatively, the arginine could 
retain a similar conformation to the lysine and push residues R469, R467 and 
the heme more towards the cavity of the substrate channel. The change of 
interactions with the heme may result in an altered heme environment producing 
the changes of the heme Soret peak shift and the ΔAmax observed in the type II 
binding studies. 
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Figure 5.32 The interactions of residue K151 in ScErg11p6×His FLC 
structure. C atoms are shown in yellow. Helix C is presented as a yellow 
cartoon. Hydrogen bonds and a salt bridge are presented as yellow dashed lines. 
5.4.5 The ScErg11p6×His G464S and Y140F G464S mutants 
The strain overexpressing ScErg11p6×His G464S did not show any change in 
the triazole susceptibility compared with the strain overexpressing 
ScErg11p6×His. However introduction of the second mutation Y140F into 
ScErg11p6×His reduced the susceptibility of the strain to short-tailed triazoles, 
FLC and VCZ more than the single Y140F mutation (Table 5.3). The single 
G464S mutation deleteriously affected function of the purified enzyme 
preparation and the introduction of the second mutation appeared to make the 
protein even less stable, with the heme poorly retained within the protein. 
Carbon monoxide binding studies showed that ScErg11p6×His G464S and 
G464S Y140F enzymes were both recovered predominantly in non-functional 
and probably denatured states. The absolute spectra of the double mutant 
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confirmed that the enzyme had lost the heme i.e. the intensity of the heme Soret 
peak was very low compared to the protein peak in enzyme preparations co-
purified with ITC. The heme Soret peak of the ScErg11p6×His G464S without 
added ligand (apo) was detected at 416.5 nm (Table 5.4). This was lower than 
for the wild type enzyme (417 nm) and the rest of the mutants considered, 
however still within the margin of error of the spectrophotometer. The intensity 
of the heme Soret peak of the G464S single mutant was comparable to the wild 
type enzyme preparation and like the heme Soret peak shift detected was most 
likely due to the residual functional protein in a mixed preparation of detergent 
solubilised affinity-purified enzyme. The carbon monoxide binding studies 
confirmed the non-functional state of the majority of the ScErg11p6×His G464S 
mutant. The heme Soret peak of the double mutant Y140F G464S enzyme was 
detected at an even lower wavelength (414 nm). It is possible that microsomal 
preparations will give more stable mutant enzyme samples for both the single 
and double mutant that could then be used for Soret peak shift or type II 
difference spectral experiments to better indicate the affinity of triazole drugs to 
this mutant. This approach was used previously for the C. albicans CYP51 
G464S mutant (Kelly et al., 1999b). 
The G464S mutation creates a hydrogen bond to one heme propionate group 
(Figure 5.30) and the Y140F mutation abolishes a hydrogen bond to the other. 
As well as making the protein unstable this change could potentially tilt the 
heme producing a resistant phenotype, implying that the orientation of the heme 
is important in resistance and protein stability. In contrast, tilting of the heme 
was not observed in any of the single mutant structures in complex with triazole 
drugs.  
5.4.6 Summary 
The G464S mutation, which excluded a water molecule and led to a new 
hydrogen bond with a heme propionate, synergised with the triazole resistance 
phenotype of ScErg11p6×His Y140F. The double mutation resulted in the 
enzyme becoming unstable for purification. In contrast, all single residue 
mutants tested in this chapter gave enzymes stable to purification and that could 
be crystallized, apart from K151R. However, in whole cells the overexpressed 
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mutant ScErg11ps were either more susceptible to triazole drugs or showed 
resistance levels similar to the strain overexpressing the wild type enzyme. This 
finding, despite the relatively high sequence similarity between the fungal 
CYP51s, indicates ScErg11p to be a model that may not always adequately 
reflect the phenotypes of the wild type and mutant CYP51s of pathogenic fungi. 
Several mutations in proximity of the heme, notably G464S, K151R and the 
double mutation Y140F G464S, alter hydrogen bonding and electrostatic 
interactions to a heme propionate, thus changing the environment of the heme 
and affecting enzyme stability. The T322I mutation of helix I alters the 
environment of the heme through indirect interactions, probably via T318 
residue in ScErg11p. The G73E/R/W mutations in the substrate channel appear 
to reduce the catalytic activity of the ScErg11p6×His enzyme but have no effect 
on the heme environment. The E/W73 residues interact with the tail of the long-










Chapter 6                            
Conclusions and future work 




The endoplasmic reticulum-associated enzyme lanosterol 14α-demethylase 
(Erg11p or CYP51) catalyses a key step in fungal ergosterol biosynthesis and is 
a major drug target used in the treatment of fungal disease. Mutations in CYP51 
that reduce the efficacy of triazole drugs are one of several mechanisms that 
fungal species have evolved to overcome the mechanism of action of these 
antifungals. The research described in this thesis set out to investigate the 
molecular basis of fluconazole binding to its target and how single site 
mutations in CYP51 that have been reported to confer resistance to triazole 
antifungals in clinical isolates of fungal pathogens modify the affinity of the 
enzyme for these drugs. The S. cerevisiae enzyme ScErg11p has been used as a 
surrogate to reproduce such mutations, principally because it was the only 
fungal CYP51 to have its structure determined at high resolution by X-ray 
crystallography (Monk et al., 2014b). Previous studies that sought to interpret 
the molecular basis of triazole binding and resistance relied instead on the 
structural homology models that used, as templates, crystal structures of CYP51 
enzymes from unrelated organisms such as M. tuberculosis (26-28% sequence 
identity with fungal CYP51s; Xiao et al., 2004, Sheng et al., 2004, Sheng et al., 
2009). The sequence similarity of CYP51s in fungi varies considerably 
(Lepesheva and Waterman, 2011), for example the sequence identity between 
ScErg11p and CaCYP51 is 65% and ScErg11p and AfCYP51A is only 51%. 
While the overall sequence similarity among CYP51s of fungal pathogens is not 
high, the substantial conservation of amino acid residues within the active site 
and entry channel that are likely to affect interactions with triazole drugs led us 
to believe that the yeast enzyme could be used as a relevant and informative 
experimental model. Since resistant phenotypes found in fungal pathogens 
could be reproduced in the ScErg11p Y140F/H and Y140F G464S mutants, 
albeit not as strongly, it is likely that the mechanism of action of these mutations 
is conserved across a variety of fungal species. On the other hand, the rest of the 
CYP51 resistance mutations reproduced in this study either had no effect on 
drug susceptibility or conferred increased susceptibility in our yeast expression 
system. Possible reasons for these apparent discrepancies are discussed in the 
next section.  




All ScErg11p6×His mutant enzymes were successfully expressed in a S. 
cerevisiae overexpression system. The mutant strains were characterised by 
determining triazole susceptibilities and the purified mutant enzymes were 
investigated using biochemical and crystallographic techniques. High-resolution 
ScErg11p6×His mutant structures have been obtained in the “apo” state by not 
adding ligands or in complex with added triazole drugs. The “apo” state was not 
entirely ligand free as discussed in Section 5.4.2. 
The effects of specific mutations on protein structure and function have been 
discussed in previous chapters. The structural impact of each mutation analysed 
appeared to be localised, with all mutant enzyme structures obtained being 
isomorphous to the wild type enzyme (Monk et al., 2014b, Sagatova et al., 
2015). The wild type and the mutant enzymes were all crystallised in a 
monoclinic space group P21, all enzymes adopted the same fold and only in a 
few instances were residues at distances greater than 5 Å from the site of the 
mutation significantly altered in conformation compared to the wild type 
enzyme.  
6.1 Limitations of this study 
The S. cerevisiae system applied in this study used the pdr1-3 gain of function 
mutation in the Pdr1p transcriptional regulator to constitutively overexpress 
open reading frames of interest from the PDR5 genomic locus (Lamping et al., 
2007, Monk et al., 2014a). This overexpression system allowed full-length, 
properly folded ScErg11p6×His to be hyper-expressed in a host that is 
hypersensitive to triazole drugs due to the deletion of 7 ABC transporters, 
including those primarily responsible for the efflux of triazole drugs in this 
organism. This system had the following advantages:  
1. Ease of genetic construction via insertion of a gene for overexpression 
into the PDR5 locus via homologous recombination. 
2. Stable expression of a single copy of the ERG11 gene. 
3. The recombinant protein was expressed at levels that gave a high signal-
to-noise ratio versus the native enzyme.  




4. Deletion of the ABC transporters allowed the accumulation of triazole 
drugs in the cell without the complication of drug efflux, giving 
unambiguous growth inhibition curves with the triazole drugs and 
allowing MIC changes to be attributable to the overexpressed ScErg11p.  
The disadvantages of this system included:  
1. A major portion of the overexpressed enzyme in ScErg11p-eGFP 
constructs (Monk et al., 2014b) appeared to be clumped near the nuclear 
membrane (the rest localises in the endoplasmic reticulum), possibly 
meaning that a significant fraction of the enzyme may be isolated from 
the ergosterol biosynthetic pathway or not physiologically active. 
2. The overexpression of ScErg11p resulted in only a 3-4-fold increase in 
triazole resistance (whole cell assays), which was at a level significantly 
lower than might be expected for the observed increase in expression of 
the recombinant protein compared with the native protein.  
CYP450 proteins require reduction by their cognate NADPH-cytochrome P450 
reductase. If the endogenous reductase becomes rate limiting it is possible that 
only a fraction of the overexpressed enzyme is physiologically active and able 
to contribute to ergosterol metabolism. An expression system that 
simultaneously overexpresses ScErg11p with its cognate NADPH-P450 
reductase may help overcome this problem. An alternative is to use 
reconstitution experiments with recombinant enzymes and/or membrane 
fractions as described below (Section 6.3). In the present study, it is also 
possible that enzyme overexpression might have led to inhibitor sequestration 
by molecules of Erg11p enzyme outside the multienzyme “ergosome” complex 
in the ergosterol biosynthesis pathway described by Mo and Bard (Mo and 
Bard, 2005). The ergosome complex includes Erg11p and Erg24p together with 
Erg25p-Erg26p mounted of the scaffold protein Erg28p. Inhibitor sequestration 
could lower the concentration of the drug available to inhibit the physiologically 
active enzyme, but the affinity of the sequestering enzyme for the drug may not 
be the same as that of the functional wild type or mutant enzyme. 




In this thesis comparisons were always made between strains with identical 
genetic backgrounds i.e. the wild type ScErg11p overexpressing strain was 
compared to a mutant ScErg11p overexpressing strain either with the native 
ERG11 intact or deleted. Perhaps a more physiologically relevant way to 
compare phenotypes of strains bearing mutant and wild type enzyme would be 
to express the mutant enzymes from the native ERG11 locus. The recombinant 
enzyme would then be expected to distribute normally in the endoplasmic 
reticulum and behave in a more physiologically relevant manner. On the other 
hand, overexpression of CYP51 is an important mechanism of resistance in 
itself. For example, in A. fumigatus resistant clinical isolates, tandem repeats in 
the CYP51A promoter cause increased expression in addition to the effects of 
single or multiple mutations in the CYP51A ORF (van der Linden et al., 2013, 
Snelders et al., 2008).  
In order to evaluate the physiological impact of resistance mutations, the 
triazole susceptibilities of strains overexpressing mutant ScErg11p6×His were 
compared to those of strains overexpressing the wild type enzyme. In some 
cases the mutant enzyme may not have been overexpressed at the same level as 
the wild type enzyme, may have been intrinsically unstable or turned over more 
rapidly at different stages of the growth cycle. This may have led to differences 
in the triazole susceptibilities observed between S. cerevisiae and those that 
occur in fungal pathogens. For example, if a mutant enzyme is overexpressed at 
a lower level than the wild type enzyme and confers reduced susceptibility to a 
drug, the contribution to resistance (per molecule of Erg11p) caused by a 
mutation may actually be higher than that inferred from MIC determinations. It 
is suggested that future studies require quantitation of functional enzyme in 
membrane preparations rather than the crude, activity-independent measures 
used in aspects of the present study that were based on the detection of the 
Coomassie stained or His-tagged protein. This could be achieved by measuring 
carbon monoxide difference spectra of the reduced enzyme in such preparations, 
provided the mutation does not affect the extinction coefficient of the heme.  




There are difficulties intrinsic to determining precise inhibitor affinities when 
tight enzyme-inhibitor complexes are formed in a near stoichiometric manner. 
As a result, this thesis has used a modified approach to the estimation of Kd 
values for type II binding of triazole drugs compared to previous studies with 
fungal CYP51s. In the studies by Warrilow and colleagues, a rearrangement of 
the Morrison equation was used to estimate the Kd values if tight binding was 
observed i.e. enzyme saturation occurred at a concentration of the drug equal to 
or less than the concentration of the enzyme (Warrilow et al., 2010b, Warrilow 
et al., 2010a). In the present study some datasets consistent with tight binding 
did not fit the rearrangement of the Morrison equation. In such instances the 
Hill equation gave a better fit and was used instead. In addition, solubilisation of 
the enzyme from the membranes can also change the ligand-binding properties 
of CYP51s as demonstrated by Warrilow et al. (Warrilow et al., 2015). Assays 
using A. fumigatus NADPH cytochrome P450 reductase reconstituted with 
membrane preparations of A. fumigatus CYP51A or CYP51B enzymes 
heterologously expressed in E. coli (discussed below, Section 6.3) gave IC50 
values 34-fold higher for FLC binding to AfCYP51A (17 µM) compared to 
AfCYP51B (0.5 µM). However, a comparison of FLC binding by these two 
CYP51 enzymes estimated using type II binding with the Ni-NTA affinity 
purified enzymes gave only a 3-fold difference in Kd values i.e. 12 µM for 
AfCYP51A and 4 µM for AfCYP51B. These differences, presumably caused by 
the solubilisation of the enzyme with detergents, highlight the importance that 
the lipid bilayer plays in positioning the enzyme, determining its conformation 
and the access of triazole inhibitors to the active site. Reconstitution of the 
affinity purified enzyme in lipid vesicles may provide a way forward towards 
obtaining more reliable and physiologically relevant estimates of the binding 
affinities of CYP51 inhibitors. We conclude that the type II binding studies 
presented in this thesis using affinity purified enzyme preparations may only 
have value in discriminating between drugs that bind tightly and weakly to the 
active site. 
During crystallographic refinement of structural models specific constraints 
were applied. The distance between the heme iron and the nitrogen atom of the 




triazole ring was set at 2.15 Å and the distance between the sulphur atom of 
C470 and the heme iron set at 2.33 Å, as described in Section 2.8.3. As 
expected, examination of electron density maps obtained at resolutions of 
around 2 Å was unable to detect significant changes in heme-ligand distances. A 
resolution of 1.5 Å is required to establish the position of individual atoms. 
Disruption in the position of the heme has been proposed to be one of the ways 
resistance mutations could affect the structure and function of CYP51 enzymes 
(Fraczek et al., 2011). Mutations Y140F/H, K151R and T322I in 
ScErg11p6×His were found to induce changes on the electronic environment of 
the heme as judged by the longer wavelength of the Soret peak in mutant “apo 
enzyme” preparations or the smaller ΔAmax of mutants that were detected in 
type II binding studies with triazole drugs. An altered tilt of the heme was not 
observed in any of the mutant structures and, given the structural resolutions 
(<2 Å) achieved with the structures, it was not possible to determine whether 
the mutations induced changes that altered the distance between the heme iron 
and the triazole drug. If the distance was altered in ScErg11p6×His mutants, the 
change is likely to be a fraction of an angstrom. Molecular dynamics could be 
used to investigate whether there are differences in the distances between the 
heme iron and the coordinated nitrogen atom of the triazole drug in mutant 
enzymes compared to the wild type. Changes in the nature of enzyme-heme and 
enzyme-drug interactions in the case of the ScErg11p6×His Y140F/H mutants 
might be enough to alter this distance.  
6.2 Implications for CYP51 inhibitor design 
The present study has identified several features that should be considered in the 
design of CYP51 inhibitors. These antifungal drugs should have a strong 
preferential affinity for a range of fungal CYP51s and not the human CYP51 
enzyme or the human CYP450 drug metabolising enzymes such as CYP3A4, 
CYP2C19, CYP2C9 (Ekroos and Sjogren, 2006, Hyland et al., 2003). It is 
known that as well as binding to and inhibiting the drug metabolising CYP450s, 
some azoles can also induce their expression (Korashy et al., 2007, Sun et al., 
2006). Thus treatment of fungal disease in patients with underlying conditions 




can become more problematic due to drug interactions caused by polypharmacy. 
For example, the imidazoles clotrimazole and ketoconazole both have the 
disadvantage of showing tight binding to human CYP51 (Warrilow et al., 2013). 
Voriconazole is metabolized by both CYP2C19 and CYP3A4 and its rates of 
metabolism and impact on the metabolism of other drugs can vary significantly 
between individuals (Hyland et al., 2003). As a result, serum levels of 
voriconazole need to be carefully monitored during prophylaxis and the 
treatment of invasive aspergillosis (Ashbee et al., 2014). The tetrazole VT-1161 
has the advantage of showing tight type II binding with the fungal CaCYP51 
enzyme (Kd = 39 nM) but not human CYP51 i.e. no binding was obtained with 
human CYP51 at a VT-1161 concentration of 86 µM (Warrilow et al., 2014). A 
crystal structure of human CYP51 in complex with this ligand is needed to 
determine whether VT-1161 binds to human CYP51 without perturbing the 
heme, or whether it binds at all. Since the tetrazole group shows ~2,000-fold 
greater selectivity for fungal CYP51 than human CYP51 (Warrilow et al., 
2014), it appears to be advantageous to use this substituent instead of the 
triazole group in future drug design. However, synthetic chemistry using 
tetrazole groups is considered to be both more expensive and dangerous as 
compounds containing such groups can be explosive. 
In order to accommodate passage of its substrate lanosterol, the entry channel of 
ScErg11p is made up of mainly hydrophobic residues and it is isolated from 
solvent exposure by the lipid bilayer. The long-tailed triazoles ITC and PCZ 
have three aromatic rings including the halogenated aromatic ring adjacent to 
the heme coordinating triazole ring, making both compounds lipophilic and 
relatively insoluble in water. There is a hydrophilic pocket in the substrate 
channel of ScErg11p, which contains the three water molecules when ITC is 
bound, including one, which forms a hydrogen bond network with the main 
chain components of H381 and S382. Apart from being generally hydrophobic, 
the long tails of novel antifungals could be designed to target this water-
containing pocket.  




There are 36 residues conserved in eukaryotic CYP51s (Lepesheva and 
Waterman, 2011). Conserved residue Y126 (S. cerevisiae numbering) is 
involved in supporting the heme via a hydrogen bond to one of the heme the 
propionate group. Our structures show movement of this residue depending on 
what ligand is bound. Binding of lanosterol, ITC or PCZ maintains the 
hydrogen bond between the Y126 and heme propionate but the binding of VCZ 
or FLC abolishes that hydrogen bond, as shown in Figure 4.8. The number of 
fungus-specific, conserved residues are limited and several of those have similar 
properties to the ones conserved in animals (Lepesheva and Waterman, 2011). 
For example, residue F241 (S. cerevisiae numbering; located at the egress 
channel) is conserved in fungi, however in animals the residue in the same 
position is a conserved tryptophan..  
New azole drugs should also be effective against azole resistant CYP51 
mutants. As a result of this study, the design of the new azole drugs can now 
begin to consider the impact of resistance-conferring mutations in CYP51. The 
findings of this thesis suggest the following considerations when designing 
novel azole drugs targeting fungal CYP51s: 
1. The hydroxyl group present in FLC and VCZ could be replaced with 
alternative substituents that circumvent the consequences of tyrosine to 
phenylalanine or histidine mutations on the B’C loop. The 1,3-dioxolane 
moiety present in ITC and PCZ does not interact via a water-mediated 
hydrogen bond network with the tyrosine and therefore mutation to 
phenylalanine or histidine will have no effect on binding.  
2. The hydrophilic pocket in the substrate channel that accommodates three 
water molecules and interacts with a nitrogen atom of the piperazine ring 
of ITC (N20) or PCZ (NBT) could be used to provide extra interactions 
for a medium length azole drug. This region at the nexus of the active 
site, entry and exit channel of ScErg11p6×His has the advantage that it 
contains Y72, F241, H381 and S382. These amino acid residues are 
conserved among major fungal pathogens, are not found in human 
CYP51 and have yet to be shown to contribute to azole resistance.  




3. The resistance to long-tailed triazoles PCZ and ITC appears to be due to 
mutations that have been mapped to the substrate channel of A. 
fumigatus. An azole drug with a tail of medium length may avoid this 
problem. For example, long tailed triazoles seem to be relatively flexible 
in their binding to CYP51s. Three distinct configurations are observed in 
the binding of ITC to ScErg11p6×His wild type and the G73E/W 
mutants. Two of those configurations have been previously observed 
with T. brucei CYP51 in complex with PCZ, which is structurally very 
similar to ITC (Chen et al., 2010). However, the conformation in 
ScErg11p6×His G73W in complex with ITC has not been observed 
previously.  
6.3 Future work 
Type I difference spectra, with a peak at 380 – 390 nm and a trough 415 – 420 
nm, are detected when a CYP51 substrate displaces the water molecule at the 
heme iron, causing the iron to adopt a high spin state (Jefcoate, 1978). Such 
studies are used to estimate the binding affinity of the substrate to the enzyme 
and can give insight into the catalytic efficiency of wild type and mutant 
enzyme preparations. Deletion of the native ERG11 from a strain designed to 
constitutively overexpress ScErg11p6×His G73W from the PDR5 locus was 
unable to give a viable phenotype, indicating that the mutant enzyme is 
catalytically inactive. The catalytic activity of this mutant could be disrupted 
due to the blockage of the entry channel by this bulky residue. Another 
possibility could be that the substrate lanosterol was prevented from entering the 
substrate channel due to potential π-stacking interactions between the 
tryptophan and lanosterol (similar to ones observed between W73 and the tail of 
ITC). It is also possible that strains overexpressing ScErg11p6×His G73E/R 
may have reduced catalytic activity. This may have contributed to the greater 
susceptibility of those strains to all triazoles tested compared to strains 
overexpressing the wild type enzyme. Partial blockage of the substrate channel 
and the presence of a charged residue at the mouth of the channel may have 
impeded the hydrophobic lanosterol molecule from readily entering the entry 




channel and reaching the active site. The use of type I binding to calculate the 
accessibility and binding affinity of the substrate lanosterol to ScErg11p6×His 
wild type and mutant enzymes could provide insight into how the G73 series of 
mutations affect catalytic activity. The opposite is true for the CaCYP51 I471T 
and S279F mutations, which have been tested using the type I binding studies. 
Those mutations were found to increase product affinity, suggesting increased 
catalytic turn over (Warrilow et al., 2010a, Warrilow et al., 2012). This increase 
in product affinity and thus increase in catalytic activity was suggested to 
explain the reduced susceptibility to the azoles by those mutants.  
There is a more direct way to determine the catalytic activity of a CYP51 
enzyme. This involves the incubation of lanosterol and NADPH with CYP51 
and its cognate P450 reductase reconstituted in an artificial lipid bilayer or with 
an E. coli membrane fraction. Estimation via gas chromatography-mass 
spectrometry of the amount of CYP51-related metabolites present can be used 
to determine kinetic parameters and incubation with a triazole drug enables 
estimation of IC50 values for the inhibitor (Warrilow et al., 2010a, Parker et al., 
2013, Park et al., 2011). A recent study by Warrilow et al. (Warrilow et al., 
2015) has utilised this assay to demonstrate that A. fumigatus CYP51A G54W 
mutant confers 11- and 34-fold increases in IC50 values to ITC and PCZ, 
respectively, compared to wild type preparations. This in vitro study affirmed 
the resistance phenotype of these mutants to long-tailed triazoles that were 
detected in clinical isolates as MIC values. Assays of ScErg11p mutants using 
this approach will enable comparative testing of the wild type and mutant 
enzyme function and their response to triazole drugs. However, these assays are 
both technically demanding and expensive. A major step forward would be the 
development of surrogate substrates that give more readily detectable products. 
There is an extensive repertoire of convenient substrates used with cytochrome 
P450 enzymes (PROMEGA luminescent substrates and coumarins; Cali et al., 
2008, Bell et al., 2008). In the case of CYP51 enzymes there is only one 
example of such an assay. A study by Riley et al. (Riley et al., 2015) has 
developed a coumarin-based high-throughput fluorescence assay to measure the 




binding of potential drugs to T. cruzi CYP51. Whether the same assay works for 
fungal CYP51s remains to be determined.  
Several azole drugs in clinical trials, such as VT-1161 and Isavuconazole have a 
hydroxyl group equivalent to that found in FLC and VCZ. This hydroxyl group 
is expected to interact with the Y140 of ScErg11p6×His via a water-mediated 
hydrogen bond network. This suggests that susceptibilities to VT-1161 and ISA 
may be reduced by mutations equivalent to ScErg11p6×His Y140F/H. It will be 
interesting to see if the medium length tails found in these drugs confer an 
advantage over the short-tailed drugs FLC and VCZ in overcoming these 
resistance mutations. Tests of susceptibility on strains overexpressing 
ScErg11p6×His wild type and Y140F/H mutants to these drugs along with X-
ray crystallographic analysis are expected to provide insight into how the tails 
of those drugs influence susceptibility patterns and drug binding. The strain 
overexpressing ScErg11p6×His and the isolated ScErg11p6×His enzyme 
provide valuable tools to investigate the cellular activity of novel azole 
antimycotics and their effects at the biochemical and structural levels. 
Overexpressed ScErg11p6×His may also be useful in investigating the role of 
the fungus-specific loop. Several mutations (D446E, Y447H, G448E, F449V, 
G450E and V456I; C. albicans numbering) found in this region of the enzyme 
surface confer resistance to triazole drugs thus indicating its importance in 
enzyme activity (Flowers et al., 2015, Alvarez-Rueda et al., 2011). Structural 
information is incomplete for some parts of the ScErg11p6×His fungus-specific 
loop in several of the crystal structures I have obtained, indicating that the loop 
is a flexible moiety. Mutating parts of the loop may give insight into its 
function. An assay using reconstituted CYP51 enzyme (Lepesheva et al., 2007) 
could be used to reveal if the mutations in the fungus-specific loop alter the 
catalytic activity of the enzyme.  
6.4  Summary 
The research carried out in this thesis investigated the applicability of ScErg11p 
as a suitable model to represent resistance mutations in CYP51 of pathogenic 




fungi. In the case of Y140F/H and Y140F G464S mutations ScErg11p was a 
suitable model and resistance phenotypes were reproduced, however the rest of 
the mutations made no difference or conferred susceptibility to triazole drugs. 
Thus the relevance of our model is site-specific. The high-resolution structure of 
wild type enzyme with FLC reveals details of how this widely used triazole 
drug interacts with its molecular target. Based on those findings we established 
a mechanism of resistance to FLC for the tyrosine to a phenylalanine or a 
histidine mutation at position 140 (S. cerevisiae numbering). These findings will 
contribute to the structure-directed design of novel azole based antimycotic 
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A.1 S. cerevisiae strains used and prepared during this study. 
Table A-1 Strains used in this study 
Strain Genotype Reference MMLY* 
ADΔ MATα PDR1-3 Δyor1::hisG 
Δsnq2::hisG Δpdr3::hisG  
Δpdr10::hisG Δpdr11::hisG 
Δycf1::hisG  Δpdr5::hisG 
Δpdr15::hisG Δura3 
ΔhisAD124567 Δpdr5::hisG 




ADΔ ScErg11p ADΔ, ∆pdr5::ScERG11-HIS1 Lamping 
et al. 
941 
ADΔ-pABC5’ ADΔ, ∆pdr5::pABC5’-HIS1 Lamping 
et al. 
1760 
AD2Δ ADΔ, Δhis1:dpl200 Chapter 3  1857 
AD2ΔScErg11p AD2Δ, ∆pdr5::ScERG11-URA3 Chapter 3 2291 
AD3ΔScErg11p AD2Δ, ∆pdr5::ScERG11-
URA3, Δerg11::HIS1 




Chapter 4  2292 
AD3ΔScErg11p_Y140F AD2Δ ScErg11p_Y140F, 
Δerg11::HIS1 




Chapter 4  not fileda 
AD3ΔScErg11p_Y140H AD2Δ ScErg11p_Y140H, 
Δerg11::HIS1 
Chapter 4  not fileda 
AD2ΔScErg11p_G73E AD2Δ, 
∆pdr5::ScERG11_G73E-URA3 
Chapter 5 2293 
AD3ΔScErg11p_G73E AD2Δ ScErg11p_G73E, 
Δerg11::HIS1 
Chapter 5 2302 
AD2ΔScErg11p_G73R AD2Δ, 
∆pdr5::ScERG11_G73R-URA3 
Chapter 5 2294 
AD3ΔScErg11p_G73R AD2Δ ScErg11p_G73R, 
Δerg11::HIS1 
Chapter 5 2303 
AD2ΔScErg11p_G73W AD2Δ, 
∆pdr5::ScERG11_G73W-URA3 
Chapter 5 2295 
AD2ΔScErg11p_T322I AD2Δ, 
∆pdr5::ScERG11_T322I-URA3 
Chapter 5 2297 
AD3ΔScErg11p_T322I AD2Δ ScErg11p_T322I, 
Δerg11::HIS1 




Chapter 5 2298 
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AD3ΔScErg11p_K151R AD2Δ ScErg11p_K151R, 
Δerg11::HIS1 




Chapter 5 2296 
AD3ΔScErg11p_G464S AD2Δ ScErg11p_G464S, 
Δerg11::HIS1 








Chapter 5 2307 
*MMLY- Molecular microbiology laboratory number. 
aThose strains were not filed into the yeast strain collection. 
A.2 Solutions used for DNA manipulations 
A.2.1 Water purification 
All solutions were prepared in either deionised distilled water ddH2O or 
ultrapure water (Milli-Q H2O). Milli-Q water was obtained by purifying the 
ddH2O using the Simplicity Water Purification System (Merck Millipore, 
Billerica, MA, USA) 
A.2.2 DNA loading dye 
DNA loading dye (10×) contained 0.25% w/v bromophenol blue, 0.25% w/v 
xylene cyanol FF and 50% v/v glycerol in ddH2O. 
A.2.3 TAE running buffer 
Tris-acetate EDTA (TAE) buffer (50×) contained 242 g Tris base (Invitrogen), 
37.2 g Na2EDTA (Merck), 114.2 mL glacial acetic acid (Merck) in 1 L of 
ddH2O and was stored at 4 °C. 
A.2.4 1 Kb plus ladder 
The DNA ladder contained 50 µL of 1Kb plus DNA ladder (Invitrogen), 200 µL 
50 mM NaCl and 250 µL 10× DNA loading dye.  
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A.2.5 Agarose gels 
Agarose gels (0.8%) were prepared by adding 0.8 g of UltraPureTM agarose 
(Invitrogen) to 100 mL of TAE buffer. The agarose containing mix was melted 
using a microwave, cooled to about 45°C, and 5 µL of ethidium bromide (50 
ng/mL) added. The solution was poured into a gel cast, a suitable comb was 
inserted and the gel was allowed to solidify at room temperature. 
A.3 Protein purification buffers 
A.3.1 Cell breakage medium 
Cell breakage buffer consisted of 20 % glycerol (w/v), 50 mM Tris, 0.5 mM 
EDTA and 0.5 mM phenylmethanesulfonyl fluoride (PMSF)* in Milli-Q H2O. 
The pH was adjusted to 7.5 at room temperature with 5 M HCl. The medium 
was stored at 4 °C prior to the addition of PMSF (Roche). 
*PMSF is unstable in aqueous solution and therefore was added to all buffers 
immediately prior to use. Stock PMSF (100 µM) is dissolved in isopropanol.  
A.3.2 GTED-20  
GTED-20 consisted of 20 % glycerol (w/v), 10 mM Tris, 0.5 mM EDTA and 
0.5 mM PMSF in Milli-Q H2O. The pH was adjusted to 7.5 at room temperature 
with 1 M HCl. The buffer was stored at 4 °C. 
A.3.3 Protein solubilisation solution 
Protein solubilisation buffer contained 10% (wt/vol) glycerol, 250 mM NaCl, 20 
mM Tris, 0.5 mM PMSF and 1 Roche EDTA-free protease inhibitor pill per 200 
mL in Milli-Q H2O. The pH was adjusted to 7.5 at room temperature with 1 M 
HCl. 
A.3.4 Protein solubilisation solution with detergent 




A.3.5 Ni-NTA affinity matrix binding solution 
Ni-NTA affinity matrix binding solution contained 10% (wt/vol) glycerol, 250 
mM NaCl, 20 mM Tris, 0.5 mM PMSF, 16 mM DM (10×CMC), 20 mM 
imidazole and 1 Roche EDTA-free protease inhibitor pill per 200 mL of the 
solution in Milli-Q H2O. The pH was adjusted to 7.5 at room temperature with 
0.1 M HCl. 
A.3.6 Ni-NTA affinity column elution buffer 
Ni-NTA affinity matrix binding solution containing 200 mM imidazole. The pH 
was adjusted to 7.5 at room temperature using 1 M HCl. 
A.3.7 Size exclusion chromatography buffer 
Size exclusion chromatography buffer contained 10% (wt/vol) glycerol, 150 
mM NaCl, 20 mM HEPES, 0.5 mM PMSF, 6.4 mM DM (4×CMC) and 1 Roche 
EDTA-free protease inhibitor pills per 200 mL. The pH of the solution was 
adjusted to 7.5 at room temperature with 1 M NaOH. The buffer was filtered 
with a 0.22 µm nitrocellulose filter (Merck Millipore) and degassed prior to use 
in FPLC. 
A.4 SDS polyacrylamide gel electrophoresis 
A.4.1 SDS PAGE running buffer 
SDS PAGE running buffer consisted of 12.6 g glycine (Merck), 2.7 g Tris and 
0.9 g sodium dodecyl sulphate (Invitrogen) dissolved in 900 mL of ddH2O. 
A.4.2 Protein loading buffer 
Protein loading buffer (6×) consisted of 7 mL of 4× upper stacking buffer, 3 mL 
glycerol, 1 g SDS, 0.2 g dithiothreitol (Roche Diagnostics) and 2 mg 





Table A-2 SDS PAGE components  




40% acrylamide 2.4 mL 0.5 mL 
4× separating buffer 
(1.5 M Tris.HCl, pH 8.8; 0.4 % 
SDS) 
3.0 mL  
4× upper stacking buffer 
(0.5 M Tris.HCl, pH 6.8; 0.4 % 
SDS) 
 1 mL 
Milli-Q H2O 6.6 mL 2.5 mL 
TEMED 8 µL 2 µL 
10% ammonium persulfate  60 µL 30 µL 
 
A.4.3 Coomassie brilliant blue stain 
Coomassie brilliant blue stain contained 0.1% Coomassie Brilliant Blue R250 
(Sigma-Aldrich Ltd), 10% glacial acetic acid and 50% methanol made up in 
ddH20 and filtered using Whatman No 1 (Thermo Fisher) filter paper. 
A.4.4 Acrylamide gel destaining solution 
The destaining solution contained 10% glacial acetic acid, 20% methanol made 
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B.1 ScERG11 cassette manipulations 
Table B-1 Generic oligonucleotide primers used for ScERG11 cassette 
manipulations 









B.1.1 Sequence of the ScERG11 transformation cassette. 
The PDR5F priming site at the 5’ end of the DNA sequence is highlighted in 
blue while the PDR5DS_R priming site at the 3’ end of the DNA sequence is 
highlighted in red. The ScERG11 open reading frame is in bold, the PGK 
terminator in italics and the URA3 selection marker highlighted in grey. The 
sequence upstream of ERG11  and the sequence downstream of URA3 are 







































































Figure B-1 Colony PCR analysis used to verify the presence and 
orientation of the S. cerevisiae ERG11 cassette. Primers PDR5_US and 
ScErg11_ORF_183R were used to amplify ERG11 from individual yeast 
colonies. The expected size of the amplimer was 1417 bp. The PCR fragments 
were separated by electrophoresis using a 0.8% agarose gel. Lane M: molecular 
markers (1 kb Plus DNA molecular ladder). Lanes 1 – 6 are clones positive for 
the insert. Lane 7: positive control (ADΔ ScErg11p strain). Lane 8: negative 









B.2 ScHis1 disruption cassette manipulations 
Table B-2 Primers used to prepare ScHis1 cassette for disruption of native 
ERG11 











B.2.1 Sequence of the ScHis1 cassette for disruption of native ERG11 
The S. cerevisiae ERG11 upstream and downstream sequences flank ScHIS1 
which is shown in bold. The ScErg11_US-759 priming site is highlighted in 
green, the ScErg11xHisF priming site in yellow, ScErg11xHisR priming site in 









































Figure B-2 Colony PCR analysis used to verify the presence of ScHIS1 
cassette. Primers ScErg11_US_801 and ScHis1_ORF_493R were used to 
amplify the disruption cassette from individual yeast colonies. The expected 
size of the amplimer was 1604 bp. The PCR fragments were separated by 
electrophoresis using a 0.8% agarose gel. Lane M: molecular markers (1 kb Plus 
DNA molecular ladder). Lanes 1 – 9 are clones positive for the insert. Lane 10: 
clone negative for the insert. Lane 11: positive control (AD3ΔScErg11p_Y140F 
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Figure C-1 SEC chromatograms (Superdex 200 10/300 column eluted with 
size exclusion chromatography buffer, Appendix A.3.7) of ScErg11p6×His 
mutants purified without added ligand. The SEC fractions for the 
ScErg11p6×His G73W (a), G73E (b), K151R (c) and T322I (d) enzyme that 
eluted within 11 – 15 mL were pooled, concentrated by centrifugal filtration and 





Figure C-2 Absolute absorbance spectra of ScErg11p6×His mutants co-
purified with ITC during SEC. The absorbance spectra of ScErg11p6×His 
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Mass spectrometry determination of the tryptic peptide coverage and 
detection of the mutated residue for ScErg11p6×His mutants 
Sequences identified by mass spectrometry from tryptic fragments of the 62 
kDa band ScErg11p6×His recovered by SDS-PAGE are bold and highlighted in 
grey. The site of the mutation in each primary sequence (single letter amino acid 
code) is highlighted in red. 
D.1 ScErg11p6×His G73E mutation  
1   MSATKSIVGE  ALEYVNIGLS  HFLALPLAQR  ISLIIIIPFI 
41  YNIVWQLLYS  LRKDRPPLVF  YWIPWVGSAV  VYEMKPYEFF 
81  EECQKKYGDI  FSFVLLGRVM  TVYLGPKGHE  FVFNAKLADV 
121 SAEAAYAHLT  TPVFGKGVIY  DCPNSRLMEQ  KKFVKGALTK 
161 EAFKSYVPLI  AEEVYKYFRD  SKNFRLNERT  TGTIDVMVTQ 
201 PEMTIFTASR  SLLGKEMRAK  LDTDFAYLYS  DLDKGFTPIN 
241 FVFPNLPLEH  YRKRDHAQKA  ISGTYMSLIK  ERRKNNDIQD 
281 RDLIDSLMKN  STYKDGVKMT  DQEIANLLIG  VLMGGQHTSA 
321 ATSAWILLHL  AERPDVQQEL  YEEQMRVLDG  GKKELTYDLL 
361 QEMPLLNQTI  KETLRMHHPL  HSLFRKVMKD  MHVPNTSYVI 
401 PAGYHVLVSP  GYTHLRDEYF  PNAHQFNIHR  WNNDSASSYS 
441 VGEEVDYGFG  AISKGVSSPY  LPFGGGRHRC  IGEHFAYCQL 
481 GVLMSIFIRT  LKWHYPEGKT  VPPPDFTSMV  TLPTGPAKII 
521 WEKRNPEQKI  GGRHHHHHH 
 
Protein sequence coverage is 79.2 %. 
D.2 ScErg11p6×His G73R mutation  
1   MSATKSIVGE  ALEYVNIGLS  HFLALPLAQR  ISLIIIIPFI  
41  YNIVWQLLYS  LRKDRPPLVF  YWIPWVGSAV  VYRMKPYEFF  
81  EECQKKYGDI  FSFVLLGRVM  TVYLGPKGHE  FVFNAKLADV 
121 SAEAAYAHLT  TPVFGKGVIY  DCPNSRLMEQ  KKFVKGALTK  
161 EAFKSYVPLI  AEEVYKYFRD  SKNFRLNERT  TGTIDVMVTQ   
201 PEMTIFTASR  SLLGKEMRAK  LDTDFAYLYS  DLDKGFTPIN  
241 FVFPNLPLEH  YRKRDHAQKA  ISGTYMSLIK  ERRKNNDIQD  
281 RDLIDSLMKN  STYKDGVKMT  DQEIANLLIG  VLMGGQHTSA  
321 ATSAWILLHL  AERPDVQQEL  YEEQMRVLDG  GKKELTYDLL  
361 QEMPLLNQTI  KETLRMHHPL  HSLFRKVMKD  MHVPNTSYVI  
401 PAGYHVLVSP  GYTHLRDEYF  PNAHQFNIHR  WNNDSASSYS  
441 VGEEVDYGFG  AISKGVSSPY  LPFGGGRHRC  IGEHFAYCQL  
481 GVLMSIFIRT  LKWHYPEGKT  VPPPDFTSMV  TLPTGPAKII  
521 WEKRNPEQKI  GGRHHHHHH 
 





D.3 ScErg11p6×His G73W mutation  
1   MSATKSIVGE  ALEYVNIGLS  HFLALPLAQR  ISLIIIIPFI  
41  YNIVWQLLYS  LRKDRPPLVF  YWIPWVGSAV  VYWMKPYEFF  
81  EECQKKYGDI  FSFVLLGRVM  TVYLGPKGHE  FVFNAKLADV 
121 SAEAAYAHLT  TPVFGKGVIY  DCPNSRLMEQ  KKFVKGALTK  
161 EAFKSYVPLI  AEEVYKYFRD  SKNFRLNERT  TGTIDVMVTQ   
201 PEMTIFTASR  SLLGKEMRAK  LDTDFAYLYS  DLDKGFTPIN  
241 FVFPNLPLEH  YRKRDHAQKA  ISGTYMSLIK  ERRKNNDIQD  
281 RDLIDSLMKN  STYKDGVKMT  DQEIANLLIG  VLMGGQHTSA  
321 ATSAWILLHL  AERPDVQQEL  YEEQMRVLDG  GKKELTYDLL  
361 QEMPLLNQTI  KETLRMHHPL  HSLFRKVMKD  MHVPNTSYVI  
401 PAGYHVLVSP  GYTHLRDEYF  PNAHQFNIHR  WNNDSASSYS  
441 VGEEVDYGFG  AISKGVSSPY  LPFGGGRHRC  IGEHFAYCQL  
481 GVLMSIFIRT  LKWHYPEGKT  VPPPDFTSMV  TLPTGPAKII 
521 WEKRNPEQKI  GGRHHHHHH  
Protein sequence coverage is 84.7% 
D.4 ScErg11p6×His K151R mutation  
1   MSATKSIVGE  ALEYVNIGLS  HFLALPLAQR  ISLIIIIPFI  
41  YNIVWQLLYS  LRKDRPPLVF  YWIPWVGSAV  VYGMKPYEFF 
81  EECQKKYGDI  FSFVLLGRVM  TVYLGPKGHE  FVFNAKLADV  
121 SAEAAYAHLT  TPVFGKGVIY  DCPNSRLMEQ  RKFVKGALTK  
161 EAFKSYVPLI  AEEVYKYFRD  SKNFRLNERT  TGTIDVMVTQ  
201 PEMTIFTASR  SLLGKEMRAK  LDTDFAYLYS  DLDKGFTPIN  
241 FVFPNLPLEH  YRKRDHAQKA  ISGTYMSLIK  ERRKNNDIQD 
281 RDLIDSLMKN  STYKDGVKMT  DQEIANLLIG  VLMGGQHTSA 
321 ATSAWILLHL  AERPDVQQEL  YEEQMRVLDG  GKKELTYDLL  
361 QEMPLLNQTI  KETLRMHHPL  HSLFRKVMKD  MHVPNTSYVI 
401 PAGYHVLVSP  GYTHLRDEYF  PNAHQFNIHR  WNNDSASSYS 
441 VGEEVDYGFG  AISKGVSSPY  LPFGGGRHRC  IGEHFAYCQL 
481 GVLMSIFIRT  LKWHYPEGKT  VPPPDFTSMV  TLPTGPAKII 
521 WEKRNPEQKI  GGRHHHHHH 
 

















D.5 ScErg11p6×His T322I mutation  
1   MSATKSIVGE  ALEYVNIGLS  HFLALPLAQR  ISLIIIIPFI  
41  YNIVWQLLYS  LRKDRPPLVF  YWIPWVGSAV  VYGMKPYEFF  
81  EECQKKYGDI  FSFVLLGRVM  TVYLGPKGHE  FVFNAKLADV  
121 SAEAAYAHLT  TPVFGKGVIY  DCPNSRLMEQ  KKFVKGALTK  
161 EAFKSYVPLI  AEEVYKYFRD  SKNFRLNERT  TGTIDVMVTQ  
201 PEMTIFTASR  SLLGKEMRAK  LDTDFAYLYS  DLDKGFTPIN  
241 FVFPNLPLEH  YRKRDHAQKA  ISGTYMSLIK  ERRKNNDIQD  
281 RDLIDSLMKN  STYKDGVKMT  DQEIANLLIG  VLMGGQHTSA  
321 AISAWILLHL  AERPDVQQEL  YEEQMRVLDG  GKKELTYDLL  
361 QEMPLLNQTI  KETLRMHHPL  HSLFRKVMKD  MHVPNTSYVI  
401 PAGYHVLVSP  GYTHLRDEYF  PNAHQFNIHR  WNNDSASSYS  
441 VGEEVDYGFG  AISKGVSSPY  LPFGGGRHRC  IGEHFAYCQL  
481 GVLMSIFIRT  LKWHYPEGKT  VPPPDFTSMV  TLPTGPAKII  
521 WEKRNPEQKI  GGRHHHHHH 
 
Protein sequence coverage is 91.4% 
D.6 ScErg11p6×His G464S mutation 
1   MSATKSIVGE  ALEYVNIGLS  HFLALPLAQR  ISLIIIIPFI  
41  YNIVWQLLYS  LRKDRPPLVF  YWIPWVGSAV  VYGMKPYEFF  
81  EECQKKYGDI  FSFVLLGRVM  TVYLGPKGHE  FVFNAKLADV 
121 SAEAAYAHLT  TPVFGKGVIY  DCPNSRLMEQ  KKFVKGALTK  
161 EAFKSYVPLI  AEEVYKYFRD  SKNFRLNERT  TGTIDVMVTQ   
201 PEMTIFTASR  SLLGKEMRAK  LDTDFAYLYS  DLDKGFTPIN  
241 FVFPNLPLEH  YRKRDHAQKA  ISGTYMSLIK  ERRKNNDIQD  
281 RDLIDSLMKN  STYKDGVKMT  DQEIANLLIG  VLMGGQHTSA  
321 ATSAWILLHL  AERPDVQQEL  YEEQMRVLDG  GKKELTYDLL  
361 QEMPLLNQTI  KETLRMHHPL  HSLFRKVMKD  MHVPNTSYVI  
401 PAGYHVLVSP  GYTHLRDEYF  PNAHQFNIHR  WNNDSASSYS  
441 VGEEVDYGFG  AISKGVSSPY  LPFSGGRHRC  IGEHFAYCQL  
481 GVLMSIFIRT  LKWHYPEGKT  VPPPDFTSMV  TLPTGPAKII 
521 WEKRNPEQKI  GGRHHHHHH 
 



















D.7 ScErg11p6×His G464S Y140F double mutation  
1   MSATKSIVGE  ALEYVNIGLS  HFLALPLAQR  ISLIIIIPFI  
41  YNIVWQLLYS  LRKDRPPLVF  YWIPWVGSAV  VYGMKPYEFF  
81  EECQKKYGDI  FSFVLLGRVM  TVYLGPKGHE  FVFNAKLADV  
121 SAEAAYAHLT  TPVFGKGVIF  DCPNSRLMEQ  KKFVKGALTK  
161 EAFKSYVPLI  AEEVYKYFRD  SKNFRLNERT  TGTIDVMVTQ  
201 PEMTIFTASR  SLLGKEMRAK  LDTDFAYLYS  DLDKGFTPIN  
241 FVFPNLPLEH  YRKRDHAQKA  ISGTYMSLIK  ERRKNNDIQD  
281 RDLIDSLMKN  STYKDGVKMT  DQEIANLLIG  VLMGGQHTSA  
321 ATSAWILLHL  AERPDVQQEL  YEEQMRVLDG  GKKELTYDLL  
361 QEMPLLNQTI  KETLRMHHPL  HSLFRKVMKD  MHVPNTSYVI  
401 PAGYHVLVSP  GYTHLRDEYF  PNAHQFNIHR  WNNDSASSYS  
441 VGEEVDYGFG  AISKGVSSPY  LPFSGGRHRC  IGEHFAYCQL  
481 GVLMSIFIRT  LKWHYPEGKT  VPPPDFTSMV  TLPTGPAKII  
521 WEKRNPEQKI  GGRHHHHHH 
 
Protein sequence coverage is 90.1% 
D.8 ScErg11p6×His Y140F mutation  
1   MSATKSIVGE  ALEYVNIGLS  HFLALPLAQR  ISLIIIIPFI 
41  YNIVWQLLYS  LRKDRPPLVF  YWIPWVGSAV  VYGMKPYEFF 
81  EECQKKYGDI  FSFVLLGRVM  TVYLGPKGHE  FVFNAKLADV 
121 SAEAAYAHLT  TPVFGKGVIF  DCPNSRLMEQ  KKFVKGALTK 
161 EAFKSYVPLI  AEEVYKYFRD  SKNFRLNERT  TGTIDVMVTQ 
201 PEMTIFTASR  SLLGKEMRAK  LDTDFAYLYS  DLDKGFTPIN 
241 FVFPNLPLEH  YRKRDHAQKA  ISGTYMSLIK  ERRKNNDIQD 
281 RDLIDSLMKN  STYKDGVKMT  DQEIANLLIG  VLMGGQHTSA 
321 ATSAWILLHL  AERPDVQQEL  YEEQMRVLDG  GKKELTYDLL 
361 QEMPLLNQTI  KETLRMHHPL  HSLFRKVMKD  MHVPNTSYVI 
401 PAGYHVLVSP  GYTHLRDEYF  PNAHQFNIHR  WNNDSASSYS 
441 VGEEVDYGFG  AISKGVSSPY  LPFGGGRHRC  IGEHFAYCQL 
481 GVLMSIFIRT  LKWHYPEGKT  VPPPDFTSMV  TLPTGPAKII 
521 WEKRNPEQKI  GGRHHHHHH 
 

















D.9 ScErg11p×His Y140H mutation  
1   MSATKSIVGE  ALEYVNIGLS  HFLALPLAQR  ISLIIIIPFI 
41  YNIVWQLLYS  LRKDRPPLVF  YWIPWVGSAV  VYGMKPYEFF 
81  EECQKKYGDI  FSFVLLGRVM  TVYLGPKGHE  FVFNAKLADV 
121 SAEAAYAHLT  TPVFGKGVIH  DCPNSRLMEQ  KKFVKGALTK 
161 EAFKSYVPLI  AEEVYKYFRD  SKNFRLNERT  TGTIDVMVTQ 
201 PEMTIFTASR  SLLGKEMRAK  LDTDFAYLYS  DLDKGFTPIN 
241 FVFPNLPLEH  YRKRDHAQKA  ISGTYMSLIK  ERRKNNDIQD 
281 RDLIDSLMKN  STYKDGVKMT  DQEIANLLIG  VLMGGQHTSA 
321 ATSAWILLHL  AERPDVQQEL  YEEQMRVLDG  GKKELTYDLL 
361 QEMPLLNQTI  KETLRMHHPL  HSLFRKVMKD  MHVPNTSYVI 
401 PAGYHVLVSP  GYTHLRDEYF  PNAHQFNIHR  WNNDSASSYS 
441 VGEEVDYGFG  AISKGVSSPY  LPFGGGRHRC  IGEHFAYCQL 
481 GVLMSIFIRT  LKWHYPEGKT  VPPPDFTSMV  TLPTGPAKII 
521 WEKRNPEQKI  GGRHHHHHH 
 




  Appendix E






The SEC purified protein concentration used in this study was estimated, as 
described in Section 2.7.1, using the A280nm peak in the absorbance spectra 
(extinction coefficient = 1.345 mg-1.mL-1.cm-1). Wild type or mutant 
ScErg11p6×His (1 µM) was titrated using the triazole drugs FLC, VCZ, ITC 
and PCZ. The range of drug concentration used was 0.05 – 15 µM. The heme 
Soret peak maximum was determined by scanning from 390 to 450 nm against a 
reagent blank using an Ultrospec™ 6300 pro UV/Vis spectrophotometer. The 
apparent Kd values for the enzyme-drug interaction were calculated by fitting 
data to the Hill equation (Equation 2.4), a rearrangement of the Morrison 
equation (Equation 2.5) or the Michaelis-Menten equation and choosing the best 
fit obtained using GraphPad Prism 6 software. The Michaelis-Menten equation 
(ΔA = ΔAmax[Azole]/([Azole] + Kd))was used when the Hill coefficient in the 
Hill equation was equal to 1. ΔAmax is the maximum change in absorbance and 
[Azole] is the azole concentration.  
E.2 Results 
Heme Soret peak shift measurements were carried out for FLC, VCZ, ITC and 
PCZ binding to the wild type and all mutant ScErg11p6×His proteins, except 
for the Y140F G464S double mutant. The binding curves, fitted to the Hill 
equation, the rearrangement of the Morrison equation or the Michaelis-Menten, 




Figure E-1 The binding of triazole drugs to ScErg11p6×His wild type and 
mutants based on the Soret heme peak shift. ScErg11p6×His (1 µM) was 
titrated with triazole drugs (a, b) FLC, (c, d) VCZ, (e, f) ITC and (g, h) PCZ. 
The wild type enzyme is represented in solid circles, the G73E mutant solid 
squares, G73R mutant solid triangles, G73W mutant solid diamonds, K151R 




The maximal red shift of the heme Soret peak was ~4 nm for the binding of 
triazoles FLC, VCZ, ITC and PCZ to wild type ScErg11p6×His. The Kd values 
for FLC, ITC and PCZ binding were determined to be in the nM range for the 
wild type enzyme (Table E-1). The Kd values in the nM range for FLC, ITC and 
PCZ for the wild type and mutant ScErg11p6×His indicate that the binding of 
these drugs is tight. Surprisingly, the binding of VCZ to wild type and mutant 
enzymes gives Kd values that appeared to be much higher than for the rest of the 
triazoles tested (Table E-1). 
ScErg11p6×His G73E/W produced a heme Soret peak shift of <3 – 4 nm on 
triazole binding (Figure E-1 a, c, e, g). However, ScErg11p6×His G73R gave a 
smaller shift of ~2.5 nm for binding of FLC and ITC (Figure E-1 a, e). The 
smaller Soret peak shift still indicated very tight binding, with Kd values of 15 
nM and 35 nM for FLC and ITC binding, respectively.  
ScErg11p6×His K151R enzyme gave a maximum Soret peak shift of ~1.5 nm 
on triazole binding (Figure E-1 b, d, f, h). The ScErg11p6×His K151R apo-
protein had a heme Soret peak of 419.2 nm, which is higher compared to the 
rest of the mutants (Table 5.2), apart from Y140F/H mutants (420 nm). The 
binding of FLC to K151R mutant enzyme appeared to be strongest with a Kd of 
13 nM determined. The ScErg11p6×His G464S mutant behaved similarly to the 
wild type enzyme (Figure E-1 b, d, f, h). While the VCZ binding curve for the 
wild type enzyme fitted the Hill equation, the binding curve for the mutant 
enzyme best fitted the rearrangement of the Morrison equation. The Kd value for 
VCZ binding for the mutant enzyme (0.31 µM) was indicative of tight binding, 
with much weaker binding obtained with the wild type enzyme (1.37 µM).  
The ScErg11p6×His T322I mutant had a maximum Soret peak shift of ~1.6 nm 
for the binding of FLC and ITC (Figure E-1 b, f) and 3 – 4 nm for binding of 
VCZ and PCZ (Figure E-1 d, h). The highest affinity binding for this mutant 
enzyme was shown by FLC and PCZ with Kd values of 3.5 nM and 0.02 nM, 
respectively. The Hill coefficient values of 3.1 for FLC and 4.9 for PCZ binding 




Table E-1 Triazole binding characteristics of ScErg11p6×His wild type and 
mutants based on the Soret heme peak shift 
ScErg11p6×His  Triazole Equation* Kd (µM) Hill no. 
WT FLC Hill 0.063 (± 0.018) 2.1 
VCZ Hill 1.37 (± 0.084) 1.8 
ITC Hill 0.026 (± 0.01) 2.3 
PCZ Hill 0.006 (± 0.006) 3.2 
G73E FLC Hill 0.170 (± 0.057) 1.5 
VCZ M-M 0.54 (± 0.04) n/a 
ITC Hill 0.009 (± 0.010) 2.4 
PCZ Hill 0.009 (± 0.010) 2.4 
G73R FLC Morrison 0.0015 (± 0.003) n/a 
VCZ Morrison 0.75 (± 0.16) n/a 
ITC Hill 0.035 (± 0.01) 2.5 
PCZ Hill 0.0014 (± 0.002) 3.6 
G73W FLC Hill 0.506 (± 0.119) 2.4 
VCZ Morrison 2.40 (± 0.73) n/a 
ITC Morrison 0.0008 (± 0.003) n/a 
PCZ Hill 0.109 (± 0.05) 1.4 
K151R FLC Hill 0.013 (± 0.009) 1.6 
VCZ Morrison 0.30 (± 0.24) n/a 
ITC Hill  0.38 (± 0.11) 0.6 
PCZ Hill 0.05 (± 0.024) 2 
T322I FLC Hill 0.0035 (± 0.001) 3.1 
VCZ Hill 0.53 (± 0.34) 1.7 
ITC Hill 0.41 (± 0.24) 0.6 
PCZ Hill 0.00002 (± 0.00004) 4.9 
G464S FLC Hill 0.017 (± 0.004) 2.1 
VCZ Morrison 0.31 (± 0.08) n/a 
ITC Hill 0.21 (± 0.07) 1.4 
PCZ Hill 0.023 (± 0.015) 1.7 
*The preferred equation to fit the data was chosen using the Akaike information 
criterion. M-M stands for Michaelis-Menten. 
E.3 Discussion 
There are inaccuracies in determining the migration of the heme Soret peak at 
drug addition. The differences recorded by the spectrophotometer are 
sometimes less than 1 nm, which is within the range of machine error. 
Inaccuracies in detecting small changes in wavelength of the heme Soret peak 
could have major effects on the shape of the binding curve and hence the Hill 
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coefficient – which would also dramatically affect calculation of the apparent 
Kd.  
The Kd values obtained from Soret peak shift experiments for VCZ with the 
wild type enzyme were much higher compared to the values obtained for ITC, 
FLC and PCZ. The high Kd values for VCZ binding from Soret peak shift 
experiments are most likely to result from experimental error such to the 
addition of an improper amount VCZ. The experiment has not been replicated. 
Repeating these studies with freshly made stocks may give more reliable Kd 
values for VCZ. Otherwise the triazole binding constants indicate that the 
binding is tight. Other issues, which arise from using this assay, are discussed in 

















  Appendix F
Crystallographic information file for 




Modifications are highlighted in grey. 
# Produced by Grade Web Server http://grade.globalphasing.org 
# --------- service provided by Global Phasing Ltd. --------- 
#   
# GEN: Generated by GRADE_PDB_LIGAND 1.2.7 (February 19 2014) 
# GEN: using MOGUL 1.6(RC5), CSD as535be, with quantum mechanics RM1 
# Compound InChI VHVPQPYKVGDNFY-DFMJLFEVSA-N 
# Compound full name 2-__2R_-butan-2-yl_-4-_4-_4-_4-___2R,4S_-2-_2,4-
dichlorophenyl_-2-_1H-1,2,4-triazol-1-ylmethyl_-1,3-dioxolan-4-
yl_methoxy_phenyl_piperazin-1-yl_phenyl_-2,4-dihydro-3H-1,2,4-triazol-3-one 
#   
# Number of restraints found: 
# Bond lengths 
#     lengths/sigmas set by mogul                50 
#     bonds to hydrogen set to neutron values    38 
#     bonds lengths set by partial QM             5 
# Bond Angles 
#     angles/sigmas set by mogul                 58 
#     non-H angles set by partial QM             21 
#     H bond angles set by partial QM            86 
# Trigonal planes (atoms bonded to 3 others that are held flat) 
#     trigonal atoms from 3 mogul bond angles     7 
#     atoms NOT trigonal from 3 mogul angles      2 
#     trigonal atoms from partial QM             18 
#     atoms not trigonal from partial QM          0 
# Torsions and 1-4 planes                                       
#     bonds where mogul states cis/trans          2 
#     bonds mogul indicates flat                  0 
#     bonds mogul indicates 3-fold staggered      2 
#     bonds mogul indicates not flat              0 
#     in flat 5/6 membered rings after PQM       28 
#     other flat bonds after partial QM           1 
#     sp3-sp3 set 3-fold staggered by QM          6 
#     All other torsions (unrestrained)          14 
# Total charge set to 0 
# Bonds defined by QM have a sigma set to 0.030 Angs 
# Angles defined by QM have a sigma set to 3.0 degrees 
# Coordinates are "ideal" after geometry minimization with restraints 
# BUSTER-KEYWORD TRUSTCOORD 































1YN C12 C  CR16 -0.036 8.034   -1.516 -0.174  
1YN C11 C  CR6  0.052  8.856   -0.417 0.041   
1YN C01 C  CH3  -0.063 14.029  -0.759 2.757   
1YN C02 C  CH2  -0.033 14.641  -0.502 1.395   
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1YN C03 C  CH1  0.055  13.742  0.392  0.505   
1YN C04 C  CH3  -0.042 14.399  0.585  -0.850  
1YN N05 N  NR6  -0.210 12.393  -0.216 0.309   
1YN C06 C  CR6  0.351  11.204  0.436  0.334   
1YN O07 O  O    -0.244 10.990  1.622  0.508   
1YN N08 N  NR6  -0.250 10.290  -0.587 0.112   
1YN C09 C  CR16 0.125  10.967  -1.776 -0.039  
1YN N10 N  NRD6 -0.157 12.283  -1.563 0.081   
1YN C13 C  CR16 -0.039 6.661   -1.359 -0.251  
1YN C14 C  CR6  0.030  6.080   -0.101 -0.118  
1YN C15 C  CR16 -0.039 6.911   1.000  0.088   
1YN C16 C  CR16 -0.036 8.283   0.844  0.173   
1YN N17 N  N    -0.327 4.698   0.049  -0.179  
1YN C18 C  CH2  0.028  4.051   1.066  0.652   
1YN C19 C  CH2  0.028  2.582   0.742  0.844   
1YN N20 N  N    -0.327 1.916   0.573  -0.450  
1YN C21 C  CH2  0.028  2.570   -0.442 -1.280  
1YN C22 C  CH2  0.028  4.034   -0.103 -1.475  
1YN C23 C  CR6  0.030  0.527   0.681  -0.513  
1YN C24 C  CR16 -0.037 -0.268  0.340  0.581   
1YN C25 C  CR16 -0.018 -1.645  0.460  0.521   
1YN C26 C  CR6  0.121  -2.248  0.916  -0.638  
1YN C27 C  CR16 -0.018 -1.474  1.248  -1.739  
1YN C28 C  CR16 -0.037 -0.096  1.136  -1.672  
1YN O29 O  O2   -0.489 -3.614  1.033  -0.557  
1YN C30 C  CH2  0.118  -4.341  1.481  -1.706  
1YN C31 C  CH1  0.119  -5.756  1.789  -1.294  
1YN C32 C  CH2  0.081  -6.729  1.832  -2.464  
1YN O33 O  O2   -0.341 -7.883  1.180  -1.985  
1YN C34 C  CT   0.219  -7.447  0.205  -1.051  
1YN O35 O  O2   -0.334 -6.270  0.736  -0.444  
1YN C36 C  CH2  0.102  -6.990  -1.099 -1.807  
1YN N37 N  NR6  -0.247 -6.606  -2.192 -0.925  
1YN C38 C  CR16 0.115  -7.162  -3.388 -0.776  
1YN N39 N  NRD6 -0.223 -6.520  -4.098 0.123   
1YN C40 C  CR16 0.138  -5.540  -3.252 0.504   
1YN N41 N  NRD6 -0.158 -5.539  -2.083 -0.095  
1YN C42 C  CR6  0.031  -8.589  0.031  -0.035  
1YN C43 C  CR6  0.051  -8.810  0.927  1.017   
1YN C44 C  CR16 -0.025 -9.852  0.754  1.911   
1YN C45 C  CR6  0.042  -10.692 -0.328 1.749   
1YN C46 C  CR16 -0.043 -10.517 -1.225 0.724   
1YN C47 C  CR16 -0.051 -9.470  -1.039 -0.159  
1YN CL8 CL CL   -0.083 -12.000 -0.561 2.875   
1YN CL9 CL CL   -0.083 -7.805  2.322  1.244   
1YN H1  H  HCR  0.064  8.421   -2.527 -0.284  
1YN H2  H  HCH3 0.023  13.804  0.162  3.292   
1YN H3  H  HCH3 0.023  13.101  -1.327 2.706   
1YN H4  H  HCH3 0.023  14.703  -1.333 3.391   
1YN H5  H  HCH2 0.028  15.606  -0.011 1.508   
1YN H6  H  HCH2 0.028  14.873  -1.440 0.893   
1YN H7  H  HCH1 0.054  13.582  1.356  0.985   
1YN H8  H  HCH3 0.025  13.839  1.263  -1.492  
1YN H9  H  HCH3 0.025  15.396  1.011  -0.743  
1YN H10 H  HCH3 0.025  14.512  -0.347 -1.403  
1YN H11 H  HCR  0.105  10.533  -2.757 -0.227  
1YN H12 H  HCR  0.064  6.046   -2.242 -0.420  
1YN H13 H  HCR  0.064  6.537   2.019  0.185   
1YN H14 H  HCR  0.064  8.851   1.756  0.347   
1YN H15 H  HCH2 0.048  4.517   1.101  1.636   
1YN H16 H  HCH2 0.048  4.160   2.069  0.242   
1YN H17 H  HCH2 0.048  2.484   -0.135 1.482   
1YN H18 H  HCH2 0.048  2.133   1.564  1.398   
1YN H19 H  HCH2 0.048  2.470   -1.440 -0.855  
1YN H20 H  HCH2 0.048  2.096   -0.509 -2.258  
1YN H21 H  HCH2 0.048  4.139   0.792  -2.087  
1YN H22 H  HCH2 0.048  4.504   -0.893 -2.059  
1YN H23 H  HCR  0.064  0.132   -0.040 1.520   
1YN H24 H  HCR  0.065  -2.258  0.197  1.381   
1YN H25 H  HCR  0.065  -1.875  1.598  -2.689  
1YN H26 H  HCR  0.064  0.493   1.420  -2.542  
1YN H27 H  HCH2 0.072  -3.911  2.392  -2.120  
1YN H28 H  HCH2 0.072  -4.314  0.713  -2.477  
1YN H29 H  HCH1 0.065  -5.772  2.706  -0.707  
1YN H30 H  HCH2 0.059  -7.045  2.838  -2.737  
1YN H31 H  HCH2 0.059  -6.359  1.374  -3.380  
1YN H32 H  HCH2 0.057  -7.768  -1.431 -2.492  
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1YN H33 H  HCH2 0.057  -6.135  -0.867 -2.439  
1YN H34 H  HCR  0.104  -8.035  -3.749 -1.318  
1YN H35 H  HCR  0.106  -4.804  -3.526 1.258   
1YN H36 H  HCR  0.065  -10.004 1.465  2.722   
1YN H37 H  HCR  0.063  -11.196 -2.070 0.615   








1YN C12 C11 aromatic 1.388 0.015  
1YN C12 C13 aromatic 1.383 0.009  
1YN C12 H1  single   1.089 0.010  
1YN C11 C16 aromatic 1.388 0.015  
1YN C11 N08 single   1.441 0.010  
1YN C01 C02 single   1.512 0.031  
1YN C01 H2  single   1.089 0.010  
1YN C01 H3  single   1.089 0.010  
1YN C01 H4  single   1.089 0.010  
1YN C02 C03 single   1.543 0.030  
1YN C02 H5  single   1.089 0.010  
1YN C02 H6  single   1.089 0.010  
1YN C03 C04 single   1.519 0.015  
1YN C03 H7  single   1.089 0.010  
1YN C03 N05 single   1.486 0.030  
1YN C04 H10 single   1.089 0.010  
1YN C04 H8  single   1.089 0.010  
1YN C04 H9  single   1.089 0.010  
1YN N05 C06 aromatic 1.356 0.011  
1YN N05 N10 aromatic 1.372 0.012  
1YN C06 N08 aromatic 1.385 0.011  
1YN C06 O07 double   1.217 0.012  
1YN N08 C09 aromatic 1.374 0.013  
1YN C09 H11 single   1.089 0.010  
1YN C09 N10 aromatic 1.348 0.030  
1YN C13 C14 aromatic 1.388 0.015  
1YN C13 H12 single   1.089 0.010  
1YN C14 C15 aromatic 1.388 0.015  
1YN C14 N17 single   1.384 0.024  
1YN C15 C16 aromatic 1.383 0.009  
1YN C15 H13 single   1.089 0.010  
1YN C16 H14 single   1.089 0.010  
1YN N17 C18 single   1.464 0.009  
1YN N17 C22 single   1.464 0.009  
1YN C18 C19 single   1.514 0.020  
1YN C18 H15 single   1.089 0.010  
1YN C18 H16 single   1.089 0.010  
1YN C19 H17 single   1.089 0.010  
1YN C19 H18 single   1.089 0.010  
1YN C19 N20 single   1.464 0.009  
1YN N20 C21 single   1.464 0.009  
1YN N20 C23 single   1.384 0.024  
1YN C21 C22 single   1.514 0.020  
1YN C21 H19 single   1.089 0.010  
1YN C21 H20 single   1.089 0.010  
1YN C22 H21 single   1.089 0.010  
1YN C22 H22 single   1.089 0.010  
1YN C23 C24 aromatic 1.388 0.015  
1YN C23 C28 aromatic 1.388 0.015  
1YN C24 C25 aromatic 1.383 0.009  
1YN C24 H23 single   1.089 0.010  
1YN C25 C26 aromatic 1.384 0.012  
1YN C25 H24 single   1.089 0.010  
1YN C26 C27 aromatic 1.384 0.012  
1YN C26 O29 single   1.371 0.012  
1YN C27 C28 aromatic 1.383 0.009  
1YN C27 H25 single   1.089 0.010  
1YN C28 H26 single   1.089 0.010  
1YN O29 C30 single   1.430 0.012  
1YN C30 C31 single   1.504 0.015  
1YN C30 H27 single   1.089 0.010  
1YN C30 H28 single   1.089 0.010  
1YN C31 C32 single   1.516 0.019  
1YN C31 H29 single   1.089 0.010  
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1YN C31 O35 single   1.441 0.012  
1YN C32 H30 single   1.089 0.010  
1YN C32 H31 single   1.089 0.010  
1YN C32 O33 single   1.421 0.023  
1YN O33 C34 single   1.421 0.009  
1YN C34 C36 single   1.562 0.030  
1YN C34 C42 single   1.503 0.030  
1YN C34 O35 single   1.426 0.010  
1YN C36 H32 single   1.089 0.010  
1YN C36 H33 single   1.089 0.010  
1YN C36 N37 single   1.455 0.005  
1YN N37 C38 aromatic 1.327 0.009  
1YN N37 N41 aromatic 1.356 0.008  
1YN C38 H34 single   1.089 0.010  
1YN C38 N39 aromatic 1.313 0.010  
1YN N39 C40 aromatic 1.351 0.014  
1YN C40 H35 single   1.089 0.010  
1YN C40 N41 aromatic 1.314 0.008  
1YN C42 C43 aromatic 1.395 0.008  
1YN C42 C47 aromatic 1.388 0.010  
1YN C43 C44 aromatic 1.381 0.010  
1YN C43 CL9 single   1.734 0.012  
1YN C44 C45 aromatic 1.379 0.010  
1YN C44 H36 single   1.089 0.010  
1YN C45 C46 aromatic 1.377 0.011  
1YN C45 CL8 single   1.742 0.013  
1YN C46 C47 aromatic 1.383 0.009  
1YN C46 H37 single   1.089 0.010  








1YN C11 C12 C13 120.4 1.0  
1YN C11 C12 H1  121.8 3.0  
1YN C13 C12 H1  117.9 3.0  
1YN C12 C11 C16 119.4 1.7  
1YN C12 C11 N08 119.6 1.0  
1YN C16 C11 N08 119.6 1.0  
1YN C02 C01 H2  112.4 3.0  
1YN C02 C01 H3  112.6 3.0  
1YN H2  C01 H3  106.7 3.0  
1YN C02 C01 H4  111.5 3.0  
1YN H2  C01 H4  106.8 3.0  
1YN H3  C01 H4  106.4 3.0  
1YN C01 C02 C03 111.3 3.0  
1YN C01 C02 H5  110.4 3.0  
1YN C03 C02 H5  108.8 3.0  
1YN C01 C02 H6  110.7 3.0  
1YN C03 C02 H6  110.8 3.0  
1YN H5  C02 H6  104.7 3.0  
1YN C02 C03 C04 110.1 3.0  
1YN C02 C03 H7  110.4 3.0  
1YN C04 C03 H7  110.5 3.0  
1YN C02 C03 N05 109.9 3.0  
1YN C04 C03 N05 109.4 3.0  
1YN H7  C03 N05 106.5 3.0  
1YN C03 C04 H10 112.8 3.0  
1YN C03 C04 H8  112.5 3.0  
1YN H10 C04 H8  106.5 3.0  
1YN C03 C04 H9  111.1 3.0  
1YN H10 C04 H9  106.8 3.0  
1YN H8  C04 H9  106.6 3.0  
1YN C03 N05 C06 126.8 3.0  
1YN C03 N05 N10 119.5 3.0  
1YN C06 N05 N10 113.6 3.0  
1YN N05 C06 N08 102.8 3.0  
1YN N05 C06 O07 129.1 1.0  
1YN N08 C06 O07 128.1 3.0  
1YN C11 N08 C06 124.2 1.1  
1YN C11 N08 C09 125.7 1.0  
1YN C06 N08 C09 109.8 3.0  
1YN N08 C09 H11 126.6 3.0  
1YN N08 C09 N10 109.1 3.0  
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1YN H11 C09 N10 124.4 3.0  
1YN N05 N10 C09 104.8 3.0  
1YN C12 C13 C14 120.4 1.0  
1YN C12 C13 H12 118.7 3.0  
1YN C14 C13 H12 120.7 3.0  
1YN C13 C14 C15 119.4 1.7  
1YN C13 C14 N17 121.4 1.1  
1YN C15 C14 N17 121.4 1.1  
1YN C14 C15 C16 120.4 1.0  
1YN C14 C15 H13 122.8 3.0  
1YN C16 C15 H13 116.6 3.0  
1YN C11 C16 C15 120.4 1.0  
1YN C11 C16 H14 122.5 3.0  
1YN C15 C16 H14 117.3 3.0  
1YN C14 N17 C18 117.4 2.3  
1YN C14 N17 C22 117.4 2.3  
1YN C18 N17 C22 111.7 1.9  
1YN N17 C18 C19 110.5 1.2  
1YN N17 C18 H15 110.0 3.0  
1YN C19 C18 H15 108.2 3.0  
1YN N17 C18 H16 112.4 3.0  
1YN C19 C18 H16 110.0 3.0  
1YN H15 C18 H16 105.5 3.0  
1YN C18 C19 H17 109.8 3.0  
1YN C18 C19 H18 108.0 3.0  
1YN H17 C19 H18 105.8 3.0  
1YN C18 C19 N20 110.5 1.2  
1YN H17 C19 N20 112.5 3.0  
1YN H18 C19 N20 110.1 3.0  
1YN C19 N20 C21 111.7 1.9  
1YN C19 N20 C23 117.4 2.3  
1YN C21 N20 C23 117.4 2.3  
1YN N20 C21 C22 110.5 1.2  
1YN N20 C21 H19 111.9 3.0  
1YN C22 C21 H19 110.3 3.0  
1YN N20 C21 H20 110.4 3.0  
1YN C22 C21 H20 108.7 3.0  
1YN H19 C21 H20 104.9 3.0  
1YN N17 C22 C21 110.5 1.2  
1YN N17 C22 H21 111.7 3.0  
1YN C21 C22 H21 110.4 3.0  
1YN N17 C22 H22 110.5 3.0  
1YN C21 C22 H22 108.9 3.0  
1YN H21 C22 H22 104.7 3.0  
1YN N20 C23 C24 121.4 1.1  
1YN N20 C23 C28 121.4 1.1  
1YN C24 C23 C28 119.4 1.7  
1YN C23 C24 C25 120.4 1.0  
1YN C23 C24 H23 123.0 3.0  
1YN C25 C24 H23 116.3 3.0  
1YN C24 C25 C26 119.8 0.7  
1YN C24 C25 H24 120.2 3.0  
1YN C26 C25 H24 119.9 3.0  
1YN C25 C26 C27 120.2 1.1  
1YN C25 C26 O29 119.9 4.7  
1YN C27 C26 O29 119.9 4.7  
1YN C26 C27 C28 119.8 0.7  
1YN C26 C27 H25 123.6 3.0  
1YN C28 C27 H25 116.6 3.0  
1YN C23 C28 C27 120.4 1.0  
1YN C23 C28 H26 120.5 3.0  
1YN C27 C28 H26 118.7 3.0  
1YN C26 O29 C30 117.9 1.6  
1YN O29 C30 C31 108.2 1.7  
1YN O29 C30 H27 111.1 3.0  
1YN C31 C30 H27 108.9 3.0  
1YN O29 C30 H28 109.9 3.0  
1YN C31 C30 H28 111.0 3.0  
1YN H27 C30 H28 108.1 3.0  
1YN C30 C31 C32 114.0 1.9  
1YN C30 C31 H29 110.3 3.0  
1YN C32 C31 H29 112.9 3.0  
1YN C30 C31 O35 108.3 3.0  
1YN C32 C31 O35 102.2 1.3  
1YN H29 C31 O35 107.4 3.0  
1YN C31 C32 H30 114.2 3.0  
1YN C31 C32 H31 114.6 3.0  
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1YN H30 C32 H31 106.2 3.0  
1YN C31 C32 O33 104.0 1.0  
1YN H30 C32 O33 106.2 3.0  
1YN H31 C32 O33 111.8 3.0  
1YN C32 O33 C34 107.3 1.5  
1YN O33 C34 C36 107.9 3.0  
1YN O33 C34 C42 107.3 3.0  
1YN C36 C34 C42 116.0 3.0  
1YN O33 C34 O35 106.1 0.7  
1YN C36 C34 O35 108.0 3.0  
1YN C42 C34 O35 110.8 3.0  
1YN C31 O35 C34 107.8 0.7  
1YN C34 C36 H32 110.3 3.0  
1YN C34 C36 H33 109.4 3.0  
1YN H32 C36 H33 105.6 3.0  
1YN C34 C36 N37 112.9 3.0  
1YN H32 C36 N37 109.9 3.0  
1YN H33 C36 N37 108.5 3.0  
1YN C36 N37 C38 129.3 0.8  
1YN C36 N37 N41 121.1 0.8  
1YN C38 N37 N41 109.4 0.5  
1YN N37 C38 H34 125.4 3.0  
1YN N37 C38 N39 111.0 0.9  
1YN H34 C38 N39 123.6 3.0  
1YN C38 N39 C40 102.2 0.8  
1YN N39 C40 H35 122.0 3.0  
1YN N39 C40 N41 115.6 0.8  
1YN H35 C40 N41 122.6 3.0  
1YN N37 N41 C40 102.0 0.5  
1YN C34 C42 C43 121.2 3.0  
1YN C34 C42 C47 121.3 3.0  
1YN C43 C42 C47 116.8 1.1  
1YN C42 C43 C44 121.6 1.0  
1YN C42 C43 CL9 121.7 0.7  
1YN C44 C43 CL9 118.5 1.2  
1YN C43 C44 C45 118.6 0.6  
1YN C43 C44 H36 120.4 3.0  
1YN C45 C44 H36 121.0 3.0  
1YN C44 C45 C46 121.7 0.8  
1YN C44 C45 CL8 119.1 0.7  
1YN C46 C45 CL8 119.3 0.8  
1YN C45 C46 C47 119.2 0.6  
1YN C45 C46 H37 120.2 3.0  
1YN C47 C46 H37 120.8 3.0  
1YN C42 C47 C46 121.4 1.5  
1YN C42 C47 H38 121.4 3.0  









1YN chir_01 C01 C02 H4  H3  both      
1YN chir_02 C02 C03 C01 H6  both      
1YN chir_03 C03 N05 C04 C02 positive  
1YN chir_04 C04 C03 H10 H9  both      
1YN chir_05 C18 C19 N17 H16 both      
1YN chir_06 C19 N20 C18 H18 both      
1YN chir_07 C21 C22 N20 H20 both      
1YN chir_08 C22 C21 N17 H22 both      
1YN chir_09 C30 C31 O29 H28 both      
1YN chir_10 C31 O35 C32 C30 positive  
1YN chir_11 C32 O33 C31 H31 both      
1YN chir_12 C34 C42 C36 O35 positive  
1YN chir_13 C36 N37 C34 H33 both      
1YN chir_14 N17 C18 C14 C22 both    #added by JT 16.4.2014 






1YN csd-C11  C11 0.020  
1YN csd-C11  C12 0.020  
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1YN csd-C11  N08 0.020  
1YN csd-C11  C16 0.020  
1YN csd-C14  C14 0.020  
1YN csd-C14  C13 0.020  
1YN csd-C14  C15 0.020  
1YN csd-C14  N17 0.020  
1YN csd-C23  C23 0.020  
1YN csd-C23  N20 0.020  
1YN csd-C23  C24 0.020  
1YN csd-C23  C28 0.020  
1YN csd-C26  C26 0.020  
1YN csd-C26  C25 0.020  
1YN csd-C26  C27 0.020  
1YN csd-C26  O29 0.020  
1YN csd-C43  C43 0.020  
1YN csd-C43  C42 0.020  
1YN csd-C43  C44 0.020  
1YN csd-C43  CL9 0.020  
1YN csd-C45  C45 0.020  
1YN csd-C45  C44 0.020  
1YN csd-C45  C46 0.020  
1YN csd-C45  CL8 0.020  
1YN csd-N37  N37 0.020  
1YN csd-N37  C36 0.020  
1YN csd-N37  C38 0.020  
1YN csd-N37  N41 0.020  
1YN csdf-01  C25 0.020  
1YN csdf-01  C26 0.020  
1YN csdf-01  O29 0.020  
1YN csdf-01  C30 0.020  
1YN qm-C06   C06 0.020  
1YN qm-C06   N05 0.020  
1YN qm-C06   O07 0.020  
1YN qm-C06   N08 0.020  
1YN qm-C09   C09 0.020  
1YN qm-C09   N08 0.020  
1YN qm-C09   H11 0.020  
1YN qm-C09   N10 0.020  
1YN qm-C12   C12 0.020  
1YN qm-C12   C11 0.020  
1YN qm-C12   C13 0.020  
1YN qm-C12   H1  0.020  
1YN qm-C13   C13 0.020  
1YN qm-C13   C12 0.020  
1YN qm-C13   C14 0.020  
1YN qm-C13   H12 0.020  
1YN qm-C15   C15 0.020  
1YN qm-C15   C14 0.020  
1YN qm-C15   C16 0.020  
1YN qm-C15   H13 0.020  
1YN qm-C16   C16 0.020  
1YN qm-C16   C11 0.020  
1YN qm-C16   C15 0.020  
1YN qm-C16   H14 0.020  
1YN qm-C24   C24 0.020  
1YN qm-C24   C23 0.020  
1YN qm-C24   C25 0.020  
1YN qm-C24   H23 0.020  
1YN qm-C25   C25 0.020  
1YN qm-C25   C24 0.020  
1YN qm-C25   C26 0.020  
1YN qm-C25   H24 0.020  
1YN qm-C27   C27 0.020  
1YN qm-C27   C26 0.020  
1YN qm-C27   C28 0.020  
1YN qm-C27   H25 0.020  
1YN qm-C28   C28 0.020  
1YN qm-C28   C23 0.020  
1YN qm-C28   C27 0.020  
1YN qm-C28   H26 0.020  
1YN qm-C38   C38 0.020  
1YN qm-C38   N37 0.020  
1YN qm-C38   N39 0.020  
1YN qm-C38   H34 0.020  
1YN qm-C40   C40 0.020  
1YN qm-C40   N39 0.020  
1YN qm-C40   N41 0.020  
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1YN qm-C40   H35 0.020  
1YN qm-C42   C42 0.020  
1YN qm-C42   C43 0.020  
1YN qm-C42   C47 0.020  
1YN qm-C42   C34 0.020  
1YN qm-C44   C44 0.020  
1YN qm-C44   C43 0.020  
1YN qm-C44   C45 0.020  
1YN qm-C44   H36 0.020  
1YN qm-C46   C46 0.020  
1YN qm-C46   C45 0.020  
1YN qm-C46   C47 0.020  
1YN qm-C46   H37 0.020  
1YN qm-C47   C47 0.020  
1YN qm-C47   C42 0.020  
1YN qm-C47   C46 0.020  
1YN qm-C47   H38 0.020  
1YN qm-N05   N05 0.020  
1YN qm-N05   C06 0.020  
1YN qm-N05   N10 0.020  
1YN qm-N05   C03 0.020  
1YN qm-N08   N08 0.020  
1YN qm-N08   C11 0.020  
1YN qm-N08   C06 0.020  
1YN qm-N08   C09 0.020  
1YN qmf-01   C12 0.020  
1YN qmf-01   C11 0.020  
1YN qmf-01   N08 0.020  
1YN qmf-01   C06 0.020  
1YN ring5A-1 N05 0.020  
1YN ring5A-1 C06 0.020  
1YN ring5A-1 N08 0.020  
1YN ring5A-1 C09 0.020  
1YN ring5A-2 C06 0.020  
1YN ring5A-2 N08 0.020  
1YN ring5A-2 C09 0.020  
1YN ring5A-2 N10 0.020  
1YN ring5A-3 N08 0.020  
1YN ring5A-3 C09 0.020  
1YN ring5A-3 N10 0.020  
1YN ring5A-3 N05 0.020  
1YN ring5A-4 C09 0.020  
1YN ring5A-4 N10 0.020  
1YN ring5A-4 N05 0.020  
1YN ring5A-4 C06 0.020  
1YN ring5A-5 N10 0.020  
1YN ring5A-5 N05 0.020  
1YN ring5A-5 C06 0.020  
1YN ring5A-5 N08 0.020  
1YN ring5B-1 N37 0.020  
1YN ring5B-1 C38 0.020  
1YN ring5B-1 N39 0.020  
1YN ring5B-1 C40 0.020  
1YN ring5B-2 C38 0.020  
1YN ring5B-2 N39 0.020  
1YN ring5B-2 C40 0.020  
1YN ring5B-2 N41 0.020  
1YN ring5B-3 N39 0.020  
1YN ring5B-3 C40 0.020  
1YN ring5B-3 N41 0.020  
1YN ring5B-3 N37 0.020  
1YN ring5B-4 C40 0.020  
1YN ring5B-4 N41 0.020  
1YN ring5B-4 N37 0.020  
1YN ring5B-4 C38 0.020  
1YN ring5B-5 N41 0.020  
1YN ring5B-5 N37 0.020  
1YN ring5B-5 C38 0.020  
1YN ring5B-5 N39 0.020  
1YN ring6A-1 C12 0.020  
1YN ring6A-1 C11 0.020  
1YN ring6A-1 C16 0.020  
1YN ring6A-1 C15 0.020  
1YN ring6A-2 C11 0.020  
1YN ring6A-2 C16 0.020  
1YN ring6A-2 C15 0.020  
1YN ring6A-2 C14 0.020  
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1YN ring6A-3 C16 0.020  
1YN ring6A-3 C15 0.020  
1YN ring6A-3 C14 0.020  
1YN ring6A-3 C13 0.020  
1YN ring6A-4 C15 0.020  
1YN ring6A-4 C14 0.020  
1YN ring6A-4 C13 0.020  
1YN ring6A-4 C12 0.020  
1YN ring6A-5 C14 0.020  
1YN ring6A-5 C13 0.020  
1YN ring6A-5 C12 0.020  
1YN ring6A-5 C11 0.020  
1YN ring6A-6 C13 0.020  
1YN ring6A-6 C12 0.020  
1YN ring6A-6 C11 0.020  
1YN ring6A-6 C16 0.020  
1YN ring6B-1 C23 0.020  
1YN ring6B-1 C24 0.020  
1YN ring6B-1 C25 0.020  
1YN ring6B-1 C26 0.020  
1YN ring6B-2 C24 0.020  
1YN ring6B-2 C25 0.020  
1YN ring6B-2 C26 0.020  
1YN ring6B-2 C27 0.020  
1YN ring6B-3 C25 0.020  
1YN ring6B-3 C26 0.020  
1YN ring6B-3 C27 0.020  
1YN ring6B-3 C28 0.020  
1YN ring6B-4 C26 0.020  
1YN ring6B-4 C27 0.020  
1YN ring6B-4 C28 0.020  
1YN ring6B-4 C23 0.020  
1YN ring6B-5 C27 0.020  
1YN ring6B-5 C28 0.020  
1YN ring6B-5 C23 0.020  
1YN ring6B-5 C24 0.020  
1YN ring6B-6 C28 0.020  
1YN ring6B-6 C23 0.020  
1YN ring6B-6 C24 0.020  
1YN ring6B-6 C25 0.020  
1YN ring6C-1 C42 0.020  
1YN ring6C-1 C43 0.020  
1YN ring6C-1 C44 0.020  
1YN ring6C-1 C45 0.020  
1YN ring6C-2 C43 0.020  
1YN ring6C-2 C44 0.020  
1YN ring6C-2 C45 0.020  
1YN ring6C-2 C46 0.020  
1YN ring6C-3 C44 0.020  
1YN ring6C-3 C45 0.020  
1YN ring6C-3 C46 0.020  
1YN ring6C-3 C47 0.020  
1YN ring6C-4 C45 0.020  
1YN ring6C-4 C46 0.020  
1YN ring6C-4 C47 0.020  
1YN ring6C-4 C42 0.020  
1YN ring6C-5 C46 0.020  
1YN ring6C-5 C47 0.020  
1YN ring6C-5 C42 0.020  
1YN ring6C-5 C43 0.020  
1YN ring6C-6 C47 0.020  
1YN ring6C-6 C42 0.020  
1YN ring6C-6 C43 0.020  











1YN CONST_ring6A-6 C13 C12 C11 C16 0.0    1000000.0 0   
1YN CONST_ring6A-5 C11 C12 C13 C14 0.0    1000000.0 0   
1YN qmf-01         C12 C11 N08 C06 180.0  1000000.0 2   
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1YN CONST_ring6A-1 C12 C11 C16 C15 0.0    1000000.0 0   
1YN qm-sp3sp3-01   H2  C01 C02 C03 180.0  15.0      3   
1YN qm-sp3sp3-02   C01 C02 C03 C04 180.0  15.0      3   
1YN qm-sp3sp3-03   C02 C03 C04 H10 180.0  15.0      3   
1YN other-001      C04 C03 N05 C06 0.0    1000000.0 10  
1YN CONST_ring5A-5 N10 N05 C06 N08 0.0    1000000.0 0   
1YN CONST_ring5A-4 C06 N05 N10 C09 0.0    1000000.0 0   
1YN CONST_ring5A-1 N05 C06 N08 C09 0.0    1000000.0 0   
1YN CONST_ring5A-2 C06 N08 C09 N10 0.0    1000000.0 0   
1YN CONST_ring5A-3 N08 C09 N10 N05 0.0    1000000.0 0   
1YN CONST_ring6A-4 C12 C13 C14 C15 0.0    1000000.0 0   
1YN CONST_ring6A-3 C13 C14 C15 C16 0.0    1000000.0 0   
1YN other-002      C13 C14 N17 C18 0.0    1000000.0 10  
1YN CONST_ring6A-2 C14 C15 C16 C11 0.0    1000000.0 0   
1YN other-003      C22 N17 C18 C19 0.0    1000000.0 10  
1YN other-004      C18 N17 C22 C21 0.0    1000000.0 10  
1YN qm-sp3sp3-04   N17 C18 C19 N20 0.0    1000000.0 3   #changed from esd 
from 15.0 to 1000000 (b), (c) make angle 0 
1YN other-005      C18 C19 N20 C21 0.0    1000000.0 3   #change from 10 to 3 
(d) 
1YN other-006      C19 N20 C21 C22 0.0    1000000.0 3    #change from 10 to 3 
(d) 
1YN other-007      C19 N20 C23 C24 0.0    1000000.0 3   #change from 10 to 3 
(d) 
1YN qm-sp3sp3-05   N20 C21 C22 N17 0.0    1000000.0 3    #changed from esd 
from 15.0 to 1000000 (b), (c) make angle 0 
1YN CONST_ring6B-6 C28 C23 C24 C25 0.0    1000000.0 0   
1YN CONST_ring6B-5 C24 C23 C28 C27 0.0    1000000.0 0   
1YN CONST_ring6B-1 C23 C24 C25 C26 0.0    1000000.0 0   
1YN CONST_ring6B-2 C24 C25 C26 C27 0.0    1000000.0 0   
1YN CONST_ring6B-3 C25 C26 C27 C28 0.0    1000000.0 0   
1YN csdf-01        C25 C26 O29 C30 180.0  1000000.0 2   
1YN CONST_ring6B-4 C26 C27 C28 C23 0.0    1000000.0 0   
1YN csd-sp3sp3-01  C31 C30 O29 C26 -180.0 12.3      3   
1YN csd-sp3sp3-02  O29 C30 C31 O35 -60.0  12.3      3   
1YN other-008      C30 C31 C32 O33 0.0    1000000.0 10  
1YN other-009      C30 C31 O35 C34 0.0    1000000.0 10  
1YN other-010      C31 C32 O33 C34 0.0    1000000.0 10  
1YN other-011      C32 O33 C34 C36 0.0    1000000.0 10  
1YN other-012      C36 C34 O35 C31 0.0    1000000.0 10  
1YN qm-sp3sp3-06   C42 C34 C36 N37 180.0  15.0      3   
1YN other-013      C36 C34 C42 C43 0.0    1000000.0 10  
1YN other-014      C34 C36 N37 C38 0.0    1000000.0 10  
1YN CONST_ring5B-5 N41 N37 C38 N39 0.0    1000000.0 0   
1YN CONST_ring5B-4 C38 N37 N41 C40 0.0    1000000.0 0   
1YN CONST_ring5B-1 N37 C38 N39 C40 0.0    1000000.0 0   
1YN CONST_ring5B-2 C38 N39 C40 N41 0.0    1000000.0 0   
1YN CONST_ring5B-3 N39 C40 N41 N37 0.0    1000000.0 0   
1YN CONST_ring6C-6 C47 C42 C43 C44 0.0    1000000.0 0   
1YN CONST_ring6C-5 C43 C42 C47 C46 0.0    1000000.0 0   
1YN CONST_ring6C-1 C42 C43 C44 C45 0.0    1000000.0 0   
1YN CONST_ring6C-2 C43 C44 C45 C46 0.0    1000000.0 0   
1YN CONST_ring6C-3 C44 C45 C46 C47 0.0    1000000.0 0   
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Table G-1 Data collection and refinement statistics for ScErg11p6xHis in 
complex with FLC (Sagatova et al., 2015) 
PDB code 4WMZ 
Space group P 1 21 1 
Resolution range (Å) 37.84 - 2.05 (2.11 - 2.05) 
Unit cell axes (Å) a = 77.24, b = 65.21 c = 81.02 
Diffraction source Australian Synchrotron MX1 
Wavelength (Å) 0.954 
Total reflections 293689 
Unique reflections 47935 
Average redundancy 6.1 (5.3) 
Completeness (%) 95.6 (84.6) 
<I/σ(I)> 12.4 (1.4) 
Wilson B-factor 33.4 
Rmerge†  0.083 (0.953) 
CC(1/2) 0.998 (0.634) 
Refinement  
Rcrystt‡ 0.20 (0.30) 
Rfree§ 0.23 (0.32) 
Number of reflections 47899 (2351) 
Number of atoms in model  
Protein 4304 
Ligand 22 
Water molecules 155 
Deviation from ideal bond lengths* (Å) 0.008 
Deviation from ideal bond angles* (⁰) 1.1 
Ramachandran analysis (%)  
     Preferred  96.5 
     Allowed  3.2 
     Residues in disallowed regions  0.2 
† Rmerge = Σhkl Σi |Ii(hkl) – [I(hkl)]| / Σhkl Σi Ii(hkl). ‡ Rcryst = Σhkl |Fobs-Fcalc|/ Σhkl 
|Fobs| computed over a working set composed of 95% of data. § Rfree = Σhkl 
|Fobs|-|Fcalc| / Σhkl |Fobs| computed over a test set composed of 5% of data.  
*The parameters for ideal values for bond lengths and bond angles used were 
defined by Engh and Huber (Engh and Huber, 1991). The validation statistics 
were obtained from Aimless (Evans, 2006) and Phenix (Chen et al., 2010). 
Note: The R values are calculations are the same in all tables of this Appendix. 
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Table G-2 X-ray structures of Saccharomyces cerevisiae Erg11p dataset statistics adapted from Monk et al. (Monk et al., 2014) 





+ FLC + VCZ + Estriol + Lanosterol 
PBD ID 
4lXJ 
Space group P21 P21 P21 P21 P21 P21 
dmin 2.4 2.2 2.5 2.8 2.1 1.9 
a 80.1 79.6 80.31 80.1 79.4 78.2 
b 67.7 67.6 67.3 67.7 67.5 67 
c 81 80.7 81.3 81.2 80.8 80.4 
α  90 90 90 90 90 90 
β  100.14 99.75 100.34 100.14 99.58 99.54 













I/σI 31.3 (3) 25 (2.6) 22.7 (1.9) 31.3 
(2.5) 












Rfree‡ 0.237 0.234 0.294 0.253 0.237 0.227 






Table G-3 Data collection and refinement statistics for the ScErg11p6×His Y140F mutant structures 
Ligand ITC PCZ FLC VCZ 
PDB code 4ZDY 4ZE1 4ZDZ 4ZE0 
Space group P 1 21 1 P 1 21 1 P 1 21 1 P 1 21 1 
Resolution range (Å) 34.27 – 2.02 (2.13 – 2.02) 37.45 – 2.05 (2.11  – 2.05) 51.75 – 2.30 (2.38 – 2.30) 51.48 – 2.20 (2.27 – 2.20) 
Unit cell (Å) a = 78.18 b = 67.07 c = 80.70 a = 78.79 b = 67.75 c = 81.06 a = 78.91 b = 67.15 c = 81.14 a = 77.22 b = 66.55 c = 80.90 
Diffraction source MX1 MX2 MX2 MX1 
Wavelength (Å) 0.954 0.954 0.954 0.954 
Total reflections 384013 285878 125003 251724 
Unique reflections 54071 52170 37123 40318 
Multiplicity 7.1 (6.8) 5.5 (5.5) 3.4 (3.3) 6.2 (5.5) 
Completeness (%) 99.6 (98.2) 98.3 (98.0) 99.1 (99.5) 97.4 (92.7) 
Mean (I/σ(I)) 15.9 (3.3) 12.9 (1.8) 3.9 (1.5) 10.8 (2.0) 
Wilson B-factor 26.88 34.16 29.89 30.50 
Rmerge†  0.087 (0.648) 0.082 (0.979) 0.151 (0.456) 0.113 (0.853) 
CC(1/2) 0.999 (0.858) 0.997 (0.538) 0.970  (0.860) 0.995 (0.907) 
Refinement     
   Rcryst‡ 0.1906 (0.2846) 0.2026 (0.3739) 0.1966 (0.2627) 0.1919 (0.2997) 
   Rfree§ 0.2294 (0.3631) 0.2427 (0.4220) 0.2372 (0.3228) 0.2390 (0.3145) 
Number of reflections 54031 52115 37100 40220 
Number of atoms in model 4548 4513 4532 4534 
Protein 4312 4323 4319 4337 
Ligand 49 51 22 25 
Water molecules 187 139 191 172 
Deviation from ideal bond lengths (Å) 0.008 0.008 0.005 0.008 
Deviation from ideal bond angles (⁰) 1.04 1.079 0.874 1.089 
Ramachandran analysis (%)     
   Preferred  97.15 95.45 96.20 96.22 
   Allowed 2.66 3.98 3.42 3.59 





Table G-4 Data collection and refinement statistics for the ScErg11p6×His Y140H mutant structures 
Ligand ITC FLC 
PDB code 4ZE2 4ZE3 
Space group P 1 21 1 P 1 21 1 
Resolution range (Å) 80.04 – 2.30 (2.38 – 2.30) 80.21 – 2.20 (2.27  – 2.20) 
Unit cell (Å) a = 77.83 b = 66.67 c = 81.01 a = 76.49  b = 64.84  c = 81.03 
Diffraction source MX2 MX2 
Wavelength (Å) 0.954 0.954 
Total reflections 144675 153351 
Unique reflections 36597 39850 
Multiplicity 4.0 (4.0) 3.8 (3.8) 
Completeness (%) 99.8 (100.0) 99.3 (98.3) 
Mean (I/σ(I)) 8.7 (1.9) 11.4 (2.2) 
Wilson B-factor 39.16 35.53 
Rmerge† 0.087 (0.643) 0.064 (0.628) 
CC(1/2) 0.994 (0.752) 0.997 (0.718) 
Refinement   
   Rcryst‡ 0.1881 (0.2971) 0.1916 (0.2952) 
   Rfree§ 0.2316 (0.3622) 0.2274 (0.3288) 
Number of reflections 36484 39809 
Number of atoms in model 4484 4436 
Protein 4325 4294 
Ligand 49 22 
Water molecules 110 120 
Deviation from ideal bond lengths (Å) 0.009 0.004 
Deviation from ideal bond angles (⁰) 1.182 0.850 
Ramachandran analysis (%)   
   Preferred 96.40 96.56 
   Allowed 3.41 3.05 





Table G-5 Data collection and refinement statistics for the ScErg11p6×His G73E/W/R mutant structures 
Mutation G73E G73W G73R G73W G73E 
Ligand ITC Apo FLC ITC FLC 
PDB code 5ESG 5ESI 5ESE 5ESH 5ESF 
Space group P 1 21 1 P 1 21 1 P 1 21 1 P 1 21 1 P 1 21 1 
Resolution range (Å) 37.90 – 1.98  
 (2.09 – 1.98) 
60.95 – 2.10  
(2.16  – 2.10) 
51.48 – 2.20  
(2.27 – 2.20) 
80.02 – 2.15  
(2.2 – 2.15) 
79.97 – 2.25  
(2.32 – 2.25) 
Unit cell (Å) a = 78.24  b = 67.31  
c = 80.83 
a = 78.90  b = 67.05 
    c = 80.98 
a = 78.35   b = 67.28  
c = 81.02 
a = 77.56   b = 66.85  
c = 80.88 
a = 78.49   b = 66.93  
 c = 81.06 
Diffraction source MX1 MX1 MX2 MX2 MX2 
Wavelength (Å) 0.954 0.954 0.954 0.954 0.954 
Total reflections 421309 324866 151591 313763 275487 
Unique reflections 57704 47947 41538 44569 39044 
Multiplicity 7.3 (7.2) 6.8 (6.5) 3.6 (3.7) 7.0 (6.9) 7.0 (6.7) 
Completeness (%) 99.6 (95.3) 98.0 (92.2) 98.1 (97.7) 99.6 (99.2) 99.7 (99.3) 
Mean (I/σ(I)) 14.3 (2.0) 11.3 (2.2) 9.2 (1.4) 12.3 (2.0) 9.5 (1.5) 
Wilson B-factor 31.40 31.63 42.3 36.09 38.65 
Rmerge†  0.093 (0.975) 0.092 (0.670) 0.071 (0.886) 0.093 (0.947) 0.13 (1.62) 
CC(1/2) 0.999 (0.739) 0.997 (0.832) 0.995  (0.362) 0.998 (0.760) 0.996 (0.683) 
Refinement      
   Rcryst‡ 0.1989 (0.3340) 0.1895 (0.2674) 0.2054 (0.3747) 0.1827 (0.2496) 0.2015 (0.4309) 
   Rfree§ 0.2345 (0.3727) 0.2261 (0.2927) 0.2364 (0.3943) 0.2221 (0.2787) 0.2529 (0.4569) 
Number of reflections 57667 47908 41472 44525 39045 
Number of atoms in model 4507 4525 4443 4522 4417 
Protein 4301 4340 4321 4324 4288 
Ligand 49 0 22 49 22 
Water molecules 157 185 100 149 107 
Deviation from ideal bond lengths (Å) 0.008 0.008 0.002 0.009 0.004 
Deviation from ideal bond angles (⁰) 1.065 1.064 0.559 1.124 0.846 
Ramachandran analysis (%)      
   Preferred  96.37 95.64 96.20 96.58 96.35 
   Allowed 3.44 4.17 3.42 3.23 3.27 




Table G-6 Data collection and refinement statistics for the ScErg11p6×His G464S and T322I mutant structures 
Mutation G464S G464S T322I T322I T322I 
Ligand ITC FLC ITC FLC Apo 
PDB code 5ESK 5ESJ 5ESL 5ESM 5ESN 
Space group P 1 21 1 P 1 21 1 P 1 21 1 P 1 21 1 P 1 21 1 
Resolution range (Å) 59.54 – 2.24  
(2.31 – 2.24) 
60.52 – 2.15  
(2.21  – 2.15) 
51.53 – 2.35  
(2.43 – 2.35) 
51.67 – 2.00  
(2.05 – 2.00) 
79.99  – 2.35  
(2.45 – 2.35) 
Unit cell (Å) a = 76.74 b = 65.53  
c = 80.74 
a = 78.14  b = 67.10  
 c = 80.82 
a = 77.09  b = 65.39  
c = 80.78 
a = 79.37  b = 67.64  
c = 81.04 
a = 77.52  b = 65.95 
 c = 80.95 
Diffraction source MX1 MX1 MX1 MX2 MX2 
Wavelength (Å) 0.954 0.954 0.954 0.954 0.954 
Total reflections 231360 167494 216339 203287 218020 
Unique reflections 38314 45106 33140 57135 33722 
Multiplicity 6.0 (6.1) 3.7 (3.7) 6.5 (5.7) 3.6 (3.6) 6.5 (6.6) 
Completeness (%) 99.9 (100.0) 100.0 (100.0) 99.4 (97.1) 99.7 (99.9) 99.7 (100.0) 
Mean (I/σ(I)) 9.9 (1.7) 7.1 (1.5) 10.2 (1.6) 8.5 (1.7) 10.4 (3.0) 
Wilson B-factor 36.60 33.59 39.83 34.83 40.78 
Rmerge†  0.108 (0.896) 0.09 (0.718) 0.104 (0.907) 0.064 (0.617) 0.101 (0.565) 
CC(1/2) 0.996 (0.646) 0.990 (0.666) 0.997  (0.717) 0.996 (0.801) 0.994 (0.890) 
Refinement      
   Rcryst‡ 0.1958 (0.3081) 0.1985 (0.3175) 0.2096 (0.2661) 0.2027 (0.3464) 0.1797 (0.2081) 
   Rfree§ 0.2394 (0.3224) 0.2302 (0.3487) 0.2662 (0.3313) 0.2331 (0.3754) 0.2282 (0.2909) 
Number of reflections 38282 45075 33048 57073 33722 
Number of atoms in model 4479 4513 4458 4539 4416 
Protein 4308 4318 4307 4315 4315 
Ligand 49 22 49 22 0 
Water molecules 122 173 102 202 101 
Deviation from ideal bond lengths (Å) 0.009 0.004 0.009 0.004 0.009 
Deviation from ideal bond angles (⁰) 1.118 0.791 1.133 0.803 1.080 
Ramachandran analysis (%)      
   Preferred  95.62 96.58 95.05 96.39 96.39 
   Allowed 4.19 3.04 4.57 3.23 3.42 
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Structural Insights into Binding of the Antifungal Drug Fluconazole to
Saccharomyces cerevisiae Lanosterol 14-Demethylase
Alia A. Sagatova,a Mikhail V. Keniya,a Rajni K. Wilson,a Brian C. Monk,a,b Joel D. A. Tyndallc
Sir John Walsh Research Institute, University of Otago, Dunedin, New Zealanda; Department of Oral Sciences, Faculty of Dentistry, University of Otago, Dunedin, New
Zealandb; New Zealand’s National School of Pharmacy, University of Otago, Dunedin, New Zealandc
Infections by fungal pathogens such as Candida albicans and Aspergillus fumigatus and their resistance to triazole drugs are
major concerns. Fungal lanosterol 14-demethylase belongs to the CYP51 class in the cytochrome P450 superfamily of enzymes.
This monospanning bitopic membrane protein is involved in ergosterol biosynthesis and is the primary target of azole antifun-
gal drugs, including fluconazole. The lack of high-resolution structural information for this drug target from fungal pathogens
has been a limiting factor for the design of modified triazole drugs that will overcome resistance. Here we report the X-ray struc-
ture of full-length Saccharomyces cerevisiae lanosterol 14-demethylase in complex with fluconazole at a resolution of 2.05 Å.
This structure shows the key interactions involved in fluconazole binding and provides insight into resistance mechanisms by
revealing a water-mediated hydrogen bonding network between the drug and tyrosine 140, a residue frequently found mutated
to histidine or phenylalanine in resistant clinical isolates.
Fungal pathogens are estimated to be responsible for 1.5 mil-lion deaths per year worldwide, with members of the genera
Candida, Cryptococcus, and Aspergillus being those most often as-
sociated with life-threatening disseminated disease (1). Comor-
bidity with infectious diseases such as malaria, tuberculosis, and
AIDS, the use of therapies that leave individuals immunocompro-
mised, and the emergence of resistant clinical isolates due to anti-
fungal prophylaxis and antifungal agrochemicals all contribute to
this problem (2). In sub-Saharan Africa, Cryptococcus species are
most often associated with comorbidity and cause about 400,000
deaths per annum. In the United States, Candida species are the
fourth-most-common cause of nosocomial bloodstream infec-
tions, accounting for 8% to 10% of all hospital-acquired infec-
tions and resulting in an attributed mortality rate of 40% (3).
Fluconazole (FLC)-resistant Candida species account for 7% of
bloodstream isolates of this organism. This results in significant
additional hospitalization costs and about 220 deaths per annum
in the United States (4). Chemotherapy and radiotherapy pa-
tients, as well as those undergoing immunosuppressive therapies
associated with organ transplants, are particularly susceptible to
life-threatening invasive mycoses, mainly those caused by Can-
dida and Aspergillus species (5).
Despite the introduction and use of the echinocandin antifun-
gals since 2001, azole drugs such as FLC remain the most widely
used class of antifungals due to their efficacy and low cost. The
azole drugs used in the clinic are categorized into imidazoles and
triazoles, depending on the nature of the iron-coordinating het-
erocycle in the drug. FLC is a first-generation triazole but has a
half-life longer than and bioavailability superior to those of the
second- and third-generation triazoles such as itraconazole (ITC),
voriconazole (VCZ; Fig. 1), and posaconazole (PCZ) (6). Despite
favorable pharmacokinetic properties and limited drug interac-
tions, FLC is less potent than other triazoles and exhibits no activ-
ity against invasive molds (7). VCZ is structurally related to FLC
but has the disadvantage of showing significant toxicity and many
major drug interactions and requires therapeutic drug monitor-
ing (8). Even so, VCZ remains the drug of choice for treatment of
disseminated aspergillosis (2).
The antifungal activity of the azoles depends on their ability to
inhibit the activity of the enzyme lanosterol 14-demethylase
(CYP51 [or Erg11p]), a member of the CYP51 class of cytochrome
P450 enzymes (9). The active site of lanosterol 14-demethylase
contains a heme cofactor where the sixth position of the octahe-
dral coordinate geometry of the iron can be occupied by a nitrogen
in either the imidazole ring or the triazole ring of the azole drugs.
The 14 demethylation of lanosterol (Fig. 1) is the rate-limiting step
in ergosterol biosynthesis in fungi (10). Inhibition of Erg11p leads to
a depletion of ergosterol from cell membranes. This affects the fluid-
ity of the lipid bilayer and slows fungal growth. Inhibition of Erg11p
also results in the accumulation of toxic metabolites such as the 14-
methyl-3,6-diol formed from 14-methyl-fecosterol (11). The com-
bined effects of ergosterol depletion and toxic metabolite production
are fungistatic for many pathogenic fungi, including Candida albi-
cans, Candida glabrata, and Aspergillus species.
Fungi have evolved several mechanisms to circumvent the ac-
tion of azoles, including mutations in the drug-binding site of
Erg11p that reduce the binding affinity of triazoles and thus confer
resistance (12–14). The innate resistance of Aspergillus fumigatus
to FLC is thought to be due to the presence of two homologues of
the drug target, with CYP51B appearing sensitive to fluconazole
whereas CYP51A confers significantly reduced susceptibility (15).
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Prokaryotic P450s are soluble cytoplasmic proteins, whereas
the eukaryotic enzymes, excluding mitochondrial P450s, possess a
single transmembrane helix that tethers the enzyme to the lipid
bilayer. Until 2014, X-ray structures of eukaryotic CYP51s were
obtained by deletion of the transmembrane helix to improve ex-
pression and crystallization (16). These CYP51s included the hu-
man CYP51 enzyme (PDB identifiers [IDs] 3LD6, 3JUV, and
3JUS) (16) and CYP51 enzymes from the protozoa Trypanosoma
cruzi and Trypanosoma brucei (PDB IDs 2WX2, 2WV2, and
2X2N) (17). Other available CYP51 structures include those of
Mycobacterium tuberculosis CYP51 (e.g., PDB ID 1EA1) (19) and
Leishmania infantum CYP51 (PDB ID 3L4D) (20). The only struc-
tural information available on fungal CYP51s was from homology
models based on the truncated structures of other P450s and,
more recently, on human CYP51 and Mycobacterium tuberculosis
CYP51 (21–23).
The first full-length structure of a fungal CYP51 was deter-
mined by X-ray crystallography of Erg11p from the yeast Saccha-
romyces cerevisiae (24). Two structures were deposited in the PDB,
one with the native substrate lanosterol (PDB ID 4LXJ) bound in
the active site in a precatalytic state and the other with the long-
tailed triazole drug ITC (PDB ID 4K0F), at resolutions of 2.19 Å
and 1.90 Å, respectively. Structures of Erg11p complexed with
FLC or VCZ could be refined only at a significantly lower resolu-
tion (2.5 Å) and were not deposited in the PDB (24). Elucidation
of the structure of the complete enzyme identified the likely ori-
entation of the enzyme in relation to the lipid bilayer. Amphi-
pathic N-terminal membrane helix 1 (MH1) and the adjacent
transmembrane helix (TMH1) are oriented at an angle of about
60° to each other, and contacts between TMH1 and the catalytic
domain help position the catalytic domain such that it is partly in the
lipid bilayer (Fig. 2). The enzyme has a common P450 fold with -he-
lices (A to L) and -sheets (1 to 4) constituting the catalytic domain,
with the heme cofactor forming the active site. The entrance to the
substrate channel is in direct contact with the surface of the lipid
bilayer. This ensures that the entry of the lipidic substrate is per-
formed directly from the surface of the membrane. In this report, we
present the high-resolution crystal structure of full-length S. cerevi-
siae Erg11p in complex with the short-tailed triazole FLC that
reveals key hydrogen bond networks in the active site.
MATERIALS AND METHODS
Yeast strains. The yeast strains used in this study are described in Table 1.
The AD2 strain was used for heterologous overexpression of the full-
length S. cerevisiae ERG11 gene containing a sequence encoding a C-ter-
minal hexahistidine tag (S. cerevisiae Erg11p6His [ScErg11p6His]).
This strain is a derivative of the AD strain previously described by Lamp-
ing et al. (25, 52) but with the HIS1 gene deleted. Both strains have the
FIG 1 The chemical structures of the substrate lanosterol, the short-tailed
triazole antifungal agents FLC and VCZ, and the long-tailed azole antifungal
ITC. An asterisk (*) indicates the 14-methyl of the lanosterol.
FIG 2 The structure of ScErg11p6His. The protein is colored from the N
terminus to the C terminus with a gradient from blue to red. The heme (purple
carbons) and FLC (green carbons) are shown in sticks. For clarity, only some of
the -helices and -sheets are labeled. FSL, fungus-specific loop.
TABLE 1 Yeast strains used in this study





Lamping et al. (25)
AD2 AD, his1 This study
AD2ScErg11p AD2, pdr5::ScERG11-URA3 This study
AD3ScErg11p AD2 ScErg11p, erg11::HIS1 This study
CYP51 Structure Complexed with Fluconazole
August 2015 Volume 59 Number 8 aac.asm.org 4983Antimicrobial Agents and Chemotherapy
 on D
ecem
















major ATP-binding cassette transporter pumps deleted and are therefore
hypersensitive to azole drugs. The ScErg11p6His strain was constitu-
tively overexpressed from the PDR5 locus due to a gain-of-function
pdr1–3 mutation in the Pdr1p transcriptional regulator (26). The endog-
enous ScERG11 gene was then replaced via homologous recombination
using a histidine (His1) marker to create strain AD3ScErg11p (Table 1)
using a previously described method (25).
MIC80 determinations. Triazole drugs are fungistatic and often give
trailing growth even at high drug concentrations. Therefore, MICs were
determined at 80% growth inhibition compared to the level seen with the
nondrug controls. In addition, the RPMI medium used for standard MIC
determinations with Candida albicans supports poor growth in S. cerevi-
siae (27) and so was not used. Instead, the MIC80s of FLC, ITC, and VCZ
for yeast cells were determined using 0.079% complete synthetic media
(Formedium, Norfolk, United Kingdom) containing 0.67% (wt/vol) yeast
nitrogen base without amino acids (BD Difco Laboratories Inc., Franklin
Lakes, NJ), 2% (wt/vol) glucose, 10 mM MES (4-morpholineethanesul-
fonic acid), and 20 mM HEPES (buffered with Tris to pH 6.8). The 96-well
microtiter plates were seeded with cells to an optical density at 600 nm
(OD600) of 0.005. The microtiter plates were incubated at 30°C with shak-
ing at 200 rpm for 48 h, and OD600 measurements were made using a
BioTek Synergy 2 multimode plate reader (BioTek Instruments, VT,
USA). MIC80 determinations were done in triplicate for each strain and in
3 separate experiments.
Protein purification. The purification of ScErg11p6His was carried
out according to methods described previously (24). In brief, crude mem-
branes were prepared from liquid cultures grown overnight in YPD me-
dium (1% [wt/vol] yeast extract [BD Difco], 2% [wt/vol] peptone [BD
Difco], 2% [wt/vol] dextrose) at 30°C with shaking at 200 rpm. Cells were
broken by bead beating, and crude membranes were obtained by differ-
ential centrifugation. Crude membranes were solubilized with 10 criti-
cal micelle concentration (CMC) n-decyl--D-maltoside (DM) (Af-
fymetrix Inc., Santa Clara, US). ScErg11p6His was purified from the
solubilized crude membrane fraction by affinity chromatography using 2
ml of packed nickel-nitrilotriacetic acid (Ni-NTA)-agarose matrix (Qia-
gen) per gram of protein. FLC was added at a final concentration of 40 M
to 5 ml of pooled eluate obtained with 200 mM imidazole. The affinity-
purified ScErg11p6His was concentrated by centrifugal filtration using
a 50-kDa-molecular-mass-cutoff Amicon Ultra-4 centrifugal filter (Mil-
lipore) and further purified by size exclusion chromatography (SEC) us-
ing a Superdex 200 10/300 GL column (GE Healthcare Life Sciences,
United Kingdom). The column was equilibrated with SEC buffer contain-
ing 10% (wt/vol) glycerol, 150 mM NaCl, 20 mM HEPES, 0.5 mM phe-
nylmethanesulfonyl fluoride, 6.4 mM DM (4 CMC), 10 M FLC, and 1
Roche EDTA-free protease inhibitor pill per 400 ml. The pooled, colored
fractions containing the 62-kDa ScErg11p6His were concentrated using
a 50-kDa-molecular-mass-cutoff Amicon Ultra-4 centrifugal filter.
Cytochrome P450 concentration. Carbon monoxide-binding spectra
were used to determine the concentrations of functional and nonfunctional
cytochrome P450 according to the protocol described by Guengerich et al.
(28). The cytochrome P450 concentration was determined using 1.5 M
ScErg11p6His in affinity chromatography medium (10% [wt/vol] glycerol,
250 mM NaCl, 20 mM Tris, 0.5 mM phenylmethanesulfonyl fluoride, 16 mM
DM [10CMC], and 1 Roche EDTA-free protease inhibitor pill, pH 7.5).
Protein spectra were measured at between 400 and 700 nm for oxidized pro-
tein and for the protein reduced with 6 mM sodium dithionite. The CO-
P450 complex was obtained by bubbling CO through the sample in 10-mm-
path-length UV transparent plastic cuvettes (GE Healthcare Life Sciences,
United Kingdom) followed by addition of sodium dithionite (28). Absorp-
tion spectra were recorded using a Cary 1 Bio UV-visible spectrophotometer.
The P450 concentration was determined using an extinction coefficient of 91
mM1 cm1 for the difference in absorbance between 445 and 490 nm (29).
Binding of triazole drugs to ScErg11p6His. The affinity purifica-
tion for drug-binding studies used affinity chromatography medium con-
taining 2 mM L-histidine for washing the enzyme-bound column and 50
mM L-histidine for elution of ScErg11pHis. L-Histidine was removed
from the preparation by washing the enzyme with affinity chromatogra-
phy medium using a 50-kDa-molecular-mass-cutoff Amicon Ultra-4 cen-
trifugal filter (Millipore). Difference spectra were obtained by titrating
affinity-purified ScErg11p6His and used to determine dissociation con-
stant (Kd) values for the binding to the triazole drugs FLC and VCZ (30,
31). Incremental additions of up to 7 l of triazole drug dissolved in
dimethyl sulfoxide (DMSO) were added to a 0.5-ml sample of 1 M
ScErg11p6His in affinity chromatography buffer in a 10-mm-path-
length cuvette. The same incremental volumes of DMSO were added to
the reference cuvette, which contained the same amount of enzyme. Dif-
ference spectra (350 to 500 nm) were recorded, and the trough-peak ab-
sorbance changes due to type II binding were used to generate drug-
binding curves. The Hill equation A 	 Amax [azole]
n/([azole]n 
 Kdn)
(where A is the change in absorbance, [azole] is the azole concentration,
and n is the apparent Hill number) was fitted to the curve and used to
calculate Kd values. The 50% inhibitory concentration (IC50) values for
the binding curves are denoted here as [azole]0.5. All calculations were
carried out using GraphPad Prism 6 software (GraphPad Prism, San Di-
ego, CA).
Crystallization and X-ray data collection. Affinity-purified ScErg11p6
His copurified with FLC by SEC was crystallized using a hanging-drop
vapor diffusion method. The crystals formed within 1 week at 18°C. The
reservoir solution contained 45% polyethylene glycol 400–100 mM glycine at
a pH range of 9.3 to 9.5. The drops were 4 l in a 1:1 ratio of reservoir solution
and20 mg/ml of the protein in SEC buffer. The crystals were flash-cooled in
liquid nitrogen prior to data collection. A complete data set was collected on
the MX1 beamline at the Australian Synchrotron using an ADSC Quantum
210r detector. The data were indexed and integrated using iMosflm (32) and
scaled with SCALA (33). Molecular replacement was carried out using Phas-
er-MR (34) from Phenix (35) and ScErg11p6His cocrystallized with lanos-
terol (PDB ID 4LXJ) as the template (24). Refinement and modeling were
performed using phenix.refine (35) and Coot (36), respectively. The inhibitor
was modeled into the appropriate density in the active site, and quantities of
water were added if at least one hydrogen bond was detected (2.5 to 3.3 Å).
Iron-to-nitrogen and iron-to-sulfur distances were constrained during re-
finement to 2.15 Å and 2.33 Å based on the average coordinate bond distance
for more than 80 known heme Fe-N (triazole) complexes and 4 heme Fe-S
complexes in the Cambridge Structural Database (see Table S2 in the supple-
mental material) (37).
Sequence accession number. The coordinates and structure factors
have been deposited in the Protein Data Bank under accession number
4WMZ.
RESULTS AND DISCUSSION
Drug susceptibility of S. cerevisiae strains expressing Erg11p. As
expected, deletion of the HIS1 ORF in the AD strain did not alter
the azole susceptibility pattern in the AD2 derivative strain. The
parent and derivative strain were equally highly sensitive to the
triazoles tested (Table 2). Constitutive hyperexpression of





AD 0.4 ( 0.04) 0.03 0.05 ( 0.001)
AD2 0.4 ( 0.04) 0.03 0.05 ( 0.001)
AD2 ScErg11p 2.4 ( 0.13) 0.106 ( 0.001) 0.24 ( 0.02)
AD3 ScErg11p 2.1 ( 0.02) 0.105 ( 0.004) 0.25 ( 0.05)
a MIC80 values were determined as described in Materials and Methods. The table
shows the means for 3 separate clones of each strain calculated using data obtained in
triplicate measurements from at least 3 different experiments (a total of 9
determinations per strain). Values for standard errors of the means (SEM) are indicated
in brackets.
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ScErg11p6His from the PDR5 locus under the control of the
gain-of-function pdr1–3 mutation increased the resistance of the
AD2 strain to FLC 6-fold, to ITC 3.5-fold, and to VCZ 5-fold.
Removal of the endogenous ScERG11 in the AD3ScErg11p
strain did not significantly increase susceptibility to these tria-
zoles. This showed that the azole resistance was dependent on the
presence of recombinant ScErg11p6His and not that of the na-
tive ScErg11p.
Spectral characteristics of purified ScErg11p. The absorbance
spectrum for ScErg11p6His in its low-spin ferric state showed a
heme Soret () band at 417 nm and , , and  peaks at 350, 535,
and 571 nm, respectively (Fig. 3). One-electron-reduced spectra
obtained using sodium dithionite gave a blue shift of the Soret
peak from 417 nm to 414 nm. CO binding to the ferrous
ScErg11p6His produced a characteristic red shift to 445 nm.
The minor shoulder at 420 nm indicated the presence of a small
amount of inactive P420 complex in the purified enzyme prepa-
ration. The absolute, reduced, and CO spectra for purified
ScErg11p6His were comparable to those obtained previously
for S. cerevisiae microsomal preparations by Yoshida and Aoyama
(38) and indicated that the ScErg11p6His preparation was al-
most completely active.
Binding of triazole drugs to ScErg11p6His. The binding of
FLC (Fig. 4a) and VCZ (data not shown) to ScErg11p6His gave
type II difference spectra caused by the coordination of the nitro-
gen atom in the triazole ring with the heme iron, replacing the
water ligand and stabilizing the low-spin form (39). The absor-
bance spectra of ScErg11p6His in the presence of the triazoles
caused a red shift of the heme Soret peak from 417 nm to 421 nm
for both VCZ and FLC. The difference spectra obtained with 1 M
ScErg11p6His enzyme in the presence of excess FLC and VCZ
were very similar, with a peak at 428 nm and a trough at 410 nm
(Table 3). The binding is normally characterized as tight if the Kd
values are lower than or equal to those of the enzyme concentra-
tion, and the Morrison equation is generally used to fit the data
(40). However, using the Hill equation for analysis of the change
in absorbance caused by drug binding versus the change in the
concentration of triazole drug added, and not the rearrangement
of the Morrison equation, gave the best fit (Fig. 4b and Table 3).
The [azole]0.5 values were similar for the two drugs, as were the Kd
values (Table 3). Similarly to previous studies performed with C.
albicans CYP51, the [azole]0.5 values were found to be about half
the P450 concentration values, indicating tight binding for VCZ
and FLC (31, 41). The Kd value for FLC of 74 ( 15 [standard
error]) nM is comparable to those previously obtained using the
Morrison equation for CaCYP51 in two different studies, i.e., 46.6
( 10.6) nM (31) and 60 ( 10) nM (42). The apparent Hill
numbers of 3 for FLC and 2.7 for VCZ are unlikely to be due to
positive cooperativity between ScErg11p monomers. They are
more likely to result from multiple interactions between the ligand
and the internal active site of an enzyme (43) that behaves as a
monomer within its own detergent vesicle. Consistent with this
hypothesis, size exclusion chromatography analysis of the affinity-
purified enzyme gives enzyme-containing detergent vesicles that
migrate with an apparent molecular mass of 100 kDa (24).
X-ray crystal structure of S. cerevisiae Erg11p in complex
with FLC. Full-length S. cerevisiae lanosterol 14-demethylase
(ScErg11p6His) copurified with FLC during SEC was used for
crystallization. Data collection parameters and refinement
statistics are presented in Table S1 in the supplemental material.
Molecular replacement was carried out using full-length
FIG 3 Spectral characterization of ScErg11p6His. Data represent the abso-
lute spectra of the ferric protein (solid trace), the ferrous protein reduced with
sodium dithionite (dashed trace), and the reduced protein with bound carbon
monoxide (dotted trace). Spectra were recorded using 1.5 M ScErg11p as
described in Materials and Methods.
FIG 4 Binding of FLC and VCZ to ScErg11p6His. (a) Difference spectra
demonstrating type II binding of FLC obtained by incremental additions of the
drug to 1 M ScErg11pHis. (b) Saturation curves for FLC (filled circles) and
VCZ (hollow circles) fitted to the Hill equation, with A plotted against azole
concentration.
CYP51 Structure Complexed with Fluconazole
August 2015 Volume 59 Number 8 aac.asm.org 4985Antimicrobial Agents and Chemotherapy
 on D
ecem
















ScErg11p6His (PDB ID 4LXJ) and revealed a single monomer in
the asymmetric unit (PDB ID 4WMZ) comprising MH1, TM1,
and the catalytic domain as seen previously (24) (Fig. 2). The
enzyme appears to be a rigid molecule, as the tertiary structure and
the shape of the substrate channel are unchanged, regardless of the
size of the ligand (lanosterol, ITC, or FLC) bound in the active site
(24). Some differences in ScErg11p6His in complex with FLC,
compared with the two previously deposited structures, were de-
tected in side chains of residues of the transmembrane helix, in
side chains of residues of helix-F= and helix-G and the F=/G loop
that connects them, and in some parts of the enzyme exposed to
the solvent. The F/G loop is buried in the membrane, and this
region has the highest -factor values together with the trans-
membrane helix and the three residues Y439, S440, and V441 in all
three structures, as previously discussed (24). Residues Y439 and
V441 are within the N-terminal portion of a fungus-specific loop
and are located at the surface of the protein.
The proposed egress channel that bifurcates from the substrate
channel shows some density in the present structure comparable
to that seen in the two previously published structures (24). The
density has been proposed to represent zymosterol rather than the
immediate product 4,4-dimethylcholesta-8,14,24-trienol, based
on mass spectrometry analysis of the purified enzyme (24). The
side chains of residues around this secondary vestibule are posi-
tioned similarly among all three structures except H128, which
has been modeled into different positions due to the limited den-
sity. This flexibility may be required to accommodate the exit of
the product or interaction with subsequent enzymes in the ergos-
terol biosynthesis pathway, e.g., Erg24 and the Erg25-Erg28 com-
plex (44).
FLC binding. FLC binds within the active site of the enzyme,
with clear evidence of the ligand apparent from the molecular
replacement seen immediately following the solution step of the
experiment (Fig. 5a). The triazole ring of FLC is coordinated to the
iron within the heme cofactor (Fe-N distance, 2.13 Å), corrobo-
rating the spectrophotometric data showing type II binding. The
immediate environment surrounding FLC is hydrophobic, as
would be expected from the nature of the lanosterol substrate.
Residues within 4 Å of FLC are illustrated in Fig. 5b and include
Y126, F134, I139, Y140, F236, G310, V311, G314, G315, T318,
L380, and M509. The 2,4-difluorophenyl ring of FLC lies in a
position adjacent to G310, and the coordinated triazole ring abuts
G314 on the GXXXG consensus motif for sterol binding on he-
lix-I. Consistent with other eukaryotic CYP51 structures, such as
the Trypanosoma CYP51 structure, the bend in helix-I of ScErg11p
at this motif is less acute than in the M. tuberculosis CYP51 struc-
ture (19). Two water molecules form hydrogen bond networks
with FLC (Fig. 5c). The first water (molecule 743) mediates hy-
drogen bonds between the hydroxyl groups of FLC and Y140 as
well as a propionate of the heme cofactor. The second water (mol-
ecule 790) forms hydrogen bonds with the carbonyl oxygen of
S382, the hydroxyl of Y126, and N4 of the second triazole ring
which points away from the heme (Fig. 5c). In the previously
published structures of ScErg11p6His complexed with lanos-
terol and ITC, neither water 743 nor water 790 was observed.
Previously reported structures of other CYP51s complexed with
FLC have the inhibitor bound in a similar manner. The orienta-
tion of the 2,4-difluorophenyl ring matches that seen in the M.
tuberculosis (PDB ID 1EA1) and T. cruzi (PDB ID 2WX2) CYP51
structures (17). The 2,4-difluorophenyl ring is rotated 180° in
several other structures, but this orientation would appear to be
potentially unfavorable, as the 2-fluoro substituent and the hy-
droxyl group of FLC are in close proximity (PDB ID 2WV2 and
2WUZ) (17). The latter alternate orientation (2WUZ) is stabilized
by a hydrogen bond between the fluorine substituent and the hy-
droxyl of Y103 (corresponding to Y126 in ScErg11p6His) (17).
This residue (Y103) shows a great deal of flexibility among the
trypanosomal structures, including occupying the site for key wa-
ter molecule 743.
VCZ, another short-tailed antifungal agent, is similar to FLC
and differs only in that the second noncoordinating triazole is
replaced with a fluoropyrimidine group along with the addition of
a methyl group. In the previous modeled structure obtained with
a lower-resolution data set (2.8 Å), the fluoropyrimidine ring is
positioned in the same plane as the triazole ring, with the fluoro
substituent positioned in the direction opposite to that seen with
the hydroxyl of the inhibitor and the methyl group (24). The pres-
ence of the key water (743) would also provide the potential for a
hydrogen bond with N3 of the fluoropyrimidine in this orienta-
tion in preference to the flipped conformation.
Antifungal resistance. Mutations which reduce the effective-
ness of azole drugs are frequently found in resistant pathogenic
fungi. Of the residues within 4 Å of FLC in ScErg11p6His that
have residues equivalent to those found to be mutated in C. albi-
cans Erg11p, only Y132F/H (Y140F/H in ScErg11p) is known
to confer resistance to FLC as a single mutation (13, 45). The
others confer resistance in combination with additional muta-
tions or confer susceptible phenotypes alone (46). The single-
amino-acid substitutions Y132F, K143R, F145L, S405F, D446E,
G448E, F449V, G450E, and G464S in C. albicans Erg11p have been
found to confer resistance to FLC (45). The FLC MICs for those
mutants were increased 4-fold compared to those for the sus-
ceptible strain. Our structure shows that only Y132F, K143R, and
G464S are located close enough to the active site and the heme
cofactor to directly affect the binding of FLC. Residues D446,
G448, F449, and G450 (fungus-specific loop) as well as F145 and
S405 are too far away to directly affect the heme or interfere with
FLC binding.
The Y132F/H mutation in C. albicans is commonly found in
clinical isolates of other fungal pathogens of humans and plants
that have reduced susceptibility to FLC and other azoles (12, 47).
As described above, a key water molecule (743) mediates hydro-
gen bonds between the hydroxyl group of the inhibitor, the hy-
droxyl group of Y140, and the propionate group of the heme
TABLE 3 Binding of triazole drugs to affinity-purified ScErg11p6Hisa
Triazole A max trough peak Kd (M) Hill no. [Azole]0.5 (M)
FLC 0.048 410 428 0.074 ( 0.015) 3.0 0.43
VCZ 0.051 410 428 0.082 ( 0.018) 2.7 0.4
a The binding of azole drugs to 1 M Ni-NTA affinity-purified ScErg11p6His was determined as described in Materials and Methods. max, maximum. Standard errors are shown
in parentheses.
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(Fig. 5c). Homologous mutations at Y140 to either phenylalanine
or histidine could disrupt this hydrogen bonding network and
therefore reduce susceptibility to FLC.
Mutations equivalent to G464S (S. cerevisiae and C. albicans
numbering) have been found in both C. albicans and A. fumigatus
(see Fig. S2 in the supplemental material). The C. albicans G464S
mutation has been found in clinical isolates and gives rise to FLC
resistance (13, 45, 48), while the equivalent G448S mutation in A.
fumigatus CYP51B is thought to confer resistance to the long-
tailed drugs ITC and PCZ but not resistance to the short-tailed
VCZ drug (49). It has been suggested that this substitution would
disrupt the positioning of the heme, reduce the binding of the
azole, and increase resistance (22). However, its differential effect
on short-tailed azoles compared to long-tailed azoles is not under-
stood. G464 is located on the same face of the heme as the coor-
dinating cysteine residue and is close to a propionate group of the
cofactor that makes a hydrogen bond to a water molecule (see Fig.
S2). The G464S mutation may replace this water and alter the
interaction with the heme carboxylate, thus potentially tilting the
heme.
The K143R mutation in C. albicans CYP51 (K151 S. cerevisiae
numbering) confers resistance to FLC (50). This residue is also
located on the same side of the heme cofactor as the coordinating
cysteine (see Fig. S2 in the supplemental material). In the current
crystal structure, the side chain of K151 forms an ionic interaction
with the carboxylate group of the heme. The change from lysine to
arginine, while being functionally conservative, results in the ad-
dition of a large guanidinium group in an environment optimized
for lysine. The change causes local disruption, but its extent is
unknown.
A. fumigatus has innate resistance to FLC, which may be a
result of sequence differences between the two homologues of
CYP51 present in this species (see Fig. S1 in the supplemental
material). Most fungal species have a threonine at the position
corresponding to T322 on helix I (S. cerevisiae numbering). A.
fumigatus CYP51A has an isoleucine at this position (A. fumigatus
CYP51A numbering, I301) whereas A. fumigatus CYP51B main-
tains the threonine (A. fumigatus CYP51B numbering, T315). It
has been hypothesized that this difference confers resistance to
FLC (51). Alanine mutagenesis at the homologous T315 position
in C. albicans has been shown to result in increased resistance to
FLC CYP51 (41). The current structure of ScErg11p shows that
T322 is located adjacent to the active site on helix-I and close to
an ethylene group of the heme but about 10 Å from the iron-
coordinated triazole group. G310 (S. cerevisiae numbering) is
within a distance of 4 Å of the drug. Glycine or alanine is accom-
modated in this position in fungal CYP51s, apart from A. fumiga-
tus CYP51A, which has threonine (T289), and in one of two se-
FIG 5 FLC binding in the active site of ScErg11p. (a) OMIT map for FLC
(Fo-Fc map [green mesh] contoured at 3; 2Fo-Fc map [blue mesh] contoured
at 1). The Fo-Fc map was calculated using Fcalc refined from coordinates with
no ligand at the active site. The 2Fo-Fc map was calculated following the final
refinement. The main chain is indicated in gray, and fluconazole is indicated as
sticks, with C atoms in cyan, N atoms blue, O atoms in red, and F atoms in pale
blue. The heme is shown as sticks, with C atoms colored magenta. (b) Side
chains of amino acid residues within 4 Å of FLC are indicated in gray. The main
chain atoms are shown for G310, G314, and G315. (c) Water-mediated hydro-
gen bonding (yellow dashed lines) between HOH743, FLC, heme, and Y140, as
well as between HOH790, FLC, and S382.
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quences available for Coccidioides immitis RS CYP51 (T303). This
residue appears to be in better position than T322 to alter the
binding of FLC (Fig. 5c).
Future prospects. The high-resolution X-ray crystal structure
of full-length recombinant S. cerevisiae CYP51 (ScErg11p6His)
complexed with FLC and the resultant discovery of hydrogen
bonding networks involving key water molecules within the active
site provide the basis for detailed exploration of both the binding
and resistance mechanisms of azole antifungal drugs, in particu-
lar, FLC and VCZ, in fungal pathogens. Due to the strong homol-
ogy of fungal CYP51s, ScErg11p can be used, both structurally and
experimentally, as a model to study the mutations that have been
observed in resistant clinical isolates of fungal pathogens. The
presence of a water-mediated hydrogen bond network between an
inhibitor and Y140 in the active site of lanosterol 14-demethylase
when complexed with the short-chain FLC but not with the long-
chain ITC, as well as the interactions of the long tail of ITC in the
enzyme entrance channel (24), may explain the differential levels
of susceptibility to FLC and ITC conferred by mutations equiva-
lent to Y140F/H. Structural and functional analysis will enable
rigorous determination of the effects of these mutations on the
protein and its affinity for these drugs.
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Triazole resistance mediated by 
mutations of a conserved active 
site tyrosine in fungal lanosterol 
14α-demethylase
Alia A. Sagatova1, Mikhail V. Keniya1, Rajni K. Wilson1, Manya Sabherwal1, Joel D. A. Tyndall2 
& Brian C. Monk1,3
Emergence of fungal strains showing resistance to triazole drugs can make treatment of fungal 
disease problematic. Triazole resistance can arise due to single mutations in the drug target lanosterol 
14α-demethylase (Erg11p/CYP51). We have determined how commonly occurring single site mutations 
in pathogenic fungi affect triazole binding using Saccharomyces cerevisiae Erg11p (ScErg11p) as a 
target surrogate. The mutations Y140F/H were introduced into full-length hexahistidine-tagged 
ScErg11p. Phenotypes and high-resolution X-ray crystal structures were determined for the mutant 
enzymes complexed with short-tailed (fluconazole and voriconazole) or long-tailed (itraconazole and 
posaconazole) triazoles and wild type enzyme complexed with voriconazole. The mutations disrupted 
a water-mediated hydrogen bond network involved in binding of short-tailed triazoles, which contain 
a tertiary hydroxyl not present in long-tailed triazoles. This appears to be the mechanism by which 
resistance to these short chain azoles occurs. Understanding how these mutations affect drug affinity 
will aid the design of azoles that overcome resistance.
Fungal infections are estimated to directly affect approximately one billion people globally and also have the 
potential to affect food security, especially in temperate and tropical climates. The increased incidence of 
potentially lethal invasive fungal infections (IFIs) and the emergence of resistant fungal pathogens are growing 
concerns1,2.
Fungal infections of humans that require medical intervention affect the immune-deficient, such as the very 
young (premature infants), females of reproductive age, the elderly and the debilitated. The most susceptible 
individuals have co-morbidities such as AIDS and cancer, or are patients who are medically immune suppressed. 
Members of the fungal species Candida, Aspergillus and Cryptococcus are the most prominent causes of IFIs in 
humans3,4. For example, in Sub-Saharan Africa where AIDS is endemic, infection by Cryptococcus neoformans 
is estimated to cause over 500,000 deaths each year5. Candida albicans is the 4th leading cause of blood stream 
infections detected in the United States6 while Aspergillus fumigatus infections have a high mortality rate among 
transplant patients7.
Fungal infection of plants, crops, fruit and stored produce is a major problem, especially in temperate and 
tropical climates. This problem is likely compounded by extensive monoculture, where natural barriers to fungal 
infection are insufficient and the widespread application of fungicides is required8 e.g. for control of the soy-
bean phytopathogen Phakopsora pakyrhizi or the wheat pathogen Zymoseptoria tritici (previously known as 
Mycosphaerella graminicola). Multiple generations of phytopathogen-targeting triazole agrochemicals have been 
used since the 1970s to counter shifts in antifungal susceptibility elicited by exposure to earlier azoles.
The triazole drugs, the largest class of antifungals used in the clinic or as agricultural fungicides, are becoming 
less effective in treating mycoses of humans and animals and in preventing the devastating effects of phyto-
pathogens on crop production. This has occurred because of the emergence of less susceptible fungal strains9. 
Resistance to azoles used in medicine has arisen, in part, because of the use of prophylaxis with susceptible 
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patients and prolonged treatment courses10,11. A contribution to this problem by azole-based agrochemicals was 
recognised recently, with these fungicides shown to induce cross-resistance to medical triazoles in A. fumigatus 
and Candida glabrata strains12,13. There is an increasingly urgent need to develop antifungals and agrochemicals 
capable of overcoming triazole resistance.
A common mechanism of resistance among fungal pathogens occurs due to mutations in the enzymatic target 
of azole drugs, the cytochrome P450 lanosterol 14α -demethylase (denoted as Erg11p or CYP51). Azoles inhibit 
the demethylase by coordinating to the heme iron in the active site via a heterocyclic nitrogen atom of an imi-
dazole, triazole or tetrazole ring14–16. In C. albicans Erg11p (CaErg11p) the Y132F/H mutations have frequently 
been detected in clinical isolates and lead to a 4-fold increase in resistance to fluconazole (FLC)17,18. Homologous 
mutations occur in the CYP51 genes of other fungal pathogens of man and plants (Fig. 1a)8,19,20. For example, the 
Y145F mutation in C. neoformans CYP5121 and Y136F mutation in Histoplasma capsulatum CYP5122 both cause 
resistance to the short-tailed triazoles FLC and voriconazole (VCZ) but not to the long-tailed triazoles posa-
conazole (PCZ) or itraconazole (ITC, Fig. 1b). Similarly, the mutations Y137F in Z. tritici CYP5123 and Y136F 
in Uncinula necator CYP5124 confer reduced susceptibility to the short-tailed azole fungicide triadimenol. In 
A. fumigatus the homologous CYP51A Y121F mutation can occur alone25 or together with the T289A mutation 
and tandem repeat 46 (TR46) in the promoter region26. The Y121F mutation confers resistance to VCZ but not 
ITC or PCZ25 while the TR46 Y121F T289A mutation is associated with failure of voriconazole therapy and a 
slightly reduced susceptibility to ITC and PCZ26.
The selection pressure exerted by individual triazole drugs can differ. For example, the Z. tritici CYP51 Y137F 
mutation arose after the introduction of triadimenol but essentially disappeared in the field following the intro-
duction of prothioconazole27, a pro-drug that is metabolised to the active short-tailed triazole agrochemical 
prothioconazole-desthio28. The accumulation of multiple mutations in CYP51 can lead to significant reductions 
in triazole susceptibility. For example the Y131F I475T combination of mutations has been detected in CYP51 
of the strains of the phytopathogen P. pachyrhizi29. The comparable double mutation Y132H I471T is found in 
Erg11p of the triazole resistant Darlington strain of C. albicans30.
Figure 1. (a) Sequence alignment of fungal CYP51s. Alignment of Histoplasma capsulatum CYP51 (HcCYP51), 
Zymoseptoria tritici CYP51 (ZtCYP51), Uncinula necator CYP51 (UnCYP51), Aspergillus fumigatus CYP51A 
(AfCYP51A), Cryptococcus neoformans CYP51 (CnCYP51), Candida albicans CYP51 (CaErg11p), and 
Saccharomyces cerevisiae CYP51 (ScCYP51). The frequently mutated tyrosine residue homologous to ScErg11p 
Y140 is highlighted in grey. (b) The chemical structures of triazole antifungals used in this study: fluconazole, 
voriconazole, itraconazole and posaconazole.
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Until recently, a paucity of structural information on fungal lanosterol 14α -demethylase has meant that 
the molecular mechanisms determining the reduced susceptibility conferred by mutations in fungal lanos-
terol 14α -demethylase were not well understood. We have reported high-resolution structures of full-length 
Saccharomyces cerevisiae hexahistidine-tagged Erg11p (ScErg11p6 × His) in complex with its substrate lanosterol 
(1.9 Å, PDB ID: 4XLJ) and the long chain azole itraconazole (2.1 Å, PDB ID: 5EQB)31. We have also described a 
high-resolution (2.05 Å) structure of ScErg11p6 × His in complex with FLC (PDB ID: 4WMZ)32. Based on the 
latter structure, the ScErg11p Y140F/H mutations were proposed to potentially modify a water-mediated hydro-
gen bond network involving the tertiary hydroxyl group of FLC, thus weakening the binding of the drug. In the 
present study, new high-resolution X-ray crystal structures of the ScErg11p6 × His Y140F mutant in complex 
with ITC, FLC, VCZ and PCZ and the Y140H mutant in complex with FLC and ITC, along with the wild type 
ScErg11p6 × His in complex with VCZ, provide evidence that disruption of this hydrogen bond network leads to 
weaker drug binding.
Results
Quantitation of the expression of ScErg11p6 × His in crude membrane fractions. The strains 
used in the present study are shown in Supplementary Information, Supplementary Table S1.
Coomassie blue R250 stained SDS-polyacrylamide gel profiles (Supplementary Fig. S1a) and western blot anal-
ysis (Supplementary Fig. S1b) of crude membrane fractions obtained from yeast overexpressing ScErg11p6 × His, 
ScErg11p6 × His Y140F or ScErg11p6 × His Y140H show that the mutant enzymes were expressed in this frac-
tion at levels at or near wild type enzyme. Analysis of the Ni-NTA and affinity-purified 61 kDa band by tryptic 
digestion and mass spectrometry showed at least 78% coverage of the primary sequence of ScErg11p6 × His and 
confirmed the presence of the expected mutations at Y140 (Supplementary Figs S2 and S3).
Azole susceptibilities of strains overexpressing ScErg11p6 × His Y140F/H. Susceptibilities to tri-
azole drugs of S. cerevisiae AD3Δ strains overexpressing Erg11p6 × His Y140F/H, but with the native ERG11 
deleted, were measured as liquid MIC80 values (Supplementary Table S2). Overexpression of ScErg11p6 × His 
Y140F in the AD3Δ ScErg11p_Y140F strain conferred 2-fold lower susceptibility to FLC than the strain overex-
pressing wild type ScErg11p6 × His i.e. MIC80 of 4.0 μ g/ml and 2.1 μ g/ml, respectively. The same mutant conferred 
a 1.7-fold reduction in susceptibility to VCZ. The MIC80 values were 0.42 μ g/ml for the strain overexpressing 
ScErg11p6 × His Y140F and 0.25 μ g/ml for the strain overexpressing wild type ScErg11p6 × His. The susceptibil-
ities to ITC were comparable for the strains overexpressing the ScErg11p6 × His Y140F, ScErg11p6 × His Y140H 
or wild type enzyme i.e. 0.09 μ g/ml, 0.77 μ g/ml and 0.105 μ g/ml, respectively. Strain AD3Δ ScErg11p_Y140H 
showed slightly greater susceptibilities to FLC (3.4 μ g/ml) and VCZ (0.29 μ g/ml) than the Y140F mutant. While 
strain AD3Δ ScErg11p_Y140H showed a reduced susceptibility to FLC, its susceptibility to VCZ was comparable 
to the control strain overexpressing the wild type enzyme.
Spectral characterisation of triazole binding to wild type and mutant ScErg11p6 × His. The 
absolute absorbance spectra for wild type ScErg11p6 × His showed an oxidised Soret peak at ~417 nm32 and for 
the Y140F/H enzymes the peak is seen at 420 nm (Fig. 2a). Carbon monoxide difference spectra33 obtained with 
dithionite-reduced wild type and mutant enzymes gave a peak at 445 nm which showed that the bulk of each 
affinity-purified enzyme was functional (Fig. 2a). The presence of a slightly larger shoulder at 420 nm for the 
mutant enzymes compared to the wild type enzyme32 indicated that the affinity-purified mutant enzyme may be 
less stable than the wild type enzyme.
Ni-NTA affinity purified mutant and wild type ScErg11p6 × His preparations (1 μ M) were used to detect and 
quantitate type II azole binding. The spectral shift of the Soret peak from 417 nm to 421–424 nm in cytochrome 
P450s is also detected by the type II difference spectra. This change is associated with the replacement of a water 
molecule coordinated to the heme iron with the azole heterocycle. Type II difference spectra were obtained for 
FLC, VCZ, ITC and PCZ binding to both mutant enzymes. The binding of FLC is shown as an example (Fig. 2b). 
The type II difference spectra for the mutant enzymes were less intense than for the wild type enzyme. They gave 
2–3-fold smaller differences in absorbance (Δ Amax), with peaks shifted from 428 nm for wild type enzyme to 424–
425 nm for the mutant enzymes plus less well-defined troughs between 406–410 nm (Supplementary Table S3). 
The type II binding curves obtained using the wild type ScErg11p6 × His and the Y140F/H mutants (1 μ M) 
showed a sigmoidal dose-response (Fig. 2c) that gave best fit using the Hill equation. The resultant [Azole]0.5 and 
Kd values are listed in Table 1. These values indicate tight binding for each drug tested. The Kd values for the wild 
type and mutant enzymes were comparable i.e. within the margin of the standard error.
X-ray crystal structures of ScErg11p6 × His Y140F/H mutants in complex with ITC and PCZ. 
X-ray crystal structures were obtained for ScErg11p6 × His Y140F in complex with ITC and PCZ (PBD 
IDs: 4ZDY and 4ZE1) at resolutions of 2.02 Å and 2.05 Å (Supplementary Table S4), respectively, and for 
ScErg11p6 × His Y140H in complex with ITC (PDB ID: 4ZE2) at a resolution of 2.30 Å (Supplementary Table S5). 
Both the ScErg11p6 × His Y140F and Y140H structures showed the binding of ITC was essentially identical 
to that seen previously with wild type ScErg11p6 × His (PDB ID: 5EQB, Fig. 3)31. In addition to detecting the 
mutated residue, a water molecule (843) not present in the wild type structure was found between an oxygen of the 
ITC 1,3-dioxolane group, the propionates of heme rings A and D and the aromatic side chain of the F140 (Fig. 3a) 
at distances of 4.0, 3.1, 2.5 and 3.3 Å, respectively. Water 843 replaced the phenolic hydroxyl group of Y140 but, 
because it makes no polar contacts with the inhibitor, it is unlikely to have any effect on ITC binding. The equiv-
alent water molecule was not detected in the structure of ScErg11p6 × His Y140F in complex with PCZ (Fig. 3b) 
or in ScErg11p6 × His Y140H in complex with ITC (Fig. 3c). Each mutant crystal structure showed the long tail 
of the triazole ligand bound within the substrate entry channel in an extended conformation, with the piperazine 
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ring in the chair conformation. This conformation was stabilized via a water-mediated hydrogen bond network 
between the tetrahedral nitrogen atom N1 of the piperazine ring and the main chain amide nitrogens of H381 
and S382 (Fig. 3d). The water mediating this hydrogen bond network resides in a hydrophilic pocket that contains 
Figure 2. Spectral characterisation of ScErg11p6 × His Y140F/H mutants. (a) The absolute (continuous 
line) and CO bound (dotted line) spectra of ScErg11p6 × His Y140F mutant. (b) Type II difference spectra 
for FLC binding to ScErg11p6 × His wild type and mutant enzymes. (c) Fluconazole binding to wild type 
ScErg11p6 × His (● ) ScErg11p6 × His Y140F (■ ) and ScErg11p6 × His Y140H (▲ ). All curves best fit the Hill 
equation.




FLC 0.43 0.074 (± 0.015) 3.0
VCZ 0.40 0.082 (± 0.018) 2.7
ITC 0.28 0.123 (± 0.027) 1.6
PCZ 0.32 0.078 (± 0.023) 2.2
Y140F
FLC 0.33 0.13 (± 0.05) 1.86
VCZ 0.27 0.03 (± 0.02) 2.60
ITC 0.33 0.13 (± 0.07) 1.83
PCZ 0.29 0.15 (± 0.07) 1.57
Y140H
FLC 0.27 0.11 (± 0.06) 1.68
VCZ 0.29 0.22 (± 0.07) 1.23
ITC 0.25 0.13 (± 0.06) 1.48
PCZ 0.23 0.10 (± 0.04) 1.57
Table 1.  Triazole binding to affinity purified wild type and ScErg11p6 × His Y140F/H. Values in brackets 
indicate standard errors. IC50 value is denoted as [Azole]0.5.
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two other waters when ITC or PCZ is bound. The binding of the long-tailed triazoles ITC and PCZ to wild type 
ScErg11p6 × His and the Y140F/H mutants pushes Y126 to a position so it forms hydrogen bonds with the heme 
ring D propionate group and the amide nitrogen of F384 (Fig. 3). The overall configuration of this residue was 
found to be less constrained in the presence of FLC, which occupies less space between the two groups (Fig. 4a).
X-ray crystal structures of ScErg11p6 × His wild type and Y140F/H mutants in complex with 
FLC and VCZ. The structures of wild type ScErg11p6 × His and the Y140F mutant enzyme in complex with 
FLC (PDB IDs: 4WMZ and 4ZDZ, respectively) showed the drug to be bound in a similar conformation, with all 
differences in the interactions between the drug and the enzyme ascribed to the mutation. As described in our 
previous report32, the structure of wild type ScErg11p6 × His in complex with FLC included a water-mediated 
(743) hydrogen bond network that involves the hydroxyl group of FLC, the hydroxyl of Y140 and the heme ring 
D propionate (Fig. 4a). In addition, the non-coordinated triazole of FLC and the main chain carbonyl of S382 
formed a hydrogen bond network mediated by water 790. This water was not detected in mutant ScErg11p6 × His 
in complex with ITC or PCZ because the tails of these ligands occupy that space. A water molecule equivalent 
to water 743 (numbered 843 in the mutant structures) was found in ScErg11p6 × His Y140F in complex with 
FLC but the hydrogen bond with Y140 was abolished as a result of the Y140F mutation (Fig. 4b, PDB: 4ZDZ). In 
Figure 3. Binding of long-tailed azoles ITC and PCZ to ScErg11p6 × His Y140F/H. (a) ScErg11p6 × His 
Y140F in complex with ITC (PDB ID: 4ZDY) and (b) PCZ (PDB ID: 4ZE1) and (c) ScErg11p6 × His Y140H 
in complex with ITC (PDB ID: 4ZE2). Panel (d) depicts the hydrophilic pocket (surface representation) in 
the substrate channel of ScErg11p6 × His Y140F. The hydrogen bonding interactions are shown between the 
water molecule (930), the N1 of the piperazine ring and the main chain amide groups of H381 and S382. The 
ScErg11p6 × His Y140F is shown in lilac cartoon and ScErg11p6 × His Y140H is depicted in yellow cartoon. 
Hydrogen bonds are shown as yellow dashed lines and water molecules as red spheres. ITC (green carbons), 
PCZ (yellow carbons), the side chains of residues 140 and 126, the backbone of F384, residues H381 and S382 
and the heme (magenta) are shown as sticks.
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addition, the Y140F mutation prevented formation of a hydrogen bond with the ring D propionate group of the 
heme. A new hydrogen bond between the propionate and water 843 now exists. Disruption of the hydrogen bond 
network by the Y140F mutation results in an additional water molecule (numbered 844), hydrogen bonded to 
water 843 and heme ring D propionate (Fig. 4b).
Wild type ScErg11p6 × His and ScErg11p6 × His Y140H complexes with FLC show the azole in similar con-
formations (Fig. 4a,c, PDB IDs: 4WMZ and 4ZE3). Water molecule 843 is present and forms a single short hydro-
gen bond with the tertiary hydroxyl group of FLC. This water displays a higher B-factor than water 743 in the wild 
type structure and water 843 in the Y140F mutant structure. A new polar contact (bond distance 2.7 Å) observed 
between N2 of the imidazole of H140 and the hydroxyl of T130 orients the H140 side chain closer to T130 than is 
seen with Y140 or F140 side chains (Fig. 4c). For ScErg11p6 × His Y140H in complex with ITC, the orientation of 
the imidazole ring was similar but the N2 of the H140 imidazole and the hydroxyl of T130 are separated by 3.4 Å.
Figure 4. Binding of short-tailed azoles FLC and VCZ to ScErg11p6 × His. Water-mediated interactions 
are shown for binding of (a) FLC and (d) VCZ to wild type ScErg11p6 × His (PDB IDs: 4WMZ and 5HS1, 
respectively). The modified interactions due to the Y140F/H mutations are depicted in panels (b) and (c) for 
FLC binding (PDB IDs: 4ZDZ and 4ZE3) and (e) for VCZ binding (PDB ID: 4ZE0). The wild type protein is 
depicted in grey cartoon (PDB IDs: 4WMZ and 5HS1), the Y140F mutant in lilac and the Y140H in yellow. The 
hydrogen bonds are shown with dashed lines and water molecules as red spheres. FLC (cyan carbons), VCZ 
(green carbons), the side chains of residue 140, 126, the backbone of S382 and F384 and the heme (magenta) are 
shown as sticks.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:26213 | DOI: 10.1038/srep26213
The crystal structure of wild type ScErg11p6 × His in complex with VCZ (PDB: 5HS1) reveals the azole drug 
binding in a similar fashion to FLC but with distinct differences due to its structure (Fig. 4d). The pyrimidine 
ring of VCZ occupies a similar position to the non-coordinating triazole ring of FLC but projects further into 
the substrate channel. The 5-fluoro substituent of the pyrimidine ring projects towards Y126 forcing this residue 
close enough to interact with the heme ring A propionate (2.8 Å; as seen in complexes with the long-tailed azoles 
PCZ and ITC). In the FLC structure (PDB ID: 4WMZ) those two groups are 4.3 Å apart. The key water molecule 
(743) is present and forms a similar hydrogen-bonding network with the phenolic hydroxyl of Y140, the heme 
ring D propionate and the tertiary hydroxyl group of VCZ (Fig. 4d). An additional hydrogen bond is present 
between the 5-fluoro substituent and the key water 743 (3.0 Å), which is shifted slightly towards Y140. The water 
molecule corresponding to water 790 in the FLC structure is not present at this position due to the projection of 
the pyrimidine ring. However, a water molecule (750, Fig. 4d) seen in complexes with the long-tailed azoles is also 
seen here. It forms hydrogen bonds between the pyrimidine nitrogen (N1), the main chain nitrogens of H381 and 
S382 plus the carbonyl of residue M509 which projects into the binding site cavity (Supplementary Fig. S5). Such 
flexibility has not been observed in this region previously. In the structure of ScErg11p6 × His in complex with 
lanosterol the carbonyl of M509 is within 2.9 Å of the tail of the substrate (PDB ID: 4XLJ) while the equivalent 
residue (M487) in human CYP51 has been implicated in substrate recognition due to its close proximity to the 
ligand ketoconazole (PDB ID: 3LD6)34.
The crystal structure of the ScErg11p6 × His Y140F mutant in complex with VCZ (Fig. 4e, PDB ID: 4ZE0) 
shows the ligand binds in a similar orientation but slightly deeper into the active site than in the wild type enzyme, 
with the quaternary carbon shifted ~0.5 Å. The mutation to phenylalanine with the corresponding removal of the 
hydroxyl group lets water 843 occupy the vacated space and thus allow the ligand to bind deeper. In addition, the 
plane of the phenyl ring of F140 is slightly shifted away from the ligand compared with the wild type complex 
with VCZ. Y126 is also in a similar position to that seen in the wild type VCZ complex. The distance between the 
heme ring A propionate and Y126 is 4.4 Å and the additional water (750) is not seen in the mutant complex. M509 
no longer projects into the active site but is adjacent to F236. In comparison to the recent structure of A. fumig-
atus CYP51B in complex with VCZ35, the pyrimidine ring is rotated 180°, allowing the ring to approach Y122 
(A. fumigatus numbering; Y126 in ScERG11p6 × His), while the 5-fluoro substituent is oriented towards F504 in 
a space in the ScErg11p6 × His structure adjacent to V510.
Discussion
We have created and analysed the structure and function of surrogate triazole resistance phenotypes in the 
yeast S. cerevisiae by creating Y140F/H single site mutations in lanosterol 14α -demethylase that have homo-
logues in numerous species of pathogenic fungi9,19. This study shows how alterations to a water-mediated 
hydrogen-bonding network, between the drug and target protein, can affect the affinity of the short-tailed triazole 
drugs FLC and VCZ but not the long-tailed triazoles ITC and PCZ. Whole cell assays (MIC80 measurements) 
were used to confirm the reduced susceptibility of ScErg11p6 × His Y140F/H mutants to FLC and VCZ. The 
<2-fold differences in MIC80 values detected using overexpression of wild type and mutant ScErg11p6 × His in 
the yeast system were not as dramatic as previously reported for the C. albicans Erg11p Y132H mutation17 but 
show a similar trend.
Triazole binding studies using affinity-purified wild type and ScErg11p6 × His Y140F/H enzymes gave dif-
ferences in both absolute absorption spectra prior to the addition of ligand and the magnitude of the change 
obtained for type II difference spectra after ligand addition. The differences in the oxidised heme Soret peak 
between the Y140F/H mutant enzymes (420 nm) and the wild type enzyme (417 nm) indicate that the mutations 
alter the electronic environment of the heme. Disruption of the short hydrogen bond between Y140 and the heme 
ring D propionate is the common feature that may explain this effect in both the Y140F and Y140H mutants.
The [Azole]0.5 and Kd values obtained from plotting the change in absorbance against the azole concentra-
tion with the wild type and mutant enzymes for each triazole drug indicated comparable high affinity bind-
ing (Table 1). The apparent lack of correlation between resistant phenotypes and azole affinity for free CYP51 
enzyme was previously reported for the C. albicans CYP51 Y132H mutant36 and the I471T mutant37. This may 
reflect difficulty in extracting the information needed to calculate inhibitor affinities due to the formation of 
near stoichiometric enzyme-inhibitor complexes. In addition, Warrilow et al. have shown that solubilisation 
of the enzyme from the membranes can also change the ligand-binding properties of CYP51s38. Assays using 
A. fumigatus NADPH cytochrome P450 reductase reconstituted with membrane preparations of A. fumigatus 
CYP51A or CYP51B enzymes heterologously expressed in E. coli gave IC50 values 34-fold higher for FLC bind-
ing to AfCYP51A (17 μ M) compared to AfCYP51B (0.5 μ M). In contrast, FLC binding by these two CYP51 
enzymes estimated using type II binding with the Ni-NTA affinity purified enzymes gave only a 3-fold difference 
in Kd values i.e. 12 μ M for AfCYP51A and 4 μ M for AfCYP51B. These discrepancies, presumably caused by the 
solubilisation of the enzyme with detergents, highlight the importance of the lipid bilayer in positioning the 
enzyme, determining its conformation and the access of triazole inhibitors to the active site. Reconstitution of 
the affinity-purified enzyme in lipid vesicles or nanodisks39 may provide methods to obtain more reliable and 
physiologically relevant estimates of the binding affinities of CYP51 inhibitors.
The ScErg11p6 × His Y140F/H mutations disrupt the water-mediated hydrogen bond network between 
enzyme and both FLC and VCZ. These findings help explain the FLC and VCZ resistance but retention of ITC 
and PCZ susceptibility in Y140F/H mutants. The key tertiary hydroxyl group in FLC and VCZ is replaced by a 
1,3-dioxolane moiety in both long-tailed triazoles with additional hydrophobic interactions with the entry chan-
nel exclusive to these inhibitors. Calorimetric studies have shown that it is energetically favourable to include a 
water molecule at the protein-ligand interface, providing evidence that water-mediated interactions can stabilise 
protein-ligand complexes40. Sharrow et al. demonstrated that the loss of water-mediated hydrogen bonding due 
to a tyrosine to phenylalanine mutation reduced favourable enthalpy and the binding affinity of a ligand to its 
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target protein41. The water-mediated polar interactions between Y140 and the tertiary hydroxyl of FLC and VCZ 
optimally stabilise the binding of these drugs.
Triazole drugs currently in clinical trials include albaconazole, ravuconazole, isavuconazole42 and VT-116116,43 
(Supplementary Fig. S6). All four of these compounds have the tertiary hydroxyl group that would interact with 
the Y140 residue. We postulate that these drugs may become less effective inhibitors of CYP51 due to mutations 
equivalent to Y140F/H (S. cerevisiae numbering). Isavuconazole has been approved for treatment of invasive 
aspergillosis in the USA44. However clinical isolates of A. fumigatus with the TR46/Y121F/T289A CYP51 muta-
tions are found in many parts of the world45–47. This mutant has the potential to be resistant to isavuconazole due 
to the Y121F mutation, which confers resistance to VCZ25,26. The novel tetrazole compound VT-1161 is currently 
in phase II clinical trials and has been shown to be a potent inhibitor of C. albicans CYP5116. A recent structure 
of the Trypanosoma cruzi CYP51 in complex with VT-1161 (PDB ID: 5AJR)48 places the hydroxyl group of the 
drug into the same position as the hydroxyl group of FLC in the ScErg11p structure (PDB ID: 4WMZ). Thus the 
tertiary hydroxyl of VT-1161 could interact with Y140 (S. cerevisiae numbering) via a water mediated hydrogen 
bond network. Therefore, mutations equivalent to ScErg11p Y140F/H have the potential to confer resistance to 
albaconazole, ravuconazole, isavuconazole or VT-1161 unless their medium-length tails in the entry channel 
confer sufficient affinity to counteract this problem. The short-tailed agrochemicals tebuconazole and prothio-
conazole have a similarly located hydroxyl group and resistance can be expected to be conferred via the equivalent 
mutations in fungal phytopathogens e.g. Z. tritici CYP51 Y137F and P. pachyrhizi CYP51 Y131F I475T.
In conclusion, ScErg11p6 × His crystal structures have revealed that the resistance conferred by the Y140F/H 
mutations via the loss of hydroxyl group results in the disruption of a water-mediated hydrogen bond network 
between the tertiary hydroxyl groups of FLC and VCZ and the enzyme. This leads directly to a decrease in bind-
ing affinity. We predict that this type of resistance could be avoided by substituting the hydroxyl of group of FLC 
and VCZ with the 1,3-dioxolanyl group found in ITC or PCZ in order to minimise those water-mediated interac-
tions. The design of azole drugs with tails that interact more effectively with the substrate entry channel than FLC 
and VCZ may also help avoid this problem.
Methods
Yeast strains and culture media. The S. cerevisiae AD2Δ host was used to create the strains used in this 
study. The strain was made by deletion of the HIS1 gene from the previously described ADΔ 49 strain. ADΔ 
and AD2Δ lack 7 major ATP-binding cassette transporters and the PDR3 gene. Both strains have the gain-of 
function pdr1–3 mutation in the PDR1 transcriptional regulator gene to provide constitutive overexpression 
of ScErg11p6 × His from the PDR5 locus. Yeast strains were grown on YPD medium: 1% (wt/vol) Bacto-yeast 
extract (BD Difco™ Laboratories Inc, Franklin Lakes, NJ), 2% (wt/vol) Bacto-peptone (BD Difco™ ) and 2% (wt/
vol) glucose. Synthetic defined (SD) medium was used for selection of transformants. It contained 2% (wt/vol) 
glucose, 0.67% (wt/vol) yeast nitrogen base without amino acids (BD Difco™ ), 2% (wt/vol) agar (Oxoid Ltd., 
Hampshire, UK) and either uracil drop-out (Qbiogene, Irvine, CA) or histidine drop-out (Formedium™ , Norfolk, 
UK) complete supplement mixture. Liquid SD media with complete supplement mixture (Formedium™) 
containing 10 mM MES and 20 mM HEPES buffered with TRIS to pH 6.8 was used for MIC80 determinations.
Materials. Desalted oligonucleotides, FLC, ITC, VCZ and PCZ were purchased from Sigma-Aldrich Ltd 
(St. Louis, MO). Colony polymerase chain reactions (PCR) were carried out using TaKaRa DNA polymerase 
(Takara Bio Inc, Shiga, Japan). All other PCR reactions were performed using KOD Hot Start DNA polymerase 
(Novagen, Madison, WI). PCR clean up and DNA gel extraction was carried out using kits from Qiagen Pty 
Ltd (Limburg, Netherlands). Genomic DNA from yeast was isolated using the Y-DER kit from Thermo Fisher 
(Waltham, MA). Yeast DNA transformation was carried out using an Alkali Cation Yeast Transformation kit 
from Qbiogene (Irvine, CA). DNA transformation cassettes and genes inserted at the PDR5 locus were confirmed 
by DNA sequence analysis performed at Genetic Analysis Services facility (University of Otago, Dunedin, New 
Zealand). The presence of the mutations Y140F/H in ScErg11p6 × His was verified by mass spectrometry at the 
Centre for Protein Research (University of Otago, New Zealand). An LTQ-Orbitrap hybrid mass spectrometer 
was used to obtain protein sequence coverage of at least 78% for each construct (Supplementary Figs S1 and S2).
Construction of yeast strains overexpressing ScErg11p6 × His Y140F/H. ScErg11p Y140F/H 
constructs were made by recombinant PCR using genomic DNA from the ADΔ ScErg11p6 × His overex-
pressing strain (Supplementary Table S1) as template. Together with standard flanking primers (PDR5F 
GAACATGAACGTTCCTCAGCGCG and PDR5DS TATGAGAAGACGGTTCGCCATTCGGACAG) 
the forward primer ScErg11_Y140F_f (AAGGTGTTATTTTCGATTGTCCAAATTC) and the 
reverse primer ScErg11_Y140F_r (TTGGACAATCGAAAATAACACCTTTACC) were used to cre-
ate fragments for recombinant PCR to introduce the Y140F mutation. Forward primer ScErg11_
Y140H_f (AAGGTGTTATTCATGATTGTCCAAATTC) and reverse primer ScErg11_Y140H_r 
(TTGGACAATCATGAATAACACCTTTACC) were used to introduce the Y140H mutation. The AD2Δ strain 
was transformed with linear mutant ScERG11 DNA constructs that included a C-terminal hexahistidine tag, 
the PGK transcription terminator, a URA3 selection marker, bordered by sequences from the PDR5 locus for 
integration into the genome via homologous recombination as described by Lamping et al.49. Transformants 
were selected using SD-Ura agar plates incubated for 48–72 hrs at 30 °C. Colony PCR was performed on the 
resultant transformants to identify clones with the insert in the correct position. The ScERG11 open reading 
frame and the presence of the expected mutation were confirmed by DNA sequence analysis. The resulting 
strains were denoted AD2Δ ScErg11_Y140F and AD2Δ ScErg11_Y140H (Supplementary Table S1). The endog-
enous ScERG11 was deleted from mutant strains by replacement with a disruption cassette containing the His1 
marker32. Transformants were selected on SD-His agar plates. Colony PCR and DNA sequence analysis were 
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used to confirm the correct inserts. The resulting strains were designated AD3Δ ScErg11_Y140F and AD3Δ 
ScErg11_Y140H (Supplementary Table S1).
Azole susceptibility of strains overexpressing ScErg11p. The susceptibilities of strains overexpress-
ing wild type ScErg11p6 × His and ScErg11p6 × His Y140F/H to triazole drugs were measured as MIC80 values 
using broth microdilution assays. The MIC80s were defined as 80% growth inhibition compared to no drug con-
trols because triazole drugs are fungistatic rather than fungicidal and can give trailing growth. MIC80s to FLC, 
ITC and VCZ were determined in 96-well microtiter plates using SD buffered to pH 6.8 instead of RPMI50. Cells 
were seeded at OD600nm = 0.005 (1.5 × 104 CFU) and the plates were incubated in 30 °C with shaking at 200 rpm 
for 48 hrs. Cell growth was assessed by measuring the OD600nm of wells using a BioTek Synergy™ 2 multi-mode 
plate reader (BioTek Instruments, Vermont, USA). Each MIC80 was determined using triplicate measurements for 
three clones of each strain in three separate experiments.
Purification of ScErg11p. The purification of Y140F/H mutant ScErg11p6 × His was carried out according 
to the methods described previously by Monk et al.31 using strains deleted of native ERG11 i.e. AD3Δ ScErg11_
Y140F and AD3Δ ScErg11_Y140H. In brief, yeast cells were grown in 1.5 L liquid cultures in YPD medium to 
OD600nm ~10 at 30 °C with shaking at 200 rpm. Harvested yeast cells were broken using a bead beating protocol 
and crude membranes were prepared by differential centrifugation. The protein concentration of crude mem-
branes were estimated using the Lowry method51 with bovine serum albumin (Thermo Fisher) as standard. Crude 
membranes were solubilised with 10× critical micelle concentration (CMC) n-decyl-β -D-maltoside (DM) in a 
medium containing 10% (wt/vol) glycerol, 250 mM NaCl, 20 mM Tris pH 7.5, 0.5 mM phenylmethanesulfonyl 
fluoride (PMSF) and 1 EDTA-free protease inhibitor pill (Roche) per 200 mL. The solubilised ScErg11p6 × His 
was affinity-purified using 2 mL of packed Ni-NTA-agarose matrix (Qiagen) per 1 gm of crude membrane pro-
tein. Affinity purification buffer containing 10% (wt/vol) glycerol, 250 mM NaCl, 20 mM Tris pH 7.5, 0.5 mM 
PMSF, 16 mM (10 × CMC) DM, 20 mM imidazole and 1 EDTA-free protease inhibitor pill per 200 mL was used 
to wash non-specifically bound proteins from the column. The ScErg11p6 × His enzyme was eluted from the 
column by using 200 mM imidazole in the affinity purification buffer. The triazole drugs ITC, FLC, VCZ or PCZ 
dissolved in dimethyl sulfoxide (DMSO) were added to the pooled fractions with final concentrations of 40 μ M 
for FLC and VCZ and 20 μ M for PCZ and ITC.
Affinity-purified fractions were further purified by size exclusion chromatography (SEC) using a Superdex 200 
10/300 GL column (GE Healthcare Life Sciences, UK). The column was equilibrated with degassed and filtered 
SEC buffer which contained 10% (wt/vol) glycerol, 150 mM NaCl, 20 mM HEPES, 0.5 mM PMSF, 6.4 mM DM 
(4 × CMC) and 2 EDTA-free protease inhibitor pills per 400 ml pH adjusted with NaOH to 7.5 at room tempera-
ture. The appropriate drug was added to the SEC buffer for co-purification; 10 μ M FLC, 10 μ M VCZ, 2 μ M ITC or 
2 μ M PCZ. The coloured fractions containing the 62 kDa ScErg11p6 × His were pooled and concentrated using 
50 kDa molecular-weight cut-off Amicon Ultra-4 centrifugal filters (Merck Millipore Ltd, Cork, Ireland).
Crystallisation and data collection. A hanging-drop vapour-diffusion method was used to crystallise the 
ScErg11p6 × His Y140F/H co-purified with a triazole drug. The reservoir solution contained 45% polyethylene 
glycol-400 in 100 mM glycine at a pH range of 9.3–9.55. Drops (total volume 4 μ l) were in a 1:1 ratio of reservoir 
solution and ~20 mg/ml of the protein in SEC buffer. Red boat-shaped crystals formed after about one week 
of incubation at 18 °C and were collected for X-ray studies. The crystals were flash-cooled in liquid nitrogen 
prior to data collection. Datasets were collected on the MX1 beamline (ADSC Quantum 210r detector) or MX2 
microbeam (ADSC Quantum 315r detector) at the Australian Synchrotron (Melbourne, Australia). During data 
collection the crystals were kept frozen under a cryostream at − 180 °C. Indexing and integration of data was 
done using iMosflm52 and scaling with SCALA53. Phaser-MR54 from Phenix was used to carry out molecular 
replacement using ScErg11p6 × His complexed with lanosterol (PDB ID: 4LXJ) as a template31. Refinement and 
modelling were performed using phenix.refine55 and Coot56. Waters were added if at least one hydrogen bond 
was detected (2.5–3.3 Å) and the inhibitors were modelled into the appropriate density in the active site and sub-
strate channel. The crystallographic information files (.cif) for triazole inhibitors were obtained from the Grade 
Global Phasing online tool (Global Phasing Ltd.). During refinement Fe – nitrogen and Fe – sulfur distances were 
constrained to 2.15 Å and 2.33 Å based on the average coordinate bond distance of more than 80 known Fe-N 
(triazole) complexes and 4 heme Fe-S in the Cambridge Structural Database57 as previously described32. The 
Ramachandran statistics for residues range from 95.45–97.15% for residues in preferred regions, 2.66–3.98% for 
residues in allowed regions and 0.38–2.15% for residues in disallowed regions for all datasets.
Spectral binding characteristics of Y140F/H mutants. The concentration of functional cytochrome 
P450 for drug binding studies was determined using the carbon monoxide binding spectra according to the 
protocol described by Guengerich et al.33. Affinity purified ScErg11p6 × His used for spectroscopic assays was 
eluted using affinity purification buffer containing 50 mM L-histidine instead of imidazole37. L-histidine was 
removed from the sample by washing the enzyme with solubilisation buffer containing 16 mM DM using 50 kDa 
molecular-weight cut-off Amicon Ultra-4 centrifugal filters (Merck Millipore Ltd, Cork, Ireland). The removal of 
l-histidine was checked by taking the absolute spectra of the sample using the Ultrospec™ 6300 pro UV/Visible 
spectrophotometer. The heme peak for wild type protein with no ligand was at ~417 nm. With L-histidine bound 
the peak was detected at ~420 nm. Enzyme concentration was determined by saturating the sample cuvette with 
CO gas prior to the addition of sodium dithionite. The reference cuvette containing the same amount of enzyme 
was treated with sodium dithionite only. The P450 concentration was determined by measuring the difference in 
absorbance between 446 and 490 nm and using the extinction coefficient of 91 mM−1 cm−1 58. Absorption spec-
tra were recorded with a Cary 1 Bio UV-visible spectrophotometer using 10 mm path UV transparent plastic 
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cuvettes (GE Healthcare Life Sciences, UK). Difference spectra were measured using 1 μ M ScErg11p6 × His wild 
type or Y140F/H enzyme titrated with the triazole drugs ITC, PCZ, VCZ and FLC. Triazole drugs dissolved in 
DMSO were added to the sample cuvette, with the same amount of DMSO added to the reference cuvette. The 
total amount of DMSO was < 2% of the total volume in the cuvette. Difference spectra between 350–500 nm were 
recorded and the trough-peak absorbance changes were used to plot binding curves. The dissociation constant 
Kd for type II binding of triazole drugs was calculated using GraphPad Prism 6 Software (GraphPad Prism, San 
Diego, CA) by applying the Hill equation using the formula Δ A = Δ Amax [Azole]n/([Azole]n + Kdn), with Δ Amax 
being the maximum change in absorbance and [Azole] the azole concentration.
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